[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fNFcOGgNlqbP7prsMZc8VzS-tj97RkvoZbWWaIhN8FDc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Baylor College of Medicine",[4],741,false,175,25,128539,113,380,[14,17,20,22,25,28,30,33],{"name":15,"count":16},"Obesity",20,{"name":18,"count":19},"Depression",14,{"name":21,"count":19},"Substance Abuse",{"name":23,"count":24},"Cocaine Dependence",12,{"name":26,"count":27},"Obsessive-Compulsive Disorder",11,{"name":29,"count":27},"Neuroblastoma",{"name":31,"count":32},"Anxiety",10,{"name":34,"count":32},"Generalized Anxiety Disorder",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT00710892","CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene","2011-11","Allodepleted T Cells",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT01192464","EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma","2012-05-29","autologous CAR.CD30 EBV specific-CTLs",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT01192555","Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma","2012-07","Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT00368082","Autologous\u002FAllogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)","2013-09","TGFbeta resistant LMP-specific CTLs",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT00586391","CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL","2014-07","CD19CAR-28-zeta T cells",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT01822652","3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN","2015-12","iC9-GD2 T Cells - frozen",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT00840853","Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT","2016-04","CD19CAR\u002Fvirus specific T cells",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT02065362","TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma \u002F RESIST-NPC","2017-03","DNR.NPC-specific T cells",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT00881920","Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL","2018-07","Kappa CD28 T cells",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT02050347","Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)","2019-10","CD19.CAR-CD28Z T Cells - dose escalation 2",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,153,199,217,244,262,296,324,350,368,392,435,453,480,498,615,652,681,707,733,751,781,799,817,843,861,888,913,939,957,983,1001,1252,1436,1481,1522,1544,1596,1643,1669,1691,1719,1751,1787,1814,1832,1855,1873,1899,1917,1944,1965,1983,2008,2026,2051,2075,2104,2122,2147,2173,2197,2216,2240,2267,2285,2309,2327,2355,2373,2391,2409,2431,2462,2480,2498,2519,2537,2566,2591,2609,2628,2650,2670,2694,2723,2741,2765,2783,2812,2836,2862,2880,2898,2916,2934,2952,2982,3000,3018,3036,3054,3080,3098,3116,3134,3152,3177,3210,3249,3273,3299,3325,3350,3394,3438,3483,3517,3550,3580,3618,3655,3692,3730,3765,3791,3817,3852,3875,3893,3917,3941,3967,3985,4003,4021,4046,4064,4082,4105,4129,4156,4174,4192,4210,4237,4255,4273,4291,4309,4327,4345,4363,4388,4406,4428,4453,4475,4499,4517,4542,4560,4581,4605,4623,4641,4659,4681,4702,4727,4752,4777,4804,4822,4845,4863,4896,4926,4951,4969,4991,5015,5042,5060,5089,5107,5125,5143,5165,5190,5214,5237,5258,5276,5303,5321,5349,5367,5393,5431,5499,5529,5571,5606,5638,5677,5699,5721,5755,5777,5816,5855,5886,5911,5929,5947,5965,5987,6012,6034,6057,6075,6098,6122,6140,6166,6184,6202,6226,6244,6268,6286,6304,6326,6351,6369,6391,6409,6427,6445,6473,6491,6509,6527,6545,6563,6581,6603,6629,6650,6668,6691,6715,6737,6762,6787,6811,6829,6853,6875,6897,6922,6944,6962,6980,6998,7022,7048,7070,7094,7117,7139,7157,7175,7199,7217,7235,7265,7291,7313,7343,7368,7394,7426,7453,7484,7513,7549,7571,7593,7615,7637,7667,7696,7719,7742,7764,7785,7809,7831,7857,7875,7893,7911,7929,7947,7965,7983,8008,8030,8048,8066,8088,8111,8134,8160,8178,8200,8218,8236,8254,8272,8290,8308,8331,8356,8378,8400,8422,8448,8466,8484,8502,8520,8541,8562,8585,8603,8628,8646,8668,8694,8715,8733,8755,8776,8799,8823,8841,8859,8877,8899,8923,8945,8969,8987,9008,9026,9050,9074,9092,9110,9133,9155,9173,9197,9215,9240,9261,9282,9305,9323,9347,9369,9395,9413,9434,9455,9473,9495,9518,9536,9554,9572,9590,9613,9631,9649,9667,9693,9715,9739,9764,9790,9808,9826,9844,9862,9885,9908,9950,9988,10026,10064,10094,10127,10153,10184,10210,10239,10278,10304,10341,10368,10409,10431,10453,10475,10503,10525,10551,10581,10605,10623,10648,10666,10684,10702,10720,10738,10756,10774,10792,10816,10834,10859,10882,10900,10923,10946,10969,10987,11010,11028,11046,11066,11096,11114,11138,11156,11174,11196,11218,11239,11257,11275,11301,11324,11346,11368,11391,11409,11433,11451,11469,11487,11505,11523,11541,11559,11577,11595,11613,11634,11660],{"intervention":95,"totalTrials":96,"cells":97},"Normal saline",3,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":121,"PHASE4":123,"NA":151},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":119},"NCT00513240","Erythropoetin Neuroprotection for Neonatal Cardiac Surgery","COMPLETED",[88,89],"2012-09","2015-09","2006-09",62,[115,116,117,118],"Congenital Heart Disease","Hypoplastic Left Heart Syndrome","Transposition of the Great Arteries","Aortic Arch Hypoplasia or Interruption",[120,95],"Erythropoetin",{"trials":122,"activeCount":100},[],{"trials":124,"activeCount":150,"soonestReadout":130},[125,138],{"nctId":126,"briefTitle":127,"status":128,"phases":129,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},"NCT06577233","Superior Hypogastric Nerve Plexus Block With Bupivacaine After Robotic Resection of Endometriosis","RECRUITING",[91],"2025-04-30","2025-08-31","2024-08-28",60,[135],"Endometriosis",[137,95],"Bupivacaine Hydrochloride",{"nctId":139,"briefTitle":140,"status":108,"phases":141,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":147},"NCT02206685","A Trial Comparing Single Intra-op Dose of Methadone Versus Placebo in Patients Undergoing Spine Surgery",[91],"2020-01-27","2014-05",74,[146],"Thoracolumbar Scoliosis",[148,149],"Methadone","Normal Saline",1,{"trials":152,"activeCount":100},[],{"intervention":154,"totalTrials":96,"cells":155},"Dexmedetomidine",{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":197},{"trials":157,"activeCount":100},[],{"trials":159,"activeCount":100},[],{"trials":161,"activeCount":100},[],{"trials":163,"activeCount":100},[],{"trials":165,"activeCount":150,"soonestReadout":191},[166,177,187],{"nctId":167,"briefTitle":168,"status":108,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":175},"NCT01255904","A Trial Of Oral Chloral Hydrate Versus Intranasal Dexmedetomidine For Sedated Abr Exams",[91],"2014-11","2011-08",90,[174],"Sedation",[176,154],"Chloral Hydrate",{"nctId":178,"briefTitle":179,"status":180,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":100,"conditions":184,"interventions":186},"NCT02915042","Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair","WITHDRAWN",[91],"2019-12","2017-12-31",[185],"Cleft Palate",[154],{"nctId":188,"briefTitle":189,"status":128,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT03384563","Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane",[91],"2025-12-31","2018-02-18",180,[195],"Pediatric Anesthesia",[154],{"trials":198,"activeCount":100},[],{"intervention":137,"totalTrials":150,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":100},[],{"trials":204,"activeCount":100},[],{"trials":206,"activeCount":100},[],{"trials":208,"activeCount":100},[],{"trials":210,"activeCount":150,"soonestReadout":130},[211],{"nctId":126,"briefTitle":127,"status":128,"phases":212,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":213,"interventions":214},[91],[135],[137,95],{"trials":216,"activeCount":100},[],{"intervention":218,"totalTrials":150,"cells":219},"Platelet-Rich Plasma (PRP) Injections",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":242},{"trials":221,"activeCount":100},[],{"trials":223,"activeCount":100},[],{"trials":225,"activeCount":100},[],{"trials":227,"activeCount":100},[],{"trials":229,"activeCount":150,"soonestReadout":235},[230],{"nctId":231,"briefTitle":232,"status":233,"phases":234,"primaryCompletion":235,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":240},"NCT06998433","Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia","NOT_YET_RECRUITING",[91],"2026-07-31","2025-09-30",56,[239],"Central Centrifugal Cicatricial Alopecia",[218,241],"Saline",{"trials":243,"activeCount":100},[],{"intervention":241,"totalTrials":150,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":260},{"trials":247,"activeCount":100},[],{"trials":249,"activeCount":100},[],{"trials":251,"activeCount":100},[],{"trials":253,"activeCount":100},[],{"trials":255,"activeCount":150,"soonestReadout":235},[256],{"nctId":231,"briefTitle":232,"status":233,"phases":257,"primaryCompletion":235,"completion":235,"start":236,"enrollment":237,"conditions":258,"interventions":259},[91],[239],[218,241],{"trials":261,"activeCount":100},[],{"intervention":263,"totalTrials":150,"cells":264},"Indocyanine Green (ICG)-Assisted Ureteral Identification",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":294},{"trials":266,"activeCount":100},[],{"trials":268,"activeCount":100},[],{"trials":270,"activeCount":100},[],{"trials":272,"activeCount":100},[],{"trials":274,"activeCount":150,"soonestReadout":279},[275],{"nctId":276,"briefTitle":277,"status":233,"phases":278,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":293},"NCT07144904","Assessing the Efficacy of Indocyanine Green for Ureter Identification During Robot-Assisted Surgery in Advanced-Stage Endometriosis",[91],"2026-02-01","2026-03-15","2025-10-01",40,[284,285,286,287,288,289,290,291,292],"Indocyanine Green (ICG)","Robotic Surgical Procedure","Deep Infiltrating Endometriosis (DIE)","Endometriosis Pelvic","Endometriosis (Diagnosis)","Endometriosis of the Cul-de-sac","Ureteral Stent Placement","Ureteral Injury","Endometriosis Ovaries",[263],{"trials":295,"activeCount":100},[],{"intervention":297,"totalTrials":150,"cells":298},"ActiveMatrix",{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":305,"PHASE4":307,"NA":322},{"trials":300,"activeCount":100},[],{"trials":302,"activeCount":100},[],{"trials":304,"activeCount":100},[],{"trials":306,"activeCount":100},[],{"trials":308,"activeCount":150,"soonestReadout":313},[309],{"nctId":310,"briefTitle":311,"status":233,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":321},"NCT05297513","Efficacy of ActiveMatrix on Spinal SSI Rate",[91],"2025-07","2026-07","2022-07",275,[318,319,320],"Spinal Stenosis Lumbar","Surgical Site Infection","Back Pain Lower Back Chronic",[297],{"trials":323,"activeCount":100},[],{"intervention":325,"totalTrials":150,"cells":326},"Vevye®",{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":348},{"trials":328,"activeCount":100},[],{"trials":330,"activeCount":100},[],{"trials":332,"activeCount":100},[],{"trials":334,"activeCount":100},[],{"trials":336,"activeCount":150,"soonestReadout":341},[337],{"nctId":338,"briefTitle":339,"status":233,"phases":340,"primaryCompletion":341,"completion":342,"start":343,"enrollment":133,"conditions":344,"interventions":346},"NCT07368595","Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks",[91],"2027-03-31","2027-06","2026-04-01",[345],"Dry Eye Disease (DED)",[325,347],"Cyclosporine emulsion",{"trials":349,"activeCount":100},[],{"intervention":347,"totalTrials":150,"cells":351},{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":360,"NA":366},{"trials":353,"activeCount":100},[],{"trials":355,"activeCount":100},[],{"trials":357,"activeCount":100},[],{"trials":359,"activeCount":100},[],{"trials":361,"activeCount":150,"soonestReadout":341},[362],{"nctId":338,"briefTitle":339,"status":233,"phases":363,"primaryCompletion":341,"completion":342,"start":343,"enrollment":133,"conditions":364,"interventions":365},[91],[345],[325,347],{"trials":367,"activeCount":100},[],{"intervention":369,"totalTrials":150,"cells":370},"betamethasone valerate 0.1% cream",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":390},{"trials":372,"activeCount":100},[],{"trials":374,"activeCount":100},[],{"trials":376,"activeCount":100},[],{"trials":378,"activeCount":100},[],{"trials":380,"activeCount":150,"soonestReadout":385},[381],{"nctId":382,"briefTitle":383,"status":128,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":282,"conditions":387,"interventions":389},"NCT07508124","Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study",[91],"2027-12","2026-04",[388],"Urinary Tract Infection",[369],{"trials":391,"activeCount":100},[],{"intervention":393,"totalTrials":394,"cells":395},"Cytarabine",2,{"EARLY_PHASE1":396,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":431,"NA":433},{"trials":397,"activeCount":100},[398],{"nctId":399,"briefTitle":400,"status":108,"phases":401,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":406,"interventions":408},"NCT03568994","Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)",[87],"2020-09-29","2025-09-20","2018-07-10",26,[407],"Acute Myeloid Leukemia",[409,393,410,411,412],"Atovaquone","Daunorubicin","Etoposide","Gemtuzumab Ozogamicin",{"trials":414,"activeCount":100},[],{"trials":416,"activeCount":100},[],{"trials":418,"activeCount":150,"soonestReadout":423},[419],{"nctId":420,"briefTitle":421,"status":128,"phases":422,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":429},"NCT02670707","Vinblastine\u002FPrednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)",[90],"2027-01","2029-01","2016-03-07",124,[428],"Langerhans Cell Histiocytosis",[393,430],"Vinblastine\u002Fprednisone",{"trials":432,"activeCount":100},[],{"trials":434,"activeCount":100},[],{"intervention":430,"totalTrials":150,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":449,"NA":451},{"trials":438,"activeCount":100},[],{"trials":440,"activeCount":100},[],{"trials":442,"activeCount":100},[],{"trials":444,"activeCount":150,"soonestReadout":423},[445],{"nctId":420,"briefTitle":421,"status":128,"phases":446,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":447,"interventions":448},[90],[428],[393,430],{"trials":450,"activeCount":100},[],{"trials":452,"activeCount":100},[],{"intervention":454,"totalTrials":150,"cells":455},"Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":476,"NA":478},{"trials":457,"activeCount":100},[],{"trials":459,"activeCount":100},[],{"trials":461,"activeCount":100},[],{"trials":463,"activeCount":150,"soonestReadout":468},[464],{"nctId":465,"briefTitle":466,"status":128,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":282,"conditions":471,"interventions":474},"NCT05304442","IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department",[90],"2025-03","2025-04","2022-09-15",[472,473],"Anemia, Iron Deficiency","Uterine Bleeding",[454,475],"Ferrous Sulfate 65 mg elemental iron",{"trials":477,"activeCount":100},[],{"trials":479,"activeCount":100},[],{"intervention":475,"totalTrials":150,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":494,"NA":496},{"trials":483,"activeCount":100},[],{"trials":485,"activeCount":100},[],{"trials":487,"activeCount":100},[],{"trials":489,"activeCount":150,"soonestReadout":468},[490],{"nctId":465,"briefTitle":466,"status":128,"phases":491,"primaryCompletion":468,"completion":469,"start":470,"enrollment":282,"conditions":492,"interventions":493},[90],[472,473],[454,475],{"trials":495,"activeCount":100},[],{"trials":497,"activeCount":100},[],{"intervention":499,"totalTrials":500,"cells":501},"Cytoxan",9,{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":567,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":503,"activeCount":100},[],{"trials":505,"activeCount":394,"soonestReadout":64},[506,519,529,545,558],{"nctId":507,"briefTitle":508,"status":180,"phases":509,"primaryCompletion":510,"completion":511,"start":512,"enrollment":100,"conditions":513,"interventions":516},"NCT04093648","T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)",[88],"2023-02","2038-01","2020-01",[514,515],"Hepatocellular Carcinoma","Hepatoblastoma",[517,499,518],"TEGAR T cells","Fludarabine",{"nctId":520,"briefTitle":521,"status":108,"phases":522,"primaryCompletion":523,"completion":524,"start":525,"enrollment":500,"conditions":526,"interventions":527},"NCT02905188","Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)",[88],"2021-11-17","2023-01-06","2019-03-28",[514],[528,499,518],"GLYCAR T cells",{"nctId":530,"briefTitle":531,"status":108,"phases":532,"primaryCompletion":533,"completion":533,"start":111,"enrollment":534,"conditions":535,"interventions":542},"NCT02379520","HPV-16\u002F18 E6\u002FE7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA",[88],"2026-01",32,[536,537,538,539,540,541],"Human Papillomavirus-Related Carcinoma","Human Papillomavirus Positive Oropharyngeal Carcinoma","Human Papillomavirus Positive Cervical Carcinoma","Human Papillomavirus Positive Anal Carcinoma","Human Papillomavirus Positive Vulvar Carcinoma","Human Papillomavirus Positive Penile Carcinoma",[543,499,518,544],"HPV Specific T Cells","Nivolumab",{"nctId":546,"briefTitle":547,"status":548,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":32,"conditions":553,"interventions":555},"NCT02932956","Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)","ACTIVE_NOT_RECRUITING",[88],"2021-09-27","2037-02","2018-12-17",[554],"Liver Cancer",[556,499,557],"GAP T cells","Fludara",{"nctId":62,"briefTitle":63,"status":548,"phases":559,"primaryCompletion":64,"completion":560,"start":561,"enrollment":27,"conditions":562,"interventions":563},[88],"2030-10","2013-08",[29],[65,564,499,557,565,566],"iC9-GD2 T Cells - fresh","Keytruda","iC9-GD2 T cells",{"trials":568,"activeCount":150,"soonestReadout":49},[569,575],{"nctId":47,"briefTitle":48,"status":548,"phases":570,"primaryCompletion":49,"completion":571,"start":572,"enrollment":27,"conditions":573,"interventions":574},[88,89],"2026-09","2010-09",[29],[50,499],{"nctId":576,"briefTitle":577,"status":578,"phases":579,"primaryCompletion":49,"completion":49,"start":580,"enrollment":581,"conditions":582,"interventions":584},"NCT00578903","Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia","TERMINATED",[89],"2002-02",22,[583],"Aplastic Anemia",[499,585,586,587],"Campath","FK-506","Methotrexate",{"trials":589,"activeCount":100},[],{"trials":591,"activeCount":100},[],{"trials":593,"activeCount":100},[594,605],{"nctId":595,"briefTitle":596,"status":108,"phases":597,"primaryCompletion":598,"completion":599,"start":600,"enrollment":282,"conditions":601,"interventions":603},"NCT00950846","Umbilical Cord Blood Transplant for Congenital Pediatric Disorders",[92],"2020-07-21","2021-02-04","2009-09",[602],"Congenital Pediatric Disorders",[604,499,518],"Busulfan",{"nctId":606,"briefTitle":607,"status":180,"phases":608,"primaryCompletion":609,"completion":609,"start":610,"enrollment":100,"conditions":611,"interventions":614},"NCT01247688","Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies",[92],"2013-12","2010-11",[612,613],"Lymphoid Hematological Malignancies","Umbilical Cord Blood Transplant",[499,518],{"intervention":616,"totalTrials":394,"cells":617},"Proflavine Hemisulfate",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":646,"PHASE4":648,"NA":650},{"trials":619,"activeCount":100},[],{"trials":621,"activeCount":100},[],{"trials":623,"activeCount":150,"soonestReadout":639},[624,635],{"nctId":625,"briefTitle":626,"status":108,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":634},"NCT04563754","The Effectiveness of High Resolution Microendoscopy for People Living With HIV",[88,89],"2024-03-28","2025-03-28","2019-07-30",163,[633],"Anal High Grade Squamous Intraepithelial Lesion",[616],{"nctId":636,"briefTitle":637,"status":128,"phases":638,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":645},"NCT06435286","Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States",[89],"2027-03-01","2025-02-17",200,[643,644],"Suspected or Known Squamous Cell Neoplasia","Prior History of Squamous Cell Dysplasia and \u002For Neoplasia",[616],{"trials":647,"activeCount":100},[],{"trials":649,"activeCount":100},[],{"trials":651,"activeCount":100},[],{"intervention":653,"totalTrials":150,"cells":654},"HPV vaccine, Imiquimod, and metformin combination therapy",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":656,"activeCount":100},[],{"trials":658,"activeCount":100},[],{"trials":660,"activeCount":150,"soonestReadout":665},[661],{"nctId":662,"briefTitle":663,"status":128,"phases":664,"primaryCompletion":665,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":674},"NCT06686043","HPV Vaccine, Imiquimod, and Metformin Combination Trial",[89],"2026-08-23","2028-08-23","2024-08-23",85,[670,671,672,673],"Cervical Carcinoma","Vaginal Carcinoma","Vulvar Carcinoma","HPV (Human Papillomavirus)-Associated Carcinoma",[653],{"trials":676,"activeCount":100},[],{"trials":678,"activeCount":100},[],{"trials":680,"activeCount":100},[],{"intervention":682,"totalTrials":150,"cells":683},"Recombinant human growth hormone",{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":685,"activeCount":100},[],{"trials":687,"activeCount":100},[],{"trials":689,"activeCount":150,"soonestReadout":694},[690],{"nctId":691,"briefTitle":692,"status":128,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":16,"conditions":697,"interventions":700},"NCT05355272","Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)",[89],"2026-12","2027-07-01","2024-03-11",[698,699],"Gulf War Syndrome","Adult Growth Hormone Deficiency",[682],{"trials":702,"activeCount":100},[],{"trials":704,"activeCount":100},[],{"trials":706,"activeCount":100},[],{"intervention":708,"totalTrials":150,"cells":709},"Albumin",{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":711,"activeCount":100},[],{"trials":713,"activeCount":100},[],{"trials":715,"activeCount":150,"soonestReadout":720},[716],{"nctId":717,"briefTitle":718,"status":128,"phases":719,"primaryCompletion":720,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":726},"NCT05867602","High Dose Albumin in Refractory Ascites",[89],"2026-03-25","2026-06-25","2019-03-25",100,[725],"Ascites",[708],{"trials":728,"activeCount":100},[],{"trials":730,"activeCount":100},[],{"trials":732,"activeCount":100},[],{"intervention":50,"totalTrials":150,"cells":734},{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":745,"PHASE4":747,"NA":749},{"trials":736,"activeCount":100},[],{"trials":738,"activeCount":100},[],{"trials":740,"activeCount":150,"soonestReadout":49},[741],{"nctId":47,"briefTitle":48,"status":548,"phases":742,"primaryCompletion":49,"completion":571,"start":572,"enrollment":27,"conditions":743,"interventions":744},[88,89],[29],[50,499],{"trials":746,"activeCount":100},[],{"trials":748,"activeCount":100},[],{"trials":750,"activeCount":100},[],{"intervention":752,"totalTrials":150,"cells":753},"Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg\u002Fm2 + Oxaliplatin 130 mg\u002Fm2",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":755,"activeCount":100},[],{"trials":757,"activeCount":100},[],{"trials":759,"activeCount":150,"soonestReadout":764},[760],{"nctId":761,"briefTitle":762,"status":128,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":772},"NCT05870800","Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER",[89],"2026-09-01","2028-01-01","2025-06-15",28,[769,770,771],"Stage I Colon Cancer","Stage II Colon Cancer","Stage III Colon Cancer",[752,773,774],"Oxaliplatin injection 85mg\u002Fm2 + Leucovorin 400mg\u002Fm2 + 5-Fluorouracil 2400mg\u002Fm2","Oxaliplatin 130mg\u002Fm2 + Capecitabine 1000mg\u002Fm2",{"trials":776,"activeCount":100},[],{"trials":778,"activeCount":100},[],{"trials":780,"activeCount":100},[],{"intervention":773,"totalTrials":150,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":784,"activeCount":100},[],{"trials":786,"activeCount":100},[],{"trials":788,"activeCount":150,"soonestReadout":764},[789],{"nctId":761,"briefTitle":762,"status":128,"phases":790,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":791,"interventions":792},[89],[769,770,771],[752,773,774],{"trials":794,"activeCount":100},[],{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":100},[],{"intervention":774,"totalTrials":150,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":802,"activeCount":100},[],{"trials":804,"activeCount":100},[],{"trials":806,"activeCount":150,"soonestReadout":764},[807],{"nctId":761,"briefTitle":762,"status":128,"phases":808,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":809,"interventions":810},[89],[769,770,771],[752,773,774],{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":100},[],{"trials":816,"activeCount":100},[],{"intervention":818,"totalTrials":150,"cells":819},"Pembrolizumab",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":821,"activeCount":100},[],{"trials":823,"activeCount":100},[],{"trials":825,"activeCount":150,"soonestReadout":830},[826],{"nctId":827,"briefTitle":828,"status":128,"phases":829,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":835},"NCT05132504","Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer",[89],"2027-05-21","2022-08-31",30,[834],"Pancreatic Ductal Adenocarcinoma",[818,836],"Folfirinox",{"trials":838,"activeCount":100},[],{"trials":840,"activeCount":100},[],{"trials":842,"activeCount":100},[],{"intervention":836,"totalTrials":150,"cells":844},{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":846,"activeCount":100},[],{"trials":848,"activeCount":100},[],{"trials":850,"activeCount":150,"soonestReadout":830},[851],{"nctId":827,"briefTitle":828,"status":128,"phases":852,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":853,"interventions":854},[89],[834],[818,836],{"trials":856,"activeCount":100},[],{"trials":858,"activeCount":100},[],{"trials":860,"activeCount":100},[],{"intervention":862,"totalTrials":150,"cells":863},"Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":865,"activeCount":100},[],{"trials":867,"activeCount":100},[],{"trials":869,"activeCount":150,"soonestReadout":874},[870],{"nctId":871,"briefTitle":872,"status":548,"phases":873,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":877,"interventions":881},"NCT04626024","Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population",[89],"2028-11-15","2020-12-22",17,[878,879,880],"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia, BCR\u002FABL-Positive, in Remission","Chronic Myeloid Leukemia in Remission",[862],{"trials":883,"activeCount":100},[],{"trials":885,"activeCount":100},[],{"trials":887,"activeCount":100},[],{"intervention":889,"totalTrials":150,"cells":890},"Tranexamic Acid 650 MG",{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":907,"PHASE4":909,"NA":911},{"trials":892,"activeCount":100},[],{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":150,"soonestReadout":901},[897],{"nctId":898,"briefTitle":899,"status":233,"phases":900,"primaryCompletion":901,"completion":560,"start":902,"enrollment":903,"conditions":904,"interventions":906},"NCT06718751","Tranexamic Acid Therapy For The Treatment of Subdural Hematomas",[89],"2029-10","2025-10",240,[905],"Chronic Subdural Hematoma",[889],{"trials":908,"activeCount":100},[],{"trials":910,"activeCount":100},[],{"trials":912,"activeCount":100},[],{"intervention":914,"totalTrials":150,"cells":915},"Durvalumab \u002F tremelimumab",{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":100},[],{"trials":921,"activeCount":150,"soonestReadout":926},[922],{"nctId":923,"briefTitle":924,"status":128,"phases":925,"primaryCompletion":926,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":931},"NCT05932199","Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma",[88,89],"2028-05-31","2024-07-03",52,[930],"Mesothelioma",[914,932],"Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab\u002Ftremelimumab",{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[],{"trials":938,"activeCount":100},[],{"intervention":932,"totalTrials":150,"cells":940},{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":942,"activeCount":100},[],{"trials":944,"activeCount":100},[],{"trials":946,"activeCount":150,"soonestReadout":926},[947],{"nctId":923,"briefTitle":924,"status":128,"phases":948,"primaryCompletion":926,"completion":926,"start":927,"enrollment":928,"conditions":949,"interventions":950},[88,89],[930],[914,932],{"trials":952,"activeCount":100},[],{"trials":954,"activeCount":100},[],{"trials":956,"activeCount":100},[],{"intervention":958,"totalTrials":150,"cells":959},"Psilocybin 15mg",{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":961,"activeCount":100},[],{"trials":963,"activeCount":100},[],{"trials":965,"activeCount":150,"soonestReadout":970},[966],{"nctId":967,"briefTitle":968,"status":128,"phases":969,"primaryCompletion":970,"completion":970,"start":971,"enrollment":972,"conditions":973,"interventions":975},"NCT06888128","State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma",[89],"2026-12-15","2025-01-30",15,[974],"PTSD",[958,976],"Psilocybin 25mg",{"trials":978,"activeCount":100},[],{"trials":980,"activeCount":100},[],{"trials":982,"activeCount":100},[],{"intervention":976,"totalTrials":150,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":986,"activeCount":100},[],{"trials":988,"activeCount":100},[],{"trials":990,"activeCount":150,"soonestReadout":970},[991],{"nctId":967,"briefTitle":968,"status":128,"phases":992,"primaryCompletion":970,"completion":970,"start":971,"enrollment":972,"conditions":993,"interventions":994},[89],[974],[958,976],{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":100},[],{"intervention":518,"totalTrials":1002,"cells":1003},23,{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1085,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1005,"activeCount":100},[],{"trials":1007,"activeCount":96,"soonestReadout":1077},[1008,1018,1022,1026,1040,1044,1056,1073],{"nctId":1009,"briefTitle":1010,"status":180,"phases":1011,"primaryCompletion":1012,"completion":560,"start":1013,"enrollment":100,"conditions":1014,"interventions":1015},"NCT02439788","3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA",[88],"2019-09","2017-08",[29],[1016,518,1017],"cyclophosphamide","GINAKIT Cells",{"nctId":507,"briefTitle":508,"status":180,"phases":1019,"primaryCompletion":510,"completion":511,"start":512,"enrollment":100,"conditions":1020,"interventions":1021},[88],[514,515],[517,499,518],{"nctId":520,"briefTitle":521,"status":108,"phases":1023,"primaryCompletion":523,"completion":524,"start":525,"enrollment":500,"conditions":1024,"interventions":1025},[88],[514],[528,499,518],{"nctId":1027,"briefTitle":1028,"status":548,"phases":1029,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":1034,"interventions":1036},"NCT00902044","Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma",[88],"2019-12-06","2032-07","2010-02-11",36,[1035],"Sarcoma",[1037,518,1038,1039],"Autologous HER2-specific T cells","Cyclophosphamide","Autologous CAR Positive T cells",{"nctId":530,"briefTitle":531,"status":108,"phases":1041,"primaryCompletion":533,"completion":533,"start":111,"enrollment":534,"conditions":1042,"interventions":1043},[88],[536,537,538,539,540,541],[543,499,518,544],{"nctId":1045,"briefTitle":1046,"status":578,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":150,"conditions":1050,"interventions":1052},"NCT00586274","Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT",[88],"2009-07","2002-03",[1051],"FANCONI ANEMIA",[518,1053,1054,1055],"T cell","Campath 1h","anti-CD45",{"nctId":1057,"briefTitle":1058,"status":548,"phases":1059,"primaryCompletion":1060,"completion":1061,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1071},"NCT02287311","Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)",[88],"2024-01-12","2029-03","2015-02",38,[1065,1066,1067,1068,1069,1070],"Hodgkin Disease","Non-Hodgkin Lymphoma","Severe Chronic Active Epstein Barr Virus","T\u002FNK-lymphoproliferative Disease","Nasopharyngeal Carcinoma","Smooth Muscle Tumor",[1072,1038,518],"MABEL CTLs",{"nctId":1074,"briefTitle":1075,"status":548,"phases":1076,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":405,"conditions":1080,"interventions":1082},"NCT01953900","iC9-GD2-CAR-VZV-CTLs\u002FRefractory or Metastatic GD2-positive Sarcoma and Neuroblastoma",[88],"2019-10-31","2034-10-31","2014-04",[1081,29],"Osteosarcoma",[1083,1084,518,1038],"GD2 T cells","VZV vaccine",{"trials":1086,"activeCount":100},[1087,1099,1117,1129,1141,1151,1163,1176,1189,1199,1209],{"nctId":1088,"briefTitle":1089,"status":578,"phases":1090,"primaryCompletion":600,"completion":600,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1096},"NCT00590460","Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia",[88,89],"2001-07",5,[1094,1095],"Fanconi Anemia","Severe Aplastic Anemia",[1097,1098,518],"CAMPATH-1H","Anti-CD45",{"nctId":1100,"briefTitle":1101,"status":578,"phases":1102,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1116},"NCT00579111","Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)",[88,89],"2009-02","2010-10","2007-06",4,[1108,1109,1110,1111,1112,1113,1114,1115],"Myelodysplastic and Myeloproliferative Disorders","Acute Myelogenous Leukemia","Acute Lymphoblastic Leukemia","Chronic Myelogenous Leukemia","Multiple Myeloma","Plasma Cell Dyscrasia","Lymphoproliferative Disorders","Hematologic Diseases",[585,604,518,586],{"nctId":1118,"briefTitle":1119,"status":578,"phases":1120,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1126},"NCT00058825","Stem Cell Transplant for Hematologic Diseases",[88,89],"2014-09","2000-08",27,[1125],"Hematologic Malignancies",[1127,518,1128],"Campath 1H","FK506 (Tacrolimus) or Cyclosporine",{"nctId":1130,"briefTitle":1131,"status":578,"phases":1132,"primaryCompletion":112,"completion":1133,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1140},"NCT00069992","Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML",[89],"2007-04","2001-12",7,[1137,1138,1139],"Chronic Myeloproliferative Disorders","Leukemia","Myelodysplastic Syndromes",[518,1127],{"nctId":1142,"briefTitle":1143,"status":578,"phases":1144,"primaryCompletion":1145,"completion":1145,"start":1146,"enrollment":394,"conditions":1147,"interventions":1149},"NCT00056979","Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases",[88,89],"2003-06","2002-06",[1148],"Inherited Metabolic Storage Diseases",[1097,1098,1150,518],"FK506",{"nctId":1152,"briefTitle":1153,"status":108,"phases":1154,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":972,"conditions":1158,"interventions":1160},"NCT00578643","Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease",[89],"2017-07-31","2017-11-24","2004-03",[1159],"Chronic Granulomatous Disease",[604,1161,1038,518,1162],"Alemtuzumab","Cyclosporine",{"nctId":1164,"briefTitle":1165,"status":578,"phases":1166,"primaryCompletion":1167,"completion":1167,"start":1168,"enrollment":96,"conditions":1169,"interventions":1174},"NCT00579137","Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders",[88,89],"2009-10","2007-10",[1170,1171,1172,1173],"Severe Combined Immunodeficiency Disease","Severe Primary Immunodeficiency Disorder","Undefined T Cell Deficiency Disorder","Wiskott-Aldrick Syndrome",[1175,518,1098],"Campath -1H",{"nctId":1177,"briefTitle":1178,"status":578,"phases":1179,"primaryCompletion":1180,"completion":1180,"start":1122,"enrollment":972,"conditions":1181,"interventions":1185},"NCT00040417","Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies",[89],"2003-11-21",[1182,1183,1184],"Sickle Cell Anemia","Hemoglobinopathy","Thalassemia",[1186,1187,1150,1188],"FLUDARABINE","CAMPATH-IH","G-SCF",{"nctId":1190,"briefTitle":1191,"status":578,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":282,"conditions":1195,"interventions":1197},"NCT00048399","Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H",[88,89],"2003-10-31","2000-12",[1196],"Graft Failure",[518,1198,1150],"CAMPATH 1H",{"nctId":1200,"briefTitle":1201,"status":108,"phases":1202,"primaryCompletion":1203,"completion":1203,"start":1204,"enrollment":282,"conditions":1205,"interventions":1207},"NCT00048412","Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H",[88,89],"2004-11-12","2000-06",[1206,1138,1112,1113,1114],"Myelodysplastic Disorders",[1186,1198,1208],"FK50",{"nctId":1210,"briefTitle":1211,"status":108,"phases":1212,"primaryCompletion":1213,"completion":1214,"start":1215,"enrollment":1216,"conditions":1217,"interventions":1219},"NCT00056966","Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases",[88,89],"2005-05","2006-12","2002-11",24,[1218],"Hematologic Malignancy",[1220,1097,1150,518],"ANTI-CD45",{"trials":1222,"activeCount":100},[],{"trials":1224,"activeCount":100},[],{"trials":1226,"activeCount":100},[1227,1236,1244,1248],{"nctId":1228,"briefTitle":1229,"status":578,"phases":1230,"primaryCompletion":1231,"completion":1231,"start":1232,"enrollment":32,"conditions":1233,"interventions":1234},"NCT00578292","Allogeneic Stem Cell Transplantation, Severe Homzygous 0\u002F+Thalassemia or Sever Variants of Beta 0\u002F+ Thalassemia, THALLO",[92],"2016-05","2004-02",[1184],[604,518,1127,1038,1235],"MESNA",{"nctId":1237,"briefTitle":1238,"status":108,"phases":1239,"primaryCompletion":84,"completion":84,"start":610,"enrollment":1240,"conditions":1241,"interventions":1243},"NCT01247701","Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies",[92],16,[1242],"Myeloid Hematological Malignancies",[604,1038,518],{"nctId":595,"briefTitle":596,"status":108,"phases":1245,"primaryCompletion":598,"completion":599,"start":600,"enrollment":282,"conditions":1246,"interventions":1247},[92],[602],[604,499,518],{"nctId":606,"briefTitle":607,"status":180,"phases":1249,"primaryCompletion":609,"completion":609,"start":610,"enrollment":100,"conditions":1250,"interventions":1251},[92],[612,613],[499,518],{"intervention":1038,"totalTrials":1253,"cells":1254},19,{"EARLY_PHASE1":1255,"PHASE1":1275,"PHASE2":1325,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1256,"activeCount":100},[1257],{"nctId":1258,"briefTitle":1259,"status":108,"phases":1260,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1106,"conditions":1264,"interventions":1268},"NCT01760226","Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies",[87],"2016-08-26","2016-12","2013-01",[1265,1266,1267],"Diffuse Large B Cell Lymphoma","Post Transplant Lymphoproliferative Disorder","Primary Mediastinal (Thymic) Large B-cell Lymphoma",[1269,587,411,1270,1271,1272,1038,1273,1274],"DA-EPOCH-R for DLBCL, PTLD, AND PMBCL","Doxorubicin","Vincristine","Rituximab","Prednisone","G-CSF",{"trials":1276,"activeCount":96,"soonestReadout":1077},[1277,1289,1293,1304,1308,1317,1321],{"nctId":1278,"briefTitle":1279,"status":108,"phases":1280,"primaryCompletion":1281,"completion":1282,"start":1283,"enrollment":1284,"conditions":1285,"interventions":1287},"NCT00206388","Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement",[88],"2008-04","2013-05","2005-04",21,[1286],"NEUROBLASTOMA",[1288,1038],"Zolendric acid",{"nctId":1009,"briefTitle":1010,"status":180,"phases":1290,"primaryCompletion":1012,"completion":560,"start":1013,"enrollment":100,"conditions":1291,"interventions":1292},[88],[29],[1016,518,1017],{"nctId":1294,"briefTitle":1295,"status":108,"phases":1296,"primaryCompletion":1167,"completion":1167,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1301},"NCT00057005","Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation",[88],"2003-02",6,[1300],"LEUKEMIA",[1097,1098,1302,1038,1303],"Ara-C","Mesna",{"nctId":1027,"briefTitle":1028,"status":548,"phases":1305,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":1306,"interventions":1307},[88],[1035],[1037,518,1038,1039],{"nctId":1309,"briefTitle":1310,"status":108,"phases":1311,"completion":1312,"start":1313,"enrollment":1216,"conditions":1314,"interventions":1316},"NCT00058578","Stem Cell Transplant to Treat Patients With Systemic Sclerosis",[88],"2004-06","1999-06",[1315],"Systemic Sclerosis",[1038,1303,1274],{"nctId":1057,"briefTitle":1058,"status":548,"phases":1318,"primaryCompletion":1060,"completion":1061,"start":1062,"enrollment":1063,"conditions":1319,"interventions":1320},[88],[1065,1066,1067,1068,1069,1070],[1072,1038,518],{"nctId":1074,"briefTitle":1075,"status":548,"phases":1322,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":405,"conditions":1323,"interventions":1324},[88],[1081,29],[1083,1084,518,1038],{"trials":1326,"activeCount":100},[1327,1344,1357,1364,1374],{"nctId":1328,"briefTitle":1329,"status":108,"phases":1330,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":1335,"interventions":1342},"NCT00368355","T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts",[89],"2015-11","2016-11","2000-04",46,[1110,1336,1337,407,1111,1338,1339,1340,1341],"Non Hodgkins Lymphoma","Myelodysplastic Syndrome","Hemophagocytic Lymphohistiocytosis (HLH)","Familial Hemophagocytic Lymphohistiocytosis (FLH)","Viral-associated Hemophagocytic Syndrome (VAHS)","X-linked Lymphoproliferative Disease (XLP)",[1302,1038,1343],"Campath-1H",{"nctId":1345,"briefTitle":1346,"status":108,"phases":1347,"primaryCompletion":1048,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1352},"NCT00578864","Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma",[89],"2015-03","2007-03",13,[29],[1353,1270,1354,1355,1038,1303,1356],"Protracted Oral Etoposide","IV Bolus Etoposide","Cisplatin","Hematopoietic Factor",{"nctId":1358,"briefTitle":1359,"status":578,"phases":1360,"primaryCompletion":1180,"completion":1180,"start":1122,"enrollment":972,"conditions":1361,"interventions":1362},"NCT00040469","Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies",[89],[1182,1183,1184],[1175,1363,604,1038],"Dilantin",{"nctId":1365,"briefTitle":1366,"status":108,"phases":1367,"completion":1368,"start":1369,"enrollment":32,"conditions":1370,"interventions":1372},"NCT00040482","High Dose Chemo\u002FRadiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis",[89],"2005-08","1999-04",[1371],"Multiple Sclerosis",[1038,1373,1235],"ATG",{"nctId":1152,"briefTitle":1153,"status":108,"phases":1375,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":972,"conditions":1376,"interventions":1377},[89],[1159],[604,1161,1038,518,1162],{"trials":1379,"activeCount":100},[],{"trials":1381,"activeCount":100},[],{"trials":1383,"activeCount":100},[1384,1395,1399,1411,1415,1426],{"nctId":1385,"briefTitle":1386,"status":578,"phases":1387,"primaryCompletion":1282,"completion":1282,"start":1168,"enrollment":405,"conditions":1388,"interventions":1393},"NCT00578461","T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE",[92],[1138,1389,1390,1391,1392],"Cancer","Lymphoma","Lymphoma, Hodgkin","Lymphoma, Non-Hodgkin",[1394,1303,1038],"Ara C",{"nctId":1228,"briefTitle":1229,"status":578,"phases":1396,"primaryCompletion":1231,"completion":1231,"start":1232,"enrollment":32,"conditions":1397,"interventions":1398},[92],[1184],[604,518,1127,1038,1235],{"nctId":1400,"briefTitle":1401,"status":108,"phases":1402,"primaryCompletion":1403,"completion":1403,"start":1404,"conditions":1405,"interventions":1407},"NCT00073879","Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation",[92],"2004-04","2003-04",[1406],"Kidney Cancer",[1408,1409,1016,1410],"alemtuzumab","graft-versus-tumor induction therapy","fludarabine phosphate",{"nctId":1237,"briefTitle":1238,"status":108,"phases":1412,"primaryCompletion":84,"completion":84,"start":610,"enrollment":1240,"conditions":1413,"interventions":1414},[92],[1242],[604,1038,518],{"nctId":1416,"briefTitle":1417,"status":578,"phases":1418,"primaryCompletion":1282,"completion":1282,"start":1168,"enrollment":1216,"conditions":1419,"interventions":1423},"NCT00578539","T-Reg Cell Kinetics, Stem Cell Transplant, REGALE",[92],[1138,1420,1421,1422],"Hodgkin Lymphoma","Non Hodgkin Lymphoma","Myeloproliferative Disorders",[1424,1038,1235,1425],"ARA C","Campath-1h",{"nctId":1427,"briefTitle":1428,"status":108,"phases":1429,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1350,"conditions":1432,"interventions":1433},"NCT02786719","High-Risk Neuroblastoma Chemotherapy Without G-CSF",[92],"2019-02-05","2016-06",[29],[1434,1038,1355,411,1271,1038,1270,1435],"Topotecan","Sargramostim",{"intervention":1437,"totalTrials":394,"cells":1438},"C7R-GD2.CART cells",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1473,"PHASE3":1475,"PHASE4":1477,"NA":1479},{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":394,"soonestReadout":1460},[1443,1456],{"nctId":1444,"briefTitle":1445,"status":128,"phases":1446,"primaryCompletion":1447,"completion":1448,"start":1449,"enrollment":237,"conditions":1450,"interventions":1455},"NCT04099797","C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)",[88],"2027-02","2041-02","2020-02-03",[1451,1452,1453,1454],"Diffuse Intrinsic Pontine Glioma","High Grade Glioma","Embryonal Tumor","Ependymal Tumor",[1437,1437],{"nctId":1457,"briefTitle":1458,"status":548,"phases":1459,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1472},"NCT03635632","C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",[88],"2023-05-16","2038-05-16","2019-04-23",94,[1465,1466,1467,1468,1469,1470,1471],"Relapsed Neuroblastoma","Refractory Neuroblastoma","Relapsed Osteosarcoma","Relapsed Ewing Sarcoma","Relapsed Rhabdomyosarcoma","Uveal Melanoma","Phyllodes Breast Tumor",[1437],{"trials":1474,"activeCount":100},[],{"trials":1476,"activeCount":100},[],{"trials":1478,"activeCount":100},[],{"trials":1480,"activeCount":100},[],{"intervention":1482,"totalTrials":394,"cells":1483},"21.15.GPC3-CAR T cells",{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1514,"PHASE3":1516,"PHASE4":1518,"NA":1520},{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":394,"soonestReadout":1492},[1488,1503],{"nctId":1489,"briefTitle":1490,"status":128,"phases":1491,"primaryCompletion":1492,"completion":1493,"start":1494,"enrollment":1284,"conditions":1495,"interventions":1502},"NCT06198296","Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells",[88],"2028-02-01","2043-02-01","2025-06-10",[515,514,1496,1497,1498,1499,1500,1501],"Wilms Tumor","Malignant Rhabdoid Tumor","Yolk Sac Tumor","Rhabdomyosarcoma","Liposarcoma","Embryonal Sarcoma of Liver",[1482],{"nctId":1504,"briefTitle":1505,"status":233,"phases":1506,"primaryCompletion":1507,"completion":1508,"start":764,"enrollment":1284,"conditions":1509,"interventions":1512},"NCT07513194","GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)",[88],"2029-10-31","2044-10-31",[1510,1511],"Atypical Teratoid Rhabdoid Tumor","Central Nervous System Rhabdoid Tumor",[1513],"21.15.GPC3-CAR T Cells",{"trials":1515,"activeCount":100},[],{"trials":1517,"activeCount":100},[],{"trials":1519,"activeCount":100},[],{"trials":1521,"activeCount":100},[],{"intervention":557,"totalTrials":394,"cells":1523},{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1536,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1525,"activeCount":100},[],{"trials":1527,"activeCount":394,"soonestReadout":64},[1528,1532],{"nctId":546,"briefTitle":547,"status":548,"phases":1529,"primaryCompletion":550,"completion":551,"start":552,"enrollment":32,"conditions":1530,"interventions":1531},[88],[554],[556,499,557],{"nctId":62,"briefTitle":63,"status":548,"phases":1533,"primaryCompletion":64,"completion":560,"start":561,"enrollment":27,"conditions":1534,"interventions":1535},[88],[29],[65,564,499,557,565,566],{"trials":1537,"activeCount":100},[],{"trials":1539,"activeCount":100},[],{"trials":1541,"activeCount":100},[],{"trials":1543,"activeCount":100},[],{"intervention":1545,"totalTrials":1106,"cells":1546},"TAA-specific CTLs",{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1579,"PHASE3":1590,"PHASE4":1592,"NA":1594},{"trials":1548,"activeCount":100},[],{"trials":1550,"activeCount":150,"soonestReadout":694},[1551,1560,1570],{"nctId":1552,"briefTitle":1553,"status":128,"phases":1554,"primaryCompletion":694,"completion":1555,"start":1556,"enrollment":1033,"conditions":1557,"interventions":1558},"NCT02291848","Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma",[88],"2027-12-22","2015-04",[1112],[1545,1559],"TAA-specific CTLs- fixed dose",{"nctId":1561,"briefTitle":1562,"status":180,"phases":1563,"primaryCompletion":1564,"completion":1565,"start":1566,"enrollment":100,"conditions":1567,"interventions":1569},"NCT05134740","(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).",[88],"2025-02-24","2030-02-01","2024-04",[1568,1336],"Hodgkins Lymphoma",[1545],{"nctId":1571,"briefTitle":1572,"status":108,"phases":1573,"primaryCompletion":1574,"completion":1575,"start":1556,"enrollment":1240,"conditions":1576,"interventions":1577},"NCT02239861","TAA-Specific CTLS for Solid Tumors (TACTASOM)",[88],"2018-10","2022-04-07",[1499],[1578],"TAA-Specific CTLs",{"trials":1580,"activeCount":100},[1581],{"nctId":1582,"briefTitle":1583,"status":108,"phases":1584,"primaryCompletion":1585,"completion":667,"start":1586,"enrollment":24,"conditions":1587,"interventions":1589},"NCT03093350","TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer",[89],"2019-05-30","2017-10-10",[1588],"Breast Cancer",[1545],{"trials":1591,"activeCount":100},[],{"trials":1593,"activeCount":100},[],{"trials":1595,"activeCount":100},[],{"intervention":1597,"totalTrials":96,"cells":1598},"Dose Level 1",{"EARLY_PHASE1":1599,"PHASE1":1601,"PHASE2":1635,"PHASE3":1637,"PHASE4":1639,"NA":1641},{"trials":1600,"activeCount":100},[],{"trials":1602,"activeCount":150,"soonestReadout":1607},[1603,1618,1625],{"nctId":1604,"briefTitle":1605,"status":233,"phases":1606,"primaryCompletion":1607,"completion":1608,"start":1609,"enrollment":1610,"conditions":1611,"interventions":1614},"NCT07297160","CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors",[88],"2029-12","2044-12","2026-06",88,[1390,1612,1613,1035,1406],"Myeloma","Solid Tumors",[1615,1597,1616,1617],"Dose Level -1","Dose Level 2","Dose Level 3",{"nctId":1619,"briefTitle":1620,"status":108,"phases":1621,"primaryCompletion":1622,"completion":1622,"start":1313,"enrollment":27,"conditions":1623,"interventions":1624},"NCT00058799","Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine",[88],"2010-06",[1138],[1597,1616,1617],{"nctId":1626,"briefTitle":1627,"status":108,"phases":1628,"primaryCompletion":1629,"completion":1629,"start":1630,"enrollment":500,"conditions":1631,"interventions":1633},"NCT00078520","Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells",[88],"2010-03","2003-01",[1138,1632],"Leukemia, B-Cell, Chronic",[1597,1616,1634],"Dose Level 2- Fixed Dose",{"trials":1636,"activeCount":100},[],{"trials":1638,"activeCount":100},[],{"trials":1640,"activeCount":100},[],{"trials":1642,"activeCount":100},[],{"intervention":1616,"totalTrials":96,"cells":1644},{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1646,"activeCount":100},[],{"trials":1648,"activeCount":150,"soonestReadout":1607},[1649,1653,1657],{"nctId":1604,"briefTitle":1605,"status":233,"phases":1650,"primaryCompletion":1607,"completion":1608,"start":1609,"enrollment":1610,"conditions":1651,"interventions":1652},[88],[1390,1612,1613,1035,1406],[1615,1597,1616,1617],{"nctId":1619,"briefTitle":1620,"status":108,"phases":1654,"primaryCompletion":1622,"completion":1622,"start":1313,"enrollment":27,"conditions":1655,"interventions":1656},[88],[1138],[1597,1616,1617],{"nctId":1626,"briefTitle":1627,"status":108,"phases":1658,"primaryCompletion":1629,"completion":1629,"start":1630,"enrollment":500,"conditions":1659,"interventions":1660},[88],[1138,1632],[1597,1616,1634],{"trials":1662,"activeCount":100},[],{"trials":1664,"activeCount":100},[],{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":100},[],{"intervention":1617,"totalTrials":394,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1683,"PHASE3":1685,"PHASE4":1687,"NA":1689},{"trials":1672,"activeCount":100},[],{"trials":1674,"activeCount":150,"soonestReadout":1607},[1675,1679],{"nctId":1604,"briefTitle":1605,"status":233,"phases":1676,"primaryCompletion":1607,"completion":1608,"start":1609,"enrollment":1610,"conditions":1677,"interventions":1678},[88],[1390,1612,1613,1035,1406],[1615,1597,1616,1617],{"nctId":1619,"briefTitle":1620,"status":108,"phases":1680,"primaryCompletion":1622,"completion":1622,"start":1313,"enrollment":27,"conditions":1681,"interventions":1682},[88],[1138],[1597,1616,1617],{"trials":1684,"activeCount":100},[],{"trials":1686,"activeCount":100},[],{"trials":1688,"activeCount":100},[],{"trials":1690,"activeCount":100},[],{"intervention":1017,"totalTrials":394,"cells":1692},{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1711,"PHASE3":1713,"PHASE4":1715,"NA":1717},{"trials":1694,"activeCount":100},[],{"trials":1696,"activeCount":150,"soonestReadout":385},[1697,1707],{"nctId":1698,"briefTitle":1699,"status":128,"phases":1700,"primaryCompletion":385,"completion":1701,"start":1702,"enrollment":1703,"conditions":1704,"interventions":1705},"NCT03294954","GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma",[88],"2040-08-10","2018-01-18",70,[29],[1017,1706],"GINAKIT cells + Etanercept",{"nctId":1009,"briefTitle":1010,"status":180,"phases":1708,"primaryCompletion":1012,"completion":560,"start":1013,"enrollment":100,"conditions":1709,"interventions":1710},[88],[29],[1016,518,1017],{"trials":1712,"activeCount":100},[],{"trials":1714,"activeCount":100},[],{"trials":1716,"activeCount":100},[],{"trials":1718,"activeCount":100},[],{"intervention":1720,"totalTrials":394,"cells":1721},"MultiTAA-specific T cells",{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1743,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1723,"activeCount":100},[],{"trials":1725,"activeCount":150,"soonestReadout":469},[1726,1736],{"nctId":1727,"briefTitle":1728,"status":108,"phases":1729,"primaryCompletion":1730,"completion":1731,"start":1732,"enrollment":282,"conditions":1733,"interventions":1735},"NCT02475707","Administration of Donor MultiTAA-Specific T Cells for ALL",[88],"2019-10-29","2024-11-18","2016-02",[1734],"Leukemia, Lymphoblastic (Acute)",[1720],{"nctId":1737,"briefTitle":1738,"status":548,"phases":1739,"primaryCompletion":469,"completion":1447,"start":1732,"enrollment":1740,"conditions":1741,"interventions":1742},"NCT02494167","Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)",[88],44,[407,1337],[1720],{"trials":1744,"activeCount":100},[],{"trials":1746,"activeCount":100},[],{"trials":1748,"activeCount":100},[],{"trials":1750,"activeCount":100},[],{"intervention":1752,"totalTrials":394,"cells":1753},"CD30.CAR-EBVST cells",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1779,"PHASE3":1781,"PHASE4":1783,"NA":1785},{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":150,"soonestReadout":1762},[1758,1770],{"nctId":1759,"briefTitle":1760,"status":128,"phases":1761,"primaryCompletion":1762,"completion":1763,"start":1764,"enrollment":1765,"conditions":1766,"interventions":1769},"NCT04288726","Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas",[88],"2026-06-01","2037-06-01","2020-09-16",18,[1767,1768],"Extranodal Natural Killer\u002FT-Cell Lymphoma, Nasal Type","Classical Hodgkin Lymphoma",[1752],{"nctId":1771,"briefTitle":1772,"status":180,"phases":1773,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":100,"conditions":1777,"interventions":1778},"NCT04952584","Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas",[88],"2025-06","2040-06","2024-03",[1767,1768],[1752],{"trials":1780,"activeCount":100},[],{"trials":1782,"activeCount":100},[],{"trials":1784,"activeCount":100},[],{"trials":1786,"activeCount":100},[],{"intervention":1788,"totalTrials":150,"cells":1789},"Treatment Arm A",{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1806,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1791,"activeCount":100},[],{"trials":1793,"activeCount":150,"soonestReadout":1798},[1794],{"nctId":1795,"briefTitle":1796,"status":233,"phases":1797,"primaryCompletion":1798,"completion":1799,"start":1800,"enrollment":24,"conditions":1801,"interventions":1805},"NCT06345027","Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)",[88],"2027-05","2042-04-01","2026-02",[1802,1803,1804],"Leukemia, Myeloid, Acute","Leukemia, B-cell","Leukemia, T-Cell",[1788],{"trials":1807,"activeCount":100},[],{"trials":1809,"activeCount":100},[],{"trials":1811,"activeCount":100},[],{"trials":1813,"activeCount":100},[],{"intervention":1615,"totalTrials":150,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1824,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":100},[],{"trials":1819,"activeCount":150,"soonestReadout":1607},[1820],{"nctId":1604,"briefTitle":1605,"status":233,"phases":1821,"primaryCompletion":1607,"completion":1608,"start":1609,"enrollment":1610,"conditions":1822,"interventions":1823},[88],[1390,1612,1613,1035,1406],[1615,1597,1616,1617],{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":100},[],{"trials":1831,"activeCount":100},[],{"intervention":85,"totalTrials":150,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1847,"PHASE3":1849,"PHASE4":1851,"NA":1853},{"trials":1835,"activeCount":100},[],{"trials":1837,"activeCount":150,"soonestReadout":84},[1838],{"nctId":82,"briefTitle":83,"status":548,"phases":1839,"primaryCompletion":84,"completion":1840,"start":1079,"enrollment":1135,"conditions":1841,"interventions":1845},[88],"2030-12",[1842,1843,1844],"Non-Hodgkin's Lymphoma","B-Cell ALL","B-Cell CLL",[85,1846],"CD19.CAR-CD28Z T Cells - dose escalation 1",{"trials":1848,"activeCount":100},[],{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[],{"trials":1854,"activeCount":100},[],{"intervention":1846,"totalTrials":150,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1865,"PHASE3":1867,"PHASE4":1869,"NA":1871},{"trials":1858,"activeCount":100},[],{"trials":1860,"activeCount":150,"soonestReadout":84},[1861],{"nctId":82,"briefTitle":83,"status":548,"phases":1862,"primaryCompletion":84,"completion":1840,"start":1079,"enrollment":1135,"conditions":1863,"interventions":1864},[88],[1842,1843,1844],[85,1846],{"trials":1866,"activeCount":100},[],{"trials":1868,"activeCount":100},[],{"trials":1870,"activeCount":100},[],{"trials":1872,"activeCount":100},[],{"intervention":1874,"totalTrials":150,"cells":1875},"EBV-specific T cells: A",{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1897},{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":150,"soonestReadout":639},[1880],{"nctId":1881,"briefTitle":1882,"status":128,"phases":1883,"primaryCompletion":639,"completion":695,"start":1884,"enrollment":1885,"conditions":1886,"interventions":1889},"NCT01555892","Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE",[88],"2013-01-14",136,[1887,1842,1888,1390],"Hodgkin's Disease","Lymphoproliferative Disease",[1874,1890],"EBV-specific T cells: B",{"trials":1892,"activeCount":100},[],{"trials":1894,"activeCount":100},[],{"trials":1896,"activeCount":100},[],{"trials":1898,"activeCount":100},[],{"intervention":1890,"totalTrials":150,"cells":1900},{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1909,"PHASE3":1911,"PHASE4":1913,"NA":1915},{"trials":1902,"activeCount":100},[],{"trials":1904,"activeCount":150,"soonestReadout":639},[1905],{"nctId":1881,"briefTitle":1882,"status":128,"phases":1906,"primaryCompletion":639,"completion":695,"start":1884,"enrollment":1885,"conditions":1907,"interventions":1908},[88],[1887,1842,1888,1390],[1874,1890],{"trials":1910,"activeCount":100},[],{"trials":1912,"activeCount":100},[],{"trials":1914,"activeCount":100},[],{"trials":1916,"activeCount":100},[],{"intervention":1918,"totalTrials":150,"cells":1919},"CATCH T cells",{"EARLY_PHASE1":1920,"PHASE1":1922,"PHASE2":1936,"PHASE3":1938,"PHASE4":1940,"NA":1942},{"trials":1921,"activeCount":100},[],{"trials":1923,"activeCount":150,"soonestReadout":1928},[1924],{"nctId":1925,"briefTitle":1926,"status":548,"phases":1927,"primaryCompletion":1928,"completion":1929,"start":1930,"enrollment":24,"conditions":1931,"interventions":1935},"NCT05103631","Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors",[88],"2025-01-13","2040-12","2021-06-17",[1932,1933,1496,1497,1498,1499,1500,1934],"Liver Cell Carcinoma","Solid Tumor","Embryonal Sarcoma of the Liver",[1918],{"trials":1937,"activeCount":100},[],{"trials":1939,"activeCount":100},[],{"trials":1941,"activeCount":100},[],{"trials":1943,"activeCount":100},[],{"intervention":75,"totalTrials":150,"cells":1945},{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1957,"PHASE3":1959,"PHASE4":1961,"NA":1963},{"trials":1947,"activeCount":100},[],{"trials":1949,"activeCount":150,"soonestReadout":74},[1950],{"nctId":72,"briefTitle":73,"status":548,"phases":1951,"primaryCompletion":74,"completion":1952,"start":1062,"enrollment":19,"conditions":1953,"interventions":1955},[88],"2033-02",[1954],"EBV-positive Nasopharyngeal Carcinoma",[75,1956],"DNR.NPC-specific T cells + cyclophosphamide + fludarabine",{"trials":1958,"activeCount":100},[],{"trials":1960,"activeCount":100},[],{"trials":1962,"activeCount":100},[],{"trials":1964,"activeCount":100},[],{"intervention":1956,"totalTrials":150,"cells":1966},{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1975,"PHASE3":1977,"PHASE4":1979,"NA":1981},{"trials":1968,"activeCount":100},[],{"trials":1970,"activeCount":150,"soonestReadout":74},[1971],{"nctId":72,"briefTitle":73,"status":548,"phases":1972,"primaryCompletion":74,"completion":1952,"start":1062,"enrollment":19,"conditions":1973,"interventions":1974},[88],[1954],[75,1956],{"trials":1976,"activeCount":100},[],{"trials":1978,"activeCount":100},[],{"trials":1980,"activeCount":100},[],{"trials":1982,"activeCount":100},[],{"intervention":1984,"totalTrials":150,"cells":1985},"15.GPC3-CAR T cells",{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":2000,"PHASE3":2002,"PHASE4":2004,"NA":2006},{"trials":1987,"activeCount":100},[],{"trials":1989,"activeCount":150,"soonestReadout":1994},[1990],{"nctId":1991,"briefTitle":1992,"status":128,"phases":1993,"primaryCompletion":1994,"completion":1995,"start":1996,"enrollment":1123,"conditions":1997,"interventions":1999},"NCT06815432","GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma",[88],"2029-12-05","2044-12-03","2025-10-10",[1998],"Glioblastoma Multiforme of Brain",[1984],{"trials":2001,"activeCount":100},[],{"trials":2003,"activeCount":100},[],{"trials":2005,"activeCount":100},[],{"trials":2007,"activeCount":100},[],{"intervention":1706,"totalTrials":150,"cells":2009},{"EARLY_PHASE1":2010,"PHASE1":2012,"PHASE2":2018,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2011,"activeCount":100},[],{"trials":2013,"activeCount":150,"soonestReadout":385},[2014],{"nctId":1698,"briefTitle":1699,"status":128,"phases":2015,"primaryCompletion":385,"completion":1701,"start":1702,"enrollment":1703,"conditions":2016,"interventions":2017},[88],[29],[1017,1706],{"trials":2019,"activeCount":100},[],{"trials":2021,"activeCount":100},[],{"trials":2023,"activeCount":100},[],{"trials":2025,"activeCount":100},[],{"intervention":2027,"totalTrials":150,"cells":2028},"Montelukast",{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2043,"PHASE3":2045,"PHASE4":2047,"NA":2049},{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":150,"soonestReadout":2037},[2033],{"nctId":2034,"briefTitle":2035,"status":128,"phases":2036,"primaryCompletion":2037,"completion":2038,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2042},"NCT05992311","Clinical Evaluation of Montelukast in Veterans With Gulf War Illness",[88],"2028-04","2028-08","2025-08-15",80,[698],[2027],{"trials":2044,"activeCount":100},[],{"trials":2046,"activeCount":100},[],{"trials":2048,"activeCount":100},[],{"trials":2050,"activeCount":100},[],{"intervention":2052,"totalTrials":150,"cells":2053},"CARE T cells",{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2055,"activeCount":100},[],{"trials":2057,"activeCount":150,"soonestReadout":2062},[2058],{"nctId":2059,"briefTitle":2060,"status":128,"phases":2061,"primaryCompletion":2062,"completion":2063,"start":2064,"enrollment":1216,"conditions":2065,"interventions":2066},"NCT04715191","Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors",[88],"2026-08-01","2041-07-03","2024-05-24",[554,1499,1497,1500,1496,1498],[2052],{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[],{"intervention":2076,"totalTrials":150,"cells":2077},"Autologous CD5.CAR\u002F28zeta CAR T cells",{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2096,"PHASE3":2098,"PHASE4":2100,"NA":2102},{"trials":2079,"activeCount":100},[],{"trials":2081,"activeCount":150,"soonestReadout":2086},[2082],{"nctId":2083,"briefTitle":2084,"status":128,"phases":2085,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2094},"NCT03081910","Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen",[88],"2028-06-01","2040-09-01","2017-11-01",54,[2091,2092,2093],"T-cell Acute Lymphoblastic Lymphoma","T-non-Hodgkin Lymphoma","T-cell Acute Lymphoblastic Leukemia",[2076,2095],"Allogeneic CD5.CAR\u002F28zeta CAR T cells",{"trials":2097,"activeCount":100},[],{"trials":2099,"activeCount":100},[],{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"intervention":2095,"totalTrials":150,"cells":2105},{"EARLY_PHASE1":2106,"PHASE1":2108,"PHASE2":2114,"PHASE3":2116,"PHASE4":2118,"NA":2120},{"trials":2107,"activeCount":100},[],{"trials":2109,"activeCount":150,"soonestReadout":2086},[2110],{"nctId":2083,"briefTitle":2084,"status":128,"phases":2111,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":2089,"conditions":2112,"interventions":2113},[88],[2091,2092,2093],[2076,2095],{"trials":2115,"activeCount":100},[],{"trials":2117,"activeCount":100},[],{"trials":2119,"activeCount":100},[],{"trials":2121,"activeCount":100},[],{"intervention":2123,"totalTrials":150,"cells":2124},"i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells",{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2126,"activeCount":100},[],{"trials":2128,"activeCount":150,"soonestReadout":2133},[2129],{"nctId":2130,"briefTitle":2131,"status":233,"phases":2132,"primaryCompletion":2133,"completion":2134,"start":2135,"enrollment":1123,"conditions":2136,"interventions":2138},"NCT07211737","NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma",[88],"2029-04","2044-04","2026-05",[1465,1466,1467,2137],"Refractory Osteosarcoma",[2123,2123,2123],{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[],{"trials":2144,"activeCount":100},[],{"trials":2146,"activeCount":100},[],{"intervention":2148,"totalTrials":150,"cells":2149},"HER2-specific T cells",{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2165,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2151,"activeCount":100},[],{"trials":2153,"activeCount":150,"soonestReadout":2158},[2154],{"nctId":2155,"briefTitle":2156,"status":548,"phases":2157,"primaryCompletion":2158,"completion":2159,"start":2160,"enrollment":32,"conditions":2161,"interventions":2164},"NCT02442297","T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors",[88],"2022-04-27","2037-04","2016-04-01",[2162,2163],"Brain Tumor, Recurrent","Brain Tumor, Refractory",[2148],{"trials":2166,"activeCount":100},[],{"trials":2168,"activeCount":100},[],{"trials":2170,"activeCount":100},[],{"trials":2172,"activeCount":100},[],{"intervention":2174,"totalTrials":150,"cells":2175},"AGAR T cells",{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2189,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2177,"activeCount":100},[],{"trials":2179,"activeCount":150,"soonestReadout":2184},[2180],{"nctId":2181,"briefTitle":2182,"status":548,"phases":2183,"primaryCompletion":2184,"completion":2185,"start":2186,"enrollment":19,"conditions":2187,"interventions":2188},"NCT04377932","Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors",[88],"2024-08-17","2040-08-26","2021-08-08",[554,1499,1497,1500,1496,1498],[2174],{"trials":2190,"activeCount":100},[],{"trials":2192,"activeCount":100},[],{"trials":2194,"activeCount":100},[],{"trials":2196,"activeCount":100},[],{"intervention":40,"totalTrials":150,"cells":2198},{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2208,"PHASE3":2210,"PHASE4":2212,"NA":2214},{"trials":2200,"activeCount":100},[],{"trials":2202,"activeCount":150,"soonestReadout":39},[2203],{"nctId":37,"briefTitle":38,"status":548,"phases":2204,"primaryCompletion":39,"completion":314,"start":2205,"enrollment":32,"conditions":2206,"interventions":2207},[88],"2008-12",[1110,1842,1337,878],[40],{"trials":2209,"activeCount":100},[],{"trials":2211,"activeCount":100},[],{"trials":2213,"activeCount":100},[],{"trials":2215,"activeCount":100},[],{"intervention":2217,"totalTrials":150,"cells":2218},"CAR T Cells",{"EARLY_PHASE1":2219,"PHASE1":2221,"PHASE2":2232,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2220,"activeCount":100},[],{"trials":2222,"activeCount":150,"soonestReadout":386},[2223],{"nctId":2224,"briefTitle":2225,"status":128,"phases":2226,"primaryCompletion":386,"completion":2227,"start":2228,"enrollment":133,"conditions":2229,"interventions":2231},"NCT02917083","CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)",[88],"2040-02","2017-05-08",[2230,1066],"Hodgkin's Lymphoma",[2217],{"trials":2233,"activeCount":100},[],{"trials":2235,"activeCount":100},[],{"trials":2237,"activeCount":100},[],{"trials":2239,"activeCount":100},[],{"intervention":2241,"totalTrials":150,"cells":2242},"Dose Escalation Phase:CD19.CAR\u002F28 and CD19.CAR\u002F28137 T cells",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2259,"PHASE3":2261,"PHASE4":2263,"NA":2265},{"trials":2244,"activeCount":100},[],{"trials":2246,"activeCount":150,"soonestReadout":694},[2247],{"nctId":2248,"briefTitle":2249,"status":128,"phases":2250,"primaryCompletion":694,"completion":2251,"start":2252,"enrollment":2253,"conditions":2254,"interventions":2257},"NCT01853631","Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)",[88],"2036-02","2014-02",64,[1066,2255,2256],"Chronic Lymphocytic Leukemia","Acute Lymphocytic Leukemia",[2241,2258],"Expansion Phase: CD19.CAR\u002F28 and CD19.CAR\u002F28137 T cells",{"trials":2260,"activeCount":100},[],{"trials":2262,"activeCount":100},[],{"trials":2264,"activeCount":100},[],{"trials":2266,"activeCount":100},[],{"intervention":2258,"totalTrials":150,"cells":2268},{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2277,"PHASE3":2279,"PHASE4":2281,"NA":2283},{"trials":2270,"activeCount":100},[],{"trials":2272,"activeCount":150,"soonestReadout":694},[2273],{"nctId":2248,"briefTitle":2249,"status":128,"phases":2274,"primaryCompletion":694,"completion":2251,"start":2252,"enrollment":2253,"conditions":2275,"interventions":2276},[88],[1066,2255,2256],[2241,2258],{"trials":2278,"activeCount":100},[],{"trials":2280,"activeCount":100},[],{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[],{"intervention":2286,"totalTrials":150,"cells":2287},"Necator americanus Hookworm Larvae",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2301,"PHASE3":2303,"PHASE4":2305,"NA":2307},{"trials":2289,"activeCount":100},[],{"trials":2291,"activeCount":150,"soonestReadout":385},[2292],{"nctId":2293,"briefTitle":2294,"status":128,"phases":2295,"primaryCompletion":385,"completion":385,"start":2296,"enrollment":2297,"conditions":2298,"interventions":2300},"NCT01940757","Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae",[88],"2015-01",35,[2299],"Hookworm Infection",[2286],{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[],{"trials":2306,"activeCount":100},[],{"trials":2308,"activeCount":100},[],{"intervention":1559,"totalTrials":150,"cells":2310},{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2319,"PHASE3":2321,"PHASE4":2323,"NA":2325},{"trials":2312,"activeCount":100},[],{"trials":2314,"activeCount":150,"soonestReadout":694},[2315],{"nctId":1552,"briefTitle":1553,"status":128,"phases":2316,"primaryCompletion":694,"completion":1555,"start":1556,"enrollment":1033,"conditions":2317,"interventions":2318},[88],[1112],[1545,1559],{"trials":2320,"activeCount":100},[],{"trials":2322,"activeCount":100},[],{"trials":2324,"activeCount":100},[],{"trials":2326,"activeCount":100},[],{"intervention":2328,"totalTrials":150,"cells":2329},"iCaspase9-transduced T cells",{"EARLY_PHASE1":2330,"PHASE1":2332,"PHASE2":2347,"PHASE3":2349,"PHASE4":2351,"NA":2353},{"trials":2331,"activeCount":100},[],{"trials":2333,"activeCount":150,"soonestReadout":2338},[2334],{"nctId":2335,"briefTitle":2336,"status":548,"phases":2337,"primaryCompletion":2338,"completion":2338,"start":39,"enrollment":972,"conditions":2339,"interventions":2345},"NCT01494103","Administration of Donor T Cells With the Caspase-9 Suicide Gene",[88],"2029-05",[1110,1337,407,1111,1421,2340,2341,2342,2343,2344],"Hemophagocytic Lymphohistiocytosis","Familial Hemophagocytic Lymphohistiocytosis","Hemophagocytic Syndrome","Epstein Barr Virus Infection","X-linked Lymphoproliferative Disease",[2328,2346],"AP1903",{"trials":2348,"activeCount":100},[],{"trials":2350,"activeCount":100},[],{"trials":2352,"activeCount":100},[],{"trials":2354,"activeCount":100},[],{"intervention":2346,"totalTrials":150,"cells":2356},{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2365,"PHASE3":2367,"PHASE4":2369,"NA":2371},{"trials":2358,"activeCount":100},[],{"trials":2360,"activeCount":150,"soonestReadout":2338},[2361],{"nctId":2335,"briefTitle":2336,"status":548,"phases":2362,"primaryCompletion":2338,"completion":2338,"start":39,"enrollment":972,"conditions":2363,"interventions":2364},[88],[1110,1337,407,1111,1421,2340,2341,2342,2343,2344],[2328,2346],{"trials":2366,"activeCount":100},[],{"trials":2368,"activeCount":100},[],{"trials":2370,"activeCount":100},[],{"trials":2372,"activeCount":100},[],{"intervention":1037,"totalTrials":150,"cells":2374},{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2383,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":150,"soonestReadout":1030},[2379],{"nctId":1027,"briefTitle":1028,"status":548,"phases":2380,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":2381,"interventions":2382},[88],[1035],[1037,518,1038,1039],{"trials":2384,"activeCount":100},[],{"trials":2386,"activeCount":100},[],{"trials":2388,"activeCount":100},[],{"trials":2390,"activeCount":100},[],{"intervention":1039,"totalTrials":150,"cells":2392},{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2401,"PHASE3":2403,"PHASE4":2405,"NA":2407},{"trials":2394,"activeCount":100},[],{"trials":2396,"activeCount":150,"soonestReadout":1030},[2397],{"nctId":1027,"briefTitle":1028,"status":548,"phases":2398,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":2399,"interventions":2400},[88],[1035],[1037,518,1038,1039],{"trials":2402,"activeCount":100},[],{"trials":2404,"activeCount":100},[],{"trials":2406,"activeCount":100},[],{"trials":2408,"activeCount":100},[],{"intervention":2410,"totalTrials":150,"cells":2411},"Magnesium sulfate",{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2423,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":150,"soonestReadout":1609},[2416],{"nctId":2417,"briefTitle":2418,"status":233,"phases":2419,"primaryCompletion":1609,"completion":314,"start":1774,"enrollment":832,"conditions":2420,"interventions":2422},"NCT06956521","Intra-Arterial Magnesium Therapy After Mechanical Thrombectomy in Acute Ischemic Stroke",[88],[2421],"Acute Ischemic Stroke",[2410],{"trials":2424,"activeCount":100},[],{"trials":2426,"activeCount":100},[],{"trials":2428,"activeCount":100},[],{"trials":2430,"activeCount":100},[],{"intervention":2432,"totalTrials":150,"cells":2433},"T cells or CAR T cells",{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2454,"PHASE3":2456,"PHASE4":2458,"NA":2460},{"trials":2435,"activeCount":100},[],{"trials":2437,"activeCount":150,"soonestReadout":2442},[2438],{"nctId":2439,"briefTitle":2440,"status":128,"phases":2441,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":9,"conditions":2445,"interventions":2451},"NCT04995003","HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma",[88],"2028-06-30","2043-06-30","2021-12-07",[1035,2446,1081,1499,2447,2448,2449,2450],"HER-2 Protein Overexpression","Ewing Sarcoma","Synovial Sarcoma","Soft Tissue Sarcoma","Undifferentiated Sarcoma",[2432,2452,2453],"Pembrolizumab Injectable Product","Nivolumab Injectable Product",{"trials":2455,"activeCount":100},[],{"trials":2457,"activeCount":100},[],{"trials":2459,"activeCount":100},[],{"trials":2461,"activeCount":100},[],{"intervention":2452,"totalTrials":150,"cells":2463},{"EARLY_PHASE1":2464,"PHASE1":2466,"PHASE2":2472,"PHASE3":2474,"PHASE4":2476,"NA":2478},{"trials":2465,"activeCount":100},[],{"trials":2467,"activeCount":150,"soonestReadout":2442},[2468],{"nctId":2439,"briefTitle":2440,"status":128,"phases":2469,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":9,"conditions":2470,"interventions":2471},[88],[1035,2446,1081,1499,2447,2448,2449,2450],[2432,2452,2453],{"trials":2473,"activeCount":100},[],{"trials":2475,"activeCount":100},[],{"trials":2477,"activeCount":100},[],{"trials":2479,"activeCount":100},[],{"intervention":2453,"totalTrials":150,"cells":2481},{"EARLY_PHASE1":2482,"PHASE1":2484,"PHASE2":2490,"PHASE3":2492,"PHASE4":2494,"NA":2496},{"trials":2483,"activeCount":100},[],{"trials":2485,"activeCount":150,"soonestReadout":2442},[2486],{"nctId":2439,"briefTitle":2440,"status":128,"phases":2487,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":9,"conditions":2488,"interventions":2489},[88],[1035,2446,1081,1499,2447,2448,2449,2450],[2432,2452,2453],{"trials":2491,"activeCount":100},[],{"trials":2493,"activeCount":100},[],{"trials":2495,"activeCount":100},[],{"trials":2497,"activeCount":100},[],{"intervention":60,"totalTrials":150,"cells":2499},{"EARLY_PHASE1":2500,"PHASE1":2502,"PHASE2":2511,"PHASE3":2513,"PHASE4":2515,"NA":2517},{"trials":2501,"activeCount":100},[],{"trials":2503,"activeCount":150,"soonestReadout":59},[2504],{"nctId":57,"briefTitle":58,"status":548,"phases":2505,"primaryCompletion":59,"completion":2506,"start":1103,"enrollment":19,"conditions":2507,"interventions":2509},[88],"2029-07",[2508,2255,2256],"B Cell Lymphoma",[60,2510],"Ipilimumab",{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[],{"intervention":2510,"totalTrials":150,"cells":2520},{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2529,"PHASE3":2531,"PHASE4":2533,"NA":2535},{"trials":2522,"activeCount":100},[],{"trials":2524,"activeCount":150,"soonestReadout":59},[2525],{"nctId":57,"briefTitle":58,"status":548,"phases":2526,"primaryCompletion":59,"completion":2506,"start":1103,"enrollment":19,"conditions":2527,"interventions":2528},[88],[2508,2255,2256],[60,2510],{"trials":2530,"activeCount":100},[],{"trials":2532,"activeCount":100},[],{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"intervention":2538,"totalTrials":150,"cells":2539},"CD19.CAR-aNKT cells",{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2558,"PHASE3":2560,"PHASE4":2562,"NA":2564},{"trials":2541,"activeCount":100},[],{"trials":2543,"activeCount":150,"soonestReadout":2548},[2544],{"nctId":2545,"briefTitle":2546,"status":548,"phases":2547,"primaryCompletion":2548,"completion":2549,"start":2550,"enrollment":1350,"conditions":2551,"interventions":2557},"NCT03774654","CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)",[88],"2025-06-05","2040-05-05","2020-04-14",[2552,2553,2554,2555,2556],"Refractory B-Cell Non-Hodgkin Lymphoma","Refractory B-Cell Small Lymphocytic Lymphoma","Relapsed Adult ALL","Relapsed CLL","Relapsed Non Hodgkin Lymphoma",[2538],{"trials":2559,"activeCount":100},[],{"trials":2561,"activeCount":100},[],{"trials":2563,"activeCount":100},[],{"trials":2565,"activeCount":100},[],{"intervention":70,"totalTrials":150,"cells":2567},{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2583,"PHASE3":2585,"PHASE4":2587,"NA":2589},{"trials":2569,"activeCount":100},[],{"trials":2571,"activeCount":150,"soonestReadout":69},[2572],{"nctId":67,"briefTitle":68,"status":548,"phases":2573,"primaryCompletion":69,"completion":2574,"start":2575,"enrollment":2576,"conditions":2577,"interventions":2581},[88],"2031-04","2009-04",68,[2578,2579,2580],"Acute Lymphoblastic Leukemia (ALL)","Chronic Lymphocytic Leukemia (CLL)","Non Hodgkin's Lymphoma",[70,2582],"Benadryl and Tylenol",{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[],{"trials":2588,"activeCount":100},[],{"trials":2590,"activeCount":100},[],{"intervention":2582,"totalTrials":150,"cells":2592},{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2601,"PHASE3":2603,"PHASE4":2605,"NA":2607},{"trials":2594,"activeCount":100},[],{"trials":2596,"activeCount":150,"soonestReadout":69},[2597],{"nctId":67,"briefTitle":68,"status":548,"phases":2598,"primaryCompletion":69,"completion":2574,"start":2575,"enrollment":2576,"conditions":2599,"interventions":2600},[88],[2578,2579,2580],[70,2582],{"trials":2602,"activeCount":100},[],{"trials":2604,"activeCount":100},[],{"trials":2606,"activeCount":100},[],{"trials":2608,"activeCount":100},[],{"intervention":80,"totalTrials":150,"cells":2610},{"EARLY_PHASE1":2611,"PHASE1":2613,"PHASE2":2620,"PHASE3":2622,"PHASE4":2624,"NA":2626},{"trials":2612,"activeCount":100},[],{"trials":2614,"activeCount":150,"soonestReadout":79},[2615],{"nctId":77,"briefTitle":78,"status":548,"phases":2616,"primaryCompletion":79,"completion":2617,"start":1048,"enrollment":2089,"conditions":2618,"interventions":2619},[88],"2035-07",[1390,1612,1138],[80],{"trials":2621,"activeCount":100},[],{"trials":2623,"activeCount":100},[],{"trials":2625,"activeCount":100},[],{"trials":2627,"activeCount":100},[],{"intervention":55,"totalTrials":150,"cells":2629},{"EARLY_PHASE1":2630,"PHASE1":2632,"PHASE2":2642,"PHASE3":2644,"PHASE4":2646,"NA":2648},{"trials":2631,"activeCount":100},[],{"trials":2633,"activeCount":150,"soonestReadout":54},[2634],{"nctId":52,"briefTitle":53,"status":548,"phases":2635,"primaryCompletion":54,"completion":2636,"start":2637,"enrollment":2638,"conditions":2639,"interventions":2641},[88],"2031-07","2006-04",8,[1390,1887,2640,1392],"Relapse",[55],{"trials":2643,"activeCount":100},[],{"trials":2645,"activeCount":100},[],{"trials":2647,"activeCount":100},[],{"trials":2649,"activeCount":100},[],{"intervention":45,"totalTrials":150,"cells":2651},{"EARLY_PHASE1":2652,"PHASE1":2654,"PHASE2":2662,"PHASE3":2664,"PHASE4":2666,"NA":2668},{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":150,"soonestReadout":44},[2656],{"nctId":42,"briefTitle":43,"status":548,"phases":2657,"primaryCompletion":44,"completion":2658,"start":2659,"enrollment":1765,"conditions":2660,"interventions":2661},[88],"2033-10","2011-05-10",[2230,1842],[45],{"trials":2663,"activeCount":100},[],{"trials":2665,"activeCount":100},[],{"trials":2667,"activeCount":100},[],{"trials":2669,"activeCount":100},[],{"intervention":2671,"totalTrials":150,"cells":2672},"CD7.CAR\u002F28zeta T Cells",{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2686,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2674,"activeCount":100},[],{"trials":2676,"activeCount":150,"soonestReadout":2681},[2677],{"nctId":2678,"briefTitle":2679,"status":128,"phases":2680,"primaryCompletion":2681,"completion":2682,"start":2683,"enrollment":1123,"conditions":2684,"interventions":2685},"NCT07220993","Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells",[88],"2028-12","2043-12","2026-05-12",[2091,2092,2093],[2671],{"trials":2687,"activeCount":100},[],{"trials":2689,"activeCount":100},[],{"trials":2691,"activeCount":100},[],{"trials":2693,"activeCount":100},[],{"intervention":2695,"totalTrials":150,"cells":2696},"C7R.CD30.CAR-EBVST cells",{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2715,"PHASE3":2717,"PHASE4":2719,"NA":2721},{"trials":2698,"activeCount":100},[],{"trials":2700,"activeCount":150,"soonestReadout":2705},[2701],{"nctId":2702,"briefTitle":2703,"status":128,"phases":2704,"primaryCompletion":2705,"completion":2706,"start":2707,"enrollment":172,"conditions":2708,"interventions":2714},"NCT06176690","Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas",[88],"2028-07-27","2043-06-27","2025-10-27",[2709,2710,2711,2712,2713,1066,1420],"CD30-Positive Diffuse Large B-Cell Lymphoma","Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type","Anaplastic Large Cell Lymphoma, ALK-Positive","Peripheral T-cell Lymphoma","Anaplastic Large Cell Lymphoma, ALK-negative",[2695],{"trials":2716,"activeCount":100},[],{"trials":2718,"activeCount":100},[],{"trials":2720,"activeCount":100},[],{"trials":2722,"activeCount":100},[],{"intervention":556,"totalTrials":150,"cells":2724},{"EARLY_PHASE1":2725,"PHASE1":2727,"PHASE2":2733,"PHASE3":2735,"PHASE4":2737,"NA":2739},{"trials":2726,"activeCount":100},[],{"trials":2728,"activeCount":150,"soonestReadout":550},[2729],{"nctId":546,"briefTitle":547,"status":548,"phases":2730,"primaryCompletion":550,"completion":551,"start":552,"enrollment":32,"conditions":2731,"interventions":2732},[88],[554],[556,499,557],{"trials":2734,"activeCount":100},[],{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":100},[],{"trials":2740,"activeCount":100},[],{"intervention":2742,"totalTrials":150,"cells":2743},"CLL-1.CAR T cells",{"EARLY_PHASE1":2744,"PHASE1":2746,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2745,"activeCount":100},[],{"trials":2747,"activeCount":150,"soonestReadout":2752},[2748],{"nctId":2749,"briefTitle":2750,"status":548,"phases":2751,"primaryCompletion":2752,"completion":2753,"start":2754,"enrollment":1765,"conditions":2755,"interventions":2756},"NCT04219163","Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen",[88],"2025-03-24","2038-07-31","2020-07-09",[407],[2742],{"trials":2758,"activeCount":100},[],{"trials":2760,"activeCount":100},[],{"trials":2762,"activeCount":100},[],{"trials":2764,"activeCount":100},[],{"intervention":1072,"totalTrials":150,"cells":2766},{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2775,"PHASE3":2777,"PHASE4":2779,"NA":2781},{"trials":2768,"activeCount":100},[],{"trials":2770,"activeCount":150,"soonestReadout":1060},[2771],{"nctId":1057,"briefTitle":1058,"status":548,"phases":2772,"primaryCompletion":1060,"completion":1061,"start":1062,"enrollment":1063,"conditions":2773,"interventions":2774},[88],[1065,1066,1067,1068,1069,1070],[1072,1038,518],{"trials":2776,"activeCount":100},[],{"trials":2778,"activeCount":100},[],{"trials":2780,"activeCount":100},[],{"trials":2782,"activeCount":100},[],{"intervention":2784,"totalTrials":150,"cells":2785},"HTR2 T Cells",{"EARLY_PHASE1":2786,"PHASE1":2788,"PHASE2":2804,"PHASE3":2806,"PHASE4":2808,"NA":2810},{"trials":2787,"activeCount":100},[],{"trials":2789,"activeCount":150,"soonestReadout":424},[2790],{"nctId":2791,"briefTitle":2792,"status":233,"phases":2793,"primaryCompletion":424,"completion":2794,"start":1609,"enrollment":1123,"conditions":2795,"interventions":2803},"NCT06251544","TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer",[88],"2044-01",[1588,2796,2797,2798,2799,2800,2801,2802],"Tumor, Breast","Breast Tumor","Malignant Neoplasm of Breast","Mammary Cancer","Mammary Neoplasm","Mammary Neoplasms, Human","Neoplasm, Breast",[2784,2784],{"trials":2805,"activeCount":100},[],{"trials":2807,"activeCount":100},[],{"trials":2809,"activeCount":100},[],{"trials":2811,"activeCount":100},[],{"intervention":2813,"totalTrials":150,"cells":2814},"CD7.CAR\u002F28zeta CAR T cells",{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2828,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2816,"activeCount":100},[],{"trials":2818,"activeCount":150,"soonestReadout":2823},[2819],{"nctId":2820,"briefTitle":2821,"status":128,"phases":2822,"primaryCompletion":2823,"completion":2824,"start":2825,"enrollment":1123,"conditions":2826,"interventions":2827},"NCT03690011","Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",[88],"2026-05-01","2040-05-01","2021-08-02",[2091,2092,2093],[2813],{"trials":2829,"activeCount":100},[],{"trials":2831,"activeCount":100},[],{"trials":2833,"activeCount":100},[],{"trials":2835,"activeCount":100},[],{"intervention":2837,"totalTrials":150,"cells":2838},"Antigen-Escalation Stage",{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2854,"PHASE3":2856,"PHASE4":2858,"NA":2860},{"trials":2840,"activeCount":100},[],{"trials":2842,"activeCount":150,"soonestReadout":550},[2843],{"nctId":2844,"briefTitle":2845,"status":548,"phases":2846,"primaryCompletion":550,"completion":2847,"start":2848,"enrollment":1033,"conditions":2849,"interventions":2850},"NCT01333046","Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL",[88],"2027-09-27","2012-01",[1420,1066,1065],[2837,2851,2852,2853],"Dose-Escalation Stage","azacytidine and multiTAA T cells Stage","Pediatric multiTAA T cells Stage",{"trials":2855,"activeCount":100},[],{"trials":2857,"activeCount":100},[],{"trials":2859,"activeCount":100},[],{"trials":2861,"activeCount":100},[],{"intervention":2851,"totalTrials":150,"cells":2863},{"EARLY_PHASE1":2864,"PHASE1":2866,"PHASE2":2872,"PHASE3":2874,"PHASE4":2876,"NA":2878},{"trials":2865,"activeCount":100},[],{"trials":2867,"activeCount":150,"soonestReadout":550},[2868],{"nctId":2844,"briefTitle":2845,"status":548,"phases":2869,"primaryCompletion":550,"completion":2847,"start":2848,"enrollment":1033,"conditions":2870,"interventions":2871},[88],[1420,1066,1065],[2837,2851,2852,2853],{"trials":2873,"activeCount":100},[],{"trials":2875,"activeCount":100},[],{"trials":2877,"activeCount":100},[],{"trials":2879,"activeCount":100},[],{"intervention":2852,"totalTrials":150,"cells":2881},{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2890,"PHASE3":2892,"PHASE4":2894,"NA":2896},{"trials":2883,"activeCount":100},[],{"trials":2885,"activeCount":150,"soonestReadout":550},[2886],{"nctId":2844,"briefTitle":2845,"status":548,"phases":2887,"primaryCompletion":550,"completion":2847,"start":2848,"enrollment":1033,"conditions":2888,"interventions":2889},[88],[1420,1066,1065],[2837,2851,2852,2853],{"trials":2891,"activeCount":100},[],{"trials":2893,"activeCount":100},[],{"trials":2895,"activeCount":100},[],{"trials":2897,"activeCount":100},[],{"intervention":2853,"totalTrials":150,"cells":2899},{"EARLY_PHASE1":2900,"PHASE1":2902,"PHASE2":2908,"PHASE3":2910,"PHASE4":2912,"NA":2914},{"trials":2901,"activeCount":100},[],{"trials":2903,"activeCount":150,"soonestReadout":550},[2904],{"nctId":2844,"briefTitle":2845,"status":548,"phases":2905,"primaryCompletion":550,"completion":2847,"start":2848,"enrollment":1033,"conditions":2906,"interventions":2907},[88],[1420,1066,1065],[2837,2851,2852,2853],{"trials":2909,"activeCount":100},[],{"trials":2911,"activeCount":100},[],{"trials":2913,"activeCount":100},[],{"trials":2915,"activeCount":100},[],{"intervention":1083,"totalTrials":150,"cells":2917},{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2926,"PHASE3":2928,"PHASE4":2930,"NA":2932},{"trials":2919,"activeCount":100},[],{"trials":2921,"activeCount":150,"soonestReadout":1077},[2922],{"nctId":1074,"briefTitle":1075,"status":548,"phases":2923,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":405,"conditions":2924,"interventions":2925},[88],[1081,29],[1083,1084,518,1038],{"trials":2927,"activeCount":100},[],{"trials":2929,"activeCount":100},[],{"trials":2931,"activeCount":100},[],{"trials":2933,"activeCount":100},[],{"intervention":1084,"totalTrials":150,"cells":2935},{"EARLY_PHASE1":2936,"PHASE1":2938,"PHASE2":2944,"PHASE3":2946,"PHASE4":2948,"NA":2950},{"trials":2937,"activeCount":100},[],{"trials":2939,"activeCount":150,"soonestReadout":1077},[2940],{"nctId":1074,"briefTitle":1075,"status":548,"phases":2941,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":405,"conditions":2942,"interventions":2943},[88],[1081,29],[1083,1084,518,1038],{"trials":2945,"activeCount":100},[],{"trials":2947,"activeCount":100},[],{"trials":2949,"activeCount":100},[],{"trials":2951,"activeCount":100},[],{"intervention":2953,"totalTrials":150,"cells":2954},"Dose Level 1A: 2 x 10^7 cells\u002Fm2",{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2974,"PHASE3":2976,"PHASE4":2978,"NA":2980},{"trials":2956,"activeCount":100},[],{"trials":2958,"activeCount":150,"soonestReadout":343},[2959],{"nctId":2960,"briefTitle":2961,"status":128,"phases":2962,"primaryCompletion":343,"completion":2963,"start":2964,"enrollment":928,"conditions":2965,"interventions":2969},"NCT04664179","EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma",[88],"2039-03-30","2022-10-31",[2966,2967,2968],"EBV-Related Hodgkin Lymphoma","EBV-Related Lymphoproliferative Disorder","EBV Related Non-Hodgkin's Lymphoma",[2953,2970,2971,2972,2973],"Dose Level 2A: 6 x 10^7 cells\u002Fm2","Dose Level 2B: 6 x 10^7 cells\u002Fm2","Dose Level 3B: 2 x 10^8 cells\u002Fm2","Dose Level 3A: 2 x 10^8 cells\u002Fm2",{"trials":2975,"activeCount":100},[],{"trials":2977,"activeCount":100},[],{"trials":2979,"activeCount":100},[],{"trials":2981,"activeCount":100},[],{"intervention":2970,"totalTrials":150,"cells":2983},{"EARLY_PHASE1":2984,"PHASE1":2986,"PHASE2":2992,"PHASE3":2994,"PHASE4":2996,"NA":2998},{"trials":2985,"activeCount":100},[],{"trials":2987,"activeCount":150,"soonestReadout":343},[2988],{"nctId":2960,"briefTitle":2961,"status":128,"phases":2989,"primaryCompletion":343,"completion":2963,"start":2964,"enrollment":928,"conditions":2990,"interventions":2991},[88],[2966,2967,2968],[2953,2970,2971,2972,2973],{"trials":2993,"activeCount":100},[],{"trials":2995,"activeCount":100},[],{"trials":2997,"activeCount":100},[],{"trials":2999,"activeCount":100},[],{"intervention":2971,"totalTrials":150,"cells":3001},{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3010,"PHASE3":3012,"PHASE4":3014,"NA":3016},{"trials":3003,"activeCount":100},[],{"trials":3005,"activeCount":150,"soonestReadout":343},[3006],{"nctId":2960,"briefTitle":2961,"status":128,"phases":3007,"primaryCompletion":343,"completion":2963,"start":2964,"enrollment":928,"conditions":3008,"interventions":3009},[88],[2966,2967,2968],[2953,2970,2971,2972,2973],{"trials":3011,"activeCount":100},[],{"trials":3013,"activeCount":100},[],{"trials":3015,"activeCount":100},[],{"trials":3017,"activeCount":100},[],{"intervention":2972,"totalTrials":150,"cells":3019},{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3028,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3021,"activeCount":100},[],{"trials":3023,"activeCount":150,"soonestReadout":343},[3024],{"nctId":2960,"briefTitle":2961,"status":128,"phases":3025,"primaryCompletion":343,"completion":2963,"start":2964,"enrollment":928,"conditions":3026,"interventions":3027},[88],[2966,2967,2968],[2953,2970,2971,2972,2973],{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[],{"trials":3033,"activeCount":100},[],{"trials":3035,"activeCount":100},[],{"intervention":2973,"totalTrials":150,"cells":3037},{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3046,"PHASE3":3048,"PHASE4":3050,"NA":3052},{"trials":3039,"activeCount":100},[],{"trials":3041,"activeCount":150,"soonestReadout":343},[3042],{"nctId":2960,"briefTitle":2961,"status":128,"phases":3043,"primaryCompletion":343,"completion":2963,"start":2964,"enrollment":928,"conditions":3044,"interventions":3045},[88],[2966,2967,2968],[2953,2970,2971,2972,2973],{"trials":3047,"activeCount":100},[],{"trials":3049,"activeCount":100},[],{"trials":3051,"activeCount":100},[],{"trials":3053,"activeCount":100},[],{"intervention":3055,"totalTrials":150,"cells":3056},"Microbiota Transplantation",{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3072,"PHASE3":3074,"PHASE4":3076,"NA":3078},{"trials":3058,"activeCount":100},[],{"trials":3060,"activeCount":150,"soonestReadout":3066},[3061],{"nctId":3062,"briefTitle":3063,"status":3064,"phases":3065,"primaryCompletion":3066,"completion":3067,"start":3068,"enrollment":24,"conditions":3069,"interventions":3071},"NCT01868373","Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea","ENROLLING_BY_INVITATION",[88],"2035-02-28","2036-02-28","2013-02-28",[3070],"Active C. Difficile Colitis",[3055],{"trials":3073,"activeCount":100},[],{"trials":3075,"activeCount":100},[],{"trials":3077,"activeCount":100},[],{"trials":3079,"activeCount":100},[],{"intervention":65,"totalTrials":150,"cells":3081},{"EARLY_PHASE1":3082,"PHASE1":3084,"PHASE2":3090,"PHASE3":3092,"PHASE4":3094,"NA":3096},{"trials":3083,"activeCount":100},[],{"trials":3085,"activeCount":150,"soonestReadout":64},[3086],{"nctId":62,"briefTitle":63,"status":548,"phases":3087,"primaryCompletion":64,"completion":560,"start":561,"enrollment":27,"conditions":3088,"interventions":3089},[88],[29],[65,564,499,557,565,566],{"trials":3091,"activeCount":100},[],{"trials":3093,"activeCount":100},[],{"trials":3095,"activeCount":100},[],{"trials":3097,"activeCount":100},[],{"intervention":564,"totalTrials":150,"cells":3099},{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3108,"PHASE3":3110,"PHASE4":3112,"NA":3114},{"trials":3101,"activeCount":100},[],{"trials":3103,"activeCount":150,"soonestReadout":64},[3104],{"nctId":62,"briefTitle":63,"status":548,"phases":3105,"primaryCompletion":64,"completion":560,"start":561,"enrollment":27,"conditions":3106,"interventions":3107},[88],[29],[65,564,499,557,565,566],{"trials":3109,"activeCount":100},[],{"trials":3111,"activeCount":100},[],{"trials":3113,"activeCount":100},[],{"trials":3115,"activeCount":100},[],{"intervention":565,"totalTrials":150,"cells":3117},{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3126,"PHASE3":3128,"PHASE4":3130,"NA":3132},{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":150,"soonestReadout":64},[3122],{"nctId":62,"briefTitle":63,"status":548,"phases":3123,"primaryCompletion":64,"completion":560,"start":561,"enrollment":27,"conditions":3124,"interventions":3125},[88],[29],[65,564,499,557,565,566],{"trials":3127,"activeCount":100},[],{"trials":3129,"activeCount":100},[],{"trials":3131,"activeCount":100},[],{"trials":3133,"activeCount":100},[],{"intervention":566,"totalTrials":150,"cells":3135},{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3144,"PHASE3":3146,"PHASE4":3148,"NA":3150},{"trials":3137,"activeCount":100},[],{"trials":3139,"activeCount":150,"soonestReadout":64},[3140],{"nctId":62,"briefTitle":63,"status":548,"phases":3141,"primaryCompletion":64,"completion":560,"start":561,"enrollment":27,"conditions":3142,"interventions":3143},[88],[29],[65,564,499,557,565,566],{"trials":3145,"activeCount":100},[],{"trials":3147,"activeCount":100},[],{"trials":3149,"activeCount":100},[],{"trials":3151,"activeCount":100},[],{"intervention":3153,"totalTrials":150,"cells":3154},"Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy",{"EARLY_PHASE1":3155,"PHASE1":3157,"PHASE2":3169,"PHASE3":3171,"PHASE4":3173,"NA":3175},{"trials":3156,"activeCount":100},[],{"trials":3158,"activeCount":150,"soonestReadout":3163},[3159],{"nctId":3160,"briefTitle":3161,"status":128,"phases":3162,"primaryCompletion":3163,"completion":3164,"start":3165,"enrollment":1063,"conditions":3166,"interventions":3168},"NCT05010564","Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)",[88],"2026-07-17","2040-03-29","2023-07-18",[3167],"Leukemia, B-Cell",[3153],{"trials":3170,"activeCount":100},[],{"trials":3172,"activeCount":100},[],{"trials":3174,"activeCount":100},[],{"trials":3176,"activeCount":100},[],{"intervention":3178,"totalTrials":150,"cells":3179},"CAdVEC",{"EARLY_PHASE1":3180,"PHASE1":3182,"PHASE2":3202,"PHASE3":3204,"PHASE4":3206,"NA":3208},{"trials":3181,"activeCount":100},[],{"trials":3183,"activeCount":150,"soonestReadout":3188},[3184],{"nctId":3185,"briefTitle":3186,"status":128,"phases":3187,"primaryCompletion":3188,"completion":3189,"start":3190,"enrollment":3191,"conditions":3192,"interventions":3201},"NCT03740256","Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",[88],"2026-12-30","2038-12-30","2020-12-14",45,[3193,3194,3195,3196,1588,3197,3198,3199,3200,1933],"Bladder Cancer","Head and Neck Squamous Cell Carcinoma","Cancer of the Salivary Gland","Lung Cancer","Gastric Cancer","Esophageal Cancer","Colorectal Cancer","Pancreatic Adenocarcinoma",[3178],{"trials":3203,"activeCount":100},[],{"trials":3205,"activeCount":100},[],{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":100},[],{"intervention":3211,"totalTrials":394,"cells":3212},"HLA-matched VSTs",{"EARLY_PHASE1":3213,"PHASE1":3215,"PHASE2":3227,"PHASE3":3229,"PHASE4":3231,"NA":3233},{"trials":3214,"activeCount":100},[],{"trials":3216,"activeCount":150,"soonestReadout":2823},[3217],{"nctId":3218,"briefTitle":3219,"status":128,"phases":3220,"primaryCompletion":2823,"completion":3221,"start":3222,"enrollment":3223,"conditions":3224,"interventions":3226},"NCT04013802","TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.",[88],"2031-05-01","2021-03-08",47,[3225],"Viral Infection",[3211],{"trials":3228,"activeCount":100},[],{"trials":3230,"activeCount":100},[],{"trials":3232,"activeCount":100},[],{"trials":3234,"activeCount":100},[3235],{"nctId":3236,"briefTitle":3237,"status":3238,"phases":3239,"conditions":3240,"interventions":3248},"NCT07104591","TETRAVI Expanded Access Program","AVAILABLE",[],[3241,3242,3243,3244,3245,3246,3247],"Epstein-Barr Virus Infection","Cytomegalovirus Infections","Adenovirus Infection","BK Virus Infection","JC Virus Infection","Viral Infections Post-Transplant","Post-Allogeneic Stem Cell Transplant Complications",[3211],{"intervention":3250,"totalTrials":150,"cells":3251},"Vitamin C",{"EARLY_PHASE1":3252,"PHASE1":3263,"PHASE2":3265,"PHASE3":3267,"PHASE4":3269,"NA":3271},{"trials":3253,"activeCount":150,"soonestReadout":3258},[3254],{"nctId":3255,"briefTitle":3256,"status":233,"phases":3257,"primaryCompletion":3258,"completion":901,"start":1609,"enrollment":2297,"conditions":3259,"interventions":3262},"NCT07197749","Vitamin C With Steroids for Gastrointestinal GVHD",[87],"2028-10",[3260,3261],"Graft-versus-host-disease (GVHD)","Gastrointestinal",[3250],{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[],{"trials":3268,"activeCount":100},[],{"trials":3270,"activeCount":100},[],{"trials":3272,"activeCount":100},[],{"intervention":3274,"totalTrials":150,"cells":3275},"Rapid whole genome sequencing",{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3282,"PHASE4":3284,"NA":3286},{"trials":3277,"activeCount":100},[],{"trials":3279,"activeCount":100},[],{"trials":3281,"activeCount":100},[],{"trials":3283,"activeCount":100},[],{"trials":3285,"activeCount":100},[],{"trials":3287,"activeCount":150,"soonestReadout":3292},[3288],{"nctId":3289,"briefTitle":3290,"status":128,"phases":3291,"primaryCompletion":3292,"completion":3293,"start":3294,"enrollment":3295,"conditions":3296,"interventions":3298},"NCT07102966","Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas",[92],"2029-03-31","2029-07-31","2025-10-28",410,[3297],"Rare Diseases",[3274],{"intervention":3300,"totalTrials":150,"cells":3301},"Genome sequencing",{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3306,"PHASE3":3308,"PHASE4":3310,"NA":3312},{"trials":3303,"activeCount":100},[],{"trials":3305,"activeCount":100},[],{"trials":3307,"activeCount":100},[],{"trials":3309,"activeCount":100},[],{"trials":3311,"activeCount":100},[],{"trials":3313,"activeCount":150,"soonestReadout":341},[3314],{"nctId":3315,"briefTitle":3316,"status":128,"phases":3317,"primaryCompletion":341,"completion":3318,"start":3319,"enrollment":9,"conditions":3320,"interventions":3324},"NCT06762795","The HIEnome Study: Genome Sequencing for Perinatal HIE",[92],"2027-06-30","2025-05-15",[3321,3322,3323],"Hypoxic Ischemic Encephalopathy of Newborn","Hypoxic Ischemic Encephalopathy","Hypoxic Ischemic Encephalopathy (HIE)",[3300],{"intervention":3326,"totalTrials":150,"cells":3327},"Observation",{"EARLY_PHASE1":3328,"PHASE1":3330,"PHASE2":3332,"PHASE3":3334,"PHASE4":3336,"NA":3338},{"trials":3329,"activeCount":100},[],{"trials":3331,"activeCount":100},[],{"trials":3333,"activeCount":100},[],{"trials":3335,"activeCount":100},[],{"trials":3337,"activeCount":100},[],{"trials":3339,"activeCount":150,"soonestReadout":3344},[3340],{"nctId":3341,"briefTitle":3342,"status":128,"phases":3343,"primaryCompletion":3344,"completion":3344,"start":3345,"enrollment":3346,"conditions":3347,"interventions":3349},"NCT05374616","Natural History Study and Establishment of a Biorepository-TANGO2-related Disorder",[],"2030-01-01","2018-05-18",300,[3348],"TANGO2-related Disorder",[3326],{"intervention":3351,"totalTrials":96,"cells":3352},"Exenatide",{"EARLY_PHASE1":3353,"PHASE1":3355,"PHASE2":3357,"PHASE3":3359,"PHASE4":3361,"NA":3392},{"trials":3354,"activeCount":100},[],{"trials":3356,"activeCount":100},[],{"trials":3358,"activeCount":100},[],{"trials":3360,"activeCount":100},[],{"trials":3362,"activeCount":100},[3363,3374,3383],{"nctId":3364,"briefTitle":3365,"status":108,"phases":3366,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":1216,"conditions":3370,"interventions":3372},"NCT01951651","Effect of Exenatide on Liver and Heart Fat and Inflammation",[91],"2012-10","2013-03","2010-04",[3371],"Type 2 Diabetes Mellitus",[3351,3373],"Glipizide",{"nctId":3375,"briefTitle":3376,"status":108,"phases":3377,"primaryCompletion":3378,"completion":3379,"start":1105,"enrollment":1216,"conditions":3380,"interventions":3381},"NCT01432405","Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes",[91],"2008-07","2009-06",[3371],[3351,3382],"Pioglitazone",{"nctId":3384,"briefTitle":3385,"status":578,"phases":3386,"primaryCompletion":3387,"completion":3387,"start":1048,"enrollment":394,"conditions":3388,"interventions":3391},"NCT00799435","Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure",[91],"2012-04",[3389,3390],"Diabetes Mellitus, Type 2","Heart Failure, Diastolic",[3351],{"trials":3393,"activeCount":100},[],{"intervention":3395,"totalTrials":96,"cells":3396},"Metformin",{"EARLY_PHASE1":3397,"PHASE1":3410,"PHASE2":3412,"PHASE3":3423,"PHASE4":3425,"NA":3436},{"trials":3398,"activeCount":100},[3399],{"nctId":3400,"briefTitle":3401,"status":108,"phases":3402,"primaryCompletion":3403,"completion":3403,"start":3404,"enrollment":3405,"conditions":3406,"interventions":3409},"NCT02981329","Fetal Hemoglobin Induction Treatment Metformin",[87],"2020-07-20","2017-03-02",37,[1182,3407,3408],"Sickle Cell Disease","Hemoglobin Disorder",[3395],{"trials":3411,"activeCount":100},[],{"trials":3413,"activeCount":100},[3414],{"nctId":3415,"briefTitle":3416,"status":108,"phases":3417,"primaryCompletion":3418,"completion":3419,"start":3420,"enrollment":405,"conditions":3421,"interventions":3422},"NCT02949700","Phase I\u002FII Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma",[88,89],"2021-06-28","2022-07-07","2017-01-26",[3194],[3395],{"trials":3424,"activeCount":100},[],{"trials":3426,"activeCount":100},[3427],{"nctId":3428,"briefTitle":3429,"status":108,"phases":3430,"primaryCompletion":64,"completion":64,"start":3367,"enrollment":1284,"conditions":3431,"interventions":3433},"NCT01718093","A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes",[91],[3432],"Type 1 Diabetes",[3434,3395,3435],"Sitagliptin","Sitagliptin + Metformin",{"trials":3437,"activeCount":100},[],{"intervention":3439,"totalTrials":96,"cells":3440},"Hepatitis B vaccine",{"EARLY_PHASE1":3441,"PHASE1":3443,"PHASE2":3465,"PHASE3":3467,"PHASE4":3469,"NA":3481},{"trials":3442,"activeCount":100},[],{"trials":3444,"activeCount":100},[3445,3454],{"nctId":3446,"briefTitle":3447,"status":108,"phases":3448,"primaryCompletion":1732,"completion":1431,"start":170,"enrollment":534,"conditions":3449,"interventions":3451},"NCT02126462","Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults",[88],[2299,3450],"Hookworm Disease",[3452,3453,3439],"Na-APR-1 (M74)\u002FAlhydrogel®","Na-GST-1\u002FAlhydrogel®",{"nctId":3455,"briefTitle":3456,"status":108,"phases":3457,"primaryCompletion":3458,"completion":525,"start":3459,"enrollment":133,"conditions":3460,"interventions":3461},"NCT02839161","Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children",[88],"2018-12-13","2017-01",[3450,2299],[3462,3463,3464],"Na-GST-1\u002FAlhydrogel","Na-APR-1 (M74)\u002FAlhydrogel","Hepatitis B Vaccine",{"trials":3466,"activeCount":100},[],{"trials":3468,"activeCount":100},[],{"trials":3470,"activeCount":100},[3471],{"nctId":3472,"briefTitle":3473,"status":3474,"phases":3475,"primaryCompletion":39,"completion":39,"start":3369,"enrollment":3476,"conditions":3477,"interventions":3479},"NCT01341275","Adolescents' Response to Hepatitis B Vaccine Booster Dose","UNKNOWN",[91],400,[3478],"Hepatitis B",[3480,3480],"hepatitis B vaccine",{"trials":3482,"activeCount":100},[],{"intervention":3484,"totalTrials":394,"cells":3485},"Atorvastatin",{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3502,"PHASE4":3504,"NA":3515},{"trials":3487,"activeCount":100},[],{"trials":3489,"activeCount":100},[],{"trials":3491,"activeCount":100},[3492],{"nctId":3493,"briefTitle":3494,"status":578,"phases":3495,"primaryCompletion":1348,"completion":3496,"start":3497,"enrollment":928,"conditions":3498,"interventions":3501},"NCT01013870","Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol",[89],"2015-06","2010-02",[3499,3500],"Traumatic Brain Injury","Post-traumatic Stress Disorder",[3484],{"trials":3503,"activeCount":100},[],{"trials":3505,"activeCount":100},[3506],{"nctId":3507,"briefTitle":3508,"status":3474,"phases":3509,"primaryCompletion":3510,"completion":3497,"start":3511,"enrollment":24,"conditions":3512,"interventions":3514},"NCT00640744","Effect of Short Term Atorvastatin Treatment,80mg\u002FDay on Early Regression of Carotid Artery Atherosclerotic Lesions",[91],"2009-11","2006-02",[3513],"Atherosclerosis",[3484],{"trials":3516,"activeCount":100},[],{"intervention":3518,"totalTrials":394,"cells":3519},"Glargine insulin",{"EARLY_PHASE1":3520,"PHASE1":3522,"PHASE2":3524,"PHASE3":3526,"PHASE4":3528,"NA":3548},{"trials":3521,"activeCount":100},[],{"trials":3523,"activeCount":100},[],{"trials":3525,"activeCount":100},[],{"trials":3527,"activeCount":100},[],{"trials":3529,"activeCount":100},[3530,3540],{"nctId":3531,"briefTitle":3532,"status":108,"phases":3533,"primaryCompletion":54,"completion":54,"start":572,"enrollment":3405,"conditions":3534,"interventions":3537},"NCT01810952","The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients",[91],[3535,3536],"Hyperglycemia","Diabetes Mellitus",[3518,3538,3539],"Lispro insulin","NPH Insulin",{"nctId":3541,"briefTitle":3542,"status":108,"phases":3543,"completion":1105,"start":3544,"enrollment":1033,"conditions":3545,"interventions":3546},"NCT00340613","Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes",[91],"2006-06",[3432],[3547],"glargine insulin",{"trials":3549,"activeCount":100},[],{"intervention":3551,"totalTrials":394,"cells":3552},"Pramlintide",{"EARLY_PHASE1":3553,"PHASE1":3555,"PHASE2":3557,"PHASE3":3559,"PHASE4":3568,"NA":3578},{"trials":3554,"activeCount":100},[],{"trials":3556,"activeCount":100},[],{"trials":3558,"activeCount":100},[],{"trials":3560,"activeCount":100},[3561],{"nctId":3562,"briefTitle":3563,"status":108,"phases":3564,"completion":3511,"start":3565,"enrollment":16,"conditions":3566,"interventions":3567},"NCT00206297","The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes",[90],"2003-10",[3432],[3551],{"trials":3569,"activeCount":100},[3570],{"nctId":3571,"briefTitle":3572,"status":108,"phases":3573,"primaryCompletion":3574,"completion":3574,"start":3575,"enrollment":1350,"conditions":3576,"interventions":3577},"NCT00291772","Continuous Subcutaneous Infusion of Pramlintide and Insulin",[91],"2007-11","2006-01",[3432],[3551],{"trials":3579,"activeCount":100},[],{"intervention":3581,"totalTrials":394,"cells":3582},"Ferrous Sulfate",{"EARLY_PHASE1":3583,"PHASE1":3585,"PHASE2":3587,"PHASE3":3589,"PHASE4":3602,"NA":3616},{"trials":3584,"activeCount":100},[],{"trials":3586,"activeCount":100},[],{"trials":3588,"activeCount":100},[],{"trials":3590,"activeCount":100},[3591],{"nctId":3592,"briefTitle":3593,"status":108,"phases":3594,"primaryCompletion":3595,"completion":3596,"start":3597,"enrollment":150,"conditions":3598,"interventions":3601},"NCT04371536","Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD)",[90],"2022-02-01","2022-03-09","2021-07-09",[3599,3600],"Iron Deficiency Anemia","Iron-deficiency",[3581],{"trials":3603,"activeCount":100},[3604],{"nctId":3605,"briefTitle":3606,"status":108,"phases":3607,"primaryCompletion":3608,"completion":3609,"start":3610,"enrollment":1350,"conditions":3611,"interventions":3614},"NCT05007899","Alternate Day Versus Daily Oral Iron Therapy in Adolescents",[91],"2022-06-30","2022-12-22","2020-12-21",[3599,3612,3613],"Heavy Menstrual Bleeding","Abnormal Uterine Bleeding",[3615],"Ferrous sulfate",{"trials":3617,"activeCount":100},[],{"intervention":3619,"totalTrials":394,"cells":3620},"Ketamine",{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3625,"PHASE3":3639,"PHASE4":3641,"NA":3653},{"trials":3622,"activeCount":100},[],{"trials":3624,"activeCount":100},[],{"trials":3626,"activeCount":100},[3627],{"nctId":3628,"briefTitle":3629,"status":108,"phases":3630,"primaryCompletion":110,"completion":3631,"start":3632,"enrollment":3633,"conditions":3634,"interventions":3637},"NCT00768430","Optimization of IV Ketamine for Treatment Resistant Depression",[89],"2012-11","2008-11",73,[3635,3636],"Major Depressive Disorder (MDD)","Treatment Resistant Depression (TRD)",[3619,3638],"Midazolam",{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":100},[3643],{"nctId":3644,"briefTitle":3645,"status":108,"phases":3646,"primaryCompletion":3378,"completion":3647,"start":1214,"enrollment":405,"conditions":3648,"interventions":3650},"NCT00419003","Research Study for Major Depressive Disorder: Investigation of Glutamate Medications",[91],"2008-09",[3649],"Major Depression",[3651,3619,3652],"Lamotrigine","Riluzole",{"trials":3654,"activeCount":100},[],{"intervention":3656,"totalTrials":394,"cells":3657},"Ropivacaine",{"EARLY_PHASE1":3658,"PHASE1":3660,"PHASE2":3662,"PHASE3":3664,"PHASE4":3666,"NA":3690},{"trials":3659,"activeCount":100},[],{"trials":3661,"activeCount":100},[],{"trials":3663,"activeCount":100},[],{"trials":3665,"activeCount":100},[],{"trials":3667,"activeCount":100},[3668,3678],{"nctId":3669,"briefTitle":3670,"status":108,"phases":3671,"primaryCompletion":3672,"completion":3673,"start":3674,"enrollment":1106,"conditions":3675,"interventions":3677},"NCT04298099","Ropivacaine Plasma Concentrations and Pharmacokinetics Following Erector Spinae Plane Block in the Pediatric Population",[91],"2021-01-27","2021-03-29","2020-12-18",[3676],"Anesthesia, Local",[3656],{"nctId":3679,"briefTitle":3680,"status":578,"phases":3681,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":3685,"conditions":3686,"interventions":3688},"NCT02056288","A Comparison of UGSB and GA to IV Narcotics and GA for Post-Op Pain in Children With Supracondylar Fractures.",[91],"2019-02-11","2019-03-01","2011-03-10",78,[3687],"Supracondylar Fractures",[3689,3656],"Fentanyl",{"trials":3691,"activeCount":100},[],{"intervention":3693,"totalTrials":394,"cells":3694},"Ezetimibe",{"EARLY_PHASE1":3695,"PHASE1":3697,"PHASE2":3699,"PHASE3":3701,"PHASE4":3703,"NA":3728},{"trials":3696,"activeCount":100},[],{"trials":3698,"activeCount":100},[],{"trials":3700,"activeCount":100},[],{"trials":3702,"activeCount":100},[],{"trials":3704,"activeCount":100},[3705,3715],{"nctId":3706,"briefTitle":3707,"status":108,"phases":3708,"primaryCompletion":3709,"completion":3709,"start":1349,"enrollment":832,"conditions":3710,"interventions":3712},"NCT00988364","Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.",[91],"2008-02",[3711],"Metabolic Syndrome",[3713,3714,3693],"Simvastatin","Vytorin",{"nctId":3716,"briefTitle":3717,"status":108,"phases":3718,"primaryCompletion":3719,"completion":3719,"start":1403,"enrollment":3720,"conditions":3721,"interventions":3723},"NCT00687076","Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)",[91],"2010-12",102,[3722],"Peripheral Arterial Disease",[3693,3724,3725,3726,3727],"Niaspan","Statin therapy","Aspirin","Clopidogrel",{"trials":3729,"activeCount":100},[],{"intervention":3731,"totalTrials":394,"cells":3732},"Spironolactone",{"EARLY_PHASE1":3733,"PHASE1":3735,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3763},{"trials":3734,"activeCount":100},[],{"trials":3736,"activeCount":100},[],{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":100},[],{"trials":3742,"activeCount":100},[3743,3753],{"nctId":3744,"briefTitle":3745,"status":108,"phases":3746,"primaryCompletion":3747,"completion":3747,"start":3748,"enrollment":3749,"conditions":3750,"interventions":3752},"NCT00206232","Novel Treatment for Diastolic Heart Failure in Women",[91],"2010-07","2004-07",48,[3751],"Heart Failure",[3731],{"nctId":3754,"briefTitle":3755,"status":3474,"phases":3756,"primaryCompletion":3757,"completion":64,"start":3758,"enrollment":3759,"conditions":3760,"interventions":3762},"NCT01468571","Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension",[91],"2015-07","2011-07",50,[3761],"Pulmonary Hypertension",[3731],{"trials":3764,"activeCount":100},[],{"intervention":3727,"totalTrials":394,"cells":3766},{"EARLY_PHASE1":3767,"PHASE1":3769,"PHASE2":3771,"PHASE3":3773,"PHASE4":3775,"NA":3789},{"trials":3768,"activeCount":100},[],{"trials":3770,"activeCount":100},[],{"trials":3772,"activeCount":100},[],{"trials":3774,"activeCount":100},[],{"trials":3776,"activeCount":100},[3777,3785],{"nctId":3778,"briefTitle":3779,"status":180,"phases":3780,"primaryCompletion":3781,"completion":79,"start":64,"enrollment":100,"conditions":3782,"interventions":3783},"NCT02626169","The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation",[91],"2018-01",[3513],[3727,3784],"Ticagrelor",{"nctId":3716,"briefTitle":3717,"status":108,"phases":3786,"primaryCompletion":3719,"completion":3719,"start":1403,"enrollment":3720,"conditions":3787,"interventions":3788},[91],[3722],[3693,3724,3725,3726,3727],{"trials":3790,"activeCount":100},[],{"intervention":3382,"totalTrials":394,"cells":3792},{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3797,"PHASE3":3799,"PHASE4":3801,"NA":3815},{"trials":3794,"activeCount":100},[],{"trials":3796,"activeCount":100},[],{"trials":3798,"activeCount":100},[],{"trials":3800,"activeCount":100},[],{"trials":3802,"activeCount":100},[3803,3807],{"nctId":3375,"briefTitle":3376,"status":108,"phases":3804,"primaryCompletion":3378,"completion":3379,"start":1105,"enrollment":1216,"conditions":3805,"interventions":3806},[91],[3371],[3351,3382],{"nctId":3808,"briefTitle":3809,"status":108,"phases":3810,"primaryCompletion":3811,"completion":3812,"start":3497,"enrollment":9,"conditions":3813,"interventions":3814},"NCT01040819","Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?",[91],"2011-10","2011-12",[3371],[3382],{"trials":3816,"activeCount":100},[],{"intervention":3818,"totalTrials":394,"cells":3819},"Pimavanserin",{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3826,"PHASE4":3828,"NA":3850},{"trials":3821,"activeCount":100},[],{"trials":3823,"activeCount":100},[],{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[],{"trials":3829,"activeCount":100},[3830,3840],{"nctId":3831,"briefTitle":3832,"status":180,"phases":3833,"primaryCompletion":3834,"completion":3834,"start":3835,"enrollment":100,"conditions":3836,"interventions":3839},"NCT04809116","Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept",[91],"2023-12-15","2022-12-15",[3837,3838],"Insomnia Chronic","Posttraumatic Stress Disorder",[3818],{"nctId":3841,"briefTitle":3842,"status":108,"phases":3843,"primaryCompletion":3844,"completion":3845,"start":3846,"enrollment":1298,"conditions":3847,"interventions":3849},"NCT04188392","Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder",[91],"2021-10-27","2021-11-10","2020-01-06",[3500,3848],"Insomnia",[3818],{"trials":3851,"activeCount":100},[],{"intervention":3853,"totalTrials":150,"cells":3854},"Benzathine penicillin G intramuscular 7.2 million units",{"EARLY_PHASE1":3855,"PHASE1":3857,"PHASE2":3859,"PHASE3":3861,"PHASE4":3863,"NA":3873},{"trials":3856,"activeCount":100},[],{"trials":3858,"activeCount":100},[],{"trials":3860,"activeCount":100},[],{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[3865],{"nctId":3866,"briefTitle":3867,"status":108,"phases":3868,"primaryCompletion":3387,"completion":3387,"start":3647,"enrollment":2253,"conditions":3869,"interventions":3871},"NCT02611765","Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study",[91],[3870],"Syphilis",[3853,3872],"Benzathine penicillin G intramuscular 2.4 million units",{"trials":3874,"activeCount":100},[],{"intervention":3872,"totalTrials":150,"cells":3876},{"EARLY_PHASE1":3877,"PHASE1":3879,"PHASE2":3881,"PHASE3":3883,"PHASE4":3885,"NA":3891},{"trials":3878,"activeCount":100},[],{"trials":3880,"activeCount":100},[],{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[3887],{"nctId":3866,"briefTitle":3867,"status":108,"phases":3888,"primaryCompletion":3387,"completion":3387,"start":3647,"enrollment":2253,"conditions":3889,"interventions":3890},[91],[3870],[3853,3872],{"trials":3892,"activeCount":100},[],{"intervention":3894,"totalTrials":150,"cells":3895},"Patiromer 25.2 g",{"EARLY_PHASE1":3896,"PHASE1":3898,"PHASE2":3900,"PHASE3":3902,"PHASE4":3904,"NA":3915},{"trials":3897,"activeCount":100},[],{"trials":3899,"activeCount":100},[],{"trials":3901,"activeCount":100},[],{"trials":3903,"activeCount":100},[],{"trials":3905,"activeCount":100},[3906],{"nctId":3907,"briefTitle":3908,"status":108,"phases":3909,"primaryCompletion":1013,"completion":1013,"start":3910,"enrollment":3911,"conditions":3912,"interventions":3914},"NCT02933450","Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)",[91],"2016-08",43,[3913],"Kidney Failure, Chronic",[3894],{"trials":3916,"activeCount":100},[],{"intervention":3918,"totalTrials":150,"cells":3919},"Acthar 80 unit",{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3926,"PHASE4":3928,"NA":3939},{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"trials":3925,"activeCount":100},[],{"trials":3927,"activeCount":100},[],{"trials":3929,"activeCount":100},[3930],{"nctId":3931,"briefTitle":3932,"status":180,"phases":3933,"primaryCompletion":3934,"completion":512,"start":1062,"enrollment":100,"conditions":3935,"interventions":3938},"NCT02382523","Acthar on Proteinuria in IgA Nephropathy Patients",[91],"2019-01",[3936,3937],"IgA Nephropathy","Proteinuria",[3918],{"trials":3940,"activeCount":100},[],{"intervention":3942,"totalTrials":150,"cells":3943},"mycophenolate mofetil",{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3948,"PHASE3":3950,"PHASE4":3952,"NA":3965},{"trials":3945,"activeCount":100},[],{"trials":3947,"activeCount":100},[],{"trials":3949,"activeCount":100},[],{"trials":3951,"activeCount":100},[],{"trials":3953,"activeCount":100},[3954],{"nctId":3955,"briefTitle":3956,"status":578,"phases":3957,"primaryCompletion":3958,"completion":3958,"start":3959,"enrollment":1350,"conditions":3960,"interventions":3964},"NCT00656266","Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation",[91],"2005-11","2004-11",[3961,3962,3963],"End-stage Liver Disease","Renal Insufficiency","Renal Failure",[3942],{"trials":3966,"activeCount":100},[],{"intervention":3538,"totalTrials":150,"cells":3968},{"EARLY_PHASE1":3969,"PHASE1":3971,"PHASE2":3973,"PHASE3":3975,"PHASE4":3977,"NA":3983},{"trials":3970,"activeCount":100},[],{"trials":3972,"activeCount":100},[],{"trials":3974,"activeCount":100},[],{"trials":3976,"activeCount":100},[],{"trials":3978,"activeCount":100},[3979],{"nctId":3531,"briefTitle":3532,"status":108,"phases":3980,"primaryCompletion":54,"completion":54,"start":572,"enrollment":3405,"conditions":3981,"interventions":3982},[91],[3535,3536],[3518,3538,3539],{"trials":3984,"activeCount":100},[],{"intervention":3539,"totalTrials":150,"cells":3986},{"EARLY_PHASE1":3987,"PHASE1":3989,"PHASE2":3991,"PHASE3":3993,"PHASE4":3995,"NA":4001},{"trials":3988,"activeCount":100},[],{"trials":3990,"activeCount":100},[],{"trials":3992,"activeCount":100},[],{"trials":3994,"activeCount":100},[],{"trials":3996,"activeCount":100},[3997],{"nctId":3531,"briefTitle":3532,"status":108,"phases":3998,"primaryCompletion":54,"completion":54,"start":572,"enrollment":3405,"conditions":3999,"interventions":4000},[91],[3535,3536],[3518,3538,3539],{"trials":4002,"activeCount":100},[],{"intervention":3373,"totalTrials":150,"cells":4004},{"EARLY_PHASE1":4005,"PHASE1":4007,"PHASE2":4009,"PHASE3":4011,"PHASE4":4013,"NA":4019},{"trials":4006,"activeCount":100},[],{"trials":4008,"activeCount":100},[],{"trials":4010,"activeCount":100},[],{"trials":4012,"activeCount":100},[],{"trials":4014,"activeCount":100},[4015],{"nctId":3364,"briefTitle":3365,"status":108,"phases":4016,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":1216,"conditions":4017,"interventions":4018},[91],[3371],[3351,3373],{"trials":4020,"activeCount":100},[],{"intervention":4022,"totalTrials":150,"cells":4023},"Growth hormone treatment and puberty",{"EARLY_PHASE1":4024,"PHASE1":4026,"PHASE2":4028,"PHASE3":4030,"PHASE4":4032,"NA":4044},{"trials":4025,"activeCount":100},[],{"trials":4027,"activeCount":100},[],{"trials":4029,"activeCount":100},[],{"trials":4031,"activeCount":100},[],{"trials":4033,"activeCount":100},[4034],{"nctId":4035,"briefTitle":4036,"status":578,"phases":4037,"primaryCompletion":4038,"completion":39,"start":4039,"enrollment":1240,"conditions":4040,"interventions":4042},"NCT00206375","Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism",[91],"2011-09","2003-05",[4041],"Hypothyroidism",[4043,4022],"Growth hormone",{"trials":4045,"activeCount":100},[],{"intervention":3651,"totalTrials":150,"cells":4047},{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4052,"PHASE3":4054,"PHASE4":4056,"NA":4062},{"trials":4049,"activeCount":100},[],{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[],{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[4058],{"nctId":3644,"briefTitle":3645,"status":108,"phases":4059,"primaryCompletion":3378,"completion":3647,"start":1214,"enrollment":405,"conditions":4060,"interventions":4061},[91],[3649],[3651,3619,3652],{"trials":4063,"activeCount":100},[],{"intervention":3652,"totalTrials":150,"cells":4065},{"EARLY_PHASE1":4066,"PHASE1":4068,"PHASE2":4070,"PHASE3":4072,"PHASE4":4074,"NA":4080},{"trials":4067,"activeCount":100},[],{"trials":4069,"activeCount":100},[],{"trials":4071,"activeCount":100},[],{"trials":4073,"activeCount":100},[],{"trials":4075,"activeCount":100},[4076],{"nctId":3644,"briefTitle":3645,"status":108,"phases":4077,"primaryCompletion":3378,"completion":3647,"start":1214,"enrollment":405,"conditions":4078,"interventions":4079},[91],[3649],[3651,3619,3652],{"trials":4081,"activeCount":100},[],{"intervention":4083,"totalTrials":150,"cells":4084},"Ziprasidone",{"EARLY_PHASE1":4085,"PHASE1":4087,"PHASE2":4089,"PHASE3":4091,"PHASE4":4093,"NA":4103},{"trials":4086,"activeCount":100},[],{"trials":4088,"activeCount":100},[],{"trials":4090,"activeCount":100},[],{"trials":4092,"activeCount":100},[],{"trials":4094,"activeCount":100},[4095],{"nctId":4096,"briefTitle":4097,"status":108,"phases":4098,"primaryCompletion":600,"completion":3510,"start":4099,"enrollment":767,"conditions":4100,"interventions":4102},"NCT00622739","Ziprasidone in Pediatric Bipolar Disorder",[91],"2007-02",[4101],"Bipolar Disorder",[4083,4083],{"trials":4104,"activeCount":100},[],{"intervention":4106,"totalTrials":150,"cells":4107},"live attenuated and inactivated influenza vaccines",{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4112,"PHASE3":4114,"PHASE4":4116,"NA":4127},{"trials":4109,"activeCount":100},[],{"trials":4111,"activeCount":100},[],{"trials":4113,"activeCount":100},[],{"trials":4115,"activeCount":100},[],{"trials":4117,"activeCount":100},[4118],{"nctId":4119,"briefTitle":4120,"status":108,"phases":4121,"primaryCompletion":1622,"completion":1622,"start":4122,"enrollment":4123,"conditions":4124,"interventions":4126},"NCT00138294","Control of Epidemic Influenza Through a School-based Influenza Vaccination Program",[91],"1998-10",29255,[4125],"Influenza",[4106],{"trials":4128,"activeCount":100},[],{"intervention":4130,"totalTrials":150,"cells":4131},"Dexmedetomidine 0.75 mcg\u002Fkg",{"EARLY_PHASE1":4132,"PHASE1":4134,"PHASE2":4136,"PHASE3":4138,"PHASE4":4140,"NA":4154},{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"trials":4137,"activeCount":100},[],{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[4142],{"nctId":4143,"briefTitle":4144,"status":108,"phases":4145,"primaryCompletion":610,"completion":3719,"start":1368,"enrollment":4146,"conditions":4147,"interventions":4150},"NCT01057381","Dexmedetomidine in Pediatric Tonsillectomy",[91],109,[4148,4149],"Pediatric Adenotonsillectomy","Post Operative Analgesia",[4130,4151,4152,4153],"Morphine 50 mcg\u002Fkg","Morphine 100 mcg\u002Fkg","Dexmedetomidine 1 mcg\u002Fkg",{"trials":4155,"activeCount":100},[],{"intervention":4151,"totalTrials":150,"cells":4157},{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4162,"PHASE3":4164,"PHASE4":4166,"NA":4172},{"trials":4159,"activeCount":100},[],{"trials":4161,"activeCount":100},[],{"trials":4163,"activeCount":100},[],{"trials":4165,"activeCount":100},[],{"trials":4167,"activeCount":100},[4168],{"nctId":4143,"briefTitle":4144,"status":108,"phases":4169,"primaryCompletion":610,"completion":3719,"start":1368,"enrollment":4146,"conditions":4170,"interventions":4171},[91],[4148,4149],[4130,4151,4152,4153],{"trials":4173,"activeCount":100},[],{"intervention":4152,"totalTrials":150,"cells":4175},{"EARLY_PHASE1":4176,"PHASE1":4178,"PHASE2":4180,"PHASE3":4182,"PHASE4":4184,"NA":4190},{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[],{"trials":4183,"activeCount":100},[],{"trials":4185,"activeCount":100},[4186],{"nctId":4143,"briefTitle":4144,"status":108,"phases":4187,"primaryCompletion":610,"completion":3719,"start":1368,"enrollment":4146,"conditions":4188,"interventions":4189},[91],[4148,4149],[4130,4151,4152,4153],{"trials":4191,"activeCount":100},[],{"intervention":4153,"totalTrials":150,"cells":4193},{"EARLY_PHASE1":4194,"PHASE1":4196,"PHASE2":4198,"PHASE3":4200,"PHASE4":4202,"NA":4208},{"trials":4195,"activeCount":100},[],{"trials":4197,"activeCount":100},[],{"trials":4199,"activeCount":100},[],{"trials":4201,"activeCount":100},[],{"trials":4203,"activeCount":100},[4204],{"nctId":4143,"briefTitle":4144,"status":108,"phases":4205,"primaryCompletion":610,"completion":3719,"start":1368,"enrollment":4146,"conditions":4206,"interventions":4207},[91],[4148,4149],[4130,4151,4152,4153],{"trials":4209,"activeCount":100},[],{"intervention":4211,"totalTrials":150,"cells":4212},"Intranasal fentanyl",{"EARLY_PHASE1":4213,"PHASE1":4215,"PHASE2":4217,"PHASE3":4219,"PHASE4":4221,"NA":4235},{"trials":4214,"activeCount":100},[],{"trials":4216,"activeCount":100},[],{"trials":4218,"activeCount":100},[],{"trials":4220,"activeCount":100},[],{"trials":4222,"activeCount":100},[4223],{"nctId":4224,"briefTitle":4225,"status":108,"phases":4226,"primaryCompletion":4227,"completion":4227,"start":4228,"enrollment":4229,"conditions":4230,"interventions":4232},"NCT01244126","Postoperative Effects of Intranasal Fentanyl, IV and IM Morphine in Children Undergoing Myringotomy",[91],"2011-05","2008-05",171,[4231],"Otitis Media",[4211,4233,4234],"morphine IM","IV morphine",{"trials":4236,"activeCount":100},[],{"intervention":4233,"totalTrials":150,"cells":4238},{"EARLY_PHASE1":4239,"PHASE1":4241,"PHASE2":4243,"PHASE3":4245,"PHASE4":4247,"NA":4253},{"trials":4240,"activeCount":100},[],{"trials":4242,"activeCount":100},[],{"trials":4244,"activeCount":100},[],{"trials":4246,"activeCount":100},[],{"trials":4248,"activeCount":100},[4249],{"nctId":4224,"briefTitle":4225,"status":108,"phases":4250,"primaryCompletion":4227,"completion":4227,"start":4228,"enrollment":4229,"conditions":4251,"interventions":4252},[91],[4231],[4211,4233,4234],{"trials":4254,"activeCount":100},[],{"intervention":4234,"totalTrials":150,"cells":4256},{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4261,"PHASE3":4263,"PHASE4":4265,"NA":4271},{"trials":4258,"activeCount":100},[],{"trials":4260,"activeCount":100},[],{"trials":4262,"activeCount":100},[],{"trials":4264,"activeCount":100},[],{"trials":4266,"activeCount":100},[4267],{"nctId":4224,"briefTitle":4225,"status":108,"phases":4268,"primaryCompletion":4227,"completion":4227,"start":4228,"enrollment":4229,"conditions":4269,"interventions":4270},[91],[4231],[4211,4233,4234],{"trials":4272,"activeCount":100},[],{"intervention":3713,"totalTrials":150,"cells":4274},{"EARLY_PHASE1":4275,"PHASE1":4277,"PHASE2":4279,"PHASE3":4281,"PHASE4":4283,"NA":4289},{"trials":4276,"activeCount":100},[],{"trials":4278,"activeCount":100},[],{"trials":4280,"activeCount":100},[],{"trials":4282,"activeCount":100},[],{"trials":4284,"activeCount":100},[4285],{"nctId":3706,"briefTitle":3707,"status":108,"phases":4286,"primaryCompletion":3709,"completion":3709,"start":1349,"enrollment":832,"conditions":4287,"interventions":4288},[91],[3711],[3713,3714,3693],{"trials":4290,"activeCount":100},[],{"intervention":3714,"totalTrials":150,"cells":4292},{"EARLY_PHASE1":4293,"PHASE1":4295,"PHASE2":4297,"PHASE3":4299,"PHASE4":4301,"NA":4307},{"trials":4294,"activeCount":100},[],{"trials":4296,"activeCount":100},[],{"trials":4298,"activeCount":100},[],{"trials":4300,"activeCount":100},[],{"trials":4302,"activeCount":100},[4303],{"nctId":3706,"briefTitle":3707,"status":108,"phases":4304,"primaryCompletion":3709,"completion":3709,"start":1349,"enrollment":832,"conditions":4305,"interventions":4306},[91],[3711],[3713,3714,3693],{"trials":4308,"activeCount":100},[],{"intervention":176,"totalTrials":150,"cells":4310},{"EARLY_PHASE1":4311,"PHASE1":4313,"PHASE2":4315,"PHASE3":4317,"PHASE4":4319,"NA":4325},{"trials":4312,"activeCount":100},[],{"trials":4314,"activeCount":100},[],{"trials":4316,"activeCount":100},[],{"trials":4318,"activeCount":100},[],{"trials":4320,"activeCount":100},[4321],{"nctId":167,"briefTitle":168,"status":108,"phases":4322,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":4323,"interventions":4324},[91],[174],[176,154],{"trials":4326,"activeCount":100},[],{"intervention":3434,"totalTrials":150,"cells":4328},{"EARLY_PHASE1":4329,"PHASE1":4331,"PHASE2":4333,"PHASE3":4335,"PHASE4":4337,"NA":4343},{"trials":4330,"activeCount":100},[],{"trials":4332,"activeCount":100},[],{"trials":4334,"activeCount":100},[],{"trials":4336,"activeCount":100},[],{"trials":4338,"activeCount":100},[4339],{"nctId":3428,"briefTitle":3429,"status":108,"phases":4340,"primaryCompletion":64,"completion":64,"start":3367,"enrollment":1284,"conditions":4341,"interventions":4342},[91],[3432],[3434,3395,3435],{"trials":4344,"activeCount":100},[],{"intervention":3435,"totalTrials":150,"cells":4346},{"EARLY_PHASE1":4347,"PHASE1":4349,"PHASE2":4351,"PHASE3":4353,"PHASE4":4355,"NA":4361},{"trials":4348,"activeCount":100},[],{"trials":4350,"activeCount":100},[],{"trials":4352,"activeCount":100},[],{"trials":4354,"activeCount":100},[],{"trials":4356,"activeCount":100},[4357],{"nctId":3428,"briefTitle":3429,"status":108,"phases":4358,"primaryCompletion":64,"completion":64,"start":3367,"enrollment":1284,"conditions":4359,"interventions":4360},[91],[3432],[3434,3395,3435],{"trials":4362,"activeCount":100},[],{"intervention":4364,"totalTrials":150,"cells":4365},"Parcopa",{"EARLY_PHASE1":4366,"PHASE1":4368,"PHASE2":4370,"PHASE3":4372,"PHASE4":4374,"NA":4386},{"trials":4367,"activeCount":100},[],{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[4376],{"nctId":4377,"briefTitle":4378,"status":108,"phases":4379,"primaryCompletion":4380,"completion":3632,"start":4381,"enrollment":16,"conditions":4382,"interventions":4384},"NCT00590122","Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study",[91],"2008-10","2006-10",[4383],"Parkinson's Disease",[4364,4385],"carbidopa-levodopa",{"trials":4387,"activeCount":100},[],{"intervention":4385,"totalTrials":150,"cells":4389},{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4396,"PHASE4":4398,"NA":4404},{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[],{"trials":4395,"activeCount":100},[],{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":100},[4400],{"nctId":4377,"briefTitle":4378,"status":108,"phases":4401,"primaryCompletion":4380,"completion":3632,"start":4381,"enrollment":16,"conditions":4402,"interventions":4403},[91],[4383],[4364,4385],{"trials":4405,"activeCount":100},[],{"intervention":4407,"totalTrials":150,"cells":4408},"Dapagliflozin",{"EARLY_PHASE1":4409,"PHASE1":4411,"PHASE2":4413,"PHASE3":4415,"PHASE4":4417,"NA":4426},{"trials":4410,"activeCount":100},[],{"trials":4412,"activeCount":100},[],{"trials":4414,"activeCount":100},[],{"trials":4416,"activeCount":100},[],{"trials":4418,"activeCount":100},[4419],{"nctId":4420,"briefTitle":4421,"status":578,"phases":4422,"primaryCompletion":4423,"completion":4423,"start":1331,"enrollment":876,"conditions":4424,"interventions":4425},"NCT02608905","Effect of Dapagliflozin on Inflammation and Endothelial Function",[91],"2019-03",[3371],[4407],{"trials":4427,"activeCount":100},[],{"intervention":4429,"totalTrials":150,"cells":4430},"Artificial tear",{"EARLY_PHASE1":4431,"PHASE1":4433,"PHASE2":4435,"PHASE3":4437,"PHASE4":4439,"NA":4451},{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":100},[],{"trials":4438,"activeCount":100},[],{"trials":4440,"activeCount":100},[4441],{"nctId":4442,"briefTitle":4443,"status":108,"phases":4444,"primaryCompletion":64,"completion":64,"start":4445,"enrollment":16,"conditions":4446,"interventions":4449},"NCT01797822","Effects of Dry Eye Treatments on the Ocular Surface",[91],"2013-02",[4447,4448],"Keratoconjunctivitis Sicca","Dry Eye Syndrome",[4450,4429],"Dexamethasone",{"trials":4452,"activeCount":100},[],{"intervention":4454,"totalTrials":150,"cells":4455},"Botulinum toxin type A",{"EARLY_PHASE1":4456,"PHASE1":4458,"PHASE2":4460,"PHASE3":4462,"PHASE4":4464,"NA":4473},{"trials":4457,"activeCount":100},[],{"trials":4459,"activeCount":100},[],{"trials":4461,"activeCount":100},[],{"trials":4463,"activeCount":100},[],{"trials":4465,"activeCount":100},[4466],{"nctId":4467,"briefTitle":4468,"status":108,"phases":4469,"primaryCompletion":171,"completion":4038,"start":2575,"enrollment":1002,"conditions":4470,"interventions":4472},"NCT00908050","Study of the Safety and Efficacy of Botox in Bruxism",[91],[4471],"Bruxism",[4454],{"trials":4474,"activeCount":100},[],{"intervention":4476,"totalTrials":150,"cells":4477},"Saxagliptin",{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4482,"PHASE3":4484,"PHASE4":4486,"NA":4497},{"trials":4479,"activeCount":100},[],{"trials":4481,"activeCount":100},[],{"trials":4483,"activeCount":100},[],{"trials":4485,"activeCount":100},[],{"trials":4487,"activeCount":100},[4488],{"nctId":4489,"briefTitle":4490,"status":578,"phases":4491,"primaryCompletion":4492,"completion":4492,"start":4493,"enrollment":2638,"conditions":4494,"interventions":4496},"NCT01548651","Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation",[91],"2017-08-25","2012-02",[4495],"Impaired Glucose Tolerance",[4476],{"trials":4498,"activeCount":100},[],{"intervention":3784,"totalTrials":150,"cells":4500},{"EARLY_PHASE1":4501,"PHASE1":4503,"PHASE2":4505,"PHASE3":4507,"PHASE4":4509,"NA":4515},{"trials":4502,"activeCount":100},[],{"trials":4504,"activeCount":100},[],{"trials":4506,"activeCount":100},[],{"trials":4508,"activeCount":100},[],{"trials":4510,"activeCount":100},[4511],{"nctId":3778,"briefTitle":3779,"status":180,"phases":4512,"primaryCompletion":3781,"completion":79,"start":64,"enrollment":100,"conditions":4513,"interventions":4514},[91],[3513],[3727,3784],{"trials":4516,"activeCount":100},[],{"intervention":4518,"totalTrials":150,"cells":4519},"Fidaxomicin 200 mg",{"EARLY_PHASE1":4520,"PHASE1":4522,"PHASE2":4524,"PHASE3":4526,"PHASE4":4528,"NA":4540},{"trials":4521,"activeCount":100},[],{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[],{"trials":4529,"activeCount":100},[4530],{"nctId":4531,"briefTitle":4532,"status":578,"phases":4533,"primaryCompletion":4534,"completion":4534,"start":2252,"enrollment":24,"conditions":4535,"interventions":4538},"NCT02355938","Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury",[91],"2016-10",[4536,4537],"Clostridium Difficile","Spinal Cord Injury",[4518,4539],"Vancomycin",{"trials":4541,"activeCount":100},[],{"intervention":4539,"totalTrials":150,"cells":4543},{"EARLY_PHASE1":4544,"PHASE1":4546,"PHASE2":4548,"PHASE3":4550,"PHASE4":4552,"NA":4558},{"trials":4545,"activeCount":100},[],{"trials":4547,"activeCount":100},[],{"trials":4549,"activeCount":100},[],{"trials":4551,"activeCount":100},[],{"trials":4553,"activeCount":100},[4554],{"nctId":4531,"briefTitle":4532,"status":578,"phases":4555,"primaryCompletion":4534,"completion":4534,"start":2252,"enrollment":24,"conditions":4556,"interventions":4557},[91],[4536,4537],[4518,4539],{"trials":4559,"activeCount":100},[],{"intervention":4561,"totalTrials":150,"cells":4562},"LUBIPROSTONE",{"EARLY_PHASE1":4563,"PHASE1":4565,"PHASE2":4567,"PHASE3":4569,"PHASE4":4571,"NA":4579},{"trials":4564,"activeCount":100},[],{"trials":4566,"activeCount":100},[],{"trials":4568,"activeCount":100},[],{"trials":4570,"activeCount":100},[],{"trials":4572,"activeCount":100},[4573],{"nctId":4574,"briefTitle":4575,"status":108,"phases":4576,"primaryCompletion":1104,"completion":1104,"start":1103,"enrollment":3685,"conditions":4577,"interventions":4578},"NCT00908076","Amitiza in Constipation Associated With PD (Parkinson's Disease)",[91],[4383],[4561],{"trials":4580,"activeCount":100},[],{"intervention":4582,"totalTrials":150,"cells":4583},"Zelapar",{"EARLY_PHASE1":4584,"PHASE1":4586,"PHASE2":4588,"PHASE3":4590,"PHASE4":4592,"NA":4603},{"trials":4585,"activeCount":100},[],{"trials":4587,"activeCount":100},[],{"trials":4589,"activeCount":100},[],{"trials":4591,"activeCount":100},[],{"trials":4593,"activeCount":100},[4594],{"nctId":4595,"briefTitle":4596,"status":108,"phases":4597,"primaryCompletion":4598,"completion":4599,"start":4600,"enrollment":3749,"conditions":4601,"interventions":4602},"NCT00640159","Selegiline to Zelapar Switch Study in Parkinson Disease Patients",[91],"2008-06","2008-08","2007-01",[4383],[4582],{"trials":4604,"activeCount":100},[],{"intervention":3724,"totalTrials":150,"cells":4606},{"EARLY_PHASE1":4607,"PHASE1":4609,"PHASE2":4611,"PHASE3":4613,"PHASE4":4615,"NA":4621},{"trials":4608,"activeCount":100},[],{"trials":4610,"activeCount":100},[],{"trials":4612,"activeCount":100},[],{"trials":4614,"activeCount":100},[],{"trials":4616,"activeCount":100},[4617],{"nctId":3716,"briefTitle":3717,"status":108,"phases":4618,"primaryCompletion":3719,"completion":3719,"start":1403,"enrollment":3720,"conditions":4619,"interventions":4620},[91],[3722],[3693,3724,3725,3726,3727],{"trials":4622,"activeCount":100},[],{"intervention":3725,"totalTrials":150,"cells":4624},{"EARLY_PHASE1":4625,"PHASE1":4627,"PHASE2":4629,"PHASE3":4631,"PHASE4":4633,"NA":4639},{"trials":4626,"activeCount":100},[],{"trials":4628,"activeCount":100},[],{"trials":4630,"activeCount":100},[],{"trials":4632,"activeCount":100},[],{"trials":4634,"activeCount":100},[4635],{"nctId":3716,"briefTitle":3717,"status":108,"phases":4636,"primaryCompletion":3719,"completion":3719,"start":1403,"enrollment":3720,"conditions":4637,"interventions":4638},[91],[3722],[3693,3724,3725,3726,3727],{"trials":4640,"activeCount":100},[],{"intervention":3726,"totalTrials":150,"cells":4642},{"EARLY_PHASE1":4643,"PHASE1":4645,"PHASE2":4647,"PHASE3":4649,"PHASE4":4651,"NA":4657},{"trials":4644,"activeCount":100},[],{"trials":4646,"activeCount":100},[],{"trials":4648,"activeCount":100},[],{"trials":4650,"activeCount":100},[],{"trials":4652,"activeCount":100},[4653],{"nctId":3716,"briefTitle":3717,"status":108,"phases":4654,"primaryCompletion":3719,"completion":3719,"start":1403,"enrollment":3720,"conditions":4655,"interventions":4656},[91],[3722],[3693,3724,3725,3726,3727],{"trials":4658,"activeCount":100},[],{"intervention":4660,"totalTrials":150,"cells":4661},"Memantine",{"EARLY_PHASE1":4662,"PHASE1":4664,"PHASE2":4666,"PHASE3":4668,"PHASE4":4670,"NA":4679},{"trials":4663,"activeCount":100},[],{"trials":4665,"activeCount":100},[],{"trials":4667,"activeCount":100},[],{"trials":4669,"activeCount":100},[],{"trials":4671,"activeCount":100},[4672],{"nctId":4673,"briefTitle":4674,"status":108,"phases":4675,"primaryCompletion":1103,"completion":4676,"start":2637,"enrollment":282,"conditions":4677,"interventions":4678},"NCT00646204","Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease",[91],"2009-03",[4383],[4660],{"trials":4680,"activeCount":100},[],{"intervention":4682,"totalTrials":150,"cells":4683},"Lantus and short acting analogs Vs NPH and short acting analogs",{"EARLY_PHASE1":4684,"PHASE1":4686,"PHASE2":4688,"PHASE3":4690,"PHASE4":4692,"NA":4700},{"trials":4685,"activeCount":100},[],{"trials":4687,"activeCount":100},[],{"trials":4689,"activeCount":100},[],{"trials":4691,"activeCount":100},[],{"trials":4693,"activeCount":100},[4694],{"nctId":4695,"briefTitle":4696,"status":108,"phases":4697,"completion":4381,"start":3959,"enrollment":133,"conditions":4698,"interventions":4699},"NCT00206401","Lantus in the Treatment of Type 1 Diabetes Children",[91],[3432],[4682],{"trials":4701,"activeCount":100},[],{"intervention":4703,"totalTrials":150,"cells":4704},"Anastrazole",{"EARLY_PHASE1":4705,"PHASE1":4707,"PHASE2":4709,"PHASE3":4711,"PHASE4":4713,"NA":4725},{"trials":4706,"activeCount":100},[],{"trials":4708,"activeCount":100},[],{"trials":4710,"activeCount":100},[],{"trials":4712,"activeCount":100},[],{"trials":4714,"activeCount":100},[4715],{"nctId":4716,"briefTitle":4717,"status":108,"phases":4718,"primaryCompletion":4719,"completion":4720,"start":1431,"enrollment":1002,"conditions":4721,"interventions":4724},"NCT02959853","Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)",[91],"2018-11-20","2018-12-20",[4722,4723],"Hypogonadism","Severe Obesity",[4703],{"trials":4726,"activeCount":100},[],{"intervention":4728,"totalTrials":150,"cells":4729},"anastrozole",{"EARLY_PHASE1":4730,"PHASE1":4732,"PHASE2":4734,"PHASE3":4736,"PHASE4":4738,"NA":4750},{"trials":4731,"activeCount":100},[],{"trials":4733,"activeCount":100},[],{"trials":4735,"activeCount":100},[],{"trials":4737,"activeCount":100},[],{"trials":4739,"activeCount":100},[4740],{"nctId":4741,"briefTitle":4742,"status":108,"phases":4743,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":4746,"conditions":4747,"interventions":4749},"NCT03490513","Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism",[91],"2025-05-31","2018-04-15",121,[4748,15],"Hypogonadism, Hypogonadotropic",[4728],{"trials":4751,"activeCount":100},[],{"intervention":4753,"totalTrials":150,"cells":4754},"Hydromorphone",{"EARLY_PHASE1":4755,"PHASE1":4757,"PHASE2":4759,"PHASE3":4761,"PHASE4":4763,"NA":4775},{"trials":4756,"activeCount":100},[],{"trials":4758,"activeCount":100},[],{"trials":4760,"activeCount":100},[],{"trials":4762,"activeCount":100},[],{"trials":4764,"activeCount":100},[4765],{"nctId":4766,"briefTitle":4767,"status":578,"phases":4768,"primaryCompletion":4769,"completion":84,"start":4770,"enrollment":113,"conditions":4771,"interventions":4773},"NCT02056301","A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excavatum Repair",[91],"2019-04-10","2012-08",[4772],"Pectus Excavatum",[4753,4774],"Morphine",{"trials":4776,"activeCount":100},[],{"intervention":4778,"totalTrials":150,"cells":4779},"Ibuprofen",{"EARLY_PHASE1":4780,"PHASE1":4782,"PHASE2":4784,"PHASE3":4786,"PHASE4":4788,"NA":4802},{"trials":4781,"activeCount":100},[],{"trials":4783,"activeCount":100},[],{"trials":4785,"activeCount":100},[],{"trials":4787,"activeCount":100},[],{"trials":4789,"activeCount":100},[4790],{"nctId":4791,"briefTitle":4792,"status":578,"phases":4793,"primaryCompletion":4794,"completion":4794,"start":4795,"enrollment":4796,"conditions":4797,"interventions":4799},"NCT05640674","Post-operative Pain Management in Children With Supracondylar Humerus Fractures",[91],"2025-12-15","2023-09-12",29,[4798],"Supracondylar Humerus Fracture",[4778,4800,4801],"Hydrocodone\u002Facetaminophen","Acetaminophen",{"trials":4803,"activeCount":100},[],{"intervention":4801,"totalTrials":150,"cells":4805},{"EARLY_PHASE1":4806,"PHASE1":4808,"PHASE2":4810,"PHASE3":4812,"PHASE4":4814,"NA":4820},{"trials":4807,"activeCount":100},[],{"trials":4809,"activeCount":100},[],{"trials":4811,"activeCount":100},[],{"trials":4813,"activeCount":100},[],{"trials":4815,"activeCount":100},[4816],{"nctId":4791,"briefTitle":4792,"status":578,"phases":4817,"primaryCompletion":4794,"completion":4794,"start":4795,"enrollment":4796,"conditions":4818,"interventions":4819},[91],[4798],[4778,4800,4801],{"trials":4821,"activeCount":100},[],{"intervention":4823,"totalTrials":150,"cells":4824},"Byetta",{"EARLY_PHASE1":4825,"PHASE1":4827,"PHASE2":4829,"PHASE3":4831,"PHASE4":4833,"NA":4843},{"trials":4826,"activeCount":100},[],{"trials":4828,"activeCount":100},[],{"trials":4830,"activeCount":100},[],{"trials":4832,"activeCount":100},[],{"trials":4834,"activeCount":100},[4835],{"nctId":4836,"briefTitle":4837,"status":108,"phases":4838,"primaryCompletion":4227,"completion":4227,"start":1048,"enrollment":1240,"conditions":4839,"interventions":4841},"NCT00950677","The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes",[91],[4840],"Type 2 Diabetes",[4823,4842],"Symlin",{"trials":4844,"activeCount":100},[],{"intervention":4842,"totalTrials":150,"cells":4846},{"EARLY_PHASE1":4847,"PHASE1":4849,"PHASE2":4851,"PHASE3":4853,"PHASE4":4855,"NA":4861},{"trials":4848,"activeCount":100},[],{"trials":4850,"activeCount":100},[],{"trials":4852,"activeCount":100},[],{"trials":4854,"activeCount":100},[],{"trials":4856,"activeCount":100},[4857],{"nctId":4836,"briefTitle":4837,"status":108,"phases":4858,"primaryCompletion":4227,"completion":4227,"start":1048,"enrollment":1240,"conditions":4859,"interventions":4860},[91],[4840],[4823,4842],{"trials":4862,"activeCount":100},[],{"intervention":4864,"totalTrials":394,"cells":4865},"Naltrexone",{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4870,"PHASE3":4880,"PHASE4":4892,"NA":4894},{"trials":4867,"activeCount":100},[],{"trials":4869,"activeCount":100},[],{"trials":4871,"activeCount":100},[4872],{"nctId":4873,"briefTitle":4874,"status":108,"phases":4875,"primaryCompletion":4227,"completion":4227,"start":3511,"enrollment":4876,"conditions":4877,"interventions":4879},"NCT00142948","Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts",[89],301,[4878],"Heroin Dependence",[4864],{"trials":4881,"activeCount":100},[4882],{"nctId":4883,"briefTitle":4884,"status":108,"phases":4885,"primaryCompletion":4886,"completion":4886,"start":4887,"enrollment":2638,"conditions":4888,"interventions":4890},"NCT05458609","Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep",[90],"2024-01-30","2023-02-09",[4889],"Alcohol Use Disorder",[4891,4864],"Lemborexant 10 mg",{"trials":4893,"activeCount":100},[],{"trials":4895,"activeCount":100},[],{"intervention":4897,"totalTrials":394,"cells":4898},"Topiramate",{"EARLY_PHASE1":4899,"PHASE1":4901,"PHASE2":4903,"PHASE3":4905,"PHASE4":4922,"NA":4924},{"trials":4900,"activeCount":100},[],{"trials":4902,"activeCount":100},[],{"trials":4904,"activeCount":100},[],{"trials":4906,"activeCount":100},[4907,4915],{"nctId":4908,"briefTitle":4909,"status":108,"phases":4910,"primaryCompletion":2205,"completion":2205,"start":4911,"enrollment":4796,"conditions":4912,"interventions":4914},"NCT00206323","A Randomized, Placebo-controlled, Tourette Syndrome Study.",[90],"2004-09",[4913],"Tourette Syndrome",[4897],{"nctId":4916,"briefTitle":4917,"status":108,"phases":4918,"primaryCompletion":2205,"completion":2205,"start":4919,"enrollment":16,"conditions":4920,"interventions":4921},"NCT00206336","An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.",[90],"2004-10",[4913],[4897],{"trials":4923,"activeCount":100},[],{"trials":4925,"activeCount":100},[],{"intervention":4927,"totalTrials":150,"cells":4928},"chlorhexidine-alcohol",{"EARLY_PHASE1":4929,"PHASE1":4931,"PHASE2":4933,"PHASE3":4935,"PHASE4":4947,"NA":4949},{"trials":4930,"activeCount":100},[],{"trials":4932,"activeCount":100},[],{"trials":4934,"activeCount":100},[],{"trials":4936,"activeCount":100},[4937],{"nctId":4938,"briefTitle":4939,"status":108,"phases":4940,"primaryCompletion":4228,"completion":4228,"start":4941,"enrollment":4942,"conditions":4943,"interventions":4945},"NCT00290290","Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections",[90],"2003-09",849,[4944],"Postoperative Wound Infection",[4927,4946],"Povidone-Iodine",{"trials":4948,"activeCount":100},[],{"trials":4950,"activeCount":100},[],{"intervention":4946,"totalTrials":150,"cells":4952},{"EARLY_PHASE1":4953,"PHASE1":4955,"PHASE2":4957,"PHASE3":4959,"PHASE4":4965,"NA":4967},{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"trials":4958,"activeCount":100},[],{"trials":4960,"activeCount":100},[4961],{"nctId":4938,"briefTitle":4939,"status":108,"phases":4962,"primaryCompletion":4228,"completion":4228,"start":4941,"enrollment":4942,"conditions":4963,"interventions":4964},[90],[4944],[4927,4946],{"trials":4966,"activeCount":100},[],{"trials":4968,"activeCount":100},[],{"intervention":4970,"totalTrials":150,"cells":4971},"Pramlintide and glucagon",{"EARLY_PHASE1":4972,"PHASE1":4974,"PHASE2":4976,"PHASE3":4978,"PHASE4":4987,"NA":4989},{"trials":4973,"activeCount":100},[],{"trials":4975,"activeCount":100},[],{"trials":4977,"activeCount":100},[],{"trials":4979,"activeCount":100},[4980],{"nctId":4981,"briefTitle":4982,"status":108,"phases":4983,"completion":1368,"start":4984,"enrollment":832,"conditions":4985,"interventions":4986},"NCT00206258","The Role of Amylin and Glucagon in T1DM",[90],"2002-07",[3432],[4970],{"trials":4988,"activeCount":100},[],{"trials":4990,"activeCount":100},[],{"intervention":4992,"totalTrials":150,"cells":4993},"Enclomiphene citrate",{"EARLY_PHASE1":4994,"PHASE1":4996,"PHASE2":4998,"PHASE3":5000,"PHASE4":5011,"NA":5013},{"trials":4995,"activeCount":100},[],{"trials":4997,"activeCount":100},[],{"trials":4999,"activeCount":100},[],{"trials":5001,"activeCount":100},[5002],{"nctId":5003,"briefTitle":5004,"status":180,"phases":5005,"primaryCompletion":5006,"completion":5006,"start":5007,"enrollment":100,"conditions":5008,"interventions":5010},"NCT02160704","Androxal in Male Infertility",[89,90],"2016-08-02","2014-09-22",[5009],"Infertility",[4992],{"trials":5012,"activeCount":100},[],{"trials":5014,"activeCount":100},[],{"intervention":5016,"totalTrials":150,"cells":5017},"Tropisetron",{"EARLY_PHASE1":5018,"PHASE1":5020,"PHASE2":5022,"PHASE3":5024,"PHASE4":5038,"NA":5040},{"trials":5019,"activeCount":100},[],{"trials":5021,"activeCount":100},[],{"trials":5023,"activeCount":100},[],{"trials":5025,"activeCount":100},[5026],{"nctId":5027,"briefTitle":5028,"status":108,"phases":5029,"primaryCompletion":5030,"completion":171,"start":5031,"enrollment":5032,"conditions":5033,"interventions":5036},"NCT00435370","Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia",[90],"2011-02","2006-11",179,[5034,5035],"Smoking Cessation","Schizophrenia",[5016,5037],"Risperidone",{"trials":5039,"activeCount":100},[],{"trials":5041,"activeCount":100},[],{"intervention":5037,"totalTrials":150,"cells":5043},{"EARLY_PHASE1":5044,"PHASE1":5046,"PHASE2":5048,"PHASE3":5050,"PHASE4":5056,"NA":5058},{"trials":5045,"activeCount":100},[],{"trials":5047,"activeCount":100},[],{"trials":5049,"activeCount":100},[],{"trials":5051,"activeCount":100},[5052],{"nctId":5027,"briefTitle":5028,"status":108,"phases":5053,"primaryCompletion":5030,"completion":171,"start":5031,"enrollment":5032,"conditions":5054,"interventions":5055},[90],[5034,5035],[5016,5037],{"trials":5057,"activeCount":100},[],{"trials":5059,"activeCount":100},[],{"intervention":5061,"totalTrials":150,"cells":5062},"Eltrombopag",{"EARLY_PHASE1":5063,"PHASE1":5065,"PHASE2":5067,"PHASE3":5069,"PHASE4":5085,"NA":5087},{"trials":5064,"activeCount":100},[],{"trials":5066,"activeCount":100},[],{"trials":5068,"activeCount":100},[],{"trials":5070,"activeCount":100},[5071],{"nctId":5072,"briefTitle":5073,"status":108,"phases":5074,"primaryCompletion":5075,"completion":5076,"start":5077,"enrollment":5078,"conditions":5079,"interventions":5081},"NCT03939637","Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children",[90],"2024-04-17","2025-02-26","2019-05-02",122,[5080],"Immune Thrombocytopenia",[5061,5082,5083,5084],"Steroids","IVIG","Rho(D) Immune Globulin",{"trials":5086,"activeCount":100},[],{"trials":5088,"activeCount":100},[],{"intervention":5082,"totalTrials":150,"cells":5090},{"EARLY_PHASE1":5091,"PHASE1":5093,"PHASE2":5095,"PHASE3":5097,"PHASE4":5103,"NA":5105},{"trials":5092,"activeCount":100},[],{"trials":5094,"activeCount":100},[],{"trials":5096,"activeCount":100},[],{"trials":5098,"activeCount":100},[5099],{"nctId":5072,"briefTitle":5073,"status":108,"phases":5100,"primaryCompletion":5075,"completion":5076,"start":5077,"enrollment":5078,"conditions":5101,"interventions":5102},[90],[5080],[5061,5082,5083,5084],{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"intervention":5083,"totalTrials":150,"cells":5108},{"EARLY_PHASE1":5109,"PHASE1":5111,"PHASE2":5113,"PHASE3":5115,"PHASE4":5121,"NA":5123},{"trials":5110,"activeCount":100},[],{"trials":5112,"activeCount":100},[],{"trials":5114,"activeCount":100},[],{"trials":5116,"activeCount":100},[5117],{"nctId":5072,"briefTitle":5073,"status":108,"phases":5118,"primaryCompletion":5075,"completion":5076,"start":5077,"enrollment":5078,"conditions":5119,"interventions":5120},[90],[5080],[5061,5082,5083,5084],{"trials":5122,"activeCount":100},[],{"trials":5124,"activeCount":100},[],{"intervention":5084,"totalTrials":150,"cells":5126},{"EARLY_PHASE1":5127,"PHASE1":5129,"PHASE2":5131,"PHASE3":5133,"PHASE4":5139,"NA":5141},{"trials":5128,"activeCount":100},[],{"trials":5130,"activeCount":100},[],{"trials":5132,"activeCount":100},[],{"trials":5134,"activeCount":100},[5135],{"nctId":5072,"briefTitle":5073,"status":108,"phases":5136,"primaryCompletion":5075,"completion":5076,"start":5077,"enrollment":5078,"conditions":5137,"interventions":5138},[90],[5080],[5061,5082,5083,5084],{"trials":5140,"activeCount":100},[],{"trials":5142,"activeCount":100},[],{"intervention":5144,"totalTrials":150,"cells":5145},"Finasteride",{"EARLY_PHASE1":5146,"PHASE1":5148,"PHASE2":5150,"PHASE3":5152,"PHASE4":5161,"NA":5163},{"trials":5147,"activeCount":100},[],{"trials":5149,"activeCount":100},[],{"trials":5151,"activeCount":100},[],{"trials":5153,"activeCount":100},[5154],{"nctId":5155,"briefTitle":5156,"status":180,"phases":5157,"primaryCompletion":1732,"completion":1732,"start":1732,"enrollment":100,"conditions":5158,"interventions":5160},"NCT02548117","H-36731: Finasteride in Management of Elevated Red Blood Cells",[90],[5159],"ERYTHROCYTOSIS",[5144],{"trials":5162,"activeCount":100},[],{"trials":5164,"activeCount":100},[],{"intervention":5166,"totalTrials":150,"cells":5167},"Donepezil",{"EARLY_PHASE1":5168,"PHASE1":5170,"PHASE2":5172,"PHASE3":5174,"PHASE4":5186,"NA":5188},{"trials":5169,"activeCount":100},[],{"trials":5171,"activeCount":100},[],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[5176],{"nctId":5177,"briefTitle":5178,"status":108,"phases":5179,"primaryCompletion":5180,"completion":5180,"start":5181,"enrollment":5182,"conditions":5183,"interventions":5185},"NCT02255799","Multicenter Evaluation of Memory Remediation After TBI With Donepezil",[90],"2024-12-04","2013-09-01",75,[3499,5184],"Memory Deficits",[5166],{"trials":5187,"activeCount":100},[],{"trials":5189,"activeCount":100},[],{"intervention":5191,"totalTrials":150,"cells":5192},"Steroid arm",{"EARLY_PHASE1":5193,"PHASE1":5195,"PHASE2":5197,"PHASE3":5199,"PHASE4":5210,"NA":5212},{"trials":5194,"activeCount":100},[],{"trials":5196,"activeCount":100},[],{"trials":5198,"activeCount":100},[],{"trials":5200,"activeCount":100},[5201],{"nctId":5202,"briefTitle":5203,"status":578,"phases":5204,"primaryCompletion":5205,"completion":5205,"start":5206,"enrollment":1765,"conditions":5207,"interventions":5209},"NCT00263562","Steroid Treatment for Sickle Cell Pain Crisis",[90],"2008-06-13","2005-12-01",[3407,5208],"Vaso-occlusive Crisis",[5191],{"trials":5211,"activeCount":100},[],{"trials":5213,"activeCount":100},[],{"intervention":5215,"totalTrials":150,"cells":5216},"oral trimethoprim\u002Fsulfamethoxazole",{"EARLY_PHASE1":5217,"PHASE1":5219,"PHASE2":5221,"PHASE3":5223,"PHASE4":5233,"NA":5235},{"trials":5218,"activeCount":100},[],{"trials":5220,"activeCount":100},[],{"trials":5222,"activeCount":100},[],{"trials":5224,"activeCount":100},[5225],{"nctId":5226,"briefTitle":5227,"status":108,"phases":5228,"primaryCompletion":3369,"completion":3369,"start":5229,"enrollment":1002,"conditions":5230,"interventions":5232},"NCT00691600","Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage",[90],"2007-12",[5231],"Abscess",[5215],{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[],{"intervention":5238,"totalTrials":150,"cells":5239},"Sertraline",{"EARLY_PHASE1":5240,"PHASE1":5242,"PHASE2":5244,"PHASE3":5246,"PHASE4":5254,"NA":5256},{"trials":5241,"activeCount":100},[],{"trials":5243,"activeCount":100},[],{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[5248],{"nctId":5249,"briefTitle":5250,"status":108,"phases":5251,"primaryCompletion":1079,"completion":1079,"start":4598,"enrollment":1463,"conditions":5252,"interventions":5253},"NCT00704379","Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury",[89,90],[3499],[5238],{"trials":5255,"activeCount":100},[],{"trials":5257,"activeCount":100},[],{"intervention":4891,"totalTrials":150,"cells":5259},{"EARLY_PHASE1":5260,"PHASE1":5262,"PHASE2":5264,"PHASE3":5266,"PHASE4":5272,"NA":5274},{"trials":5261,"activeCount":100},[],{"trials":5263,"activeCount":100},[],{"trials":5265,"activeCount":100},[],{"trials":5267,"activeCount":100},[5268],{"nctId":4883,"briefTitle":4884,"status":108,"phases":5269,"primaryCompletion":4886,"completion":4886,"start":4887,"enrollment":2638,"conditions":5270,"interventions":5271},[90],[4889],[4891,4864],{"trials":5273,"activeCount":100},[],{"trials":5275,"activeCount":100},[],{"intervention":5277,"totalTrials":150,"cells":5278},"labetalol",{"EARLY_PHASE1":5279,"PHASE1":5281,"PHASE2":5283,"PHASE3":5285,"PHASE4":5299,"NA":5301},{"trials":5280,"activeCount":100},[],{"trials":5282,"activeCount":100},[],{"trials":5284,"activeCount":100},[],{"trials":5286,"activeCount":100},[5287],{"nctId":5288,"briefTitle":5289,"status":180,"phases":5290,"primaryCompletion":3459,"completion":3459,"start":3496,"enrollment":100,"conditions":5291,"interventions":5297},"NCT00293735","Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial",[89,90],[5292,5293,5294,5295,5296],"Preeclampsia","Pregnancy Induced Hypertension","Gestational Hypertension","Chronic Hypertension","Superimposed Preeclampsia",[5277,5298],"MgSO4",{"trials":5300,"activeCount":100},[],{"trials":5302,"activeCount":100},[],{"intervention":5298,"totalTrials":150,"cells":5304},{"EARLY_PHASE1":5305,"PHASE1":5307,"PHASE2":5309,"PHASE3":5311,"PHASE4":5317,"NA":5319},{"trials":5306,"activeCount":100},[],{"trials":5308,"activeCount":100},[],{"trials":5310,"activeCount":100},[],{"trials":5312,"activeCount":100},[5313],{"nctId":5288,"briefTitle":5289,"status":180,"phases":5314,"primaryCompletion":3459,"completion":3459,"start":3496,"enrollment":100,"conditions":5315,"interventions":5316},[89,90],[5292,5293,5294,5295,5296],[5277,5298],{"trials":5318,"activeCount":100},[],{"trials":5320,"activeCount":100},[],{"intervention":5322,"totalTrials":150,"cells":5323},"Dermacell",{"EARLY_PHASE1":5324,"PHASE1":5326,"PHASE2":5328,"PHASE3":5330,"PHASE4":5345,"NA":5347},{"trials":5325,"activeCount":100},[],{"trials":5327,"activeCount":100},[],{"trials":5329,"activeCount":100},[],{"trials":5331,"activeCount":100},[5332],{"nctId":5333,"briefTitle":5334,"status":108,"phases":5335,"primaryCompletion":5336,"completion":5337,"start":5338,"enrollment":5339,"conditions":5340,"interventions":5343},"NCT03476876","Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers",[89,90],"2020-10-29","2021-04-02","2018-04-02",34,[5341,5342],"Diabetic Foot Ulcer","Deep Diabetic Foot Ulcer",[5322,5344],"Integra",{"trials":5346,"activeCount":100},[],{"trials":5348,"activeCount":100},[],{"intervention":5344,"totalTrials":150,"cells":5350},{"EARLY_PHASE1":5351,"PHASE1":5353,"PHASE2":5355,"PHASE3":5357,"PHASE4":5363,"NA":5365},{"trials":5352,"activeCount":100},[],{"trials":5354,"activeCount":100},[],{"trials":5356,"activeCount":100},[],{"trials":5358,"activeCount":100},[5359],{"nctId":5333,"briefTitle":5334,"status":108,"phases":5360,"primaryCompletion":5336,"completion":5337,"start":5338,"enrollment":5339,"conditions":5361,"interventions":5362},[89,90],[5341,5342],[5322,5344],{"trials":5364,"activeCount":100},[],{"trials":5366,"activeCount":100},[],{"intervention":5368,"totalTrials":150,"cells":5369},"Sodium Chloride 0.9%",{"EARLY_PHASE1":5370,"PHASE1":5372,"PHASE2":5374,"PHASE3":5376,"PHASE4":5389,"NA":5391},{"trials":5371,"activeCount":100},[],{"trials":5373,"activeCount":100},[],{"trials":5375,"activeCount":100},[],{"trials":5377,"activeCount":100},[5378],{"nctId":5379,"briefTitle":5380,"status":180,"phases":5381,"primaryCompletion":5382,"completion":5383,"start":5384,"enrollment":100,"conditions":5385,"interventions":5387},"NCT02329756","Tranexamic Acid in Adherent Placenta (TAP)",[90],"2020-12","2021-12","2018-12",[5386],"Placenta Accreta",[5388,5368],"Tranexamic Acid",{"trials":5390,"activeCount":100},[],{"trials":5392,"activeCount":100},[],{"intervention":1098,"totalTrials":1298,"cells":5394},{"EARLY_PHASE1":5395,"PHASE1":5397,"PHASE2":5407,"PHASE3":5425,"PHASE4":5427,"NA":5429},{"trials":5396,"activeCount":100},[],{"trials":5398,"activeCount":100},[5399,5403],{"nctId":1294,"briefTitle":1295,"status":108,"phases":5400,"primaryCompletion":1167,"completion":1167,"start":1297,"enrollment":1298,"conditions":5401,"interventions":5402},[88],[1300],[1097,1098,1302,1038,1303],{"nctId":1045,"briefTitle":1046,"status":578,"phases":5404,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":150,"conditions":5405,"interventions":5406},[88],[1051],[518,1053,1054,1055],{"trials":5408,"activeCount":100},[5409,5413,5417,5421],{"nctId":1088,"briefTitle":1089,"status":578,"phases":5410,"primaryCompletion":600,"completion":600,"start":1091,"enrollment":1092,"conditions":5411,"interventions":5412},[88,89],[1094,1095],[1097,1098,518],{"nctId":1142,"briefTitle":1143,"status":578,"phases":5414,"primaryCompletion":1145,"completion":1145,"start":1146,"enrollment":394,"conditions":5415,"interventions":5416},[88,89],[1148],[1097,1098,1150,518],{"nctId":1164,"briefTitle":1165,"status":578,"phases":5418,"primaryCompletion":1167,"completion":1167,"start":1168,"enrollment":96,"conditions":5419,"interventions":5420},[88,89],[1170,1171,1172,1173],[1175,518,1098],{"nctId":1210,"briefTitle":1211,"status":108,"phases":5422,"primaryCompletion":1213,"completion":1214,"start":1215,"enrollment":1216,"conditions":5423,"interventions":5424},[88,89],[1218],[1220,1097,1150,518],{"trials":5426,"activeCount":100},[],{"trials":5428,"activeCount":100},[],{"trials":5430,"activeCount":100},[],{"intervention":5432,"totalTrials":1298,"cells":5433},"Doxazosin",{"EARLY_PHASE1":5434,"PHASE1":5436,"PHASE2":5484,"PHASE3":5493,"PHASE4":5495,"NA":5497},{"trials":5435,"activeCount":100},[],{"trials":5437,"activeCount":100},[5438,5448,5455,5464,5474],{"nctId":5439,"briefTitle":5440,"status":108,"phases":5441,"primaryCompletion":5442,"completion":5442,"start":5443,"enrollment":1350,"conditions":5444,"interventions":5447},"NCT01062945","The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine",[88],"2011-01","2010-01",[5445,5446,23,21],"Cocaine Addiction","Cocaine Abuse",[5432],{"nctId":5449,"briefTitle":5450,"status":108,"phases":5451,"primaryCompletion":5452,"completion":3812,"start":600,"enrollment":2297,"conditions":5453,"interventions":5454},"NCT00880997","The Efficacy of Doxazosin for Cocaine Users",[88],"2011-04",[23],[5432],{"nctId":5456,"briefTitle":5457,"status":108,"phases":5458,"primaryCompletion":5459,"completion":5459,"start":2848,"enrollment":832,"conditions":5460,"interventions":5461},"NCT02308202","DOXAZOSIN FOR PTSD",[88],"2014-06-30",[974],[5462,5463],"doxazosin","Perindopril",{"nctId":5465,"briefTitle":5466,"status":108,"phases":5467,"primaryCompletion":5468,"completion":5468,"start":5469,"enrollment":27,"conditions":5470,"interventions":5472},"NCT02785393","DOX as a Potential Treatment for Methamphetamine Dependence",[88],"2016-03","2011-03",[5471],"Substance-Related Disorders",[5473,5432],"Sugar Pill",{"nctId":5475,"briefTitle":5476,"status":108,"phases":5477,"primaryCompletion":5478,"completion":5478,"start":5479,"enrollment":3191,"conditions":5480,"interventions":5481},"NCT02538744","Complementary Combination Therapy for Cocaine Dependence",[88],"2018-08-21","2015-08",[23],[5432,5482,5483],"Modafinil","cocaine",{"trials":5485,"activeCount":100},[5486],{"nctId":5487,"briefTitle":5488,"status":108,"phases":5489,"primaryCompletion":111,"completion":111,"start":1629,"enrollment":5490,"conditions":5491,"interventions":5492},"NCT01145183","Pharmacogenetics of Doxazosin for Cocaine Dependence",[89],96,[23],[5432],{"trials":5494,"activeCount":100},[],{"trials":5496,"activeCount":100},[],{"trials":5498,"activeCount":100},[],{"intervention":1150,"totalTrials":1106,"cells":5500},{"EARLY_PHASE1":5501,"PHASE1":5503,"PHASE2":5505,"PHASE3":5523,"PHASE4":5525,"NA":5527},{"trials":5502,"activeCount":100},[],{"trials":5504,"activeCount":100},[],{"trials":5506,"activeCount":100},[5507,5511,5515,5519],{"nctId":1142,"briefTitle":1143,"status":578,"phases":5508,"primaryCompletion":1145,"completion":1145,"start":1146,"enrollment":394,"conditions":5509,"interventions":5510},[88,89],[1148],[1097,1098,1150,518],{"nctId":1177,"briefTitle":1178,"status":578,"phases":5512,"primaryCompletion":1180,"completion":1180,"start":1122,"enrollment":972,"conditions":5513,"interventions":5514},[89],[1182,1183,1184],[1186,1187,1150,1188],{"nctId":1190,"briefTitle":1191,"status":578,"phases":5516,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":282,"conditions":5517,"interventions":5518},[88,89],[1196],[518,1198,1150],{"nctId":1210,"briefTitle":1211,"status":108,"phases":5520,"primaryCompletion":1213,"completion":1214,"start":1215,"enrollment":1216,"conditions":5521,"interventions":5522},[88,89],[1218],[1220,1097,1150,518],{"trials":5524,"activeCount":100},[],{"trials":5526,"activeCount":100},[],{"trials":5528,"activeCount":100},[],{"intervention":5530,"totalTrials":96,"cells":5531},"Hydroxyurea",{"EARLY_PHASE1":5532,"PHASE1":5542,"PHASE2":5544,"PHASE3":5565,"PHASE4":5567,"NA":5569},{"trials":5533,"activeCount":100},[5534],{"nctId":5535,"briefTitle":5536,"status":108,"phases":5537,"primaryCompletion":5538,"completion":5538,"start":5539,"enrollment":1703,"conditions":5540,"interventions":5541},"NCT02042222","Novel Dose Escalation to Predict Treatment With Hydroxyurea",[87],"2020-07-31","2013-10",[3407],[5530],{"trials":5543,"activeCount":100},[],{"trials":5545,"activeCount":100},[5546,5555],{"nctId":5547,"briefTitle":5548,"status":578,"phases":5549,"primaryCompletion":5550,"completion":5550,"start":5551,"enrollment":150,"conditions":5552,"interventions":5554},"NCT02640573","Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)",[89],"2017-11-16","2015-10-12",[5553],"Hemoglobin SC Disease",[5530],{"nctId":5556,"briefTitle":5557,"status":578,"phases":5558,"primaryCompletion":5559,"completion":5560,"start":5561,"enrollment":534,"conditions":5562,"interventions":5563},"NCT02336373","Treatment of Hemoglobin SC Disease With Hydroxyurea",[89],"2017-02","2017-03-31","2014-12",[5553],[5564],"hydroxyurea",{"trials":5566,"activeCount":100},[],{"trials":5568,"activeCount":100},[],{"trials":5570,"activeCount":100},[],{"intervention":1272,"totalTrials":96,"cells":5572},{"EARLY_PHASE1":5573,"PHASE1":5588,"PHASE2":5590,"PHASE3":5600,"PHASE4":5602,"NA":5604},{"trials":5574,"activeCount":100},[5575,5579],{"nctId":1258,"briefTitle":1259,"status":108,"phases":5576,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1106,"conditions":5577,"interventions":5578},[87],[1265,1266,1267],[1269,587,411,1270,1271,1272,1038,1273,1274],{"nctId":5580,"briefTitle":5581,"status":108,"phases":5582,"primaryCompletion":3459,"completion":3459,"start":3496,"enrollment":16,"conditions":5583,"interventions":5587},"NCT02484053","Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders",[87],[5584,5585,5586],"Hematologic Disorders","Oncologic Disorders","Rheumatologic Disorders",[1272],{"trials":5589,"activeCount":100},[],{"trials":5591,"activeCount":100},[5592],{"nctId":5593,"briefTitle":5594,"status":180,"phases":5595,"start":1105,"enrollment":100,"conditions":5596,"interventions":5599},"NCT00578591","Rituximab for GVHD",[89],[5597,5598],"Graft vs Host Disease","Alogenic Hematopoietic Transplant",[1272],{"trials":5601,"activeCount":100},[],{"trials":5603,"activeCount":100},[],{"trials":5605,"activeCount":100},[],{"intervention":5607,"totalTrials":394,"cells":5608},"disulfiram",{"EARLY_PHASE1":5609,"PHASE1":5611,"PHASE2":5613,"PHASE3":5632,"PHASE4":5634,"NA":5636},{"trials":5610,"activeCount":100},[],{"trials":5612,"activeCount":100},[],{"trials":5614,"activeCount":100},[5615,5621],{"nctId":5616,"briefTitle":5617,"status":108,"phases":5618,"primaryCompletion":1431,"completion":1431,"start":2637,"enrollment":928,"conditions":5619,"interventions":5620},"NCT00729300","A Study of the Relationship Between Disulfiram and Cocaine Self-administration.",[88,89],[5445],[5607],{"nctId":5622,"briefTitle":5623,"status":108,"phases":5624,"primaryCompletion":5625,"completion":5625,"start":5626,"enrollment":5627,"conditions":5628,"interventions":5630},"NCT00149630","Pharmacogenetics of Disulfiram for Cocaine",[89],"2009-12","2005-01",93,[23,5629],"Opioid Dependence",[5631,148],"Disulfiram",{"trials":5633,"activeCount":100},[],{"trials":5635,"activeCount":100},[],{"trials":5637,"activeCount":100},[],{"intervention":5639,"totalTrials":394,"cells":5640},"IL-2",{"EARLY_PHASE1":5641,"PHASE1":5643,"PHASE2":5657,"PHASE3":5671,"PHASE4":5673,"NA":5675},{"trials":5642,"activeCount":100},[],{"trials":5644,"activeCount":100},[5645],{"nctId":5646,"briefTitle":5647,"status":180,"phases":5648,"primaryCompletion":5625,"completion":5625,"start":5649,"enrollment":100,"conditions":5650,"interventions":5652},"NCT00224354","Lymphocytic B-Leukemia (B-CLL) w\u002FHuman IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells",[88],"2005-09",[5651],"CHRONIC LYMPHOCYTIC B-LEUKEMIA",[5653,5639,5654,5655,5656],"IL-2 secreting and hCL4OL-expressing autologous B-CLL cells","CD40L","ONTAK","immunotoxin dose",{"trials":5658,"activeCount":100},[5659],{"nctId":5660,"briefTitle":5661,"status":108,"phases":5662,"primaryCompletion":5663,"completion":5664,"start":1105,"enrollment":9,"conditions":5665,"interventions":5670},"NCT00539695","Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD",[89],"2013-04","2014-03",[1110,5666,1109,5667,1111,1337,5668,1420,1066,5669],"ALL","AML","Myeloproliferative Disorder","Non-malignant Diseases Requiring Allogeneic HSCT",[5639],{"trials":5672,"activeCount":100},[],{"trials":5674,"activeCount":100},[],{"trials":5676,"activeCount":100},[],{"intervention":585,"totalTrials":394,"cells":5678},{"EARLY_PHASE1":5679,"PHASE1":5681,"PHASE2":5683,"PHASE3":5693,"PHASE4":5695,"NA":5697},{"trials":5680,"activeCount":100},[],{"trials":5682,"activeCount":100},[],{"trials":5684,"activeCount":100},[5685,5689],{"nctId":1100,"briefTitle":1101,"status":578,"phases":5686,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":5687,"interventions":5688},[88,89],[1108,1109,1110,1111,1112,1113,1114,1115],[585,604,518,586],{"nctId":576,"briefTitle":577,"status":578,"phases":5690,"primaryCompletion":49,"completion":49,"start":580,"enrollment":581,"conditions":5691,"interventions":5692},[89],[583],[499,585,586,587],{"trials":5694,"activeCount":100},[],{"trials":5696,"activeCount":100},[],{"trials":5698,"activeCount":100},[],{"intervention":586,"totalTrials":394,"cells":5700},{"EARLY_PHASE1":5701,"PHASE1":5703,"PHASE2":5705,"PHASE3":5715,"PHASE4":5717,"NA":5719},{"trials":5702,"activeCount":100},[],{"trials":5704,"activeCount":100},[],{"trials":5706,"activeCount":100},[5707,5711],{"nctId":1100,"briefTitle":1101,"status":578,"phases":5708,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":5709,"interventions":5710},[88,89],[1108,1109,1110,1111,1112,1113,1114,1115],[585,604,518,586],{"nctId":576,"briefTitle":577,"status":578,"phases":5712,"primaryCompletion":49,"completion":49,"start":580,"enrollment":581,"conditions":5713,"interventions":5714},[89],[583],[499,585,586,587],{"trials":5716,"activeCount":100},[],{"trials":5718,"activeCount":100},[],{"trials":5720,"activeCount":100},[],{"intervention":5722,"totalTrials":394,"cells":5723},"Valacyclovir",{"EARLY_PHASE1":5724,"PHASE1":5726,"PHASE2":5739,"PHASE3":5749,"PHASE4":5751,"NA":5753},{"trials":5725,"activeCount":100},[],{"trials":5727,"activeCount":100},[5728],{"nctId":5729,"briefTitle":5730,"status":108,"phases":5731,"primaryCompletion":5732,"completion":5733,"start":5734,"enrollment":3405,"conditions":5735,"interventions":5738},"NCT00059592","Valacyclovir in Immunocompromised Children",[88],"2004-12-30","2005-05-05","1998-04-07",[5736,5737],"Shingles","Bone Marrow Transplantation",[5722],{"trials":5740,"activeCount":100},[5741],{"nctId":5742,"briefTitle":5743,"status":108,"phases":5744,"primaryCompletion":1213,"completion":1213,"start":5745,"enrollment":832,"conditions":5746,"interventions":5748},"NCT00042328","A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients",[89],"2001-08",[5747],"Neoplasms",[5722],{"trials":5750,"activeCount":100},[],{"trials":5752,"activeCount":100},[],{"trials":5754,"activeCount":100},[],{"intervention":1175,"totalTrials":394,"cells":5756},{"EARLY_PHASE1":5757,"PHASE1":5759,"PHASE2":5761,"PHASE3":5771,"PHASE4":5773,"NA":5775},{"trials":5758,"activeCount":100},[],{"trials":5760,"activeCount":100},[],{"trials":5762,"activeCount":100},[5763,5767],{"nctId":1358,"briefTitle":1359,"status":578,"phases":5764,"primaryCompletion":1180,"completion":1180,"start":1122,"enrollment":972,"conditions":5765,"interventions":5766},[89],[1182,1183,1184],[1175,1363,604,1038],{"nctId":1164,"briefTitle":1165,"status":578,"phases":5768,"primaryCompletion":1167,"completion":1167,"start":1168,"enrollment":96,"conditions":5769,"interventions":5770},[88,89],[1170,1171,1172,1173],[1175,518,1098],{"trials":5772,"activeCount":100},[],{"trials":5774,"activeCount":100},[],{"trials":5776,"activeCount":100},[],{"intervention":5778,"totalTrials":394,"cells":5779},"Bevacizumab",{"EARLY_PHASE1":5780,"PHASE1":5782,"PHASE2":5784,"PHASE3":5810,"PHASE4":5812,"NA":5814},{"trials":5781,"activeCount":100},[],{"trials":5783,"activeCount":100},[],{"trials":5785,"activeCount":100},[5786,5803],{"nctId":5787,"briefTitle":5788,"status":108,"phases":5789,"primaryCompletion":5790,"completion":5791,"start":5792,"enrollment":1063,"conditions":5793,"interventions":5801},"NCT00879437","Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma",[89],"2015-08-30","2017-10-02","2009-09-01",[5794,5795,5796,5797,5798,5799,5800,1451],"Glial Cell Tumors","Malignant Gliomas","Glioblastoma Multiforme","Anaplastic Astrocytoma","Gliomatosis Cerebri","Gliosarcoma","Brainstem Glioma",[5802,5778],"Valproic acid",{"nctId":5804,"briefTitle":5805,"status":180,"phases":5806,"primaryCompletion":5030,"completion":5030,"start":1048,"enrollment":100,"conditions":5807,"interventions":5809},"NCT00908219","A Study of Bevacizumab to Prevent Malignant Ascites",[89],[5808],"Malignant Ascites",[5778],{"trials":5811,"activeCount":100},[],{"trials":5813,"activeCount":100},[],{"trials":5815,"activeCount":100},[],{"intervention":5817,"totalTrials":394,"cells":5818},"Docetaxel",{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5849,"PHASE4":5851,"NA":5853},{"trials":5820,"activeCount":100},[],{"trials":5822,"activeCount":100},[],{"trials":5824,"activeCount":100},[5825,5835],{"nctId":5826,"briefTitle":5827,"status":108,"phases":5828,"primaryCompletion":5829,"completion":3757,"start":3510,"enrollment":16,"conditions":5830,"interventions":5831},"NCT00953420","Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes",[89],"2014-06",[1069],[5817,5832,4450,5833,5834],"Carboplatin","EBV-specific cytotoxic T lymphocytes","G-CSF or Peg-GCSF",{"nctId":5836,"briefTitle":5837,"status":578,"phases":5838,"primaryCompletion":5839,"completion":5839,"start":5840,"enrollment":96,"conditions":5841,"interventions":5844},"NCT05567835","A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer",[89],"2025-02-20","2024-03-06",[5842,5843],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[5845,5846,5847,5817,5848],"Fluorouracil","Leucovorin","Oxaliplatin","GSCF",{"trials":5850,"activeCount":100},[],{"trials":5852,"activeCount":100},[],{"trials":5854,"activeCount":100},[],{"intervention":3462,"totalTrials":394,"cells":5856},{"EARLY_PHASE1":5857,"PHASE1":5859,"PHASE2":5865,"PHASE3":5880,"PHASE4":5882,"NA":5884},{"trials":5858,"activeCount":100},[],{"trials":5860,"activeCount":100},[5861],{"nctId":3455,"briefTitle":3456,"status":108,"phases":5862,"primaryCompletion":3458,"completion":525,"start":3459,"enrollment":133,"conditions":5863,"interventions":5864},[88],[3450,2299],[3462,3463,3464],{"trials":5866,"activeCount":100},[5867],{"nctId":5868,"briefTitle":5869,"status":108,"phases":5870,"primaryCompletion":5871,"completion":971,"start":5872,"enrollment":5873,"conditions":5874,"interventions":5876},"NCT03172975","Efficacy of Na-GST-1\u002FAlhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection",[89],"2024-12-31","2018-03-01",39,[5875],"Hookworm Infections",[3462,5877,5878,5879],"Na-GST-1\u002FAlhydrogel + CPG 10104","Na-GST-1\u002FAlhydrogel + GLA-AF","Albendazole",{"trials":5881,"activeCount":100},[],{"trials":5883,"activeCount":100},[],{"trials":5885,"activeCount":100},[],{"intervention":5887,"totalTrials":150,"cells":5888},"Dronabinol",{"EARLY_PHASE1":5889,"PHASE1":5891,"PHASE2":5893,"PHASE3":5905,"PHASE4":5907,"NA":5909},{"trials":5890,"activeCount":100},[],{"trials":5892,"activeCount":100},[],{"trials":5894,"activeCount":100},[5895],{"nctId":5896,"briefTitle":5897,"status":180,"phases":5898,"primaryCompletion":5899,"completion":5900,"start":343,"enrollment":100,"conditions":5901,"interventions":5904},"NCT06834997","Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital",[89],"2028-03-01","2028-12-30",[135,5902,5903],"Endometriosis Related Pain","Endometriosis, Pain",[5887],{"trials":5906,"activeCount":100},[],{"trials":5908,"activeCount":100},[],{"trials":5910,"activeCount":100},[],{"intervention":1353,"totalTrials":150,"cells":5912},{"EARLY_PHASE1":5913,"PHASE1":5915,"PHASE2":5917,"PHASE3":5923,"PHASE4":5925,"NA":5927},{"trials":5914,"activeCount":100},[],{"trials":5916,"activeCount":100},[],{"trials":5918,"activeCount":100},[5919],{"nctId":1345,"briefTitle":1346,"status":108,"phases":5920,"primaryCompletion":1048,"completion":1348,"start":1349,"enrollment":1350,"conditions":5921,"interventions":5922},[89],[29],[1353,1270,1354,1355,1038,1303,1356],{"trials":5924,"activeCount":100},[],{"trials":5926,"activeCount":100},[],{"trials":5928,"activeCount":100},[],{"intervention":1354,"totalTrials":150,"cells":5930},{"EARLY_PHASE1":5931,"PHASE1":5933,"PHASE2":5935,"PHASE3":5941,"PHASE4":5943,"NA":5945},{"trials":5932,"activeCount":100},[],{"trials":5934,"activeCount":100},[],{"trials":5936,"activeCount":100},[5937],{"nctId":1345,"briefTitle":1346,"status":108,"phases":5938,"primaryCompletion":1048,"completion":1348,"start":1349,"enrollment":1350,"conditions":5939,"interventions":5940},[89],[29],[1353,1270,1354,1355,1038,1303,1356],{"trials":5942,"activeCount":100},[],{"trials":5944,"activeCount":100},[],{"trials":5946,"activeCount":100},[],{"intervention":1356,"totalTrials":150,"cells":5948},{"EARLY_PHASE1":5949,"PHASE1":5951,"PHASE2":5953,"PHASE3":5959,"PHASE4":5961,"NA":5963},{"trials":5950,"activeCount":100},[],{"trials":5952,"activeCount":100},[],{"trials":5954,"activeCount":100},[5955],{"nctId":1345,"briefTitle":1346,"status":108,"phases":5956,"primaryCompletion":1048,"completion":1348,"start":1349,"enrollment":1350,"conditions":5957,"interventions":5958},[89],[29],[1353,1270,1354,1355,1038,1303,1356],{"trials":5960,"activeCount":100},[],{"trials":5962,"activeCount":100},[],{"trials":5964,"activeCount":100},[],{"intervention":5966,"totalTrials":150,"cells":5967},"Lidocaine",{"EARLY_PHASE1":5968,"PHASE1":5970,"PHASE2":5972,"PHASE3":5981,"PHASE4":5983,"NA":5985},{"trials":5969,"activeCount":100},[],{"trials":5971,"activeCount":100},[],{"trials":5973,"activeCount":100},[5974],{"nctId":5975,"briefTitle":5976,"status":180,"phases":5977,"primaryCompletion":1079,"start":561,"enrollment":100,"conditions":5978,"interventions":5980},"NCT01930877","Effect of Perioperative Intravenous Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery",[89],[5979],"Pain",[5966],{"trials":5982,"activeCount":100},[],{"trials":5984,"activeCount":100},[],{"trials":5986,"activeCount":100},[],{"intervention":5988,"totalTrials":150,"cells":5989},"Mirabegron",{"EARLY_PHASE1":5990,"PHASE1":5992,"PHASE2":5994,"PHASE3":6006,"PHASE4":6008,"NA":6010},{"trials":5991,"activeCount":100},[],{"trials":5993,"activeCount":100},[],{"trials":5995,"activeCount":100},[5996],{"nctId":5997,"briefTitle":5998,"status":108,"phases":5999,"primaryCompletion":1077,"completion":1077,"start":6000,"enrollment":6001,"conditions":6002,"interventions":6005},"NCT02744430","Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain",[89],"2017-07-22",33,[6003,6004],"Ureteral Obstruction","Flank Pain",[5988],{"trials":6007,"activeCount":100},[],{"trials":6009,"activeCount":100},[],{"trials":6011,"activeCount":100},[],{"intervention":6013,"totalTrials":150,"cells":6014},"trimethoprim\u002Fsulfamethoxazole",{"EARLY_PHASE1":6015,"PHASE1":6017,"PHASE2":6019,"PHASE3":6028,"PHASE4":6030,"NA":6032},{"trials":6016,"activeCount":100},[],{"trials":6018,"activeCount":100},[],{"trials":6020,"activeCount":100},[6021],{"nctId":6022,"briefTitle":6023,"status":180,"phases":6024,"enrollment":100,"conditions":6025,"interventions":6027},"NCT00789464","Probiotics for Girls With Recurring Urinary Tract Infections",[89],[6026],"Recurrent Urinary Tract Infection",[6013],{"trials":6029,"activeCount":100},[],{"trials":6031,"activeCount":100},[],{"trials":6033,"activeCount":100},[],{"intervention":6035,"totalTrials":150,"cells":6036},"SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP",{"EARLY_PHASE1":6037,"PHASE1":6039,"PHASE2":6041,"PHASE3":6051,"PHASE4":6053,"NA":6055},{"trials":6038,"activeCount":100},[],{"trials":6040,"activeCount":100},[],{"trials":6042,"activeCount":100},[6043],{"nctId":6044,"briefTitle":6045,"status":108,"phases":6046,"primaryCompletion":4227,"completion":6047,"start":4598,"enrollment":1135,"conditions":6048,"interventions":6049},"NCT00703222","A Phase I\u002FII Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells",[88,89],"2025-05",[29],[6035,6050],"SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP",{"trials":6052,"activeCount":100},[],{"trials":6054,"activeCount":100},[],{"trials":6056,"activeCount":100},[],{"intervention":6050,"totalTrials":150,"cells":6058},{"EARLY_PHASE1":6059,"PHASE1":6061,"PHASE2":6063,"PHASE3":6069,"PHASE4":6071,"NA":6073},{"trials":6060,"activeCount":100},[],{"trials":6062,"activeCount":100},[],{"trials":6064,"activeCount":100},[6065],{"nctId":6044,"briefTitle":6045,"status":108,"phases":6066,"primaryCompletion":4227,"completion":6047,"start":4598,"enrollment":1135,"conditions":6067,"interventions":6068},[88,89],[29],[6035,6050],{"trials":6070,"activeCount":100},[],{"trials":6072,"activeCount":100},[],{"trials":6074,"activeCount":100},[],{"intervention":6076,"totalTrials":150,"cells":6077},"Daclizumab",{"EARLY_PHASE1":6078,"PHASE1":6080,"PHASE2":6082,"PHASE3":6092,"PHASE4":6094,"NA":6096},{"trials":6079,"activeCount":100},[],{"trials":6081,"activeCount":100},[],{"trials":6083,"activeCount":100},[6084],{"nctId":6085,"briefTitle":6086,"status":578,"phases":6087,"primaryCompletion":6088,"completion":6088,"start":3565,"enrollment":150,"conditions":6089,"interventions":6091},"NCT00284531","Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients",[88,89],"2007-05",[6090],"Cardiac Transplantation",[6076],{"trials":6093,"activeCount":100},[],{"trials":6095,"activeCount":100},[],{"trials":6097,"activeCount":100},[],{"intervention":6099,"totalTrials":150,"cells":6100},"Tamoxifen Citrate",{"EARLY_PHASE1":6101,"PHASE1":6103,"PHASE2":6105,"PHASE3":6116,"PHASE4":6118,"NA":6120},{"trials":6102,"activeCount":100},[],{"trials":6104,"activeCount":100},[],{"trials":6106,"activeCount":100},[6107],{"nctId":6108,"briefTitle":6109,"status":108,"phases":6110,"primaryCompletion":6111,"completion":6112,"start":6113,"enrollment":972,"conditions":6114,"interventions":6115},"NCT02197897","Evaluation the Treatment of Tamoxifen of Low\u002FIntermediate Risk Bladder Tumors",[89],"2017-09-12","2019-06-28","2015-04-01",[3193],[6099],{"trials":6117,"activeCount":100},[],{"trials":6119,"activeCount":100},[],{"trials":6121,"activeCount":100},[],{"intervention":120,"totalTrials":150,"cells":6123},{"EARLY_PHASE1":6124,"PHASE1":6126,"PHASE2":6128,"PHASE3":6134,"PHASE4":6136,"NA":6138},{"trials":6125,"activeCount":100},[],{"trials":6127,"activeCount":100},[],{"trials":6129,"activeCount":100},[6130],{"nctId":106,"briefTitle":107,"status":108,"phases":6131,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":6132,"interventions":6133},[88,89],[115,116,117,118],[120,95],{"trials":6135,"activeCount":100},[],{"trials":6137,"activeCount":100},[],{"trials":6139,"activeCount":100},[],{"intervention":6141,"totalTrials":150,"cells":6142},"Dermaprazole 1%",{"EARLY_PHASE1":6143,"PHASE1":6145,"PHASE2":6147,"PHASE3":6160,"PHASE4":6162,"NA":6164},{"trials":6144,"activeCount":100},[],{"trials":6146,"activeCount":100},[],{"trials":6148,"activeCount":100},[6149],{"nctId":6150,"briefTitle":6151,"status":578,"phases":6152,"primaryCompletion":6153,"completion":6154,"start":6155,"enrollment":96,"conditions":6156,"interventions":6158},"NCT05269160","Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)",[88,89],"2023-06-26","2024-04-15","2023-04-24",[6157,1588],"Radiation Dermatitis",[6141,6159],"Dermaprazole 2%",{"trials":6161,"activeCount":100},[],{"trials":6163,"activeCount":100},[],{"trials":6165,"activeCount":100},[],{"intervention":6159,"totalTrials":150,"cells":6167},{"EARLY_PHASE1":6168,"PHASE1":6170,"PHASE2":6172,"PHASE3":6178,"PHASE4":6180,"NA":6182},{"trials":6169,"activeCount":100},[],{"trials":6171,"activeCount":100},[],{"trials":6173,"activeCount":100},[6174],{"nctId":6150,"briefTitle":6151,"status":578,"phases":6175,"primaryCompletion":6153,"completion":6154,"start":6155,"enrollment":96,"conditions":6176,"interventions":6177},[88,89],[6157,1588],[6141,6159],{"trials":6179,"activeCount":100},[],{"trials":6181,"activeCount":100},[],{"trials":6183,"activeCount":100},[],{"intervention":1363,"totalTrials":150,"cells":6185},{"EARLY_PHASE1":6186,"PHASE1":6188,"PHASE2":6190,"PHASE3":6196,"PHASE4":6198,"NA":6200},{"trials":6187,"activeCount":100},[],{"trials":6189,"activeCount":100},[],{"trials":6191,"activeCount":100},[6192],{"nctId":1358,"briefTitle":1359,"status":578,"phases":6193,"primaryCompletion":1180,"completion":1180,"start":1122,"enrollment":972,"conditions":6194,"interventions":6195},[89],[1182,1183,1184],[1175,1363,604,1038],{"trials":6197,"activeCount":100},[],{"trials":6199,"activeCount":100},[],{"trials":6201,"activeCount":100},[],{"intervention":6203,"totalTrials":150,"cells":6204},"ABVE-PC",{"EARLY_PHASE1":6205,"PHASE1":6207,"PHASE2":6209,"PHASE3":6220,"PHASE4":6222,"NA":6224},{"trials":6206,"activeCount":100},[],{"trials":6208,"activeCount":100},[],{"trials":6210,"activeCount":100},[6211],{"nctId":6212,"briefTitle":6213,"status":108,"phases":6214,"primaryCompletion":6215,"completion":6215,"start":6216,"enrollment":282,"conditions":6217,"interventions":6218},"NCT01858922","Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A",[89],"2019-08-12","2012-12-19",[1065],[6203,6219],"DECA",{"trials":6221,"activeCount":100},[],{"trials":6223,"activeCount":100},[],{"trials":6225,"activeCount":100},[],{"intervention":6219,"totalTrials":150,"cells":6227},{"EARLY_PHASE1":6228,"PHASE1":6230,"PHASE2":6232,"PHASE3":6238,"PHASE4":6240,"NA":6242},{"trials":6229,"activeCount":100},[],{"trials":6231,"activeCount":100},[],{"trials":6233,"activeCount":100},[6234],{"nctId":6212,"briefTitle":6213,"status":108,"phases":6235,"primaryCompletion":6215,"completion":6215,"start":6216,"enrollment":282,"conditions":6236,"interventions":6237},[89],[1065],[6203,6219],{"trials":6239,"activeCount":100},[],{"trials":6241,"activeCount":100},[],{"trials":6243,"activeCount":100},[],{"intervention":6245,"totalTrials":150,"cells":6246},"Thrombolytic Agent",{"EARLY_PHASE1":6247,"PHASE1":6249,"PHASE2":6251,"PHASE3":6262,"PHASE4":6264,"NA":6266},{"trials":6248,"activeCount":100},[],{"trials":6250,"activeCount":100},[],{"trials":6252,"activeCount":100},[6253],{"nctId":6254,"briefTitle":6255,"status":3474,"phases":6256,"primaryCompletion":6257,"completion":6258,"start":6259,"enrollment":832,"conditions":6260,"interventions":6261},"NCT05415150","Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic",[88,89],"2023-08-01","2024-05-31","2022-02-18",[2421],[6245],{"trials":6263,"activeCount":100},[],{"trials":6265,"activeCount":100},[],{"trials":6267,"activeCount":100},[],{"intervention":5802,"totalTrials":150,"cells":6269},{"EARLY_PHASE1":6270,"PHASE1":6272,"PHASE2":6274,"PHASE3":6280,"PHASE4":6282,"NA":6284},{"trials":6271,"activeCount":100},[],{"trials":6273,"activeCount":100},[],{"trials":6275,"activeCount":100},[6276],{"nctId":5787,"briefTitle":5788,"status":108,"phases":6277,"primaryCompletion":5790,"completion":5791,"start":5792,"enrollment":1063,"conditions":6278,"interventions":6279},[89],[5794,5795,5796,5797,5798,5799,5800,1451],[5802,5778],{"trials":6281,"activeCount":100},[],{"trials":6283,"activeCount":100},[],{"trials":6285,"activeCount":100},[],{"intervention":1128,"totalTrials":150,"cells":6287},{"EARLY_PHASE1":6288,"PHASE1":6290,"PHASE2":6292,"PHASE3":6298,"PHASE4":6300,"NA":6302},{"trials":6289,"activeCount":100},[],{"trials":6291,"activeCount":100},[],{"trials":6293,"activeCount":100},[6294],{"nctId":1118,"briefTitle":1119,"status":578,"phases":6295,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":6296,"interventions":6297},[88,89],[1125],[1127,518,1128],{"trials":6299,"activeCount":100},[],{"trials":6301,"activeCount":100},[],{"trials":6303,"activeCount":100},[],{"intervention":6305,"totalTrials":150,"cells":6306},"Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection",{"EARLY_PHASE1":6307,"PHASE1":6309,"PHASE2":6311,"PHASE3":6320,"PHASE4":6322,"NA":6324},{"trials":6308,"activeCount":100},[],{"trials":6310,"activeCount":100},[],{"trials":6312,"activeCount":100},[6313],{"nctId":6314,"briefTitle":6315,"status":108,"phases":6316,"primaryCompletion":3367,"completion":561,"start":3632,"enrollment":3759,"conditions":6317,"interventions":6319},"NCT00711035","Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)",[88,89],[3243,6318],"EBV Infection",[6305],{"trials":6321,"activeCount":100},[],{"trials":6323,"activeCount":100},[],{"trials":6325,"activeCount":100},[],{"intervention":6327,"totalTrials":150,"cells":6328},"MEDI4736",{"EARLY_PHASE1":6329,"PHASE1":6331,"PHASE2":6333,"PHASE3":6345,"PHASE4":6347,"NA":6349},{"trials":6330,"activeCount":100},[],{"trials":6332,"activeCount":100},[],{"trials":6334,"activeCount":100},[6335],{"nctId":6336,"briefTitle":6337,"status":108,"phases":6338,"primaryCompletion":6339,"completion":6340,"start":6341,"enrollment":1216,"conditions":6342,"interventions":6343},"NCT02592551","MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma",[89],"2019-08-06","2022-09-01","2016-05-11",[930],[6327,6344],"Tremelimumab",{"trials":6346,"activeCount":100},[],{"trials":6348,"activeCount":100},[],{"trials":6350,"activeCount":100},[],{"intervention":6344,"totalTrials":150,"cells":6352},{"EARLY_PHASE1":6353,"PHASE1":6355,"PHASE2":6357,"PHASE3":6363,"PHASE4":6365,"NA":6367},{"trials":6354,"activeCount":100},[],{"trials":6356,"activeCount":100},[],{"trials":6358,"activeCount":100},[6359],{"nctId":6336,"briefTitle":6337,"status":108,"phases":6360,"primaryCompletion":6339,"completion":6340,"start":6341,"enrollment":1216,"conditions":6361,"interventions":6362},[89],[930],[6327,6344],{"trials":6364,"activeCount":100},[],{"trials":6366,"activeCount":100},[],{"trials":6368,"activeCount":100},[],{"intervention":6370,"totalTrials":150,"cells":6371},"TA-CD Vaccination",{"EARLY_PHASE1":6372,"PHASE1":6374,"PHASE2":6376,"PHASE3":6385,"PHASE4":6387,"NA":6389},{"trials":6373,"activeCount":100},[],{"trials":6375,"activeCount":100},[],{"trials":6377,"activeCount":100},[6378],{"nctId":6379,"briefTitle":6380,"status":108,"phases":6381,"primaryCompletion":4770,"completion":59,"start":6382,"enrollment":3346,"conditions":6383,"interventions":6384},"NCT00969878","Multisite Controlled Trial of Cocaine Vaccine",[89],"2010-08",[23],[6370],{"trials":6386,"activeCount":100},[],{"trials":6388,"activeCount":100},[],{"trials":6390,"activeCount":100},[],{"intervention":5832,"totalTrials":150,"cells":6392},{"EARLY_PHASE1":6393,"PHASE1":6395,"PHASE2":6397,"PHASE3":6403,"PHASE4":6405,"NA":6407},{"trials":6394,"activeCount":100},[],{"trials":6396,"activeCount":100},[],{"trials":6398,"activeCount":100},[6399],{"nctId":5826,"briefTitle":5827,"status":108,"phases":6400,"primaryCompletion":5829,"completion":3757,"start":3510,"enrollment":16,"conditions":6401,"interventions":6402},[89],[1069],[5817,5832,4450,5833,5834],{"trials":6404,"activeCount":100},[],{"trials":6406,"activeCount":100},[],{"trials":6408,"activeCount":100},[],{"intervention":5833,"totalTrials":150,"cells":6410},{"EARLY_PHASE1":6411,"PHASE1":6413,"PHASE2":6415,"PHASE3":6421,"PHASE4":6423,"NA":6425},{"trials":6412,"activeCount":100},[],{"trials":6414,"activeCount":100},[],{"trials":6416,"activeCount":100},[6417],{"nctId":5826,"briefTitle":5827,"status":108,"phases":6418,"primaryCompletion":5829,"completion":3757,"start":3510,"enrollment":16,"conditions":6419,"interventions":6420},[89],[1069],[5817,5832,4450,5833,5834],{"trials":6422,"activeCount":100},[],{"trials":6424,"activeCount":100},[],{"trials":6426,"activeCount":100},[],{"intervention":5834,"totalTrials":150,"cells":6428},{"EARLY_PHASE1":6429,"PHASE1":6431,"PHASE2":6433,"PHASE3":6439,"PHASE4":6441,"NA":6443},{"trials":6430,"activeCount":100},[],{"trials":6432,"activeCount":100},[],{"trials":6434,"activeCount":100},[6435],{"nctId":5826,"briefTitle":5827,"status":108,"phases":6436,"primaryCompletion":5829,"completion":3757,"start":3510,"enrollment":16,"conditions":6437,"interventions":6438},[89],[1069],[5817,5832,4450,5833,5834],{"trials":6440,"activeCount":100},[],{"trials":6442,"activeCount":100},[],{"trials":6444,"activeCount":100},[],{"intervention":6446,"totalTrials":150,"cells":6447},"Sm-TSP-2\u002FAlhydrogel® vaccine",{"EARLY_PHASE1":6448,"PHASE1":6450,"PHASE2":6452,"PHASE3":6467,"PHASE4":6469,"NA":6471},{"trials":6449,"activeCount":100},[],{"trials":6451,"activeCount":100},[],{"trials":6453,"activeCount":100},[6454],{"nctId":6455,"briefTitle":6456,"status":108,"phases":6457,"primaryCompletion":6458,"completion":6458,"start":6459,"enrollment":6460,"conditions":6461,"interventions":6464},"NCT03910972","Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults",[88,89],"2024-11-13","2019-10-07",290,[6462,6463],"Schistosomiasis","Schistosoma Mansoni",[6446,6465,6466],"Sm-TSP-2\u002FAlhydrogel® vaccine plus AP 10-701","ENGERIX-B Hepatitis B Vaccine",{"trials":6468,"activeCount":100},[],{"trials":6470,"activeCount":100},[],{"trials":6472,"activeCount":100},[],{"intervention":6465,"totalTrials":150,"cells":6474},{"EARLY_PHASE1":6475,"PHASE1":6477,"PHASE2":6479,"PHASE3":6485,"PHASE4":6487,"NA":6489},{"trials":6476,"activeCount":100},[],{"trials":6478,"activeCount":100},[],{"trials":6480,"activeCount":100},[6481],{"nctId":6455,"briefTitle":6456,"status":108,"phases":6482,"primaryCompletion":6458,"completion":6458,"start":6459,"enrollment":6460,"conditions":6483,"interventions":6484},[88,89],[6462,6463],[6446,6465,6466],{"trials":6486,"activeCount":100},[],{"trials":6488,"activeCount":100},[],{"trials":6490,"activeCount":100},[],{"intervention":6466,"totalTrials":150,"cells":6492},{"EARLY_PHASE1":6493,"PHASE1":6495,"PHASE2":6497,"PHASE3":6503,"PHASE4":6505,"NA":6507},{"trials":6494,"activeCount":100},[],{"trials":6496,"activeCount":100},[],{"trials":6498,"activeCount":100},[6499],{"nctId":6455,"briefTitle":6456,"status":108,"phases":6500,"primaryCompletion":6458,"completion":6458,"start":6459,"enrollment":6460,"conditions":6501,"interventions":6502},[88,89],[6462,6463],[6446,6465,6466],{"trials":6504,"activeCount":100},[],{"trials":6506,"activeCount":100},[],{"trials":6508,"activeCount":100},[],{"intervention":5845,"totalTrials":150,"cells":6510},{"EARLY_PHASE1":6511,"PHASE1":6513,"PHASE2":6515,"PHASE3":6521,"PHASE4":6523,"NA":6525},{"trials":6512,"activeCount":100},[],{"trials":6514,"activeCount":100},[],{"trials":6516,"activeCount":100},[6517],{"nctId":5836,"briefTitle":5837,"status":578,"phases":6518,"primaryCompletion":5839,"completion":5839,"start":5840,"enrollment":96,"conditions":6519,"interventions":6520},[89],[5842,5843],[5845,5846,5847,5817,5848],{"trials":6522,"activeCount":100},[],{"trials":6524,"activeCount":100},[],{"trials":6526,"activeCount":100},[],{"intervention":5846,"totalTrials":150,"cells":6528},{"EARLY_PHASE1":6529,"PHASE1":6531,"PHASE2":6533,"PHASE3":6539,"PHASE4":6541,"NA":6543},{"trials":6530,"activeCount":100},[],{"trials":6532,"activeCount":100},[],{"trials":6534,"activeCount":100},[6535],{"nctId":5836,"briefTitle":5837,"status":578,"phases":6536,"primaryCompletion":5839,"completion":5839,"start":5840,"enrollment":96,"conditions":6537,"interventions":6538},[89],[5842,5843],[5845,5846,5847,5817,5848],{"trials":6540,"activeCount":100},[],{"trials":6542,"activeCount":100},[],{"trials":6544,"activeCount":100},[],{"intervention":5847,"totalTrials":150,"cells":6546},{"EARLY_PHASE1":6547,"PHASE1":6549,"PHASE2":6551,"PHASE3":6557,"PHASE4":6559,"NA":6561},{"trials":6548,"activeCount":100},[],{"trials":6550,"activeCount":100},[],{"trials":6552,"activeCount":100},[6553],{"nctId":5836,"briefTitle":5837,"status":578,"phases":6554,"primaryCompletion":5839,"completion":5839,"start":5840,"enrollment":96,"conditions":6555,"interventions":6556},[89],[5842,5843],[5845,5846,5847,5817,5848],{"trials":6558,"activeCount":100},[],{"trials":6560,"activeCount":100},[],{"trials":6562,"activeCount":100},[],{"intervention":5848,"totalTrials":150,"cells":6564},{"EARLY_PHASE1":6565,"PHASE1":6567,"PHASE2":6569,"PHASE3":6575,"PHASE4":6577,"NA":6579},{"trials":6566,"activeCount":100},[],{"trials":6568,"activeCount":100},[],{"trials":6570,"activeCount":100},[6571],{"nctId":5836,"briefTitle":5837,"status":578,"phases":6572,"primaryCompletion":5839,"completion":5839,"start":5840,"enrollment":96,"conditions":6573,"interventions":6574},[89],[5842,5843],[5845,5846,5847,5817,5848],{"trials":6576,"activeCount":100},[],{"trials":6578,"activeCount":100},[],{"trials":6580,"activeCount":100},[],{"intervention":6582,"totalTrials":150,"cells":6583},"PS-341",{"EARLY_PHASE1":6584,"PHASE1":6586,"PHASE2":6588,"PHASE3":6597,"PHASE4":6599,"NA":6601},{"trials":6585,"activeCount":100},[],{"trials":6587,"activeCount":100},[],{"trials":6589,"activeCount":100},[6590],{"nctId":6591,"briefTitle":6592,"status":108,"phases":6593,"primaryCompletion":3631,"completion":609,"start":1134,"enrollment":282,"conditions":6594,"interventions":6596},"NCT00425503","PS-341 Followed by Removal of Prostate for Those With Prostate Cancer",[89],[6595],"Prostate Neoplasms",[6582],{"trials":6598,"activeCount":100},[],{"trials":6600,"activeCount":100},[],{"trials":6602,"activeCount":100},[],{"intervention":6604,"totalTrials":150,"cells":6605},"Ceftaroline Fosamil",{"EARLY_PHASE1":6606,"PHASE1":6608,"PHASE2":6610,"PHASE3":6623,"PHASE4":6625,"NA":6627},{"trials":6607,"activeCount":100},[],{"trials":6609,"activeCount":100},[],{"trials":6611,"activeCount":100},[6612],{"nctId":6613,"briefTitle":6614,"status":108,"phases":6615,"primaryCompletion":6616,"completion":6616,"start":6617,"enrollment":27,"conditions":6618,"interventions":6622},"NCT02335905","Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children",[88,89],"2020-06-16","2015-06-03",[6619,6620,6621],"Hematogenously Acquired Staphylococcus Aureus Osteomyelitis","Bone Infection","Osteomyelitis",[6604],{"trials":6624,"activeCount":100},[],{"trials":6626,"activeCount":100},[],{"trials":6628,"activeCount":100},[],{"intervention":6630,"totalTrials":150,"cells":6631},"NK1 Antagoist",{"EARLY_PHASE1":6632,"PHASE1":6634,"PHASE2":6636,"PHASE3":6644,"PHASE4":6646,"NA":6648},{"trials":6633,"activeCount":100},[],{"trials":6635,"activeCount":100},[],{"trials":6637,"activeCount":100},[6638],{"nctId":6639,"briefTitle":6640,"status":108,"phases":6641,"primaryCompletion":3379,"completion":3379,"start":112,"enrollment":3223,"conditions":6642,"interventions":6643},"NCT00383786","Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder",[89],[974],[6630],{"trials":6645,"activeCount":100},[],{"trials":6647,"activeCount":100},[],{"trials":6649,"activeCount":100},[],{"intervention":1373,"totalTrials":150,"cells":6651},{"EARLY_PHASE1":6652,"PHASE1":6654,"PHASE2":6656,"PHASE3":6662,"PHASE4":6664,"NA":6666},{"trials":6653,"activeCount":100},[],{"trials":6655,"activeCount":100},[],{"trials":6657,"activeCount":100},[6658],{"nctId":1365,"briefTitle":1366,"status":108,"phases":6659,"completion":1368,"start":1369,"enrollment":32,"conditions":6660,"interventions":6661},[89],[1371],[1038,1373,1235],{"trials":6663,"activeCount":100},[],{"trials":6665,"activeCount":100},[],{"trials":6667,"activeCount":100},[],{"intervention":6669,"totalTrials":150,"cells":6670},"Etanercept",{"EARLY_PHASE1":6671,"PHASE1":6673,"PHASE2":6675,"PHASE3":6685,"PHASE4":6687,"NA":6689},{"trials":6672,"activeCount":100},[],{"trials":6674,"activeCount":100},[],{"trials":6676,"activeCount":100},[6677],{"nctId":6678,"briefTitle":6679,"status":108,"phases":6680,"completion":1403,"start":6681,"enrollment":16,"conditions":6682,"interventions":6684},"NCT00048373","Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL",[89],"2001-10",[6683],"Histiocytosis, Langerhans-Cell",[6669],{"trials":6686,"activeCount":100},[],{"trials":6688,"activeCount":100},[],{"trials":6690,"activeCount":100},[],{"intervention":6692,"totalTrials":150,"cells":6693},"Nondigestible oligosaccharide",{"EARLY_PHASE1":6694,"PHASE1":6696,"PHASE2":6698,"PHASE3":6709,"PHASE4":6711,"NA":6713},{"trials":6695,"activeCount":100},[],{"trials":6697,"activeCount":100},[],{"trials":6699,"activeCount":100},[6700],{"nctId":6701,"briefTitle":6702,"status":108,"phases":6703,"primaryCompletion":5626,"completion":5031,"start":6704,"enrollment":723,"conditions":6705,"interventions":6708},"NCT00022867","Encouraging Calcium Absorption and Bone Formation During Early Puberty",[88,89],"2001-05",[6706,6707],"Osteoporosis","Osteopenia",[6692],{"trials":6710,"activeCount":100},[],{"trials":6712,"activeCount":100},[],{"trials":6714,"activeCount":100},[],{"intervention":6716,"totalTrials":150,"cells":6717},"Hydrocortisone",{"EARLY_PHASE1":6718,"PHASE1":6720,"PHASE2":6722,"PHASE3":6731,"PHASE4":6733,"NA":6735},{"trials":6719,"activeCount":100},[],{"trials":6721,"activeCount":100},[],{"trials":6723,"activeCount":100},[6724],{"nctId":6725,"briefTitle":6726,"status":108,"phases":6727,"primaryCompletion":5625,"completion":5625,"start":1297,"enrollment":1765,"conditions":6728,"interventions":6730},"NCT00590018","Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease",[89],[6729],"Cardiac Output, Low",[6716],{"trials":6732,"activeCount":100},[],{"trials":6734,"activeCount":100},[],{"trials":6736,"activeCount":100},[],{"intervention":6738,"totalTrials":150,"cells":6739},"Oxytocin",{"EARLY_PHASE1":6740,"PHASE1":6742,"PHASE2":6744,"PHASE3":6756,"PHASE4":6758,"NA":6760},{"trials":6741,"activeCount":100},[],{"trials":6743,"activeCount":100},[],{"trials":6745,"activeCount":100},[6746],{"nctId":6747,"briefTitle":6748,"status":578,"phases":6749,"primaryCompletion":6750,"completion":6750,"start":6751,"enrollment":394,"conditions":6752,"interventions":6755},"NCT05405257","Oxytocin for Hypermobile Ehlers-Danlos Syndrome",[88,89],"2025-03-11","2022-05-13",[6753,6754],"Hypermobile Ehlers-Danlos Syndrome","Pain Assessment",[6738],{"trials":6757,"activeCount":100},[],{"trials":6759,"activeCount":100},[],{"trials":6761,"activeCount":100},[],{"intervention":6763,"totalTrials":150,"cells":6764},"Avelumab",{"EARLY_PHASE1":6765,"PHASE1":6767,"PHASE2":6769,"PHASE3":6781,"PHASE4":6783,"NA":6785},{"trials":6766,"activeCount":100},[],{"trials":6768,"activeCount":100},[],{"trials":6770,"activeCount":100},[6771],{"nctId":6772,"briefTitle":6773,"status":578,"phases":6774,"primaryCompletion":6775,"completion":6775,"start":6776,"enrollment":150,"conditions":6777,"interventions":6780},"NCT03498196","A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer",[88,89],"2019-12-09","2018-12-14",[3193,6778,6779],"Metastatic Bladder Cancer","Invasive Bladder Cancer",[6763],{"trials":6782,"activeCount":100},[],{"trials":6784,"activeCount":100},[],{"trials":6786,"activeCount":100},[],{"intervention":6788,"totalTrials":150,"cells":6789},"Oral Budesonide",{"EARLY_PHASE1":6790,"PHASE1":6792,"PHASE2":6794,"PHASE3":6805,"PHASE4":6807,"NA":6809},{"trials":6791,"activeCount":100},[],{"trials":6793,"activeCount":100},[],{"trials":6795,"activeCount":100},[6796],{"nctId":6797,"briefTitle":6798,"status":578,"phases":6799,"primaryCompletion":6800,"completion":6800,"start":6801,"enrollment":96,"conditions":6802,"interventions":6804},"NCT01821898","Eosinophilic Esophagitis Clinical Therapy Comparison Trial",[89],"2018-09-24","2013-07-09",[6803],"Eosinophilic Esophagitis",[6788],{"trials":6806,"activeCount":100},[],{"trials":6808,"activeCount":100},[],{"trials":6810,"activeCount":100},[],{"intervention":1162,"totalTrials":150,"cells":6812},{"EARLY_PHASE1":6813,"PHASE1":6815,"PHASE2":6817,"PHASE3":6823,"PHASE4":6825,"NA":6827},{"trials":6814,"activeCount":100},[],{"trials":6816,"activeCount":100},[],{"trials":6818,"activeCount":100},[6819],{"nctId":1152,"briefTitle":1153,"status":108,"phases":6820,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":972,"conditions":6821,"interventions":6822},[89],[1159],[604,1161,1038,518,1162],{"trials":6824,"activeCount":100},[],{"trials":6826,"activeCount":100},[],{"trials":6828,"activeCount":100},[],{"intervention":6830,"totalTrials":150,"cells":6831},"Mg Pidolate",{"EARLY_PHASE1":6832,"PHASE1":6834,"PHASE2":6836,"PHASE3":6847,"PHASE4":6849,"NA":6851},{"trials":6833,"activeCount":100},[],{"trials":6835,"activeCount":100},[],{"trials":6837,"activeCount":100},[6838],{"nctId":6839,"briefTitle":6840,"status":578,"phases":6841,"completion":6842,"start":6843,"enrollment":24,"conditions":6844,"interventions":6846},"NCT00040456","Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate",[89],"2006-05","2001-01",[6845],"HEMOGLOBIN SC DISEASE",[6830],{"trials":6848,"activeCount":100},[],{"trials":6850,"activeCount":100},[],{"trials":6852,"activeCount":100},[],{"intervention":6854,"totalTrials":150,"cells":6855},"Candesartan with CBT",{"EARLY_PHASE1":6856,"PHASE1":6858,"PHASE2":6860,"PHASE3":6869,"PHASE4":6871,"NA":6873},{"trials":6857,"activeCount":100},[],{"trials":6859,"activeCount":100},[],{"trials":6861,"activeCount":100},[6862],{"nctId":6863,"briefTitle":6864,"status":578,"phases":6865,"primaryCompletion":6866,"completion":6866,"start":1263,"enrollment":832,"conditions":6867,"interventions":6868},"NCT01938664","A Pilot Study of Candesartan as a Treatment for Cocaine Dependence",[89],"2016-07",[23],[6854],{"trials":6870,"activeCount":100},[],{"trials":6872,"activeCount":100},[],{"trials":6874,"activeCount":100},[],{"intervention":6876,"totalTrials":150,"cells":6877},"sodium oxybate",{"EARLY_PHASE1":6878,"PHASE1":6880,"PHASE2":6882,"PHASE3":6891,"PHASE4":6893,"NA":6895},{"trials":6879,"activeCount":100},[],{"trials":6881,"activeCount":100},[],{"trials":6883,"activeCount":100},[6884],{"nctId":6885,"briefTitle":6886,"status":108,"phases":6887,"primaryCompletion":3378,"completion":3632,"start":4911,"enrollment":832,"conditions":6888,"interventions":6890},"NCT00641186","Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)",[89],[6889],"Parkinson Disease",[6876],{"trials":6892,"activeCount":100},[],{"trials":6894,"activeCount":100},[],{"trials":6896,"activeCount":100},[],{"intervention":6898,"totalTrials":150,"cells":6899},"Pentoxifylline",{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6916,"PHASE4":6918,"NA":6920},{"trials":6901,"activeCount":100},[],{"trials":6903,"activeCount":100},[],{"trials":6905,"activeCount":100},[6906],{"nctId":6907,"briefTitle":6908,"status":578,"phases":6909,"primaryCompletion":6910,"completion":6911,"start":6912,"enrollment":876,"conditions":6913,"interventions":6915},"NCT01774487","Pentoxifylline Therapy in Biliary Atresia",[89],"2018-02-07","2023-02-20","2013-02-04",[6914],"Biliary Atresia",[6898],{"trials":6917,"activeCount":100},[],{"trials":6919,"activeCount":100},[],{"trials":6921,"activeCount":100},[],{"intervention":6923,"totalTrials":150,"cells":6924},"N-Acetyl cysteine",{"EARLY_PHASE1":6925,"PHASE1":6927,"PHASE2":6929,"PHASE3":6938,"PHASE4":6940,"NA":6942},{"trials":6926,"activeCount":100},[],{"trials":6928,"activeCount":100},[],{"trials":6930,"activeCount":100},[6931],{"nctId":6932,"briefTitle":6933,"status":108,"phases":6934,"primaryCompletion":2964,"completion":6935,"start":3345,"enrollment":1350,"conditions":6936,"interventions":6937},"NCT03499249","N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy",[89],"2024-03-23",[6914],[6923],{"trials":6939,"activeCount":100},[],{"trials":6941,"activeCount":100},[],{"trials":6943,"activeCount":100},[],{"intervention":5877,"totalTrials":150,"cells":6945},{"EARLY_PHASE1":6946,"PHASE1":6948,"PHASE2":6950,"PHASE3":6956,"PHASE4":6958,"NA":6960},{"trials":6947,"activeCount":100},[],{"trials":6949,"activeCount":100},[],{"trials":6951,"activeCount":100},[6952],{"nctId":5868,"briefTitle":5869,"status":108,"phases":6953,"primaryCompletion":5871,"completion":971,"start":5872,"enrollment":5873,"conditions":6954,"interventions":6955},[89],[5875],[3462,5877,5878,5879],{"trials":6957,"activeCount":100},[],{"trials":6959,"activeCount":100},[],{"trials":6961,"activeCount":100},[],{"intervention":5878,"totalTrials":150,"cells":6963},{"EARLY_PHASE1":6964,"PHASE1":6966,"PHASE2":6968,"PHASE3":6974,"PHASE4":6976,"NA":6978},{"trials":6965,"activeCount":100},[],{"trials":6967,"activeCount":100},[],{"trials":6969,"activeCount":100},[6970],{"nctId":5868,"briefTitle":5869,"status":108,"phases":6971,"primaryCompletion":5871,"completion":971,"start":5872,"enrollment":5873,"conditions":6972,"interventions":6973},[89],[5875],[3462,5877,5878,5879],{"trials":6975,"activeCount":100},[],{"trials":6977,"activeCount":100},[],{"trials":6979,"activeCount":100},[],{"intervention":5879,"totalTrials":150,"cells":6981},{"EARLY_PHASE1":6982,"PHASE1":6984,"PHASE2":6986,"PHASE3":6992,"PHASE4":6994,"NA":6996},{"trials":6983,"activeCount":100},[],{"trials":6985,"activeCount":100},[],{"trials":6987,"activeCount":100},[6988],{"nctId":5868,"briefTitle":5869,"status":108,"phases":6989,"primaryCompletion":5871,"completion":971,"start":5872,"enrollment":5873,"conditions":6990,"interventions":6991},[89],[5875],[3462,5877,5878,5879],{"trials":6993,"activeCount":100},[],{"trials":6995,"activeCount":100},[],{"trials":6997,"activeCount":100},[],{"intervention":6999,"totalTrials":150,"cells":7000},"multiTAA specific T cells",{"EARLY_PHASE1":7001,"PHASE1":7003,"PHASE2":7005,"PHASE3":7016,"PHASE4":7018,"NA":7020},{"trials":7002,"activeCount":100},[],{"trials":7004,"activeCount":100},[],{"trials":7006,"activeCount":100},[7007],{"nctId":7008,"briefTitle":7009,"status":108,"phases":7010,"primaryCompletion":7011,"completion":7012,"start":1702,"enrollment":3405,"conditions":7013,"interventions":7015},"NCT03192462","TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer",[88,89],"2020-06-15","2025-07-31",[7014],"Pancreatic Cancer",[6999],{"trials":7017,"activeCount":100},[],{"trials":7019,"activeCount":100},[],{"trials":7021,"activeCount":100},[],{"intervention":7023,"totalTrials":150,"cells":7024},"Mesenchymal Stromal Cells",{"EARLY_PHASE1":7025,"PHASE1":7027,"PHASE2":7029,"PHASE3":7042,"PHASE4":7044,"NA":7046},{"trials":7026,"activeCount":100},[],{"trials":7028,"activeCount":100},[],{"trials":7030,"activeCount":100},[7031],{"nctId":7032,"briefTitle":7033,"status":108,"phases":7034,"primaryCompletion":7035,"completion":7035,"start":7036,"enrollment":767,"conditions":7037,"interventions":7041},"NCT04345601","Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)",[88,89],"2023-01-10","2021-02-12",[7038,7039,7040],"Sars-CoV2","Acute Respiratory Distress Syndrome","COVID-19",[7023],{"trials":7043,"activeCount":100},[],{"trials":7045,"activeCount":100},[],{"trials":7047,"activeCount":100},[],{"intervention":7049,"totalTrials":150,"cells":7050},"saracatinib",{"EARLY_PHASE1":7051,"PHASE1":7053,"PHASE2":7055,"PHASE3":7064,"PHASE4":7066,"NA":7068},{"trials":7052,"activeCount":100},[],{"trials":7054,"activeCount":100},[],{"trials":7056,"activeCount":100},[7057],{"nctId":7058,"briefTitle":7059,"status":578,"phases":7060,"primaryCompletion":630,"completion":630,"start":69,"enrollment":767,"conditions":7061,"interventions":7063},"NCT02737202","Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis",[89],[7062],"Pulmonary Lymphangioleiomyomatosis",[7049],{"trials":7065,"activeCount":100},[],{"trials":7067,"activeCount":100},[],{"trials":7069,"activeCount":100},[],{"intervention":7071,"totalTrials":150,"cells":7072},"Autologous CMV-specific CTL",{"EARLY_PHASE1":7073,"PHASE1":7075,"PHASE2":7077,"PHASE3":7088,"PHASE4":7090,"NA":7092},{"trials":7074,"activeCount":100},[],{"trials":7076,"activeCount":100},[],{"trials":7078,"activeCount":100},[7079],{"nctId":7080,"briefTitle":7081,"status":578,"phases":7082,"primaryCompletion":2848,"completion":7083,"start":610,"enrollment":394,"conditions":7084,"interventions":7087},"NCT01205334","Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme",[88,89],"2012-03",[5796,7085,7086],"GBM","Brain Cancer",[7071],{"trials":7089,"activeCount":100},[],{"trials":7091,"activeCount":100},[],{"trials":7093,"activeCount":100},[],{"intervention":7095,"totalTrials":150,"cells":7096},"BOTOX-A",{"EARLY_PHASE1":7097,"PHASE1":7099,"PHASE2":7101,"PHASE3":7111,"PHASE4":7113,"NA":7115},{"trials":7098,"activeCount":100},[],{"trials":7100,"activeCount":100},[],{"trials":7102,"activeCount":100},[7103],{"nctId":7104,"briefTitle":7105,"status":578,"phases":7106,"primaryCompletion":3497,"completion":3497,"start":7107,"enrollment":150,"conditions":7108,"interventions":7110},"NCT00711087","Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)",[89],"2007-07",[7109,4537],"Neurogenic Bladder Dysfunction Nos",[7095],{"trials":7112,"activeCount":100},[],{"trials":7114,"activeCount":100},[],{"trials":7116,"activeCount":100},[],{"intervention":7118,"totalTrials":150,"cells":7119},"Everolimus",{"EARLY_PHASE1":7120,"PHASE1":7122,"PHASE2":7124,"PHASE3":7133,"PHASE4":7135,"NA":7137},{"trials":7121,"activeCount":100},[],{"trials":7123,"activeCount":100},[],{"trials":7125,"activeCount":100},[7126],{"nctId":7127,"briefTitle":7128,"status":180,"phases":7129,"primaryCompletion":69,"completion":69,"start":1079,"enrollment":100,"conditions":7130,"interventions":7132},"NCT01997255","Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)",[89],[7131],"Sturge Weber Syndrome",[7118],{"trials":7134,"activeCount":100},[],{"trials":7136,"activeCount":100},[],{"trials":7138,"activeCount":100},[],{"intervention":1187,"totalTrials":150,"cells":7140},{"EARLY_PHASE1":7141,"PHASE1":7143,"PHASE2":7145,"PHASE3":7151,"PHASE4":7153,"NA":7155},{"trials":7142,"activeCount":100},[],{"trials":7144,"activeCount":100},[],{"trials":7146,"activeCount":100},[7147],{"nctId":1177,"briefTitle":1178,"status":578,"phases":7148,"primaryCompletion":1180,"completion":1180,"start":1122,"enrollment":972,"conditions":7149,"interventions":7150},[89],[1182,1183,1184],[1186,1187,1150,1188],{"trials":7152,"activeCount":100},[],{"trials":7154,"activeCount":100},[],{"trials":7156,"activeCount":100},[],{"intervention":1188,"totalTrials":150,"cells":7158},{"EARLY_PHASE1":7159,"PHASE1":7161,"PHASE2":7163,"PHASE3":7169,"PHASE4":7171,"NA":7173},{"trials":7160,"activeCount":100},[],{"trials":7162,"activeCount":100},[],{"trials":7164,"activeCount":100},[7165],{"nctId":1177,"briefTitle":1178,"status":578,"phases":7166,"primaryCompletion":1180,"completion":1180,"start":1122,"enrollment":972,"conditions":7167,"interventions":7168},[89],[1182,1183,1184],[1186,1187,1150,1188],{"trials":7170,"activeCount":100},[],{"trials":7172,"activeCount":100},[],{"trials":7174,"activeCount":100},[],{"intervention":7176,"totalTrials":150,"cells":7177},"Carisbamate",{"EARLY_PHASE1":7178,"PHASE1":7180,"PHASE2":7182,"PHASE3":7193,"PHASE4":7195,"NA":7197},{"trials":7179,"activeCount":100},[],{"trials":7181,"activeCount":100},[],{"trials":7183,"activeCount":100},[7184],{"nctId":7185,"briefTitle":7186,"status":108,"phases":7187,"primaryCompletion":7188,"completion":7188,"start":4445,"enrollment":27,"conditions":7189,"interventions":7192},"NCT02435381","Carisbamate as a Potential Treatment for Alcohol Dependence",[88,89],"2013-09-30",[7190,7191,21],"Alcohol Dependence","Alcohol Abuse",[7176],{"trials":7194,"activeCount":100},[],{"trials":7196,"activeCount":100},[],{"trials":7198,"activeCount":100},[],{"intervention":3638,"totalTrials":150,"cells":7200},{"EARLY_PHASE1":7201,"PHASE1":7203,"PHASE2":7205,"PHASE3":7211,"PHASE4":7213,"NA":7215},{"trials":7202,"activeCount":100},[],{"trials":7204,"activeCount":100},[],{"trials":7206,"activeCount":100},[7207],{"nctId":3628,"briefTitle":3629,"status":108,"phases":7208,"primaryCompletion":110,"completion":3631,"start":3632,"enrollment":3633,"conditions":7209,"interventions":7210},[89],[3635,3636],[3619,3638],{"trials":7212,"activeCount":100},[],{"trials":7214,"activeCount":100},[],{"trials":7216,"activeCount":100},[],{"intervention":1208,"totalTrials":150,"cells":7218},{"EARLY_PHASE1":7219,"PHASE1":7221,"PHASE2":7223,"PHASE3":7229,"PHASE4":7231,"NA":7233},{"trials":7220,"activeCount":100},[],{"trials":7222,"activeCount":100},[],{"trials":7224,"activeCount":100},[7225],{"nctId":1200,"briefTitle":1201,"status":108,"phases":7226,"primaryCompletion":1203,"completion":1203,"start":1204,"enrollment":282,"conditions":7227,"interventions":7228},[88,89],[1206,1138,1112,1113,1114],[1186,1198,1208],{"trials":7230,"activeCount":100},[],{"trials":7232,"activeCount":100},[],{"trials":7234,"activeCount":100},[],{"intervention":3463,"totalTrials":394,"cells":7236},{"EARLY_PHASE1":7237,"PHASE1":7239,"PHASE2":7257,"PHASE3":7259,"PHASE4":7261,"NA":7263},{"trials":7238,"activeCount":100},[],{"trials":7240,"activeCount":100},[7241,7253],{"nctId":7242,"briefTitle":7243,"status":108,"phases":7244,"primaryCompletion":7245,"completion":7246,"start":7247,"enrollment":133,"conditions":7248,"interventions":7249},"NCT02476773","Study of Na-APR-1 (M74)\u002FAlhydrogel® Co-administered With Na-GST-1\u002FAlhydrogel in Brazilian Adults",[88],"2017-06","2017-12","2016-01",[2299,3450],[7250,3463,7251,7252],"Na-GST-1\u002FAlhydrogel plus GLA-AF","Na-APR-1 (M74)\u002FAlhydrogel plus GLA-AF","Sterile Saline Placebo",{"nctId":3455,"briefTitle":3456,"status":108,"phases":7254,"primaryCompletion":3458,"completion":525,"start":3459,"enrollment":133,"conditions":7255,"interventions":7256},[88],[3450,2299],[3462,3463,3464],{"trials":7258,"activeCount":100},[],{"trials":7260,"activeCount":100},[],{"trials":7262,"activeCount":100},[],{"trials":7264,"activeCount":100},[],{"intervention":5482,"totalTrials":394,"cells":7266},{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7283,"PHASE3":7285,"PHASE4":7287,"NA":7289},{"trials":7268,"activeCount":100},[],{"trials":7270,"activeCount":100},[7271,7279],{"nctId":7272,"briefTitle":7273,"status":108,"phases":7274,"primaryCompletion":3758,"completion":3758,"start":6382,"enrollment":2576,"conditions":7275,"interventions":7276},"NCT01601730","Modafinil - Escitalopram Study for Cocaine Dependence",[88],[23,5446,5445,21],[7277,5482,7278],"Modafinil and Escitalopram","Escitalopram",{"nctId":5475,"briefTitle":5476,"status":108,"phases":7280,"primaryCompletion":5478,"completion":5478,"start":5479,"enrollment":3191,"conditions":7281,"interventions":7282},[88],[23],[5432,5482,5483],{"trials":7284,"activeCount":100},[],{"trials":7286,"activeCount":100},[],{"trials":7288,"activeCount":100},[],{"trials":7290,"activeCount":100},[],{"intervention":1274,"totalTrials":394,"cells":7292},{"EARLY_PHASE1":7293,"PHASE1":7299,"PHASE2":7305,"PHASE3":7307,"PHASE4":7309,"NA":7311},{"trials":7294,"activeCount":100},[7295],{"nctId":1258,"briefTitle":1259,"status":108,"phases":7296,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1106,"conditions":7297,"interventions":7298},[87],[1265,1266,1267],[1269,587,411,1270,1271,1272,1038,1273,1274],{"trials":7300,"activeCount":100},[7301],{"nctId":1309,"briefTitle":1310,"status":108,"phases":7302,"completion":1312,"start":1313,"enrollment":1216,"conditions":7303,"interventions":7304},[88],[1315],[1038,1303,1274],{"trials":7306,"activeCount":100},[],{"trials":7308,"activeCount":100},[],{"trials":7310,"activeCount":100},[],{"trials":7312,"activeCount":100},[],{"intervention":7314,"totalTrials":394,"cells":7315},"Varenicline",{"EARLY_PHASE1":7316,"PHASE1":7318,"PHASE2":7335,"PHASE3":7337,"PHASE4":7339,"NA":7341},{"trials":7317,"activeCount":100},[],{"trials":7319,"activeCount":100},[7320,7328],{"nctId":7321,"briefTitle":7322,"status":108,"phases":7323,"primaryCompletion":4493,"completion":4493,"start":5442,"enrollment":876,"conditions":7324,"interventions":7327},"NCT01571167","Varenicline as a Treatment for Methamphetamine Dependence",[88],[7325,7326,21],"Methamphetamine Dependence","Methamphetamine Abuse",[7314,7314],{"nctId":7329,"briefTitle":7330,"status":180,"phases":7331,"primaryCompletion":4599,"completion":4599,"start":7332,"enrollment":100,"conditions":7333,"interventions":7334},"NCT00733967","Varenicline-Methamphetamine Interaction Study (2008)",[88],"2008-01",[7325,21,7326],[7314],{"trials":7336,"activeCount":100},[],{"trials":7338,"activeCount":100},[],{"trials":7340,"activeCount":100},[],{"trials":7342,"activeCount":100},[],{"intervention":3452,"totalTrials":394,"cells":7344},{"EARLY_PHASE1":7345,"PHASE1":7347,"PHASE2":7360,"PHASE3":7362,"PHASE4":7364,"NA":7366},{"trials":7346,"activeCount":100},[],{"trials":7348,"activeCount":100},[7349,7353],{"nctId":3446,"briefTitle":3447,"status":108,"phases":7350,"primaryCompletion":1732,"completion":1431,"start":170,"enrollment":534,"conditions":7351,"interventions":7352},[88],[2299,3450],[3452,3453,3439],{"nctId":7354,"briefTitle":7355,"status":108,"phases":7356,"primaryCompletion":3496,"completion":111,"start":54,"enrollment":282,"conditions":7357,"interventions":7358},"NCT01717950","Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults",[88],[2299,3450],[3452,7359],"Gluco-Pyranosylphospho-Lipid A Aqueous Formulation",{"trials":7361,"activeCount":100},[],{"trials":7363,"activeCount":100},[],{"trials":7365,"activeCount":100},[],{"trials":7367,"activeCount":100},[],{"intervention":3453,"totalTrials":394,"cells":7369},{"EARLY_PHASE1":7370,"PHASE1":7372,"PHASE2":7386,"PHASE3":7388,"PHASE4":7390,"NA":7392},{"trials":7371,"activeCount":100},[],{"trials":7373,"activeCount":100},[7374,7378],{"nctId":3446,"briefTitle":3447,"status":108,"phases":7375,"primaryCompletion":1732,"completion":1431,"start":170,"enrollment":534,"conditions":7376,"interventions":7377},[88],[2299,3450],[3452,3453,3439],{"nctId":7379,"briefTitle":7380,"status":108,"phases":7381,"primaryCompletion":1431,"completion":4534,"start":7382,"enrollment":1216,"conditions":7383,"interventions":7384},"NCT02143518","Safety and Immunogenicity Study of Na-GST-1 With or Without CpG",[88],"2014-10",[2299,3450],[3453,7385],"CpG 10104",{"trials":7387,"activeCount":100},[],{"trials":7389,"activeCount":100},[],{"trials":7391,"activeCount":100},[],{"trials":7393,"activeCount":100},[],{"intervention":544,"totalTrials":394,"cells":7395},{"EARLY_PHASE1":7396,"PHASE1":7398,"PHASE2":7418,"PHASE3":7420,"PHASE4":7422,"NA":7424},{"trials":7397,"activeCount":100},[],{"trials":7399,"activeCount":100},[7400,7414],{"nctId":7401,"briefTitle":7402,"status":108,"phases":7403,"primaryCompletion":7404,"completion":7405,"start":7406,"enrollment":2638,"conditions":7407,"interventions":7412},"NCT02973113","Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed\u002FRefractory EBV Positive Lymphoma (PREVALE)",[88],"2019-09-05","2020-07-11","2016-02-16",[7408,1114,7409,7410,1420,2968,7411],"NonHodgkin Lymphoma","EBV Related Lymphoma","EBV-Related PTLD","EBV Related Hodgkin's Lymphoma",[7413,544],"EBVST Cells",{"nctId":530,"briefTitle":531,"status":108,"phases":7415,"primaryCompletion":533,"completion":533,"start":111,"enrollment":534,"conditions":7416,"interventions":7417},[88],[536,537,538,539,540,541],[543,499,518,544],{"trials":7419,"activeCount":100},[],{"trials":7421,"activeCount":100},[],{"trials":7423,"activeCount":100},[],{"trials":7425,"activeCount":100},[],{"intervention":5463,"totalTrials":394,"cells":7427},{"EARLY_PHASE1":7428,"PHASE1":7430,"PHASE2":7445,"PHASE3":7447,"PHASE4":7449,"NA":7451},{"trials":7429,"activeCount":100},[],{"trials":7431,"activeCount":100},[7432,7436],{"nctId":5456,"briefTitle":5457,"status":108,"phases":7433,"primaryCompletion":5459,"completion":5459,"start":2848,"enrollment":832,"conditions":7434,"interventions":7435},[88],[974],[5462,5463],{"nctId":7437,"briefTitle":7438,"status":108,"phases":7439,"primaryCompletion":7440,"completion":7440,"start":7441,"enrollment":2040,"conditions":7442,"interventions":7443},"NCT01062451","An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence",[88],"2013-11-20","2009-05",[7325,7326,21],[5463,7444],"Candesartan",{"trials":7446,"activeCount":100},[],{"trials":7448,"activeCount":100},[],{"trials":7450,"activeCount":100},[],{"trials":7452,"activeCount":100},[],{"intervention":7454,"totalTrials":394,"cells":7455},"EBV specific T cells",{"EARLY_PHASE1":7456,"PHASE1":7458,"PHASE2":7476,"PHASE3":7478,"PHASE4":7480,"NA":7482},{"trials":7457,"activeCount":100},[],{"trials":7459,"activeCount":100},[7460,7469],{"nctId":7461,"briefTitle":7462,"status":108,"phases":7463,"primaryCompletion":59,"completion":59,"start":7464,"enrollment":7465,"conditions":7466,"interventions":7468},"NCT00058812","Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts",[88],"1993-05",69,[7467],"Epstein-Barr Virus Infections",[7454],{"nctId":7470,"briefTitle":7471,"status":578,"phases":7472,"primaryCompletion":3511,"completion":7332,"start":3565,"enrollment":1106,"conditions":7473,"interventions":7474},"NCT00082225","LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)",[88],[1390],[7475,7454],"CD45 antibodies",{"trials":7477,"activeCount":100},[],{"trials":7479,"activeCount":100},[],{"trials":7481,"activeCount":100},[],{"trials":7483,"activeCount":100},[],{"intervention":7485,"totalTrials":394,"cells":7486},"CPG 10104",{"EARLY_PHASE1":7487,"PHASE1":7489,"PHASE2":7505,"PHASE3":7507,"PHASE4":7509,"NA":7511},{"trials":7488,"activeCount":100},[],{"trials":7490,"activeCount":100},[7491,7501],{"nctId":7492,"briefTitle":7493,"status":108,"phases":7494,"primaryCompletion":7495,"completion":7496,"start":7497,"enrollment":1216,"conditions":7498,"interventions":7499},"NCT03373214","Na-GST-1\u002FAlhydrogel With or Without CpG 10104 in Gabonese Adults",[88],"2019-02-28","2019-03-30","2018-02-01",[2299,3450],[7500,7485],"Na-GST-1",{"nctId":7379,"briefTitle":7380,"status":108,"phases":7502,"primaryCompletion":1431,"completion":4534,"start":7382,"enrollment":1216,"conditions":7503,"interventions":7504},[88],[2299,3450],[3453,7385],{"trials":7506,"activeCount":100},[],{"trials":7508,"activeCount":100},[],{"trials":7510,"activeCount":100},[],{"trials":7512,"activeCount":100},[],{"intervention":7514,"totalTrials":394,"cells":7515},"10 μg Na-GST-1\u002FAlhydrogel",{"EARLY_PHASE1":7516,"PHASE1":7518,"PHASE2":7541,"PHASE3":7543,"PHASE4":7545,"NA":7547},{"trials":7517,"activeCount":100},[],{"trials":7519,"activeCount":100},[7520,7532],{"nctId":7521,"briefTitle":7522,"status":108,"phases":7523,"primaryCompletion":2296,"completion":3496,"start":7524,"enrollment":282,"conditions":7525,"interventions":7526},"NCT01385189","Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant",[88],"2012-05",[2299,3450],[7514,7527,7528,7529,7530,7530,7531],"30 μg Na-GST-1\u002FAlhydrogel","100 μg Na-GST-1\u002FAlhydrogel","10 μg Na-GST-1\u002FAlhydrogel\u002FGLA-AF","30 μg Na-GST-1\u002FAlhydrogel\u002FGLA-AF","100 μg Na-GST-1\u002FAlhydrogel\u002FGLA-AF",{"nctId":7533,"briefTitle":7534,"status":108,"phases":7535,"primaryCompletion":7536,"completion":5561,"start":39,"enrollment":3720,"conditions":7537,"interventions":7538},"NCT01261130","Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults",[88],"2014-08",[2299,3450],[7514,7527,7528,7539,7530,7531,7540],"10 μg Na-GST-1\u002F Alhydrogel\u002FGLA-AF","Butang® hepatitis B vaccine",{"trials":7542,"activeCount":100},[],{"trials":7544,"activeCount":100},[],{"trials":7546,"activeCount":100},[],{"trials":7548,"activeCount":100},[],{"intervention":7527,"totalTrials":394,"cells":7550},{"EARLY_PHASE1":7551,"PHASE1":7553,"PHASE2":7563,"PHASE3":7565,"PHASE4":7567,"NA":7569},{"trials":7552,"activeCount":100},[],{"trials":7554,"activeCount":100},[7555,7559],{"nctId":7521,"briefTitle":7522,"status":108,"phases":7556,"primaryCompletion":2296,"completion":3496,"start":7524,"enrollment":282,"conditions":7557,"interventions":7558},[88],[2299,3450],[7514,7527,7528,7529,7530,7530,7531],{"nctId":7533,"briefTitle":7534,"status":108,"phases":7560,"primaryCompletion":7536,"completion":5561,"start":39,"enrollment":3720,"conditions":7561,"interventions":7562},[88],[2299,3450],[7514,7527,7528,7539,7530,7531,7540],{"trials":7564,"activeCount":100},[],{"trials":7566,"activeCount":100},[],{"trials":7568,"activeCount":100},[],{"trials":7570,"activeCount":100},[],{"intervention":7528,"totalTrials":394,"cells":7572},{"EARLY_PHASE1":7573,"PHASE1":7575,"PHASE2":7585,"PHASE3":7587,"PHASE4":7589,"NA":7591},{"trials":7574,"activeCount":100},[],{"trials":7576,"activeCount":100},[7577,7581],{"nctId":7521,"briefTitle":7522,"status":108,"phases":7578,"primaryCompletion":2296,"completion":3496,"start":7524,"enrollment":282,"conditions":7579,"interventions":7580},[88],[2299,3450],[7514,7527,7528,7529,7530,7530,7531],{"nctId":7533,"briefTitle":7534,"status":108,"phases":7582,"primaryCompletion":7536,"completion":5561,"start":39,"enrollment":3720,"conditions":7583,"interventions":7584},[88],[2299,3450],[7514,7527,7528,7539,7530,7531,7540],{"trials":7586,"activeCount":100},[],{"trials":7588,"activeCount":100},[],{"trials":7590,"activeCount":100},[],{"trials":7592,"activeCount":100},[],{"intervention":7530,"totalTrials":394,"cells":7594},{"EARLY_PHASE1":7595,"PHASE1":7597,"PHASE2":7607,"PHASE3":7609,"PHASE4":7611,"NA":7613},{"trials":7596,"activeCount":100},[],{"trials":7598,"activeCount":100},[7599,7603],{"nctId":7521,"briefTitle":7522,"status":108,"phases":7600,"primaryCompletion":2296,"completion":3496,"start":7524,"enrollment":282,"conditions":7601,"interventions":7602},[88],[2299,3450],[7514,7527,7528,7529,7530,7530,7531],{"nctId":7533,"briefTitle":7534,"status":108,"phases":7604,"primaryCompletion":7536,"completion":5561,"start":39,"enrollment":3720,"conditions":7605,"interventions":7606},[88],[2299,3450],[7514,7527,7528,7539,7530,7531,7540],{"trials":7608,"activeCount":100},[],{"trials":7610,"activeCount":100},[],{"trials":7612,"activeCount":100},[],{"trials":7614,"activeCount":100},[],{"intervention":7531,"totalTrials":394,"cells":7616},{"EARLY_PHASE1":7617,"PHASE1":7619,"PHASE2":7629,"PHASE3":7631,"PHASE4":7633,"NA":7635},{"trials":7618,"activeCount":100},[],{"trials":7620,"activeCount":100},[7621,7625],{"nctId":7521,"briefTitle":7522,"status":108,"phases":7622,"primaryCompletion":2296,"completion":3496,"start":7524,"enrollment":282,"conditions":7623,"interventions":7624},[88],[2299,3450],[7514,7527,7528,7529,7530,7530,7531],{"nctId":7533,"briefTitle":7534,"status":108,"phases":7626,"primaryCompletion":7536,"completion":5561,"start":39,"enrollment":3720,"conditions":7627,"interventions":7628},[88],[2299,3450],[7514,7527,7528,7539,7530,7531,7540],{"trials":7630,"activeCount":100},[],{"trials":7632,"activeCount":100},[],{"trials":7634,"activeCount":100},[],{"trials":7636,"activeCount":100},[],{"intervention":7638,"totalTrials":394,"cells":7639},"Gemcitabine",{"EARLY_PHASE1":7640,"PHASE1":7642,"PHASE2":7659,"PHASE3":7661,"PHASE4":7663,"NA":7665},{"trials":7641,"activeCount":100},[],{"trials":7643,"activeCount":100},[7644,7652],{"nctId":7645,"briefTitle":7646,"status":578,"phases":7647,"primaryCompletion":7648,"completion":1133,"start":1134,"enrollment":32,"conditions":7649,"interventions":7651},"NCT00074607","Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine",[88],"2005-07",[7650,5747],"Meningitis",[7638],{"nctId":7653,"briefTitle":7654,"status":108,"phases":7655,"primaryCompletion":1776,"completion":468,"start":1262,"enrollment":581,"conditions":7656,"interventions":7657},"NCT02885974","Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer",[88],[3193],[7658,7638,1355],"Celecoxib",{"trials":7660,"activeCount":100},[],{"trials":7662,"activeCount":100},[],{"trials":7664,"activeCount":100},[],{"trials":7666,"activeCount":100},[],{"intervention":7668,"totalTrials":394,"cells":7669},"Intravenous injection of EBV specific CTLs",{"EARLY_PHASE1":7670,"PHASE1":7672,"PHASE2":7688,"PHASE3":7690,"PHASE4":7692,"NA":7694},{"trials":7671,"activeCount":100},[],{"trials":7673,"activeCount":100},[7674,7680],{"nctId":7675,"briefTitle":7676,"status":108,"phases":7677,"primaryCompletion":2205,"completion":2205,"start":6843,"enrollment":24,"conditions":7678,"interventions":7679},"NCT00058604","Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).",[88],[7467,1114],[7668],{"nctId":7681,"briefTitle":7682,"status":108,"phases":7683,"primaryCompletion":2205,"completion":2205,"start":7684,"enrollment":1350,"conditions":7685,"interventions":7686},"NCT00058591","Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)",[88],"2000-01",[7467],[7687],"Intravenous injection of EBV specific CTLS",{"trials":7689,"activeCount":100},[],{"trials":7691,"activeCount":100},[],{"trials":7693,"activeCount":100},[],{"trials":7695,"activeCount":100},[],{"intervention":7697,"totalTrials":150,"cells":7698},"autologous EBV specific CTLs",{"EARLY_PHASE1":7699,"PHASE1":7701,"PHASE2":7711,"PHASE3":7713,"PHASE4":7715,"NA":7717},{"trials":7700,"activeCount":100},[],{"trials":7702,"activeCount":100},[7703],{"nctId":7704,"briefTitle":7705,"status":108,"phases":7706,"primaryCompletion":1168,"completion":7707,"start":5745,"enrollment":9,"conditions":7708,"interventions":7710},"NCT00609219","T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC",[88],"2012-06",[7709],"Head and Neck Cancer",[7697],{"trials":7712,"activeCount":100},[],{"trials":7714,"activeCount":100},[],{"trials":7716,"activeCount":100},[],{"trials":7718,"activeCount":100},[],{"intervention":7720,"totalTrials":150,"cells":7721},"GVG",{"EARLY_PHASE1":7722,"PHASE1":7724,"PHASE2":7734,"PHASE3":7736,"PHASE4":7738,"NA":7740},{"trials":7723,"activeCount":100},[],{"trials":7725,"activeCount":100},[7726],{"nctId":7727,"briefTitle":7728,"status":108,"phases":7729,"primaryCompletion":1281,"completion":4598,"start":7730,"enrollment":876,"conditions":7731,"interventions":7733},"NCT00506935","Assessment of GVG for the Treatment of Methamphetamine Dependence",[88],"2006-07",[7732],"Methamphetamine Addiction",[7720],{"trials":7735,"activeCount":100},[],{"trials":7737,"activeCount":100},[],{"trials":7739,"activeCount":100},[],{"trials":7741,"activeCount":100},[],{"intervention":7743,"totalTrials":150,"cells":7744},"Pramipexole",{"EARLY_PHASE1":7745,"PHASE1":7747,"PHASE2":7756,"PHASE3":7758,"PHASE4":7760,"NA":7762},{"trials":7746,"activeCount":100},[],{"trials":7748,"activeCount":100},[7749],{"nctId":7750,"briefTitle":7751,"status":108,"phases":7752,"primaryCompletion":7753,"completion":7753,"start":3811,"enrollment":32,"conditions":7754,"interventions":7755},"NCT01651377","Pramipexole as a Treatment for Cocaine Dependence",[88],"2012-12",[5445,5446,23,21],[7743],{"trials":7757,"activeCount":100},[],{"trials":7759,"activeCount":100},[],{"trials":7761,"activeCount":100},[],{"trials":7763,"activeCount":100},[],{"intervention":7765,"totalTrials":150,"cells":7766},"Cabergoline",{"EARLY_PHASE1":7767,"PHASE1":7769,"PHASE2":7777,"PHASE3":7779,"PHASE4":7781,"NA":7783},{"trials":7768,"activeCount":100},[],{"trials":7770,"activeCount":100},[7771],{"nctId":7772,"briefTitle":7773,"status":108,"phases":7774,"primaryCompletion":3811,"completion":3811,"start":3758,"enrollment":27,"conditions":7775,"interventions":7776},"NCT01651364","A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence",[88],[23,5446,5445,21],[7765],{"trials":7778,"activeCount":100},[],{"trials":7780,"activeCount":100},[],{"trials":7782,"activeCount":100},[],{"trials":7784,"activeCount":100},[],{"intervention":7786,"totalTrials":150,"cells":7787},"Acetaminophen and Diphenhydramine Only Product",{"EARLY_PHASE1":7788,"PHASE1":7790,"PHASE2":7801,"PHASE3":7803,"PHASE4":7805,"NA":7807},{"trials":7789,"activeCount":100},[],{"trials":7791,"activeCount":100},[7792],{"nctId":7793,"briefTitle":7794,"status":3474,"phases":7795,"primaryCompletion":7796,"completion":7797,"start":7798,"enrollment":16,"conditions":7799,"interventions":7800},"NCT04741139","Post IVIG Medication in Children With Immune Thrombocytopenia",[88],"2022-12","2023-10","2021-09-02",[5080],[7786],{"trials":7802,"activeCount":100},[],{"trials":7804,"activeCount":100},[],{"trials":7806,"activeCount":100},[],{"trials":7808,"activeCount":100},[],{"intervention":7810,"totalTrials":150,"cells":7811},"CTL administration",{"EARLY_PHASE1":7812,"PHASE1":7814,"PHASE2":7823,"PHASE3":7825,"PHASE4":7827,"NA":7829},{"trials":7813,"activeCount":100},[],{"trials":7815,"activeCount":100},[7816],{"nctId":7817,"briefTitle":7818,"status":108,"phases":7819,"primaryCompletion":5442,"completion":5442,"start":7820,"enrollment":19,"conditions":7821,"interventions":7822},"NCT00590083","Administration of Virus-Specific Cytotoxic T-Lymphocytes",[88],"2003-07",[3243],[7810],{"trials":7824,"activeCount":100},[],{"trials":7826,"activeCount":100},[],{"trials":7828,"activeCount":100},[],{"trials":7830,"activeCount":100},[],{"intervention":7832,"totalTrials":150,"cells":7833},"Rivastigmine 3 mg",{"EARLY_PHASE1":7834,"PHASE1":7836,"PHASE2":7849,"PHASE3":7851,"PHASE4":7853,"NA":7855},{"trials":7835,"activeCount":100},[],{"trials":7837,"activeCount":100},[7838],{"nctId":7839,"briefTitle":7840,"status":108,"phases":7841,"primaryCompletion":5829,"completion":5829,"start":7842,"enrollment":7843,"conditions":7844,"interventions":7845},"NCT01030692","Rivastigmine and Huperzine A as Treatments for Cocaine Dependence",[88],"2009-01",72,[23,5445,5446,21],[7832,7846,7847,7848],"Huperzine A 0.4 mg","Rivastigmine 6 mg","Huperzine A 0.8 mg",{"trials":7850,"activeCount":100},[],{"trials":7852,"activeCount":100},[],{"trials":7854,"activeCount":100},[],{"trials":7856,"activeCount":100},[],{"intervention":7846,"totalTrials":150,"cells":7858},{"EARLY_PHASE1":7859,"PHASE1":7861,"PHASE2":7867,"PHASE3":7869,"PHASE4":7871,"NA":7873},{"trials":7860,"activeCount":100},[],{"trials":7862,"activeCount":100},[7863],{"nctId":7839,"briefTitle":7840,"status":108,"phases":7864,"primaryCompletion":5829,"completion":5829,"start":7842,"enrollment":7843,"conditions":7865,"interventions":7866},[88],[23,5445,5446,21],[7832,7846,7847,7848],{"trials":7868,"activeCount":100},[],{"trials":7870,"activeCount":100},[],{"trials":7872,"activeCount":100},[],{"trials":7874,"activeCount":100},[],{"intervention":7847,"totalTrials":150,"cells":7876},{"EARLY_PHASE1":7877,"PHASE1":7879,"PHASE2":7885,"PHASE3":7887,"PHASE4":7889,"NA":7891},{"trials":7878,"activeCount":100},[],{"trials":7880,"activeCount":100},[7881],{"nctId":7839,"briefTitle":7840,"status":108,"phases":7882,"primaryCompletion":5829,"completion":5829,"start":7842,"enrollment":7843,"conditions":7883,"interventions":7884},[88],[23,5445,5446,21],[7832,7846,7847,7848],{"trials":7886,"activeCount":100},[],{"trials":7888,"activeCount":100},[],{"trials":7890,"activeCount":100},[],{"trials":7892,"activeCount":100},[],{"intervention":7848,"totalTrials":150,"cells":7894},{"EARLY_PHASE1":7895,"PHASE1":7897,"PHASE2":7903,"PHASE3":7905,"PHASE4":7907,"NA":7909},{"trials":7896,"activeCount":100},[],{"trials":7898,"activeCount":100},[7899],{"nctId":7839,"briefTitle":7840,"status":108,"phases":7900,"primaryCompletion":5829,"completion":5829,"start":7842,"enrollment":7843,"conditions":7901,"interventions":7902},[88],[23,5445,5446,21],[7832,7846,7847,7848],{"trials":7904,"activeCount":100},[],{"trials":7906,"activeCount":100},[],{"trials":7908,"activeCount":100},[],{"trials":7910,"activeCount":100},[],{"intervention":5653,"totalTrials":150,"cells":7912},{"EARLY_PHASE1":7913,"PHASE1":7915,"PHASE2":7921,"PHASE3":7923,"PHASE4":7925,"NA":7927},{"trials":7914,"activeCount":100},[],{"trials":7916,"activeCount":100},[7917],{"nctId":5646,"briefTitle":5647,"status":180,"phases":7918,"primaryCompletion":5625,"completion":5625,"start":5649,"enrollment":100,"conditions":7919,"interventions":7920},[88],[5651],[5653,5639,5654,5655,5656],{"trials":7922,"activeCount":100},[],{"trials":7924,"activeCount":100},[],{"trials":7926,"activeCount":100},[],{"trials":7928,"activeCount":100},[],{"intervention":5654,"totalTrials":150,"cells":7930},{"EARLY_PHASE1":7931,"PHASE1":7933,"PHASE2":7939,"PHASE3":7941,"PHASE4":7943,"NA":7945},{"trials":7932,"activeCount":100},[],{"trials":7934,"activeCount":100},[7935],{"nctId":5646,"briefTitle":5647,"status":180,"phases":7936,"primaryCompletion":5625,"completion":5625,"start":5649,"enrollment":100,"conditions":7937,"interventions":7938},[88],[5651],[5653,5639,5654,5655,5656],{"trials":7940,"activeCount":100},[],{"trials":7942,"activeCount":100},[],{"trials":7944,"activeCount":100},[],{"trials":7946,"activeCount":100},[],{"intervention":5655,"totalTrials":150,"cells":7948},{"EARLY_PHASE1":7949,"PHASE1":7951,"PHASE2":7957,"PHASE3":7959,"PHASE4":7961,"NA":7963},{"trials":7950,"activeCount":100},[],{"trials":7952,"activeCount":100},[7953],{"nctId":5646,"briefTitle":5647,"status":180,"phases":7954,"primaryCompletion":5625,"completion":5625,"start":5649,"enrollment":100,"conditions":7955,"interventions":7956},[88],[5651],[5653,5639,5654,5655,5656],{"trials":7958,"activeCount":100},[],{"trials":7960,"activeCount":100},[],{"trials":7962,"activeCount":100},[],{"trials":7964,"activeCount":100},[],{"intervention":5656,"totalTrials":150,"cells":7966},{"EARLY_PHASE1":7967,"PHASE1":7969,"PHASE2":7975,"PHASE3":7977,"PHASE4":7979,"NA":7981},{"trials":7968,"activeCount":100},[],{"trials":7970,"activeCount":100},[7971],{"nctId":5646,"briefTitle":5647,"status":180,"phases":7972,"primaryCompletion":5625,"completion":5625,"start":5649,"enrollment":100,"conditions":7973,"interventions":7974},[88],[5651],[5653,5639,5654,5655,5656],{"trials":7976,"activeCount":100},[],{"trials":7978,"activeCount":100},[],{"trials":7980,"activeCount":100},[],{"trials":7982,"activeCount":100},[],{"intervention":7984,"totalTrials":150,"cells":7985},"L-Citrulline",{"EARLY_PHASE1":7986,"PHASE1":7988,"PHASE2":8000,"PHASE3":8002,"PHASE4":8004,"NA":8006},{"trials":7987,"activeCount":100},[],{"trials":7989,"activeCount":100},[7990],{"nctId":7991,"briefTitle":7992,"status":108,"phases":7993,"primaryCompletion":7994,"completion":7995,"start":7996,"enrollment":32,"conditions":7997,"interventions":7999},"NCT03952234","L-Citrulline Dose Finding Safety Study in MELAS",[88],"2024-04-30","2024-06-01","2021-04-22",[7998],"MELAS Syndrome",[7984],{"trials":8001,"activeCount":100},[],{"trials":8003,"activeCount":100},[],{"trials":8005,"activeCount":100},[],{"trials":8007,"activeCount":100},[],{"intervention":8009,"totalTrials":150,"cells":8010},"Na-ASP-2\u002FAlhydrogel Hookworm Vaccine",{"EARLY_PHASE1":8011,"PHASE1":8013,"PHASE2":8022,"PHASE3":8024,"PHASE4":8026,"NA":8028},{"trials":8012,"activeCount":100},[],{"trials":8014,"activeCount":100},[8015],{"nctId":8016,"briefTitle":8017,"status":108,"phases":8018,"primaryCompletion":112,"completion":112,"start":1283,"enrollment":1033,"conditions":8019,"interventions":8020},"NCT00120081","Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection",[88],[2299],[8009,8021],"Saline placebo",{"trials":8023,"activeCount":100},[],{"trials":8025,"activeCount":100},[],{"trials":8027,"activeCount":100},[],{"trials":8029,"activeCount":100},[],{"intervention":8021,"totalTrials":150,"cells":8031},{"EARLY_PHASE1":8032,"PHASE1":8034,"PHASE2":8040,"PHASE3":8042,"PHASE4":8044,"NA":8046},{"trials":8033,"activeCount":100},[],{"trials":8035,"activeCount":100},[8036],{"nctId":8016,"briefTitle":8017,"status":108,"phases":8037,"primaryCompletion":112,"completion":112,"start":1283,"enrollment":1033,"conditions":8038,"interventions":8039},[88],[2299],[8009,8021],{"trials":8041,"activeCount":100},[],{"trials":8043,"activeCount":100},[],{"trials":8045,"activeCount":100},[],{"trials":8047,"activeCount":100},[],{"intervention":1288,"totalTrials":150,"cells":8049},{"EARLY_PHASE1":8050,"PHASE1":8052,"PHASE2":8058,"PHASE3":8060,"PHASE4":8062,"NA":8064},{"trials":8051,"activeCount":100},[],{"trials":8053,"activeCount":100},[8054],{"nctId":1278,"briefTitle":1279,"status":108,"phases":8055,"primaryCompletion":1281,"completion":1282,"start":1283,"enrollment":1284,"conditions":8056,"interventions":8057},[88],[1286],[1288,1038],{"trials":8059,"activeCount":100},[],{"trials":8061,"activeCount":100},[],{"trials":8063,"activeCount":100},[],{"trials":8065,"activeCount":100},[],{"intervention":8067,"totalTrials":150,"cells":8068},"Fecal Microbiota Transplant",{"EARLY_PHASE1":8069,"PHASE1":8071,"PHASE2":8080,"PHASE3":8082,"PHASE4":8084,"NA":8086},{"trials":8070,"activeCount":100},[],{"trials":8072,"activeCount":100},[8073],{"nctId":8074,"briefTitle":8075,"status":108,"phases":8076,"primaryCompletion":5561,"completion":1231,"start":2252,"enrollment":1298,"conditions":8077,"interventions":8079},"NCT01947101","Fecal Microbiota Transplantation (FMT) for Treatment of Ulcerative Colitis in Children",[88],[8078],"Ulcerative Colitis",[8067],{"trials":8081,"activeCount":100},[],{"trials":8083,"activeCount":100},[],{"trials":8085,"activeCount":100},[],{"trials":8087,"activeCount":100},[],{"intervention":8089,"totalTrials":150,"cells":8090},"Cycloserine",{"EARLY_PHASE1":8091,"PHASE1":8093,"PHASE2":8103,"PHASE3":8105,"PHASE4":8107,"NA":8109},{"trials":8092,"activeCount":100},[],{"trials":8094,"activeCount":100},[8095],{"nctId":8096,"briefTitle":8097,"status":108,"phases":8098,"primaryCompletion":8099,"completion":572,"start":7441,"enrollment":5339,"conditions":8100,"interventions":8102},"NCT01062932","Investigation of Cycloserine as a Smoking Cessation Treatment",[88],"2010-05",[8101],"Nicotine Addiction",[8089],{"trials":8104,"activeCount":100},[],{"trials":8106,"activeCount":100},[],{"trials":8108,"activeCount":100},[],{"trials":8110,"activeCount":100},[],{"intervention":8112,"totalTrials":150,"cells":8113},"Irinotecan",{"EARLY_PHASE1":8114,"PHASE1":8116,"PHASE2":8126,"PHASE3":8128,"PHASE4":8130,"NA":8132},{"trials":8115,"activeCount":100},[],{"trials":8117,"activeCount":100},[8118],{"nctId":8119,"briefTitle":8120,"status":108,"phases":8121,"primaryCompletion":1213,"completion":8122,"start":8123,"enrollment":1002,"conditions":8124,"interventions":8125},"NCT00062842","Study of Irinotecan on a Weekly Schedule in Children",[88],"2006-09-12","1998-09-09",[1389],[8112],{"trials":8127,"activeCount":100},[],{"trials":8129,"activeCount":100},[],{"trials":8131,"activeCount":100},[],{"trials":8133,"activeCount":100},[],{"intervention":8135,"totalTrials":150,"cells":8136},"CD19.CAR-multiVST for Group A",{"EARLY_PHASE1":8137,"PHASE1":8139,"PHASE2":8152,"PHASE3":8154,"PHASE4":8156,"NA":8158},{"trials":8138,"activeCount":100},[],{"trials":8140,"activeCount":100},[8141],{"nctId":8142,"briefTitle":8143,"status":180,"phases":8144,"primaryCompletion":8145,"completion":8146,"start":8147,"enrollment":100,"conditions":8148,"interventions":8150},"NCT03768310","CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)",[88],"2025-08","2040-08","2022-06",[8149,1110],"Non-hodgkin Lymphoma",[8135,8151],"CD19.CAR-multiVST for Group B",{"trials":8153,"activeCount":100},[],{"trials":8155,"activeCount":100},[],{"trials":8157,"activeCount":100},[],{"trials":8159,"activeCount":100},[],{"intervention":8151,"totalTrials":150,"cells":8161},{"EARLY_PHASE1":8162,"PHASE1":8164,"PHASE2":8170,"PHASE3":8172,"PHASE4":8174,"NA":8176},{"trials":8163,"activeCount":100},[],{"trials":8165,"activeCount":100},[8166],{"nctId":8142,"briefTitle":8143,"status":180,"phases":8167,"primaryCompletion":8145,"completion":8146,"start":8147,"enrollment":100,"conditions":8168,"interventions":8169},[88],[8149,1110],[8135,8151],{"trials":8171,"activeCount":100},[],{"trials":8173,"activeCount":100},[],{"trials":8175,"activeCount":100},[],{"trials":8177,"activeCount":100},[],{"intervention":8179,"totalTrials":150,"cells":8180},"Multi-virus Specific T cells",{"EARLY_PHASE1":8181,"PHASE1":8183,"PHASE2":8192,"PHASE3":8194,"PHASE4":8196,"NA":8198},{"trials":8182,"activeCount":100},[],{"trials":8184,"activeCount":100},[8185],{"nctId":8186,"briefTitle":8187,"status":108,"phases":8188,"primaryCompletion":1282,"completion":1079,"start":5442,"enrollment":32,"conditions":8189,"interventions":8191},"NCT01070797","Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)",[88],[3243,7467,3242,8190],"Stem Cell Transplant",[8179],{"trials":8193,"activeCount":100},[],{"trials":8195,"activeCount":100},[],{"trials":8197,"activeCount":100},[],{"trials":8199,"activeCount":100},[],{"intervention":7250,"totalTrials":150,"cells":8201},{"EARLY_PHASE1":8202,"PHASE1":8204,"PHASE2":8210,"PHASE3":8212,"PHASE4":8214,"NA":8216},{"trials":8203,"activeCount":100},[],{"trials":8205,"activeCount":100},[8206],{"nctId":7242,"briefTitle":7243,"status":108,"phases":8207,"primaryCompletion":7245,"completion":7246,"start":7247,"enrollment":133,"conditions":8208,"interventions":8209},[88],[2299,3450],[7250,3463,7251,7252],{"trials":8211,"activeCount":100},[],{"trials":8213,"activeCount":100},[],{"trials":8215,"activeCount":100},[],{"trials":8217,"activeCount":100},[],{"intervention":7251,"totalTrials":150,"cells":8219},{"EARLY_PHASE1":8220,"PHASE1":8222,"PHASE2":8228,"PHASE3":8230,"PHASE4":8232,"NA":8234},{"trials":8221,"activeCount":100},[],{"trials":8223,"activeCount":100},[8224],{"nctId":7242,"briefTitle":7243,"status":108,"phases":8225,"primaryCompletion":7245,"completion":7246,"start":7247,"enrollment":133,"conditions":8226,"interventions":8227},[88],[2299,3450],[7250,3463,7251,7252],{"trials":8229,"activeCount":100},[],{"trials":8231,"activeCount":100},[],{"trials":8233,"activeCount":100},[],{"trials":8235,"activeCount":100},[],{"intervention":7252,"totalTrials":150,"cells":8237},{"EARLY_PHASE1":8238,"PHASE1":8240,"PHASE2":8246,"PHASE3":8248,"PHASE4":8250,"NA":8252},{"trials":8239,"activeCount":100},[],{"trials":8241,"activeCount":100},[8242],{"nctId":7242,"briefTitle":7243,"status":108,"phases":8243,"primaryCompletion":7245,"completion":7246,"start":7247,"enrollment":133,"conditions":8244,"interventions":8245},[88],[2299,3450],[7250,3463,7251,7252],{"trials":8247,"activeCount":100},[],{"trials":8249,"activeCount":100},[],{"trials":8251,"activeCount":100},[],{"trials":8253,"activeCount":100},[],{"intervention":7277,"totalTrials":150,"cells":8255},{"EARLY_PHASE1":8256,"PHASE1":8258,"PHASE2":8264,"PHASE3":8266,"PHASE4":8268,"NA":8270},{"trials":8257,"activeCount":100},[],{"trials":8259,"activeCount":100},[8260],{"nctId":7272,"briefTitle":7273,"status":108,"phases":8261,"primaryCompletion":3758,"completion":3758,"start":6382,"enrollment":2576,"conditions":8262,"interventions":8263},[88],[23,5446,5445,21],[7277,5482,7278],{"trials":8265,"activeCount":100},[],{"trials":8267,"activeCount":100},[],{"trials":8269,"activeCount":100},[],{"trials":8271,"activeCount":100},[],{"intervention":7278,"totalTrials":150,"cells":8273},{"EARLY_PHASE1":8274,"PHASE1":8276,"PHASE2":8282,"PHASE3":8284,"PHASE4":8286,"NA":8288},{"trials":8275,"activeCount":100},[],{"trials":8277,"activeCount":100},[8278],{"nctId":7272,"briefTitle":7273,"status":108,"phases":8279,"primaryCompletion":3758,"completion":3758,"start":6382,"enrollment":2576,"conditions":8280,"interventions":8281},[88],[23,5446,5445,21],[7277,5482,7278],{"trials":8283,"activeCount":100},[],{"trials":8285,"activeCount":100},[],{"trials":8287,"activeCount":100},[],{"trials":8289,"activeCount":100},[],{"intervention":517,"totalTrials":150,"cells":8291},{"EARLY_PHASE1":8292,"PHASE1":8294,"PHASE2":8300,"PHASE3":8302,"PHASE4":8304,"NA":8306},{"trials":8293,"activeCount":100},[],{"trials":8295,"activeCount":100},[8296],{"nctId":507,"briefTitle":508,"status":180,"phases":8297,"primaryCompletion":510,"completion":511,"start":512,"enrollment":100,"conditions":8298,"interventions":8299},[88],[514,515],[517,499,518],{"trials":8301,"activeCount":100},[],{"trials":8303,"activeCount":100},[],{"trials":8305,"activeCount":100},[],{"trials":8307,"activeCount":100},[],{"intervention":8309,"totalTrials":150,"cells":8310},"Gene Modified Neuroblastoma Cells",{"EARLY_PHASE1":8311,"PHASE1":8313,"PHASE2":8323,"PHASE3":8325,"PHASE4":8327,"NA":8329},{"trials":8312,"activeCount":100},[],{"trials":8314,"activeCount":100},[8315],{"nctId":8316,"briefTitle":8317,"status":108,"phases":8318,"primaryCompletion":5745,"completion":8319,"start":8320,"enrollment":500,"conditions":8321,"interventions":8322},"NCT00062855","Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed\u002FRefractory Neuroblastoma",[88],"2006-03","1997-11",[29],[8309],{"trials":8324,"activeCount":100},[],{"trials":8326,"activeCount":100},[],{"trials":8328,"activeCount":100},[],{"trials":8330,"activeCount":100},[],{"intervention":8332,"totalTrials":150,"cells":8333},"Injection of EBV Specific CTLs",{"EARLY_PHASE1":8334,"PHASE1":8336,"PHASE2":8348,"PHASE3":8350,"PHASE4":8352,"NA":8354},{"trials":8335,"activeCount":100},[],{"trials":8337,"activeCount":100},[8338],{"nctId":8339,"briefTitle":8340,"status":108,"phases":8341,"primaryCompletion":171,"completion":59,"start":8342,"enrollment":1350,"conditions":8343,"interventions":8347},"NCT00058617","Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL",[88],"1996-01",[8344,8345,8346],"Epstein-Barr Virus-Related Hodgkin Lymphoma","Epstein-Barr Virus-Related Non-Hodgkin Lymphoma","EBV Positive Plasma Cell Neoplasm",[8332],{"trials":8349,"activeCount":100},[],{"trials":8351,"activeCount":100},[],{"trials":8353,"activeCount":100},[],{"trials":8355,"activeCount":100},[],{"intervention":8357,"totalTrials":150,"cells":8358},"CMV\u002FAdV specific T cells",{"EARLY_PHASE1":8359,"PHASE1":8361,"PHASE2":8370,"PHASE3":8372,"PHASE4":8374,"NA":8376},{"trials":8360,"activeCount":100},[],{"trials":8362,"activeCount":100},[8363],{"nctId":8364,"briefTitle":8365,"status":108,"phases":8366,"primaryCompletion":561,"completion":5829,"start":7441,"enrollment":500,"conditions":8367,"interventions":8369},"NCT00880789","Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus",[88],[8368,3243],"Cytomegalovirus Infection",[8357],{"trials":8371,"activeCount":100},[],{"trials":8373,"activeCount":100},[],{"trials":8375,"activeCount":100},[],{"trials":8377,"activeCount":100},[],{"intervention":8379,"totalTrials":150,"cells":8380},"Human Albumin",{"EARLY_PHASE1":8381,"PHASE1":8383,"PHASE2":8392,"PHASE3":8394,"PHASE4":8396,"NA":8398},{"trials":8382,"activeCount":100},[],{"trials":8384,"activeCount":100},[8385],{"nctId":8386,"briefTitle":8387,"status":578,"phases":8388,"primaryCompletion":3747,"completion":4227,"start":3544,"enrollment":3223,"conditions":8389,"interventions":8391},"NCT01747408","Treatment of Subarachnoid Hemorrhage With Human Albumin",[88],[8390],"Subarachnoid Hemorrhage",[8379],{"trials":8393,"activeCount":100},[],{"trials":8395,"activeCount":100},[],{"trials":8397,"activeCount":100},[],{"trials":8399,"activeCount":100},[],{"intervention":8401,"totalTrials":150,"cells":8402},"Probiotic",{"EARLY_PHASE1":8403,"PHASE1":8405,"PHASE2":8414,"PHASE3":8416,"PHASE4":8418,"NA":8420},{"trials":8404,"activeCount":100},[],{"trials":8406,"activeCount":100},[8407],{"nctId":8408,"briefTitle":8409,"status":108,"phases":8410,"primaryCompletion":609,"completion":609,"start":600,"enrollment":1284,"conditions":8411,"interventions":8413},"NCT00971711","Safety Study of Probiotics in Adults With Irritable Bowel Syndrome",[88],[8412],"Irritable Bowel Syndrome",[8401],{"trials":8415,"activeCount":100},[],{"trials":8417,"activeCount":100},[],{"trials":8419,"activeCount":100},[],{"trials":8421,"activeCount":100},[],{"intervention":8423,"totalTrials":150,"cells":8424},"T-Cell Infusion Dose Level -1",{"EARLY_PHASE1":8425,"PHASE1":8427,"PHASE2":8440,"PHASE3":8442,"PHASE4":8444,"NA":8446},{"trials":8426,"activeCount":100},[],{"trials":8428,"activeCount":100},[8429],{"nctId":8430,"briefTitle":8431,"status":108,"phases":8432,"primaryCompletion":3647,"completion":3647,"start":8433,"enrollment":27,"conditions":8434,"interventions":8435},"NCT00586547","Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation",[88],"2000-07",[1138,1389],[8423,8436,8437,8438,8439],"T-Cell Infusion Dose Level 1","T-Cell Infusion Dose Level 2","T-Cell Infusion Dose Level 3","T-Cell Infusion- Dose Level 4",{"trials":8441,"activeCount":100},[],{"trials":8443,"activeCount":100},[],{"trials":8445,"activeCount":100},[],{"trials":8447,"activeCount":100},[],{"intervention":8436,"totalTrials":150,"cells":8449},{"EARLY_PHASE1":8450,"PHASE1":8452,"PHASE2":8458,"PHASE3":8460,"PHASE4":8462,"NA":8464},{"trials":8451,"activeCount":100},[],{"trials":8453,"activeCount":100},[8454],{"nctId":8430,"briefTitle":8431,"status":108,"phases":8455,"primaryCompletion":3647,"completion":3647,"start":8433,"enrollment":27,"conditions":8456,"interventions":8457},[88],[1138,1389],[8423,8436,8437,8438,8439],{"trials":8459,"activeCount":100},[],{"trials":8461,"activeCount":100},[],{"trials":8463,"activeCount":100},[],{"trials":8465,"activeCount":100},[],{"intervention":8437,"totalTrials":150,"cells":8467},{"EARLY_PHASE1":8468,"PHASE1":8470,"PHASE2":8476,"PHASE3":8478,"PHASE4":8480,"NA":8482},{"trials":8469,"activeCount":100},[],{"trials":8471,"activeCount":100},[8472],{"nctId":8430,"briefTitle":8431,"status":108,"phases":8473,"primaryCompletion":3647,"completion":3647,"start":8433,"enrollment":27,"conditions":8474,"interventions":8475},[88],[1138,1389],[8423,8436,8437,8438,8439],{"trials":8477,"activeCount":100},[],{"trials":8479,"activeCount":100},[],{"trials":8481,"activeCount":100},[],{"trials":8483,"activeCount":100},[],{"intervention":8438,"totalTrials":150,"cells":8485},{"EARLY_PHASE1":8486,"PHASE1":8488,"PHASE2":8494,"PHASE3":8496,"PHASE4":8498,"NA":8500},{"trials":8487,"activeCount":100},[],{"trials":8489,"activeCount":100},[8490],{"nctId":8430,"briefTitle":8431,"status":108,"phases":8491,"primaryCompletion":3647,"completion":3647,"start":8433,"enrollment":27,"conditions":8492,"interventions":8493},[88],[1138,1389],[8423,8436,8437,8438,8439],{"trials":8495,"activeCount":100},[],{"trials":8497,"activeCount":100},[],{"trials":8499,"activeCount":100},[],{"trials":8501,"activeCount":100},[],{"intervention":8439,"totalTrials":150,"cells":8503},{"EARLY_PHASE1":8504,"PHASE1":8506,"PHASE2":8512,"PHASE3":8514,"PHASE4":8516,"NA":8518},{"trials":8505,"activeCount":100},[],{"trials":8507,"activeCount":100},[8508],{"nctId":8430,"briefTitle":8431,"status":108,"phases":8509,"primaryCompletion":3647,"completion":3647,"start":8433,"enrollment":27,"conditions":8510,"interventions":8511},[88],[1138,1389],[8423,8436,8437,8438,8439],{"trials":8513,"activeCount":100},[],{"trials":8515,"activeCount":100},[],{"trials":8517,"activeCount":100},[],{"trials":8519,"activeCount":100},[],{"intervention":8521,"totalTrials":150,"cells":8522},"autologous or syngeneic PBTLs and EBV-CTLs",{"EARLY_PHASE1":8523,"PHASE1":8525,"PHASE2":8533,"PHASE3":8535,"PHASE4":8537,"NA":8539},{"trials":8524,"activeCount":100},[],{"trials":8526,"activeCount":100},[8527],{"nctId":8528,"briefTitle":8529,"status":108,"phases":8530,"primaryCompletion":7524,"completion":6047,"start":1048,"enrollment":96,"conditions":8531,"interventions":8532},"NCT00709033","T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL",[88],[1066,2255],[8521],{"trials":8534,"activeCount":100},[],{"trials":8536,"activeCount":100},[],{"trials":8538,"activeCount":100},[],{"trials":8540,"activeCount":100},[],{"intervention":8542,"totalTrials":150,"cells":8543},"EBV specific CTLs",{"EARLY_PHASE1":8544,"PHASE1":8546,"PHASE2":8554,"PHASE3":8556,"PHASE4":8558,"NA":8560},{"trials":8545,"activeCount":100},[],{"trials":8547,"activeCount":100},[8548],{"nctId":8549,"briefTitle":8550,"status":108,"phases":8551,"primaryCompletion":5443,"completion":8145,"start":1404,"enrollment":1253,"conditions":8552,"interventions":8553},"NCT00085930","Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients",[88],[29],[8542],{"trials":8555,"activeCount":100},[],{"trials":8557,"activeCount":100},[],{"trials":8559,"activeCount":100},[],{"trials":8561,"activeCount":100},[],{"intervention":8563,"totalTrials":150,"cells":8564},"Genetically modified CTLs",{"EARLY_PHASE1":8565,"PHASE1":8567,"PHASE2":8577,"PHASE3":8579,"PHASE4":8581,"NA":8583},{"trials":8566,"activeCount":100},[],{"trials":8568,"activeCount":100},[8569],{"nctId":8570,"briefTitle":8571,"status":108,"phases":8572,"primaryCompletion":7753,"completion":8573,"start":8574,"enrollment":1002,"conditions":8575,"interventions":8576},"NCT00516087","LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)",[88],"2013-07","2007-08",[1069],[8563],{"trials":8578,"activeCount":100},[],{"trials":8580,"activeCount":100},[],{"trials":8582,"activeCount":100},[],{"trials":8584,"activeCount":100},[],{"intervention":528,"totalTrials":150,"cells":8586},{"EARLY_PHASE1":8587,"PHASE1":8589,"PHASE2":8595,"PHASE3":8597,"PHASE4":8599,"NA":8601},{"trials":8588,"activeCount":100},[],{"trials":8590,"activeCount":100},[8591],{"nctId":520,"briefTitle":521,"status":108,"phases":8592,"primaryCompletion":523,"completion":524,"start":525,"enrollment":500,"conditions":8593,"interventions":8594},[88],[514],[528,499,518],{"trials":8596,"activeCount":100},[],{"trials":8598,"activeCount":100},[],{"trials":8600,"activeCount":100},[],{"trials":8602,"activeCount":100},[],{"intervention":8604,"totalTrials":150,"cells":8605},"LMP specific T cells",{"EARLY_PHASE1":8606,"PHASE1":8608,"PHASE2":8620,"PHASE3":8622,"PHASE4":8624,"NA":8626},{"trials":8607,"activeCount":100},[],{"trials":8609,"activeCount":100},[8610],{"nctId":8611,"briefTitle":8612,"status":108,"phases":8613,"primaryCompletion":1348,"completion":8614,"start":4493,"enrollment":3405,"conditions":8615,"interventions":8619},"NCT01447056","Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases",[88],"2020-01-22",[1420,1066,8616,1069,8617,8618],"Lymphoproliferative Disorder","Leiomyosarcoma","Severe Chronic Active EBV (SCAEBV)",[8604],{"trials":8621,"activeCount":100},[],{"trials":8623,"activeCount":100},[],{"trials":8625,"activeCount":100},[],{"trials":8627,"activeCount":100},[],{"intervention":7413,"totalTrials":150,"cells":8629},{"EARLY_PHASE1":8630,"PHASE1":8632,"PHASE2":8638,"PHASE3":8640,"PHASE4":8642,"NA":8644},{"trials":8631,"activeCount":100},[],{"trials":8633,"activeCount":100},[8634],{"nctId":7401,"briefTitle":7402,"status":108,"phases":8635,"primaryCompletion":7404,"completion":7405,"start":7406,"enrollment":2638,"conditions":8636,"interventions":8637},[88],[7408,1114,7409,7410,1420,2968,7411],[7413,544],{"trials":8639,"activeCount":100},[],{"trials":8641,"activeCount":100},[],{"trials":8643,"activeCount":100},[],{"trials":8645,"activeCount":100},[],{"intervention":8647,"totalTrials":150,"cells":8648},"CMV CTL",{"EARLY_PHASE1":8649,"PHASE1":8651,"PHASE2":8660,"PHASE3":8662,"PHASE4":8664,"NA":8666},{"trials":8650,"activeCount":100},[],{"trials":8652,"activeCount":100},[8653],{"nctId":8654,"briefTitle":8655,"status":108,"phases":8656,"primaryCompletion":3747,"completion":8657,"start":1403,"enrollment":405,"conditions":8658,"interventions":8659},"NCT00078533","Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant",[88],"2011-06",[3242],[8647],{"trials":8661,"activeCount":100},[],{"trials":8663,"activeCount":100},[],{"trials":8665,"activeCount":100},[],{"trials":8667,"activeCount":100},[],{"intervention":8669,"totalTrials":150,"cells":8670},"ARM 1: AdMSC: adipose stem cells",{"EARLY_PHASE1":8671,"PHASE1":8673,"PHASE2":8686,"PHASE3":8688,"PHASE4":8690,"NA":8692},{"trials":8672,"activeCount":100},[],{"trials":8674,"activeCount":100},[8675],{"nctId":8676,"briefTitle":8677,"status":180,"phases":8678,"primaryCompletion":8679,"completion":8680,"start":8681,"enrollment":100,"conditions":8682,"interventions":8685},"NCT02107118","Stem Cells for the Improvement of Erectile and Cardiac Function in Aging Men",[88],"2020-03","2022-02","2015-05",[8683,8684],"Erectile Dysfunction","Cardiac Disease",[8669],{"trials":8687,"activeCount":100},[],{"trials":8689,"activeCount":100},[],{"trials":8691,"activeCount":100},[],{"trials":8693,"activeCount":100},[],{"intervention":8695,"totalTrials":150,"cells":8696},"CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE",{"EARLY_PHASE1":8697,"PHASE1":8699,"PHASE2":8707,"PHASE3":8709,"PHASE4":8711,"NA":8713},{"trials":8698,"activeCount":100},[],{"trials":8700,"activeCount":100},[8701],{"nctId":8702,"briefTitle":8703,"status":108,"phases":8704,"primaryCompletion":4380,"completion":561,"start":1214,"enrollment":1298,"conditions":8705,"interventions":8706},"NCT00458679","Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells",[88],[2579],[8695],{"trials":8708,"activeCount":100},[],{"trials":8710,"activeCount":100},[],{"trials":8712,"activeCount":100},[],{"trials":8714,"activeCount":100},[],{"intervention":543,"totalTrials":150,"cells":8716},{"EARLY_PHASE1":8717,"PHASE1":8719,"PHASE2":8725,"PHASE3":8727,"PHASE4":8729,"NA":8731},{"trials":8718,"activeCount":100},[],{"trials":8720,"activeCount":100},[8721],{"nctId":530,"briefTitle":531,"status":108,"phases":8722,"primaryCompletion":533,"completion":533,"start":111,"enrollment":534,"conditions":8723,"interventions":8724},[88],[536,537,538,539,540,541],[543,499,518,544],{"trials":8726,"activeCount":100},[],{"trials":8728,"activeCount":100},[],{"trials":8730,"activeCount":100},[],{"trials":8732,"activeCount":100},[],{"intervention":8734,"totalTrials":150,"cells":8735},"Polyphenon E",{"EARLY_PHASE1":8736,"PHASE1":8738,"PHASE2":8747,"PHASE3":8749,"PHASE4":8751,"NA":8753},{"trials":8737,"activeCount":100},[],{"trials":8739,"activeCount":100},[8740],{"nctId":8741,"briefTitle":8742,"status":108,"phases":8743,"primaryCompletion":7536,"completion":3757,"start":3719,"enrollment":1002,"conditions":8744,"interventions":8746},"NCT01433289","Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals",[88],[8745],"HIV Infection",[8734],{"trials":8748,"activeCount":100},[],{"trials":8750,"activeCount":100},[],{"trials":8752,"activeCount":100},[],{"trials":8754,"activeCount":100},[],{"intervention":8756,"totalTrials":150,"cells":8757},"Rivastigmine",{"EARLY_PHASE1":8758,"PHASE1":8760,"PHASE2":8768,"PHASE3":8770,"PHASE4":8772,"NA":8774},{"trials":8759,"activeCount":100},[],{"trials":8761,"activeCount":100},[8762],{"nctId":8763,"briefTitle":8764,"status":108,"phases":8765,"primaryCompletion":3747,"completion":3747,"start":1048,"enrollment":876,"conditions":8766,"interventions":8767},"NCT01073319","Rivastigmine as a Treatment for Methamphetamine Dependence",[88],[7325,21,7326],[8756,8756],{"trials":8769,"activeCount":100},[],{"trials":8771,"activeCount":100},[],{"trials":8773,"activeCount":100},[],{"trials":8775,"activeCount":100},[],{"intervention":8777,"totalTrials":150,"cells":8778},"HER.CAR CMV-specific CTLs",{"EARLY_PHASE1":8779,"PHASE1":8781,"PHASE2":8791,"PHASE3":8793,"PHASE4":8795,"NA":8797},{"trials":8780,"activeCount":100},[],{"trials":8782,"activeCount":100},[8783],{"nctId":8784,"briefTitle":8785,"status":108,"phases":8786,"primaryCompletion":5829,"completion":8787,"start":1104,"enrollment":1240,"conditions":8788,"interventions":8790},"NCT01109095","CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM",[88],"2018-03-07",[8789],"Glioblastoma Multiforme (GBM)",[8777],{"trials":8792,"activeCount":100},[],{"trials":8794,"activeCount":100},[],{"trials":8796,"activeCount":100},[],{"trials":8798,"activeCount":100},[],{"intervention":8800,"totalTrials":150,"cells":8801},"LMP1\u002F2 CTLs",{"EARLY_PHASE1":8802,"PHASE1":8804,"PHASE2":8815,"PHASE3":8817,"PHASE4":8819,"NA":8821},{"trials":8803,"activeCount":100},[],{"trials":8805,"activeCount":100},[8806],{"nctId":8807,"briefTitle":8808,"status":108,"phases":8809,"primaryCompletion":1079,"completion":8810,"start":4941,"enrollment":144,"conditions":8811,"interventions":8813},"NCT00062868","LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma",[88],"2020-04",[1065,1421,8812,8617],"Lymphoepithelioma",[8800,8800,8800,8814,8814,8814,8800,8800,8800],"LMP2 CTLs",{"trials":8816,"activeCount":100},[],{"trials":8818,"activeCount":100},[],{"trials":8820,"activeCount":100},[],{"trials":8822,"activeCount":100},[],{"intervention":8814,"totalTrials":150,"cells":8824},{"EARLY_PHASE1":8825,"PHASE1":8827,"PHASE2":8833,"PHASE3":8835,"PHASE4":8837,"NA":8839},{"trials":8826,"activeCount":100},[],{"trials":8828,"activeCount":100},[8829],{"nctId":8807,"briefTitle":8808,"status":108,"phases":8830,"primaryCompletion":1079,"completion":8810,"start":4941,"enrollment":144,"conditions":8831,"interventions":8832},[88],[1065,1421,8812,8617],[8800,8800,8800,8814,8814,8814,8800,8800,8800],{"trials":8834,"activeCount":100},[],{"trials":8836,"activeCount":100},[],{"trials":8838,"activeCount":100},[],{"trials":8840,"activeCount":100},[],{"intervention":1053,"totalTrials":150,"cells":8842},{"EARLY_PHASE1":8843,"PHASE1":8845,"PHASE2":8851,"PHASE3":8853,"PHASE4":8855,"NA":8857},{"trials":8844,"activeCount":100},[],{"trials":8846,"activeCount":100},[8847],{"nctId":1045,"briefTitle":1046,"status":578,"phases":8848,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":150,"conditions":8849,"interventions":8850},[88],[1051],[518,1053,1054,1055],{"trials":8852,"activeCount":100},[],{"trials":8854,"activeCount":100},[],{"trials":8856,"activeCount":100},[],{"trials":8858,"activeCount":100},[],{"intervention":7359,"totalTrials":150,"cells":8860},{"EARLY_PHASE1":8861,"PHASE1":8863,"PHASE2":8869,"PHASE3":8871,"PHASE4":8873,"NA":8875},{"trials":8862,"activeCount":100},[],{"trials":8864,"activeCount":100},[8865],{"nctId":7354,"briefTitle":7355,"status":108,"phases":8866,"primaryCompletion":3496,"completion":111,"start":54,"enrollment":282,"conditions":8867,"interventions":8868},[88],[2299,3450],[3452,7359],{"trials":8870,"activeCount":100},[],{"trials":8872,"activeCount":100},[],{"trials":8874,"activeCount":100},[],{"trials":8876,"activeCount":100},[],{"intervention":8878,"totalTrials":150,"cells":8879},"genetically modified CTLs in combo with CD45 antibodies",{"EARLY_PHASE1":8880,"PHASE1":8882,"PHASE2":8891,"PHASE3":8893,"PHASE4":8895,"NA":8897},{"trials":8881,"activeCount":100},[],{"trials":8883,"activeCount":100},[8884],{"nctId":8885,"briefTitle":8886,"status":180,"phases":8887,"primaryCompletion":6382,"completion":6382,"start":8574,"enrollment":100,"conditions":8888,"interventions":8890},"NCT00515957","Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)",[88],[8889],"NASOPHARYNGEAL CARCINOMA",[8878],{"trials":8892,"activeCount":100},[],{"trials":8894,"activeCount":100},[],{"trials":8896,"activeCount":100},[],{"trials":8898,"activeCount":100},[],{"intervention":8900,"totalTrials":150,"cells":8901},"Infusion of EBV Specific Cytotoxic T-Lymphocytes",{"EARLY_PHASE1":8902,"PHASE1":8904,"PHASE2":8915,"PHASE3":8917,"PHASE4":8919,"NA":8921},{"trials":8903,"activeCount":100},[],{"trials":8905,"activeCount":100},[8906],{"nctId":8907,"briefTitle":8908,"status":578,"phases":8909,"primaryCompletion":8910,"completion":8911,"start":8342,"enrollment":1092,"conditions":8912,"interventions":8914},"NCT00058773","Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease",[88],"2002-04","2006-08",[1065,8913],"Non-Hodgkins Lymphoma",[8900],{"trials":8916,"activeCount":100},[],{"trials":8918,"activeCount":100},[],{"trials":8920,"activeCount":100},[],{"trials":8922,"activeCount":100},[],{"intervention":8924,"totalTrials":150,"cells":8925},"Pemetrexed",{"EARLY_PHASE1":8926,"PHASE1":8928,"PHASE2":8937,"PHASE3":8939,"PHASE4":8941,"NA":8943},{"trials":8927,"activeCount":100},[],{"trials":8929,"activeCount":100},[8930],{"nctId":8931,"briefTitle":8932,"status":578,"phases":8933,"primaryCompletion":7404,"completion":7404,"start":8934,"enrollment":1135,"conditions":8935,"interventions":8936},"NCT02838745","Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM",[88],"2016-09",[930],[8924,1355],{"trials":8938,"activeCount":100},[],{"trials":8940,"activeCount":100},[],{"trials":8942,"activeCount":100},[],{"trials":8944,"activeCount":100},[],{"intervention":8946,"totalTrials":150,"cells":8947},"IL-12 gene",{"EARLY_PHASE1":8948,"PHASE1":8950,"PHASE2":8961,"PHASE3":8963,"PHASE4":8965,"NA":8967},{"trials":8949,"activeCount":100},[],{"trials":8951,"activeCount":100},[8952],{"nctId":8953,"briefTitle":8954,"status":108,"phases":8955,"primaryCompletion":5229,"completion":5229,"start":8956,"enrollment":1106,"conditions":8957,"interventions":8960},"NCT00406939","Vector Delivery of the IL-12 Gene in Men With Prostate Cancer",[88],"1998-06",[8958,8959],"Prostatic Neoplasms","Prostate Cancer",[8946],{"trials":8962,"activeCount":100},[],{"trials":8964,"activeCount":100},[],{"trials":8966,"activeCount":100},[],{"trials":8968,"activeCount":100},[],{"intervention":7500,"totalTrials":150,"cells":8970},{"EARLY_PHASE1":8971,"PHASE1":8973,"PHASE2":8979,"PHASE3":8981,"PHASE4":8983,"NA":8985},{"trials":8972,"activeCount":100},[],{"trials":8974,"activeCount":100},[8975],{"nctId":7492,"briefTitle":7493,"status":108,"phases":8976,"primaryCompletion":7495,"completion":7496,"start":7497,"enrollment":1216,"conditions":8977,"interventions":8978},[88],[2299,3450],[7500,7485],{"trials":8980,"activeCount":100},[],{"trials":8982,"activeCount":100},[],{"trials":8984,"activeCount":100},[],{"trials":8986,"activeCount":100},[],{"intervention":8988,"totalTrials":150,"cells":8989},"Kareniticin and cyclophosphamide",{"EARLY_PHASE1":8990,"PHASE1":8992,"PHASE2":9000,"PHASE3":9002,"PHASE4":9004,"NA":9006},{"trials":8991,"activeCount":100},[],{"trials":8993,"activeCount":100},[8994],{"nctId":8995,"briefTitle":8996,"status":108,"phases":8997,"primaryCompletion":5442,"completion":5442,"start":4099,"enrollment":972,"conditions":8998,"interventions":8999},"NCT00586560","Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)",[88],[1613],[8988],{"trials":9001,"activeCount":100},[],{"trials":9003,"activeCount":100},[],{"trials":9005,"activeCount":100},[],{"trials":9007,"activeCount":100},[],{"intervention":7529,"totalTrials":150,"cells":9009},{"EARLY_PHASE1":9010,"PHASE1":9012,"PHASE2":9018,"PHASE3":9020,"PHASE4":9022,"NA":9024},{"trials":9011,"activeCount":100},[],{"trials":9013,"activeCount":100},[9014],{"nctId":7521,"briefTitle":7522,"status":108,"phases":9015,"primaryCompletion":2296,"completion":3496,"start":7524,"enrollment":282,"conditions":9016,"interventions":9017},[88],[2299,3450],[7514,7527,7528,7529,7530,7530,7531],{"trials":9019,"activeCount":100},[],{"trials":9021,"activeCount":100},[],{"trials":9023,"activeCount":100},[],{"trials":9025,"activeCount":100},[],{"intervention":9027,"totalTrials":150,"cells":9028},"CVD908ssb-TXSVN",{"EARLY_PHASE1":9029,"PHASE1":9031,"PHASE2":9042,"PHASE3":9044,"PHASE4":9046,"NA":9048},{"trials":9030,"activeCount":100},[],{"trials":9032,"activeCount":100},[9033],{"nctId":9034,"briefTitle":9035,"status":108,"phases":9036,"primaryCompletion":9037,"completion":9038,"start":9039,"enrollment":150,"conditions":9040,"interventions":9041},"NCT03762291","Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine",[88],"2022-03-22","2024-08-05","2021-08-06",[1112],[9027],{"trials":9043,"activeCount":100},[],{"trials":9045,"activeCount":100},[],{"trials":9047,"activeCount":100},[],{"trials":9049,"activeCount":100},[],{"intervention":9051,"totalTrials":150,"cells":9052},"Peanut Oral Immunotherapy",{"EARLY_PHASE1":9053,"PHASE1":9055,"PHASE2":9066,"PHASE3":9068,"PHASE4":9070,"NA":9072},{"trials":9054,"activeCount":100},[],{"trials":9056,"activeCount":100},[9057],{"nctId":9058,"briefTitle":9059,"status":108,"phases":9060,"primaryCompletion":9061,"completion":9061,"start":9062,"enrollment":972,"conditions":9063,"interventions":9065},"NCT02203799","Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour)",[88],"2020-02-11","2014-07-31",[9064],"Peanut Allergic Subjects",[9051],{"trials":9067,"activeCount":100},[],{"trials":9069,"activeCount":100},[],{"trials":9071,"activeCount":100},[],{"trials":9073,"activeCount":100},[],{"intervention":1634,"totalTrials":150,"cells":9075},{"EARLY_PHASE1":9076,"PHASE1":9078,"PHASE2":9084,"PHASE3":9086,"PHASE4":9088,"NA":9090},{"trials":9077,"activeCount":100},[],{"trials":9079,"activeCount":100},[9080],{"nctId":1626,"briefTitle":1627,"status":108,"phases":9081,"primaryCompletion":1629,"completion":1629,"start":1630,"enrollment":500,"conditions":9082,"interventions":9083},[88],[1138,1632],[1597,1616,1634],{"trials":9085,"activeCount":100},[],{"trials":9087,"activeCount":100},[],{"trials":9089,"activeCount":100},[],{"trials":9091,"activeCount":100},[],{"intervention":7658,"totalTrials":150,"cells":9093},{"EARLY_PHASE1":9094,"PHASE1":9096,"PHASE2":9102,"PHASE3":9104,"PHASE4":9106,"NA":9108},{"trials":9095,"activeCount":100},[],{"trials":9097,"activeCount":100},[9098],{"nctId":7653,"briefTitle":7654,"status":108,"phases":9099,"primaryCompletion":1776,"completion":468,"start":1262,"enrollment":581,"conditions":9100,"interventions":9101},[88],[3193],[7658,7638,1355],{"trials":9103,"activeCount":100},[],{"trials":9105,"activeCount":100},[],{"trials":9107,"activeCount":100},[],{"trials":9109,"activeCount":100},[],{"intervention":9111,"totalTrials":150,"cells":9112},"Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells",{"EARLY_PHASE1":9113,"PHASE1":9115,"PHASE2":9125,"PHASE3":9127,"PHASE4":9129,"NA":9131},{"trials":9114,"activeCount":100},[],{"trials":9116,"activeCount":100},[9117],{"nctId":9118,"briefTitle":9119,"status":108,"phases":9120,"primaryCompletion":1629,"completion":1629,"start":9121,"enrollment":500,"conditions":9122,"interventions":9124},"NCT00058786","Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells",[88],"2002-12",[9123],"Chronic Lymphocytic B-Leukemia",[9111],{"trials":9126,"activeCount":100},[],{"trials":9128,"activeCount":100},[],{"trials":9130,"activeCount":100},[],{"trials":9132,"activeCount":100},[],{"intervention":9134,"totalTrials":150,"cells":9135},"LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES",{"EARLY_PHASE1":9136,"PHASE1":9138,"PHASE2":9147,"PHASE3":9149,"PHASE4":9151,"NA":9153},{"trials":9137,"activeCount":100},[],{"trials":9139,"activeCount":100},[9140],{"nctId":9141,"briefTitle":9142,"status":578,"phases":9143,"primaryCompletion":3497,"completion":3497,"start":112,"enrollment":1298,"conditions":9144,"interventions":9145},"NCT00383097","Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma",[88],[1568,1066],[9134,9146],"LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES",{"trials":9148,"activeCount":100},[],{"trials":9150,"activeCount":100},[],{"trials":9152,"activeCount":100},[],{"trials":9154,"activeCount":100},[],{"intervention":9146,"totalTrials":150,"cells":9156},{"EARLY_PHASE1":9157,"PHASE1":9159,"PHASE2":9165,"PHASE3":9167,"PHASE4":9169,"NA":9171},{"trials":9158,"activeCount":100},[],{"trials":9160,"activeCount":100},[9161],{"nctId":9141,"briefTitle":9142,"status":578,"phases":9162,"primaryCompletion":3497,"completion":3497,"start":112,"enrollment":1298,"conditions":9163,"interventions":9164},[88],[1568,1066],[9134,9146],{"trials":9166,"activeCount":100},[],{"trials":9168,"activeCount":100},[],{"trials":9170,"activeCount":100},[],{"trials":9172,"activeCount":100},[],{"intervention":9174,"totalTrials":150,"cells":9175},"EBV specific CTL",{"EARLY_PHASE1":9176,"PHASE1":9178,"PHASE2":9189,"PHASE3":9191,"PHASE4":9193,"NA":9195},{"trials":9177,"activeCount":100},[],{"trials":9179,"activeCount":100},[9180],{"nctId":9181,"briefTitle":9182,"status":108,"phases":9183,"primaryCompletion":4600,"completion":1133,"start":4941,"enrollment":24,"conditions":9184,"interventions":9187},"NCT00078546","EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)",[88],[9185,9186],"Nasopharyngeal Cancer","EBV Infections",[9174,9188],"Anti CD45 monoclonal antibody",{"trials":9190,"activeCount":100},[],{"trials":9192,"activeCount":100},[],{"trials":9194,"activeCount":100},[],{"trials":9196,"activeCount":100},[],{"intervention":9188,"totalTrials":150,"cells":9198},{"EARLY_PHASE1":9199,"PHASE1":9201,"PHASE2":9207,"PHASE3":9209,"PHASE4":9211,"NA":9213},{"trials":9200,"activeCount":100},[],{"trials":9202,"activeCount":100},[9203],{"nctId":9181,"briefTitle":9182,"status":108,"phases":9204,"primaryCompletion":4600,"completion":1133,"start":4941,"enrollment":24,"conditions":9205,"interventions":9206},[88],[9185,9186],[9174,9188],{"trials":9208,"activeCount":100},[],{"trials":9210,"activeCount":100},[],{"trials":9212,"activeCount":100},[],{"trials":9214,"activeCount":100},[],{"intervention":9216,"totalTrials":150,"cells":9217},"Lanicemine",{"EARLY_PHASE1":9218,"PHASE1":9220,"PHASE2":9232,"PHASE3":9234,"PHASE4":9236,"NA":9238},{"trials":9219,"activeCount":100},[],{"trials":9221,"activeCount":100},[9222],{"nctId":9223,"briefTitle":9224,"status":108,"phases":9225,"primaryCompletion":9226,"completion":9227,"start":9228,"enrollment":1216,"conditions":9229,"interventions":9231},"NCT03166501","NMDA Receptor Modulation for Hyperarousal in PTSD",[88],"2019-11-12","2019-11-14","2018-09-01",[18,9230],"Post Traumatic Stress Disorder",[9216],{"trials":9233,"activeCount":100},[],{"trials":9235,"activeCount":100},[],{"trials":9237,"activeCount":100},[],{"trials":9239,"activeCount":100},[],{"intervention":9241,"totalTrials":150,"cells":9242},"NY-ESO-1\u002FLAGE-1 HLA class I\u002FII peptide vaccine",{"EARLY_PHASE1":9243,"PHASE1":9245,"PHASE2":9253,"PHASE3":9255,"PHASE4":9257,"NA":9259},{"trials":9244,"activeCount":100},[],{"trials":9246,"activeCount":100},[9247],{"nctId":9248,"briefTitle":9249,"status":108,"phases":9250,"primaryCompletion":3758,"completion":3758,"start":2637,"enrollment":19,"conditions":9251,"interventions":9252},"NCT00616291","Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer",[88],[8959],[9241],{"trials":9254,"activeCount":100},[],{"trials":9256,"activeCount":100},[],{"trials":9258,"activeCount":100},[],{"trials":9260,"activeCount":100},[],{"intervention":9262,"totalTrials":150,"cells":9263},"N-acetylcysteine",{"EARLY_PHASE1":9264,"PHASE1":9266,"PHASE2":9274,"PHASE3":9276,"PHASE4":9278,"NA":9280},{"trials":9265,"activeCount":100},[],{"trials":9267,"activeCount":100},[9268],{"nctId":9269,"briefTitle":9270,"status":108,"phases":9271,"primaryCompletion":3758,"completion":3758,"start":1629,"enrollment":32,"conditions":9272,"interventions":9273},"NCT01063205","NAC as a Potential Treatment for Methamphetamine Dependence",[88],[7326,7325,21],[9262,9262],{"trials":9275,"activeCount":100},[],{"trials":9277,"activeCount":100},[],{"trials":9279,"activeCount":100},[],{"trials":9281,"activeCount":100},[],{"intervention":9283,"totalTrials":150,"cells":9284},"B-CLL Vaccine",{"EARLY_PHASE1":9285,"PHASE1":9287,"PHASE2":9297,"PHASE3":9299,"PHASE4":9301,"NA":9303},{"trials":9286,"activeCount":100},[],{"trials":9288,"activeCount":100},[9289],{"nctId":9290,"briefTitle":9291,"status":578,"phases":9292,"primaryCompletion":1556,"completion":1556,"start":4445,"enrollment":394,"conditions":9293,"interventions":9295},"NCT01604031","Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide",[88],[9294],"B-cell Chronic Lymphocytic Leukemia",[9283,9296],"Lenalidomide",{"trials":9298,"activeCount":100},[],{"trials":9300,"activeCount":100},[],{"trials":9302,"activeCount":100},[],{"trials":9304,"activeCount":100},[],{"intervention":9296,"totalTrials":150,"cells":9306},{"EARLY_PHASE1":9307,"PHASE1":9309,"PHASE2":9315,"PHASE3":9317,"PHASE4":9319,"NA":9321},{"trials":9308,"activeCount":100},[],{"trials":9310,"activeCount":100},[9311],{"nctId":9290,"briefTitle":9291,"status":578,"phases":9312,"primaryCompletion":1556,"completion":1556,"start":4445,"enrollment":394,"conditions":9313,"interventions":9314},[88],[9294],[9283,9296],{"trials":9316,"activeCount":100},[],{"trials":9318,"activeCount":100},[],{"trials":9320,"activeCount":100},[],{"trials":9322,"activeCount":100},[],{"intervention":9324,"totalTrials":150,"cells":9325},"Fresolimumab",{"EARLY_PHASE1":9326,"PHASE1":9328,"PHASE2":9339,"PHASE3":9341,"PHASE4":9343,"NA":9345},{"trials":9327,"activeCount":100},[],{"trials":9329,"activeCount":100},[9330],{"nctId":9331,"briefTitle":9332,"status":108,"phases":9333,"primaryCompletion":9334,"completion":9334,"start":9335,"enrollment":27,"conditions":9336,"interventions":9338},"NCT03064074","Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta",[88],"2022-07-04","2017-11-15",[9337],"Osteogenesis Imperfecta",[9324],{"trials":9340,"activeCount":100},[],{"trials":9342,"activeCount":100},[],{"trials":9344,"activeCount":100},[],{"trials":9346,"activeCount":100},[],{"intervention":9348,"totalTrials":150,"cells":9349},"CGTG-102",{"EARLY_PHASE1":9350,"PHASE1":9352,"PHASE2":9361,"PHASE3":9363,"PHASE4":9365,"NA":9367},{"trials":9351,"activeCount":100},[],{"trials":9353,"activeCount":100},[9354],{"nctId":9355,"briefTitle":9356,"status":180,"phases":9357,"enrollment":100,"conditions":9358,"interventions":9360},"NCT01437280","GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers",[88],[9359,1613],"Tumors",[9348],{"trials":9362,"activeCount":100},[],{"trials":9364,"activeCount":100},[],{"trials":9366,"activeCount":100},[],{"trials":9368,"activeCount":100},[],{"intervention":9370,"totalTrials":150,"cells":9371},"Dose Finding Phase",{"EARLY_PHASE1":9372,"PHASE1":9374,"PHASE2":9387,"PHASE3":9389,"PHASE4":9391,"NA":9393},{"trials":9373,"activeCount":100},[],{"trials":9375,"activeCount":100},[9376],{"nctId":9377,"briefTitle":9378,"status":578,"phases":9379,"primaryCompletion":9380,"completion":9380,"start":9381,"enrollment":1106,"conditions":9382,"interventions":9385},"NCT04401410","Anti-SARS Cov-2 T Cell Infusions for COVID 19",[88],"2021-10-12","2020-11-04",[9383,3225,9384],"SARS-CoV 2","COVID 19",[9370,9386],"Partially HLA-matched SARS-CoVSTs",{"trials":9388,"activeCount":100},[],{"trials":9390,"activeCount":100},[],{"trials":9392,"activeCount":100},[],{"trials":9394,"activeCount":100},[],{"intervention":9386,"totalTrials":150,"cells":9396},{"EARLY_PHASE1":9397,"PHASE1":9399,"PHASE2":9405,"PHASE3":9407,"PHASE4":9409,"NA":9411},{"trials":9398,"activeCount":100},[],{"trials":9400,"activeCount":100},[9401],{"nctId":9377,"briefTitle":9378,"status":578,"phases":9402,"primaryCompletion":9380,"completion":9380,"start":9381,"enrollment":1106,"conditions":9403,"interventions":9404},[88],[9383,3225,9384],[9370,9386],{"trials":9406,"activeCount":100},[],{"trials":9408,"activeCount":100},[],{"trials":9410,"activeCount":100},[],{"trials":9412,"activeCount":100},[],{"intervention":9414,"totalTrials":150,"cells":9415},"RTVP-1 Gene",{"EARLY_PHASE1":9416,"PHASE1":9418,"PHASE2":9426,"PHASE3":9428,"PHASE4":9430,"NA":9432},{"trials":9417,"activeCount":100},[],{"trials":9419,"activeCount":100},[9420],{"nctId":9421,"briefTitle":9422,"status":108,"phases":9423,"primaryCompletion":5452,"completion":5452,"start":8911,"enrollment":1253,"conditions":9424,"interventions":9425},"NCT00403221","Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer",[88],[8958],[9414],{"trials":9427,"activeCount":100},[],{"trials":9429,"activeCount":100},[],{"trials":9431,"activeCount":100},[],{"trials":9433,"activeCount":100},[],{"intervention":9435,"totalTrials":150,"cells":9436},"RTI-336",{"EARLY_PHASE1":9437,"PHASE1":9439,"PHASE2":9447,"PHASE3":9449,"PHASE4":9451,"NA":9453},{"trials":9438,"activeCount":100},[],{"trials":9440,"activeCount":100},[9441],{"nctId":9442,"briefTitle":9443,"status":180,"phases":9444,"primaryCompletion":2848,"completion":2848,"start":5443,"enrollment":100,"conditions":9445,"interventions":9446},"NCT01601717","RTI-336 as a Treatment for Methamphetamine Dependence",[88],[7325,21,7326],[9435],{"trials":9448,"activeCount":100},[],{"trials":9450,"activeCount":100},[],{"trials":9452,"activeCount":100},[],{"trials":9454,"activeCount":100},[],{"intervention":5473,"totalTrials":150,"cells":9456},{"EARLY_PHASE1":9457,"PHASE1":9459,"PHASE2":9465,"PHASE3":9467,"PHASE4":9469,"NA":9471},{"trials":9458,"activeCount":100},[],{"trials":9460,"activeCount":100},[9461],{"nctId":5465,"briefTitle":5466,"status":108,"phases":9462,"primaryCompletion":5468,"completion":5468,"start":5469,"enrollment":27,"conditions":9463,"interventions":9464},[88],[5471],[5473,5432],{"trials":9466,"activeCount":100},[],{"trials":9468,"activeCount":100},[],{"trials":9470,"activeCount":100},[],{"trials":9472,"activeCount":100},[],{"intervention":9474,"totalTrials":150,"cells":9475},"Injection of allogeneic neuroblastoma cells",{"EARLY_PHASE1":9476,"PHASE1":9478,"PHASE2":9487,"PHASE3":9489,"PHASE4":9491,"NA":9493},{"trials":9477,"activeCount":100},[],{"trials":9479,"activeCount":100},[9480],{"nctId":9481,"briefTitle":9482,"status":108,"phases":9483,"primaryCompletion":6843,"completion":69,"start":9484,"enrollment":534,"conditions":9485,"interventions":9486},"NCT01713439","Allogeneic Neuroblastoma Cells for Relapsed\u002F Refractory Neuroblastoma, CYCHEALL",[88],"1997-12",[29],[9474],{"trials":9488,"activeCount":100},[],{"trials":9490,"activeCount":100},[],{"trials":9492,"activeCount":100},[],{"trials":9494,"activeCount":100},[],{"intervention":9496,"totalTrials":150,"cells":9497},"TGFBeta resistant HER2\u002FEBV-CTLs",{"EARLY_PHASE1":9498,"PHASE1":9500,"PHASE2":9510,"PHASE3":9512,"PHASE4":9514,"NA":9516},{"trials":9499,"activeCount":100},[],{"trials":9501,"activeCount":100},[9502],{"nctId":9503,"briefTitle":9504,"status":108,"phases":9505,"primaryCompletion":3757,"completion":9506,"start":7441,"enrollment":16,"conditions":9507,"interventions":9509},"NCT00889954","Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy",[88],"2018-01-21",[9508],"HER2 Positive Malignancies",[9496],{"trials":9511,"activeCount":100},[],{"trials":9513,"activeCount":100},[],{"trials":9515,"activeCount":100},[],{"trials":9517,"activeCount":100},[],{"intervention":5483,"totalTrials":150,"cells":9519},{"EARLY_PHASE1":9520,"PHASE1":9522,"PHASE2":9528,"PHASE3":9530,"PHASE4":9532,"NA":9534},{"trials":9521,"activeCount":100},[],{"trials":9523,"activeCount":100},[9524],{"nctId":5475,"briefTitle":5476,"status":108,"phases":9525,"primaryCompletion":5478,"completion":5478,"start":5479,"enrollment":3191,"conditions":9526,"interventions":9527},[88],[23],[5432,5482,5483],{"trials":9529,"activeCount":100},[],{"trials":9531,"activeCount":100},[],{"trials":9533,"activeCount":100},[],{"trials":9535,"activeCount":100},[],{"intervention":7539,"totalTrials":150,"cells":9537},{"EARLY_PHASE1":9538,"PHASE1":9540,"PHASE2":9546,"PHASE3":9548,"PHASE4":9550,"NA":9552},{"trials":9539,"activeCount":100},[],{"trials":9541,"activeCount":100},[9542],{"nctId":7533,"briefTitle":7534,"status":108,"phases":9543,"primaryCompletion":7536,"completion":5561,"start":39,"enrollment":3720,"conditions":9544,"interventions":9545},[88],[2299,3450],[7514,7527,7528,7539,7530,7531,7540],{"trials":9547,"activeCount":100},[],{"trials":9549,"activeCount":100},[],{"trials":9551,"activeCount":100},[],{"trials":9553,"activeCount":100},[],{"intervention":7540,"totalTrials":150,"cells":9555},{"EARLY_PHASE1":9556,"PHASE1":9558,"PHASE2":9564,"PHASE3":9566,"PHASE4":9568,"NA":9570},{"trials":9557,"activeCount":100},[],{"trials":9559,"activeCount":100},[9560],{"nctId":7533,"briefTitle":7534,"status":108,"phases":9561,"primaryCompletion":7536,"completion":5561,"start":39,"enrollment":3720,"conditions":9562,"interventions":9563},[88],[2299,3450],[7514,7527,7528,7539,7530,7531,7540],{"trials":9565,"activeCount":100},[],{"trials":9567,"activeCount":100},[],{"trials":9569,"activeCount":100},[],{"trials":9571,"activeCount":100},[],{"intervention":7475,"totalTrials":150,"cells":9573},{"EARLY_PHASE1":9574,"PHASE1":9576,"PHASE2":9582,"PHASE3":9584,"PHASE4":9586,"NA":9588},{"trials":9575,"activeCount":100},[],{"trials":9577,"activeCount":100},[9578],{"nctId":7470,"briefTitle":7471,"status":578,"phases":9579,"primaryCompletion":3511,"completion":7332,"start":3565,"enrollment":1106,"conditions":9580,"interventions":9581},[88],[1390],[7475,7454],{"trials":9583,"activeCount":100},[],{"trials":9585,"activeCount":100},[],{"trials":9587,"activeCount":100},[],{"trials":9589,"activeCount":100},[],{"intervention":9591,"totalTrials":150,"cells":9592},"Peppermint oil",{"EARLY_PHASE1":9593,"PHASE1":9595,"PHASE2":9605,"PHASE3":9607,"PHASE4":9609,"NA":9611},{"trials":9594,"activeCount":100},[],{"trials":9596,"activeCount":100},[9597],{"nctId":9598,"briefTitle":9599,"status":180,"phases":9600,"primaryCompletion":9601,"completion":9601,"start":2754,"enrollment":100,"conditions":9602,"interventions":9604},"NCT04497870","Peppermint Oil Pharmacokinetics\u002FDynamics",[88],"2023-09-14",[9603],"Abdominal Pain",[9591],{"trials":9606,"activeCount":100},[],{"trials":9608,"activeCount":100},[],{"trials":9610,"activeCount":100},[],{"trials":9612,"activeCount":100},[],{"intervention":7444,"totalTrials":150,"cells":9614},{"EARLY_PHASE1":9615,"PHASE1":9617,"PHASE2":9623,"PHASE3":9625,"PHASE4":9627,"NA":9629},{"trials":9616,"activeCount":100},[],{"trials":9618,"activeCount":100},[9619],{"nctId":7437,"briefTitle":7438,"status":108,"phases":9620,"primaryCompletion":7440,"completion":7440,"start":7441,"enrollment":2040,"conditions":9621,"interventions":9622},[88],[7325,7326,21],[5463,7444],{"trials":9624,"activeCount":100},[],{"trials":9626,"activeCount":100},[],{"trials":9628,"activeCount":100},[],{"trials":9630,"activeCount":100},[],{"intervention":1269,"totalTrials":150,"cells":9632},{"EARLY_PHASE1":9633,"PHASE1":9639,"PHASE2":9641,"PHASE3":9643,"PHASE4":9645,"NA":9647},{"trials":9634,"activeCount":100},[9635],{"nctId":1258,"briefTitle":1259,"status":108,"phases":9636,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1106,"conditions":9637,"interventions":9638},[87],[1265,1266,1267],[1269,587,411,1270,1271,1272,1038,1273,1274],{"trials":9640,"activeCount":100},[],{"trials":9642,"activeCount":100},[],{"trials":9644,"activeCount":100},[],{"trials":9646,"activeCount":100},[],{"trials":9648,"activeCount":100},[],{"intervention":1273,"totalTrials":150,"cells":9650},{"EARLY_PHASE1":9651,"PHASE1":9657,"PHASE2":9659,"PHASE3":9661,"PHASE4":9663,"NA":9665},{"trials":9652,"activeCount":100},[9653],{"nctId":1258,"briefTitle":1259,"status":108,"phases":9654,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1106,"conditions":9655,"interventions":9656},[87],[1265,1266,1267],[1269,587,411,1270,1271,1272,1038,1273,1274],{"trials":9658,"activeCount":100},[],{"trials":9660,"activeCount":100},[],{"trials":9662,"activeCount":100},[],{"trials":9664,"activeCount":100},[],{"trials":9666,"activeCount":100},[],{"intervention":9668,"totalTrials":150,"cells":9669},"Fentanyl Citrate",{"EARLY_PHASE1":9670,"PHASE1":9683,"PHASE2":9685,"PHASE3":9687,"PHASE4":9689,"NA":9691},{"trials":9671,"activeCount":100},[9672],{"nctId":9673,"briefTitle":9674,"status":108,"phases":9675,"primaryCompletion":9676,"completion":9676,"start":9677,"enrollment":172,"conditions":9678,"interventions":9682},"NCT05051189","Effect of Opioids on Central Control of Ventilation in Children With Obstructive Sleep Apnea",[87],"2024-11-01","2021-12-01",[9679,9680,9681],"OSA","Opioid","Adenotonsillectomy",[9668],{"trials":9684,"activeCount":100},[],{"trials":9686,"activeCount":100},[],{"trials":9688,"activeCount":100},[],{"trials":9690,"activeCount":100},[],{"trials":9692,"activeCount":100},[],{"intervention":9694,"totalTrials":150,"cells":9695},"pregabalin",{"EARLY_PHASE1":9696,"PHASE1":9705,"PHASE2":9707,"PHASE3":9709,"PHASE4":9711,"NA":9713},{"trials":9697,"activeCount":100},[9698],{"nctId":9699,"briefTitle":9700,"status":108,"phases":9701,"primaryCompletion":2205,"completion":2205,"start":3544,"enrollment":16,"conditions":9702,"interventions":9704},"NCT00646451","Pregabalin in the Treatment of Essential Tremor",[87],[9703],"Essential Tremor",[9694],{"trials":9706,"activeCount":100},[],{"trials":9708,"activeCount":100},[],{"trials":9710,"activeCount":100},[],{"trials":9712,"activeCount":100},[],{"trials":9714,"activeCount":100},[],{"intervention":9716,"totalTrials":150,"cells":9717},"5-Azacytidine",{"EARLY_PHASE1":9718,"PHASE1":9729,"PHASE2":9731,"PHASE3":9733,"PHASE4":9735,"NA":9737},{"trials":9719,"activeCount":100},[9720],{"nctId":9721,"briefTitle":9722,"status":180,"phases":9723,"primaryCompletion":9724,"completion":9725,"start":8145,"enrollment":100,"conditions":9726,"interventions":9728},"NCT06598332","5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)",[87],"2028-05-01","2029-05-01",[9727],"Graft-Versus-Host Disease(GVHD)",[9716],{"trials":9730,"activeCount":100},[],{"trials":9732,"activeCount":100},[],{"trials":9734,"activeCount":100},[],{"trials":9736,"activeCount":100},[],{"trials":9738,"activeCount":100},[],{"intervention":9740,"totalTrials":150,"cells":9741},"Natesto Nasal Product",{"EARLY_PHASE1":9742,"PHASE1":9754,"PHASE2":9756,"PHASE3":9758,"PHASE4":9760,"NA":9762},{"trials":9743,"activeCount":100},[9744],{"nctId":9745,"briefTitle":9746,"status":180,"phases":9747,"primaryCompletion":5871,"completion":5871,"start":9748,"enrollment":100,"conditions":9749,"interventions":9753},"NCT04717362","The Effects of Natesto For Treatment Of Hypogonadism",[87],"2024-03-01",[9750,9751,9752],"Hypogonadism, Male","Infertility, Male","Testosterone Deficiency",[9740],{"trials":9755,"activeCount":100},[],{"trials":9757,"activeCount":100},[],{"trials":9759,"activeCount":100},[],{"trials":9761,"activeCount":100},[],{"trials":9763,"activeCount":100},[],{"intervention":9765,"totalTrials":150,"cells":9766},"Entolimod",{"EARLY_PHASE1":9767,"PHASE1":9780,"PHASE2":9782,"PHASE3":9784,"PHASE4":9786,"NA":9788},{"trials":9768,"activeCount":100},[9769],{"nctId":9770,"briefTitle":9771,"status":108,"phases":9772,"primaryCompletion":9773,"completion":9774,"start":9775,"enrollment":282,"conditions":9776,"interventions":9778},"NCT03063736","Entolimod, an Adjuvant for Vaccine Augmentation",[87],"2018-03-09","2019-12-31","2017-12-08",[9777],"Substance Use Disorders",[9765,9779],"Td Vaccine",{"trials":9781,"activeCount":100},[],{"trials":9783,"activeCount":100},[],{"trials":9785,"activeCount":100},[],{"trials":9787,"activeCount":100},[],{"trials":9789,"activeCount":100},[],{"intervention":9779,"totalTrials":150,"cells":9791},{"EARLY_PHASE1":9792,"PHASE1":9798,"PHASE2":9800,"PHASE3":9802,"PHASE4":9804,"NA":9806},{"trials":9793,"activeCount":100},[9794],{"nctId":9770,"briefTitle":9771,"status":108,"phases":9795,"primaryCompletion":9773,"completion":9774,"start":9775,"enrollment":282,"conditions":9796,"interventions":9797},[87],[9777],[9765,9779],{"trials":9799,"activeCount":100},[],{"trials":9801,"activeCount":100},[],{"trials":9803,"activeCount":100},[],{"trials":9805,"activeCount":100},[],{"trials":9807,"activeCount":100},[],{"intervention":409,"totalTrials":150,"cells":9809},{"EARLY_PHASE1":9810,"PHASE1":9816,"PHASE2":9818,"PHASE3":9820,"PHASE4":9822,"NA":9824},{"trials":9811,"activeCount":100},[9812],{"nctId":399,"briefTitle":400,"status":108,"phases":9813,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":9814,"interventions":9815},[87],[407],[409,393,410,411,412],{"trials":9817,"activeCount":100},[],{"trials":9819,"activeCount":100},[],{"trials":9821,"activeCount":100},[],{"trials":9823,"activeCount":100},[],{"trials":9825,"activeCount":100},[],{"intervention":410,"totalTrials":150,"cells":9827},{"EARLY_PHASE1":9828,"PHASE1":9834,"PHASE2":9836,"PHASE3":9838,"PHASE4":9840,"NA":9842},{"trials":9829,"activeCount":100},[9830],{"nctId":399,"briefTitle":400,"status":108,"phases":9831,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":9832,"interventions":9833},[87],[407],[409,393,410,411,412],{"trials":9835,"activeCount":100},[],{"trials":9837,"activeCount":100},[],{"trials":9839,"activeCount":100},[],{"trials":9841,"activeCount":100},[],{"trials":9843,"activeCount":100},[],{"intervention":412,"totalTrials":150,"cells":9845},{"EARLY_PHASE1":9846,"PHASE1":9852,"PHASE2":9854,"PHASE3":9856,"PHASE4":9858,"NA":9860},{"trials":9847,"activeCount":100},[9848],{"nctId":399,"briefTitle":400,"status":108,"phases":9849,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":9850,"interventions":9851},[87],[407],[409,393,410,411,412],{"trials":9853,"activeCount":100},[],{"trials":9855,"activeCount":100},[],{"trials":9857,"activeCount":100},[],{"trials":9859,"activeCount":100},[],{"trials":9861,"activeCount":100},[],{"intervention":9863,"totalTrials":150,"cells":9864},"gabapentin 600 mg po",{"EARLY_PHASE1":9865,"PHASE1":9875,"PHASE2":9877,"PHASE3":9879,"PHASE4":9881,"NA":9883},{"trials":9866,"activeCount":100},[9867],{"nctId":9868,"briefTitle":9869,"status":180,"phases":9870,"primaryCompletion":5829,"completion":5829,"start":2848,"enrollment":100,"conditions":9871,"interventions":9874},"NCT01441531","Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension",[87],[9872,9873],"Tourniquet-induced Pain","Tourniquet-induced Hypertension",[9863],{"trials":9876,"activeCount":100},[],{"trials":9878,"activeCount":100},[],{"trials":9880,"activeCount":100},[],{"trials":9882,"activeCount":100},[],{"trials":9884,"activeCount":100},[],{"intervention":9886,"totalTrials":150,"cells":9887},"Ketamine Hydrochloride",{"EARLY_PHASE1":9888,"PHASE1":9898,"PHASE2":9900,"PHASE3":9902,"PHASE4":9904,"NA":9906},{"trials":9889,"activeCount":100},[9890],{"nctId":9891,"briefTitle":9892,"status":578,"phases":9893,"primaryCompletion":9894,"completion":9894,"start":9895,"enrollment":150,"conditions":9896,"interventions":9897},"NCT04712071","Ketamine in Veterans With Gulf War Illness",[87],"2022-02-16","2021-02-01",[698],[9886],{"trials":9899,"activeCount":100},[],{"trials":9901,"activeCount":100},[],{"trials":9903,"activeCount":100},[],{"trials":9905,"activeCount":100},[],{"trials":9907,"activeCount":100},[],{"intervention":1303,"totalTrials":1135,"cells":9909},{"EARLY_PHASE1":9910,"PHASE1":9912,"PHASE2":9922,"PHASE3":9932,"PHASE4":9934,"NA":9936},{"trials":9911,"activeCount":100},[],{"trials":9913,"activeCount":100},[9914,9918],{"nctId":1294,"briefTitle":1295,"status":108,"phases":9915,"primaryCompletion":1167,"completion":1167,"start":1297,"enrollment":1298,"conditions":9916,"interventions":9917},[88],[1300],[1097,1098,1302,1038,1303],{"nctId":1309,"briefTitle":1310,"status":108,"phases":9919,"completion":1312,"start":1313,"enrollment":1216,"conditions":9920,"interventions":9921},[88],[1315],[1038,1303,1274],{"trials":9923,"activeCount":100},[9924,9928],{"nctId":1345,"briefTitle":1346,"status":108,"phases":9925,"primaryCompletion":1048,"completion":1348,"start":1349,"enrollment":1350,"conditions":9926,"interventions":9927},[89],[29],[1353,1270,1354,1355,1038,1303,1356],{"nctId":1365,"briefTitle":1366,"status":108,"phases":9929,"completion":1368,"start":1369,"enrollment":32,"conditions":9930,"interventions":9931},[89],[1371],[1038,1373,1235],{"trials":9933,"activeCount":100},[],{"trials":9935,"activeCount":100},[],{"trials":9937,"activeCount":100},[9938,9942,9946],{"nctId":1385,"briefTitle":1386,"status":578,"phases":9939,"primaryCompletion":1282,"completion":1282,"start":1168,"enrollment":405,"conditions":9940,"interventions":9941},[92],[1138,1389,1390,1391,1392],[1394,1303,1038],{"nctId":1228,"briefTitle":1229,"status":578,"phases":9943,"primaryCompletion":1231,"completion":1231,"start":1232,"enrollment":32,"conditions":9944,"interventions":9945},[92],[1184],[604,518,1127,1038,1235],{"nctId":1416,"briefTitle":1417,"status":578,"phases":9947,"primaryCompletion":1282,"completion":1282,"start":1168,"enrollment":1216,"conditions":9948,"interventions":9949},[92],[1138,1420,1421,1422],[1424,1038,1235,1425],{"intervention":1097,"totalTrials":1298,"cells":9951},{"EARLY_PHASE1":9952,"PHASE1":9954,"PHASE2":9960,"PHASE3":9978,"PHASE4":9980,"NA":9982},{"trials":9953,"activeCount":100},[],{"trials":9955,"activeCount":100},[9956],{"nctId":1294,"briefTitle":1295,"status":108,"phases":9957,"primaryCompletion":1167,"completion":1167,"start":1297,"enrollment":1298,"conditions":9958,"interventions":9959},[88],[1300],[1097,1098,1302,1038,1303],{"trials":9961,"activeCount":100},[9962,9966,9970,9974],{"nctId":1328,"briefTitle":1329,"status":108,"phases":9963,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":9964,"interventions":9965},[89],[1110,1336,1337,407,1111,1338,1339,1340,1341],[1302,1038,1343],{"nctId":1088,"briefTitle":1089,"status":578,"phases":9967,"primaryCompletion":600,"completion":600,"start":1091,"enrollment":1092,"conditions":9968,"interventions":9969},[88,89],[1094,1095],[1097,1098,518],{"nctId":1142,"briefTitle":1143,"status":578,"phases":9971,"primaryCompletion":1145,"completion":1145,"start":1146,"enrollment":394,"conditions":9972,"interventions":9973},[88,89],[1148],[1097,1098,1150,518],{"nctId":1210,"briefTitle":1211,"status":108,"phases":9975,"primaryCompletion":1213,"completion":1214,"start":1215,"enrollment":1216,"conditions":9976,"interventions":9977},[88,89],[1218],[1220,1097,1150,518],{"trials":9979,"activeCount":100},[],{"trials":9981,"activeCount":100},[],{"trials":9983,"activeCount":100},[9984],{"nctId":1416,"briefTitle":1417,"status":578,"phases":9985,"primaryCompletion":1282,"completion":1282,"start":1168,"enrollment":1216,"conditions":9986,"interventions":9987},[92],[1138,1420,1421,1422],[1424,1038,1235,1425],{"intervention":604,"totalTrials":1298,"cells":9989},{"EARLY_PHASE1":9990,"PHASE1":9992,"PHASE2":9994,"PHASE3":10008,"PHASE4":10010,"NA":10012},{"trials":9991,"activeCount":100},[],{"trials":9993,"activeCount":100},[],{"trials":9995,"activeCount":100},[9996,10000,10004],{"nctId":1100,"briefTitle":1101,"status":578,"phases":9997,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":9998,"interventions":9999},[88,89],[1108,1109,1110,1111,1112,1113,1114,1115],[585,604,518,586],{"nctId":1358,"briefTitle":1359,"status":578,"phases":10001,"primaryCompletion":1180,"completion":1180,"start":1122,"enrollment":972,"conditions":10002,"interventions":10003},[89],[1182,1183,1184],[1175,1363,604,1038],{"nctId":1152,"briefTitle":1153,"status":108,"phases":10005,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":972,"conditions":10006,"interventions":10007},[89],[1159],[604,1161,1038,518,1162],{"trials":10009,"activeCount":100},[],{"trials":10011,"activeCount":100},[],{"trials":10013,"activeCount":100},[10014,10018,10022],{"nctId":1228,"briefTitle":1229,"status":578,"phases":10015,"primaryCompletion":1231,"completion":1231,"start":1232,"enrollment":32,"conditions":10016,"interventions":10017},[92],[1184],[604,518,1127,1038,1235],{"nctId":1237,"briefTitle":1238,"status":108,"phases":10019,"primaryCompletion":84,"completion":84,"start":610,"enrollment":1240,"conditions":10020,"interventions":10021},[92],[1242],[604,1038,518],{"nctId":595,"briefTitle":596,"status":108,"phases":10023,"primaryCompletion":598,"completion":599,"start":600,"enrollment":282,"conditions":10024,"interventions":10025},[92],[602],[604,499,518],{"intervention":1127,"totalTrials":1298,"cells":10027},{"EARLY_PHASE1":10028,"PHASE1":10030,"PHASE2":10036,"PHASE3":10054,"PHASE4":10056,"NA":10058},{"trials":10029,"activeCount":100},[],{"trials":10031,"activeCount":100},[10032],{"nctId":1045,"briefTitle":1046,"status":578,"phases":10033,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":150,"conditions":10034,"interventions":10035},[88],[1051],[518,1053,1054,1055],{"trials":10037,"activeCount":100},[10038,10042,10046,10050],{"nctId":1118,"briefTitle":1119,"status":578,"phases":10039,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":10040,"interventions":10041},[88,89],[1125],[1127,518,1128],{"nctId":1130,"briefTitle":1131,"status":578,"phases":10043,"primaryCompletion":112,"completion":1133,"start":1134,"enrollment":1135,"conditions":10044,"interventions":10045},[89],[1137,1138,1139],[518,1127],{"nctId":1190,"briefTitle":1191,"status":578,"phases":10047,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":282,"conditions":10048,"interventions":10049},[88,89],[1196],[518,1198,1150],{"nctId":1200,"briefTitle":1201,"status":108,"phases":10051,"primaryCompletion":1203,"completion":1203,"start":1204,"enrollment":282,"conditions":10052,"interventions":10053},[88,89],[1206,1138,1112,1113,1114],[1186,1198,1208],{"trials":10055,"activeCount":100},[],{"trials":10057,"activeCount":100},[],{"trials":10059,"activeCount":100},[10060],{"nctId":1228,"briefTitle":1229,"status":578,"phases":10061,"primaryCompletion":1231,"completion":1231,"start":1232,"enrollment":32,"conditions":10062,"interventions":10063},[92],[1184],[604,518,1127,1038,1235],{"intervention":1355,"totalTrials":1106,"cells":10065},{"EARLY_PHASE1":10066,"PHASE1":10068,"PHASE2":10078,"PHASE3":10084,"PHASE4":10086,"NA":10088},{"trials":10067,"activeCount":100},[],{"trials":10069,"activeCount":100},[10070,10074],{"nctId":8931,"briefTitle":8932,"status":578,"phases":10071,"primaryCompletion":7404,"completion":7404,"start":8934,"enrollment":1135,"conditions":10072,"interventions":10073},[88],[930],[8924,1355],{"nctId":7653,"briefTitle":7654,"status":108,"phases":10075,"primaryCompletion":1776,"completion":468,"start":1262,"enrollment":581,"conditions":10076,"interventions":10077},[88],[3193],[7658,7638,1355],{"trials":10079,"activeCount":100},[10080],{"nctId":1345,"briefTitle":1346,"status":108,"phases":10081,"primaryCompletion":1048,"completion":1348,"start":1349,"enrollment":1350,"conditions":10082,"interventions":10083},[89],[29],[1353,1270,1354,1355,1038,1303,1356],{"trials":10085,"activeCount":100},[],{"trials":10087,"activeCount":100},[],{"trials":10089,"activeCount":100},[10090],{"nctId":1427,"briefTitle":1428,"status":108,"phases":10091,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1350,"conditions":10092,"interventions":10093},[92],[29],[1434,1038,1355,411,1271,1038,1270,1435],{"intervention":1302,"totalTrials":96,"cells":10095},{"EARLY_PHASE1":10096,"PHASE1":10098,"PHASE2":10104,"PHASE3":10110,"PHASE4":10112,"NA":10114},{"trials":10097,"activeCount":100},[],{"trials":10099,"activeCount":100},[10100],{"nctId":1294,"briefTitle":1295,"status":108,"phases":10101,"primaryCompletion":1167,"completion":1167,"start":1297,"enrollment":1298,"conditions":10102,"interventions":10103},[88],[1300],[1097,1098,1302,1038,1303],{"trials":10105,"activeCount":100},[10106],{"nctId":1328,"briefTitle":1329,"status":108,"phases":10107,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":10108,"interventions":10109},[89],[1110,1336,1337,407,1111,1338,1339,1340,1341],[1302,1038,1343],{"trials":10111,"activeCount":100},[],{"trials":10113,"activeCount":100},[],{"trials":10115,"activeCount":100},[10116],{"nctId":10117,"briefTitle":10118,"status":108,"phases":10119,"primaryCompletion":7536,"completion":3459,"start":1146,"enrollment":5182,"conditions":10120,"interventions":10121},"NCT01702961","Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease",[92],[1390,1887],[10122,1302,10123,10124,10125,10126],"Melphalan","VP-16","BCNU","Rituxan","Stem Cells",{"intervention":1270,"totalTrials":96,"cells":10128},{"EARLY_PHASE1":10129,"PHASE1":10135,"PHASE2":10137,"PHASE3":10143,"PHASE4":10145,"NA":10147},{"trials":10130,"activeCount":100},[10131],{"nctId":1258,"briefTitle":1259,"status":108,"phases":10132,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1106,"conditions":10133,"interventions":10134},[87],[1265,1266,1267],[1269,587,411,1270,1271,1272,1038,1273,1274],{"trials":10136,"activeCount":100},[],{"trials":10138,"activeCount":100},[10139],{"nctId":1345,"briefTitle":1346,"status":108,"phases":10140,"primaryCompletion":1048,"completion":1348,"start":1349,"enrollment":1350,"conditions":10141,"interventions":10142},[89],[29],[1353,1270,1354,1355,1038,1303,1356],{"trials":10144,"activeCount":100},[],{"trials":10146,"activeCount":100},[],{"trials":10148,"activeCount":100},[10149],{"nctId":1427,"briefTitle":1428,"status":108,"phases":10150,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1350,"conditions":10151,"interventions":10152},[92],[29],[1434,1038,1355,411,1271,1038,1270,1435],{"intervention":587,"totalTrials":96,"cells":10154},{"EARLY_PHASE1":10155,"PHASE1":10161,"PHASE2":10163,"PHASE3":10169,"PHASE4":10171,"NA":10173},{"trials":10156,"activeCount":100},[10157],{"nctId":1258,"briefTitle":1259,"status":108,"phases":10158,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1106,"conditions":10159,"interventions":10160},[87],[1265,1266,1267],[1269,587,411,1270,1271,1272,1038,1273,1274],{"trials":10162,"activeCount":100},[],{"trials":10164,"activeCount":100},[10165],{"nctId":576,"briefTitle":577,"status":578,"phases":10166,"primaryCompletion":49,"completion":49,"start":580,"enrollment":581,"conditions":10167,"interventions":10168},[89],[583],[499,585,586,587],{"trials":10170,"activeCount":100},[],{"trials":10172,"activeCount":100},[],{"trials":10174,"activeCount":100},[10175],{"nctId":10176,"briefTitle":10177,"status":108,"phases":10178,"primaryCompletion":10179,"completion":10180,"start":10181,"enrollment":1002,"conditions":10182,"interventions":10183},"NCT02076997","Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate",[92],"2017-05-30","2019-05-10","2014-01-01",[1389],[587],{"intervention":411,"totalTrials":96,"cells":10185},{"EARLY_PHASE1":10186,"PHASE1":10196,"PHASE2":10198,"PHASE3":10200,"PHASE4":10202,"NA":10204},{"trials":10187,"activeCount":100},[10188,10192],{"nctId":1258,"briefTitle":1259,"status":108,"phases":10189,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1106,"conditions":10190,"interventions":10191},[87],[1265,1266,1267],[1269,587,411,1270,1271,1272,1038,1273,1274],{"nctId":399,"briefTitle":400,"status":108,"phases":10193,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":10194,"interventions":10195},[87],[407],[409,393,410,411,412],{"trials":10197,"activeCount":100},[],{"trials":10199,"activeCount":100},[],{"trials":10201,"activeCount":100},[],{"trials":10203,"activeCount":100},[],{"trials":10205,"activeCount":100},[10206],{"nctId":1427,"briefTitle":1428,"status":108,"phases":10207,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1350,"conditions":10208,"interventions":10209},[92],[29],[1434,1038,1355,411,1271,1038,1270,1435],{"intervention":148,"totalTrials":96,"cells":10211},{"EARLY_PHASE1":10212,"PHASE1":10214,"PHASE2":10216,"PHASE3":10222,"PHASE4":10224,"NA":10230},{"trials":10213,"activeCount":100},[],{"trials":10215,"activeCount":100},[],{"trials":10217,"activeCount":100},[10218],{"nctId":5622,"briefTitle":5623,"status":108,"phases":10219,"primaryCompletion":5625,"completion":5625,"start":5626,"enrollment":5627,"conditions":10220,"interventions":10221},[89],[23,5629],[5631,148],{"trials":10223,"activeCount":100},[],{"trials":10225,"activeCount":100},[10226],{"nctId":139,"briefTitle":140,"status":108,"phases":10227,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":10228,"interventions":10229},[91],[146],[148,149],{"trials":10231,"activeCount":100},[10232],{"nctId":10233,"briefTitle":10234,"status":578,"phases":10235,"primaryCompletion":59,"completion":59,"start":4038,"enrollment":876,"conditions":10236,"interventions":10238},"NCT01430182","Intraoperative Methadone vs Morphine for Postoperative Pain Control in Patients Undergoing Surgery of the Tibia",[92],[10237],"Pain, Postoperative",[148,4774],{"intervention":3689,"totalTrials":96,"cells":10240},{"EARLY_PHASE1":10241,"PHASE1":10243,"PHASE2":10245,"PHASE3":10247,"PHASE4":10249,"NA":10255},{"trials":10242,"activeCount":100},[],{"trials":10244,"activeCount":100},[],{"trials":10246,"activeCount":100},[],{"trials":10248,"activeCount":100},[],{"trials":10250,"activeCount":100},[10251],{"nctId":3679,"briefTitle":3680,"status":578,"phases":10252,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":3685,"conditions":10253,"interventions":10254},[91],[3687],[3689,3656],{"trials":10256,"activeCount":100},[10257,10267],{"nctId":10258,"briefTitle":10259,"status":108,"phases":10260,"primaryCompletion":10261,"completion":10261,"start":10262,"enrollment":928,"conditions":10263,"interventions":10266},"NCT03938259","Effect of Opioids on Ventilation in Children With Obstructive Sleep Apnea",[],"2020-08-30","2019-07-01",[10264,10265],"Respiratory Depression","Obstructive Sleep Apnea",[3689],{"nctId":10268,"briefTitle":10269,"status":180,"phases":10270,"primaryCompletion":1431,"completion":1431,"start":5468,"enrollment":100,"conditions":10271,"interventions":10274},"NCT02460055","Trial- Dysphagia From ETT or GI Endoscopy",[92],[10272,10273],"Dysphagia","Respiratory Complications",[10275,3689,4450,10276,10277],"propofol","Ondansetron","sevoflurane, nitrous oxide and oxygen",{"intervention":4450,"totalTrials":96,"cells":10279},{"EARLY_PHASE1":10280,"PHASE1":10282,"PHASE2":10284,"PHASE3":10290,"PHASE4":10292,"NA":10298},{"trials":10281,"activeCount":100},[],{"trials":10283,"activeCount":100},[],{"trials":10285,"activeCount":100},[10286],{"nctId":5826,"briefTitle":5827,"status":108,"phases":10287,"primaryCompletion":5829,"completion":3757,"start":3510,"enrollment":16,"conditions":10288,"interventions":10289},[89],[1069],[5817,5832,4450,5833,5834],{"trials":10291,"activeCount":100},[],{"trials":10293,"activeCount":100},[10294],{"nctId":4442,"briefTitle":4443,"status":108,"phases":10295,"primaryCompletion":64,"completion":64,"start":4445,"enrollment":16,"conditions":10296,"interventions":10297},[91],[4447,4448],[4450,4429],{"trials":10299,"activeCount":100},[10300],{"nctId":10268,"briefTitle":10269,"status":180,"phases":10301,"primaryCompletion":1431,"completion":1431,"start":5468,"enrollment":100,"conditions":10302,"interventions":10303},[92],[10272,10273],[10275,3689,4450,10276,10277],{"intervention":10305,"totalTrials":96,"cells":10306},"Propofol",{"EARLY_PHASE1":10307,"PHASE1":10309,"PHASE2":10311,"PHASE3":10313,"PHASE4":10323,"NA":10325},{"trials":10308,"activeCount":100},[],{"trials":10310,"activeCount":100},[],{"trials":10312,"activeCount":100},[],{"trials":10314,"activeCount":100},[10315],{"nctId":10316,"briefTitle":10317,"status":108,"phases":10318,"primaryCompletion":3812,"completion":3812,"start":10319,"enrollment":2040,"conditions":10320,"interventions":10322},"NCT01242241","Propofol in Obese Children",[90],"2008-04-01",[10321,15],"Pharmacodynamics",[10305,10305],{"trials":10324,"activeCount":100},[],{"trials":10326,"activeCount":100},[10327,10331],{"nctId":10268,"briefTitle":10269,"status":180,"phases":10328,"primaryCompletion":1431,"completion":1431,"start":5468,"enrollment":100,"conditions":10329,"interventions":10330},[92],[10272,10273],[10275,3689,4450,10276,10277],{"nctId":10332,"briefTitle":10333,"status":108,"phases":10334,"primaryCompletion":1622,"completion":1622,"start":600,"enrollment":2040,"conditions":10335,"interventions":10337},"NCT00983918","Pain After Laparoscopic Cholecystectomy",[92],[10336],"Postoperative Pain",[10338,10339,10340,10305],"Desflurane","Sevoflurane","Isoflurane",{"intervention":4043,"totalTrials":394,"cells":10342},{"EARLY_PHASE1":10343,"PHASE1":10345,"PHASE2":10347,"PHASE3":10349,"PHASE4":10351,"NA":10357},{"trials":10344,"activeCount":100},[],{"trials":10346,"activeCount":100},[],{"trials":10348,"activeCount":100},[],{"trials":10350,"activeCount":100},[],{"trials":10352,"activeCount":100},[10353],{"nctId":4035,"briefTitle":4036,"status":578,"phases":10354,"primaryCompletion":4038,"completion":39,"start":4039,"enrollment":1240,"conditions":10355,"interventions":10356},[91],[4041],[4043,4022],{"trials":10358,"activeCount":100},[10359],{"nctId":10360,"briefTitle":10361,"status":3474,"phases":10362,"primaryCompletion":10363,"completion":10363,"start":3575,"enrollment":16,"conditions":10364,"interventions":10366},"NCT00362063","304-C03\u002FL3301n: Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency",[92],"2018-04",[10365],"Growth Hormone Deficiency",[10367],"growth hormone",{"intervention":10369,"totalTrials":394,"cells":10370},"Intrathecal Mafosfamide",{"EARLY_PHASE1":10371,"PHASE1":10373,"PHASE2":10383,"PHASE3":10385,"PHASE4":10387,"NA":10389},{"trials":10372,"activeCount":100},[],{"trials":10374,"activeCount":100},[10375],{"nctId":10376,"briefTitle":10369,"status":108,"phases":10377,"completion":5649,"start":10378,"enrollment":10379,"conditions":10380,"interventions":10382},"NCT00062881",[88],"1990-06",65,[10381],"Malignant Meningeal Neoplasms",[10369],{"trials":10384,"activeCount":100},[],{"trials":10386,"activeCount":100},[],{"trials":10388,"activeCount":100},[],{"trials":10390,"activeCount":100},[10391],{"nctId":10392,"briefTitle":10393,"status":108,"phases":10394,"primaryCompletion":10395,"completion":3544,"start":10396,"enrollment":10397,"conditions":10398,"interventions":10400},"NCT00042367","Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors",[92],"2005-12","2000-04-04",119,[10399],"Brain Tumors",[10401,10402,10403,10404,10369,10405,10406,10407,10408],"Induction therapy (Regimen 1, Course 1, Cycle A1","Regimen 1, Course 1, Cycle A2","Cycle B","Regimen 1, Course 2","Regimen 1 Course 2, IT mafosfamide","Regimen 2, Course 1","Regimen 2, Course, 1, Cycle C1","Regimen 2, Course 2",{"intervention":1394,"totalTrials":394,"cells":10410},{"EARLY_PHASE1":10411,"PHASE1":10413,"PHASE2":10415,"PHASE3":10417,"PHASE4":10419,"NA":10421},{"trials":10412,"activeCount":100},[],{"trials":10414,"activeCount":100},[],{"trials":10416,"activeCount":100},[],{"trials":10418,"activeCount":100},[],{"trials":10420,"activeCount":100},[],{"trials":10422,"activeCount":100},[10423,10427],{"nctId":1385,"briefTitle":1386,"status":578,"phases":10424,"primaryCompletion":1282,"completion":1282,"start":1168,"enrollment":405,"conditions":10425,"interventions":10426},[92],[1138,1389,1390,1391,1392],[1394,1303,1038],{"nctId":1416,"briefTitle":1417,"status":578,"phases":10428,"primaryCompletion":1282,"completion":1282,"start":1168,"enrollment":1216,"conditions":10429,"interventions":10430},[92],[1138,1420,1421,1422],[1424,1038,1235,1425],{"intervention":1271,"totalTrials":394,"cells":10432},{"EARLY_PHASE1":10433,"PHASE1":10439,"PHASE2":10441,"PHASE3":10443,"PHASE4":10445,"NA":10447},{"trials":10434,"activeCount":100},[10435],{"nctId":1258,"briefTitle":1259,"status":108,"phases":10436,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1106,"conditions":10437,"interventions":10438},[87],[1265,1266,1267],[1269,587,411,1270,1271,1272,1038,1273,1274],{"trials":10440,"activeCount":100},[],{"trials":10442,"activeCount":100},[],{"trials":10444,"activeCount":100},[],{"trials":10446,"activeCount":100},[],{"trials":10448,"activeCount":100},[10449],{"nctId":1427,"briefTitle":1428,"status":108,"phases":10450,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1350,"conditions":10451,"interventions":10452},[92],[29],[1434,1038,1355,411,1271,1038,1270,1435],{"intervention":4774,"totalTrials":394,"cells":10454},{"EARLY_PHASE1":10455,"PHASE1":10457,"PHASE2":10459,"PHASE3":10461,"PHASE4":10463,"NA":10469},{"trials":10456,"activeCount":100},[],{"trials":10458,"activeCount":100},[],{"trials":10460,"activeCount":100},[],{"trials":10462,"activeCount":100},[],{"trials":10464,"activeCount":100},[10465],{"nctId":4766,"briefTitle":4767,"status":578,"phases":10466,"primaryCompletion":4769,"completion":84,"start":4770,"enrollment":113,"conditions":10467,"interventions":10468},[91],[4772],[4753,4774],{"trials":10470,"activeCount":100},[10471],{"nctId":10233,"briefTitle":10234,"status":578,"phases":10472,"primaryCompletion":59,"completion":59,"start":4038,"enrollment":876,"conditions":10473,"interventions":10474},[92],[10237],[148,4774],{"intervention":5388,"totalTrials":394,"cells":10476},{"EARLY_PHASE1":10477,"PHASE1":10479,"PHASE2":10481,"PHASE3":10483,"PHASE4":10489,"NA":10491},{"trials":10478,"activeCount":100},[],{"trials":10480,"activeCount":100},[],{"trials":10482,"activeCount":100},[],{"trials":10484,"activeCount":100},[10485],{"nctId":5379,"briefTitle":5380,"status":180,"phases":10486,"primaryCompletion":5382,"completion":5383,"start":5384,"enrollment":100,"conditions":10487,"interventions":10488},[90],[5386],[5388,5368],{"trials":10490,"activeCount":100},[],{"trials":10492,"activeCount":100},[10493],{"nctId":10494,"briefTitle":10495,"status":108,"phases":10496,"primaryCompletion":10497,"completion":10498,"start":5872,"enrollment":16,"conditions":10499,"interventions":10502},"NCT03676023","Tranexamic Acid Per Inhalation for Treatment of Pulmonary Hemorrhage in Pediatric Patients",[],"2020-02-01","2020-05-01",[10500,10501],"Pulmonary Hemorrhage","MAPCA - Major Aortopulmonary Collateral Artery",[5388],{"intervention":1408,"totalTrials":394,"cells":10504},{"EARLY_PHASE1":10505,"PHASE1":10507,"PHASE2":10509,"PHASE3":10515,"PHASE4":10517,"NA":10519},{"trials":10506,"activeCount":100},[],{"trials":10508,"activeCount":100},[],{"trials":10510,"activeCount":100},[10511],{"nctId":1152,"briefTitle":1153,"status":108,"phases":10512,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":972,"conditions":10513,"interventions":10514},[89],[1159],[604,1161,1038,518,1162],{"trials":10516,"activeCount":100},[],{"trials":10518,"activeCount":100},[],{"trials":10520,"activeCount":100},[10521],{"nctId":1400,"briefTitle":1401,"status":108,"phases":10522,"primaryCompletion":1403,"completion":1403,"start":1404,"conditions":10523,"interventions":10524},[92],[1406],[1408,1409,1016,1410],{"intervention":1434,"totalTrials":394,"cells":10526},{"EARLY_PHASE1":10527,"PHASE1":10529,"PHASE2":10539,"PHASE3":10541,"PHASE4":10543,"NA":10545},{"trials":10528,"activeCount":100},[],{"trials":10530,"activeCount":100},[10531],{"nctId":10532,"briefTitle":10533,"status":108,"phases":10534,"primaryCompletion":6382,"completion":3719,"start":10535,"enrollment":581,"conditions":10536,"interventions":10538},"NCT00674674","Phase 1 Intrathecal Topotecan for Neoplastic Meningitis",[88],"2005-10",[10537],"Neoplastic Meningitis",[1434,1434,1434],{"trials":10540,"activeCount":100},[],{"trials":10542,"activeCount":100},[],{"trials":10544,"activeCount":100},[],{"trials":10546,"activeCount":100},[10547],{"nctId":1427,"briefTitle":1428,"status":108,"phases":10548,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1350,"conditions":10549,"interventions":10550},[92],[29],[1434,1038,1355,411,1271,1038,1270,1435],{"intervention":10552,"totalTrials":394,"cells":10553},"hydrocodone\u002Facetaminophen",{"EARLY_PHASE1":10554,"PHASE1":10556,"PHASE2":10558,"PHASE3":10560,"PHASE4":10562,"NA":10568},{"trials":10555,"activeCount":100},[],{"trials":10557,"activeCount":100},[],{"trials":10559,"activeCount":100},[],{"trials":10561,"activeCount":100},[],{"trials":10563,"activeCount":100},[10564],{"nctId":4791,"briefTitle":4792,"status":578,"phases":10565,"primaryCompletion":4794,"completion":4794,"start":4795,"enrollment":4796,"conditions":10566,"interventions":10567},[91],[4798],[4778,4800,4801],{"trials":10569,"activeCount":100},[10570],{"nctId":10571,"briefTitle":10572,"status":108,"phases":10573,"primaryCompletion":2848,"completion":8681,"start":1103,"enrollment":668,"conditions":10574,"interventions":10579},"NCT01053637","Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair",[92],[10575,10576,10577,10578,5979],"Children","Lacerations","Procedures","Child",[10552,10580],"Sugar water",{"intervention":10582,"totalTrials":150,"cells":10583},"Intervention: Budesonide",{"EARLY_PHASE1":10584,"PHASE1":10586,"PHASE2":10588,"PHASE3":10590,"PHASE4":10592,"NA":10594},{"trials":10585,"activeCount":100},[],{"trials":10587,"activeCount":100},[],{"trials":10589,"activeCount":100},[],{"trials":10591,"activeCount":100},[],{"trials":10593,"activeCount":100},[],{"trials":10595,"activeCount":100},[10596],{"nctId":10597,"briefTitle":10598,"status":180,"phases":10599,"primaryCompletion":10600,"completion":10600,"start":10600,"enrollment":100,"conditions":10601,"interventions":10603},"NCT00388739","Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department",[92],"2006-11-01",[10602],"Asthma",[10582,10604],"Usual care: albuterol + systemic steroids",{"intervention":10604,"totalTrials":150,"cells":10606},{"EARLY_PHASE1":10607,"PHASE1":10609,"PHASE2":10611,"PHASE3":10613,"PHASE4":10615,"NA":10617},{"trials":10608,"activeCount":100},[],{"trials":10610,"activeCount":100},[],{"trials":10612,"activeCount":100},[],{"trials":10614,"activeCount":100},[],{"trials":10616,"activeCount":100},[],{"trials":10618,"activeCount":100},[10619],{"nctId":10597,"briefTitle":10598,"status":180,"phases":10620,"primaryCompletion":10600,"completion":10600,"start":10600,"enrollment":100,"conditions":10621,"interventions":10622},[92],[10602],[10582,10604],{"intervention":10624,"totalTrials":150,"cells":10625},"18 F-DOPA",{"EARLY_PHASE1":10626,"PHASE1":10628,"PHASE2":10630,"PHASE3":10632,"PHASE4":10634,"NA":10636},{"trials":10627,"activeCount":100},[],{"trials":10629,"activeCount":100},[],{"trials":10631,"activeCount":100},[],{"trials":10633,"activeCount":100},[],{"trials":10635,"activeCount":100},[],{"trials":10637,"activeCount":100},[10638],{"nctId":10639,"briefTitle":10640,"status":10641,"phases":10642,"conditions":10643,"interventions":10647},"NCT02533219","Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia","NO_LONGER_AVAILABLE",[],[10644,10645,10646],"Hyperinsulinemic Hypoglycemia, Persistent","Congenital Hyperinsulinism","Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)",[10624],{"intervention":10401,"totalTrials":150,"cells":10649},{"EARLY_PHASE1":10650,"PHASE1":10652,"PHASE2":10654,"PHASE3":10656,"PHASE4":10658,"NA":10660},{"trials":10651,"activeCount":100},[],{"trials":10653,"activeCount":100},[],{"trials":10655,"activeCount":100},[],{"trials":10657,"activeCount":100},[],{"trials":10659,"activeCount":100},[],{"trials":10661,"activeCount":100},[10662],{"nctId":10392,"briefTitle":10393,"status":108,"phases":10663,"primaryCompletion":10395,"completion":3544,"start":10396,"enrollment":10397,"conditions":10664,"interventions":10665},[92],[10399],[10401,10402,10403,10404,10369,10405,10406,10407,10408],{"intervention":10402,"totalTrials":150,"cells":10667},{"EARLY_PHASE1":10668,"PHASE1":10670,"PHASE2":10672,"PHASE3":10674,"PHASE4":10676,"NA":10678},{"trials":10669,"activeCount":100},[],{"trials":10671,"activeCount":100},[],{"trials":10673,"activeCount":100},[],{"trials":10675,"activeCount":100},[],{"trials":10677,"activeCount":100},[],{"trials":10679,"activeCount":100},[10680],{"nctId":10392,"briefTitle":10393,"status":108,"phases":10681,"primaryCompletion":10395,"completion":3544,"start":10396,"enrollment":10397,"conditions":10682,"interventions":10683},[92],[10399],[10401,10402,10403,10404,10369,10405,10406,10407,10408],{"intervention":10403,"totalTrials":150,"cells":10685},{"EARLY_PHASE1":10686,"PHASE1":10688,"PHASE2":10690,"PHASE3":10692,"PHASE4":10694,"NA":10696},{"trials":10687,"activeCount":100},[],{"trials":10689,"activeCount":100},[],{"trials":10691,"activeCount":100},[],{"trials":10693,"activeCount":100},[],{"trials":10695,"activeCount":100},[],{"trials":10697,"activeCount":100},[10698],{"nctId":10392,"briefTitle":10393,"status":108,"phases":10699,"primaryCompletion":10395,"completion":3544,"start":10396,"enrollment":10397,"conditions":10700,"interventions":10701},[92],[10399],[10401,10402,10403,10404,10369,10405,10406,10407,10408],{"intervention":10404,"totalTrials":150,"cells":10703},{"EARLY_PHASE1":10704,"PHASE1":10706,"PHASE2":10708,"PHASE3":10710,"PHASE4":10712,"NA":10714},{"trials":10705,"activeCount":100},[],{"trials":10707,"activeCount":100},[],{"trials":10709,"activeCount":100},[],{"trials":10711,"activeCount":100},[],{"trials":10713,"activeCount":100},[],{"trials":10715,"activeCount":100},[10716],{"nctId":10392,"briefTitle":10393,"status":108,"phases":10717,"primaryCompletion":10395,"completion":3544,"start":10396,"enrollment":10397,"conditions":10718,"interventions":10719},[92],[10399],[10401,10402,10403,10404,10369,10405,10406,10407,10408],{"intervention":10405,"totalTrials":150,"cells":10721},{"EARLY_PHASE1":10722,"PHASE1":10724,"PHASE2":10726,"PHASE3":10728,"PHASE4":10730,"NA":10732},{"trials":10723,"activeCount":100},[],{"trials":10725,"activeCount":100},[],{"trials":10727,"activeCount":100},[],{"trials":10729,"activeCount":100},[],{"trials":10731,"activeCount":100},[],{"trials":10733,"activeCount":100},[10734],{"nctId":10392,"briefTitle":10393,"status":108,"phases":10735,"primaryCompletion":10395,"completion":3544,"start":10396,"enrollment":10397,"conditions":10736,"interventions":10737},[92],[10399],[10401,10402,10403,10404,10369,10405,10406,10407,10408],{"intervention":10406,"totalTrials":150,"cells":10739},{"EARLY_PHASE1":10740,"PHASE1":10742,"PHASE2":10744,"PHASE3":10746,"PHASE4":10748,"NA":10750},{"trials":10741,"activeCount":100},[],{"trials":10743,"activeCount":100},[],{"trials":10745,"activeCount":100},[],{"trials":10747,"activeCount":100},[],{"trials":10749,"activeCount":100},[],{"trials":10751,"activeCount":100},[10752],{"nctId":10392,"briefTitle":10393,"status":108,"phases":10753,"primaryCompletion":10395,"completion":3544,"start":10396,"enrollment":10397,"conditions":10754,"interventions":10755},[92],[10399],[10401,10402,10403,10404,10369,10405,10406,10407,10408],{"intervention":10407,"totalTrials":150,"cells":10757},{"EARLY_PHASE1":10758,"PHASE1":10760,"PHASE2":10762,"PHASE3":10764,"PHASE4":10766,"NA":10768},{"trials":10759,"activeCount":100},[],{"trials":10761,"activeCount":100},[],{"trials":10763,"activeCount":100},[],{"trials":10765,"activeCount":100},[],{"trials":10767,"activeCount":100},[],{"trials":10769,"activeCount":100},[10770],{"nctId":10392,"briefTitle":10393,"status":108,"phases":10771,"primaryCompletion":10395,"completion":3544,"start":10396,"enrollment":10397,"conditions":10772,"interventions":10773},[92],[10399],[10401,10402,10403,10404,10369,10405,10406,10407,10408],{"intervention":10408,"totalTrials":150,"cells":10775},{"EARLY_PHASE1":10776,"PHASE1":10778,"PHASE2":10780,"PHASE3":10782,"PHASE4":10784,"NA":10786},{"trials":10777,"activeCount":100},[],{"trials":10779,"activeCount":100},[],{"trials":10781,"activeCount":100},[],{"trials":10783,"activeCount":100},[],{"trials":10785,"activeCount":100},[],{"trials":10787,"activeCount":100},[10788],{"nctId":10392,"briefTitle":10393,"status":108,"phases":10789,"primaryCompletion":10395,"completion":3544,"start":10396,"enrollment":10397,"conditions":10790,"interventions":10791},[92],[10399],[10401,10402,10403,10404,10369,10405,10406,10407,10408],{"intervention":10793,"totalTrials":150,"cells":10794},"Sodium Benzoate",{"EARLY_PHASE1":10795,"PHASE1":10797,"PHASE2":10799,"PHASE3":10801,"PHASE4":10803,"NA":10805},{"trials":10796,"activeCount":100},[],{"trials":10798,"activeCount":100},[],{"trials":10800,"activeCount":100},[],{"trials":10802,"activeCount":100},[],{"trials":10804,"activeCount":100},[],{"trials":10806,"activeCount":100},[10807],{"nctId":10808,"briefTitle":10809,"status":108,"phases":10810,"primaryCompletion":10811,"completion":10811,"start":1121,"enrollment":1135,"conditions":10812,"interventions":10814},"NCT02111200","Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders",[92],"2015-10",[10813],"Urea Cycle Disorders, Inborn",[10793,10815],"Sodium Phenylbutyrate",{"intervention":10815,"totalTrials":150,"cells":10817},{"EARLY_PHASE1":10818,"PHASE1":10820,"PHASE2":10822,"PHASE3":10824,"PHASE4":10826,"NA":10828},{"trials":10819,"activeCount":100},[],{"trials":10821,"activeCount":100},[],{"trials":10823,"activeCount":100},[],{"trials":10825,"activeCount":100},[],{"trials":10827,"activeCount":100},[],{"trials":10829,"activeCount":100},[10830],{"nctId":10808,"briefTitle":10809,"status":108,"phases":10831,"primaryCompletion":10811,"completion":10811,"start":1121,"enrollment":1135,"conditions":10832,"interventions":10833},[92],[10813],[10793,10815],{"intervention":10835,"totalTrials":150,"cells":10836},"Testosterone replacement",{"EARLY_PHASE1":10837,"PHASE1":10839,"PHASE2":10841,"PHASE3":10843,"PHASE4":10845,"NA":10847},{"trials":10838,"activeCount":100},[],{"trials":10840,"activeCount":100},[],{"trials":10842,"activeCount":100},[],{"trials":10844,"activeCount":100},[],{"trials":10846,"activeCount":100},[],{"trials":10848,"activeCount":100},[10849],{"nctId":10850,"briefTitle":10851,"status":108,"phases":10852,"primaryCompletion":10853,"completion":10853,"start":10854,"enrollment":1063,"conditions":10855,"interventions":10858},"NCT03256292","Long-term Lifestyle Change and Testosterone Replacement",[],"2020-08-31","2017-08-21",[4722,10856,10857],"Aging","Overweight and Obesity",[10835],{"intervention":10860,"totalTrials":150,"cells":10861},"Dopamine",{"EARLY_PHASE1":10862,"PHASE1":10864,"PHASE2":10866,"PHASE3":10868,"PHASE4":10870,"NA":10872},{"trials":10863,"activeCount":100},[],{"trials":10865,"activeCount":100},[],{"trials":10867,"activeCount":100},[],{"trials":10869,"activeCount":100},[],{"trials":10871,"activeCount":100},[],{"trials":10873,"activeCount":100},[10874],{"nctId":10875,"briefTitle":10876,"status":108,"phases":10877,"primaryCompletion":1263,"completion":54,"start":5469,"enrollment":1703,"conditions":10878,"interventions":10880},"NCT01318278","Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants",[92],[10879],"Hypotension",[10860,10881],"Arginine Vasopressin",{"intervention":10881,"totalTrials":150,"cells":10883},{"EARLY_PHASE1":10884,"PHASE1":10886,"PHASE2":10888,"PHASE3":10890,"PHASE4":10892,"NA":10894},{"trials":10885,"activeCount":100},[],{"trials":10887,"activeCount":100},[],{"trials":10889,"activeCount":100},[],{"trials":10891,"activeCount":100},[],{"trials":10893,"activeCount":100},[],{"trials":10895,"activeCount":100},[10896],{"nctId":10875,"briefTitle":10876,"status":108,"phases":10897,"primaryCompletion":1263,"completion":54,"start":5469,"enrollment":1703,"conditions":10898,"interventions":10899},[92],[10879],[10860,10881],{"intervention":10901,"totalTrials":150,"cells":10902},"Trivirus-Specific CTLs",{"EARLY_PHASE1":10903,"PHASE1":10905,"PHASE2":10907,"PHASE3":10909,"PHASE4":10911,"NA":10913},{"trials":10904,"activeCount":100},[],{"trials":10906,"activeCount":100},[],{"trials":10908,"activeCount":100},[],{"trials":10910,"activeCount":100},[],{"trials":10912,"activeCount":100},[],{"trials":10914,"activeCount":100},[10915],{"nctId":10916,"briefTitle":10917,"status":10641,"phases":10918,"conditions":10919,"interventions":10922},"NCT01945619","Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent\u002FRecurrent Viral Infection Post-HSCT (EAP CHALLAH)",[],[6318,10920,10921],"CMV Infection","Adenoviral Infection",[10901],{"intervention":10924,"totalTrials":150,"cells":10925},"Curcumin+Bioprine",{"EARLY_PHASE1":10926,"PHASE1":10928,"PHASE2":10930,"PHASE3":10932,"PHASE4":10934,"NA":10936},{"trials":10927,"activeCount":100},[],{"trials":10929,"activeCount":100},[],{"trials":10931,"activeCount":100},[],{"trials":10933,"activeCount":100},[],{"trials":10935,"activeCount":100},[],{"trials":10937,"activeCount":100},[10938],{"nctId":10939,"briefTitle":10940,"status":108,"phases":10941,"primaryCompletion":6088,"completion":6382,"start":1283,"enrollment":10942,"conditions":10943,"interventions":10945},"NCT01514266","Effect of Curcumin on Lung Inflammation",[92],57,[10944],"Chronic Obstructive Pulmonary Disease",[10924],{"intervention":10947,"totalTrials":150,"cells":10948},"Cyclosporin 0.05% emulsion",{"EARLY_PHASE1":10949,"PHASE1":10951,"PHASE2":10953,"PHASE3":10955,"PHASE4":10957,"NA":10959},{"trials":10950,"activeCount":100},[],{"trials":10952,"activeCount":100},[],{"trials":10954,"activeCount":100},[],{"trials":10956,"activeCount":100},[],{"trials":10958,"activeCount":100},[],{"trials":10960,"activeCount":100},[10961],{"nctId":10962,"briefTitle":10963,"status":578,"phases":10964,"primaryCompletion":64,"completion":64,"start":5664,"enrollment":1106,"conditions":10965,"interventions":10967},"NCT02199964","The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface",[92],[10966],"Dry Eye",[10947,10968],"Endura, Refresh artificial tears",{"intervention":10968,"totalTrials":150,"cells":10970},{"EARLY_PHASE1":10971,"PHASE1":10973,"PHASE2":10975,"PHASE3":10977,"PHASE4":10979,"NA":10981},{"trials":10972,"activeCount":100},[],{"trials":10974,"activeCount":100},[],{"trials":10976,"activeCount":100},[],{"trials":10978,"activeCount":100},[],{"trials":10980,"activeCount":100},[],{"trials":10982,"activeCount":100},[10983],{"nctId":10962,"briefTitle":10963,"status":578,"phases":10984,"primaryCompletion":64,"completion":64,"start":5664,"enrollment":1106,"conditions":10985,"interventions":10986},[92],[10966],[10947,10968],{"intervention":10988,"totalTrials":150,"cells":10989},"Intranasal Oxytocin",{"EARLY_PHASE1":10990,"PHASE1":10992,"PHASE2":10994,"PHASE3":10996,"PHASE4":10998,"NA":11000},{"trials":10991,"activeCount":100},[],{"trials":10993,"activeCount":100},[],{"trials":10995,"activeCount":100},[],{"trials":10997,"activeCount":100},[],{"trials":10999,"activeCount":100},[],{"trials":11001,"activeCount":100},[11002],{"nctId":11003,"briefTitle":11004,"status":108,"phases":11005,"primaryCompletion":4423,"completion":4423,"start":8099,"enrollment":11006,"conditions":11007,"interventions":11009},"NCT02737436","Intranasal Oxytocin and Maternal Neglect",[92],132,[11008],"Maternal Behavior",[10988],{"intervention":1409,"totalTrials":150,"cells":11011},{"EARLY_PHASE1":11012,"PHASE1":11014,"PHASE2":11016,"PHASE3":11018,"PHASE4":11020,"NA":11022},{"trials":11013,"activeCount":100},[],{"trials":11015,"activeCount":100},[],{"trials":11017,"activeCount":100},[],{"trials":11019,"activeCount":100},[],{"trials":11021,"activeCount":100},[],{"trials":11023,"activeCount":100},[11024],{"nctId":1400,"briefTitle":1401,"status":108,"phases":11025,"primaryCompletion":1403,"completion":1403,"start":1404,"conditions":11026,"interventions":11027},[92],[1406],[1408,1409,1016,1410],{"intervention":1410,"totalTrials":150,"cells":11029},{"EARLY_PHASE1":11030,"PHASE1":11032,"PHASE2":11034,"PHASE3":11036,"PHASE4":11038,"NA":11040},{"trials":11031,"activeCount":100},[],{"trials":11033,"activeCount":100},[],{"trials":11035,"activeCount":100},[],{"trials":11037,"activeCount":100},[],{"trials":11039,"activeCount":100},[],{"trials":11041,"activeCount":100},[11042],{"nctId":1400,"briefTitle":1401,"status":108,"phases":11043,"primaryCompletion":1403,"completion":1403,"start":1404,"conditions":11044,"interventions":11045},[92],[1406],[1408,1409,1016,1410],{"intervention":11047,"totalTrials":150,"cells":11048},"25% human albumin",{"EARLY_PHASE1":11049,"PHASE1":11051,"PHASE2":11053,"PHASE3":11055,"PHASE4":11057,"NA":11059},{"trials":11050,"activeCount":100},[],{"trials":11052,"activeCount":100},[],{"trials":11054,"activeCount":100},[],{"trials":11056,"activeCount":100},[],{"trials":11058,"activeCount":100},[],{"trials":11060,"activeCount":100},[11061],{"nctId":11062,"briefTitle":8387,"status":578,"phases":11063,"primaryCompletion":5442,"completion":5452,"start":3575,"enrollment":3223,"conditions":11064,"interventions":11065},"NCT00283400",[92],[8390],[11047],{"intervention":11067,"totalTrials":150,"cells":11068},"Niacin",{"EARLY_PHASE1":11069,"PHASE1":11071,"PHASE2":11073,"PHASE3":11075,"PHASE4":11077,"NA":11079},{"trials":11070,"activeCount":100},[],{"trials":11072,"activeCount":100},[],{"trials":11074,"activeCount":100},[],{"trials":11076,"activeCount":100},[],{"trials":11078,"activeCount":100},[],{"trials":11080,"activeCount":100},[11081],{"nctId":11082,"briefTitle":11083,"status":108,"phases":11084,"primaryCompletion":600,"completion":4493,"start":11085,"enrollment":11086,"conditions":11087,"interventions":11094},"NCT00246376","Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia",[92],"2004-01",221,[11088,11089,11090,11091,11092,11093,3513],"Cardiovascular Diseases","Heart Diseases","HIV Infections","Hyperlipidemia","Hypertriglyceridemia","Insulin Resistance",[11067,11095],"Fenofibrate",{"intervention":11095,"totalTrials":150,"cells":11097},{"EARLY_PHASE1":11098,"PHASE1":11100,"PHASE2":11102,"PHASE3":11104,"PHASE4":11106,"NA":11108},{"trials":11099,"activeCount":100},[],{"trials":11101,"activeCount":100},[],{"trials":11103,"activeCount":100},[],{"trials":11105,"activeCount":100},[],{"trials":11107,"activeCount":100},[],{"trials":11109,"activeCount":100},[11110],{"nctId":11082,"briefTitle":11083,"status":108,"phases":11111,"primaryCompletion":600,"completion":4493,"start":11085,"enrollment":11086,"conditions":11112,"interventions":11113},[92],[11088,11089,11090,11091,11092,11093,3513],[11067,11095],{"intervention":11115,"totalTrials":150,"cells":11116},"20 ml of ropivacaine 0.5%",{"EARLY_PHASE1":11117,"PHASE1":11119,"PHASE2":11121,"PHASE3":11123,"PHASE4":11125,"NA":11127},{"trials":11118,"activeCount":100},[],{"trials":11120,"activeCount":100},[],{"trials":11122,"activeCount":100},[],{"trials":11124,"activeCount":100},[],{"trials":11126,"activeCount":100},[],{"trials":11128,"activeCount":100},[11129],{"nctId":11130,"briefTitle":11131,"status":180,"phases":11132,"primaryCompletion":3719,"completion":3719,"start":7441,"enrollment":100,"conditions":11133,"interventions":11135},"NCT00923494","Effectiveness of Ultrasound (US) Guided Supraclavicular Block",[92],[11134,5979],"Analgesia",[11115,11136,11137],"30 ml of ropivacaine 0.5%","40 ml of ropivacaine 0.5%",{"intervention":11136,"totalTrials":150,"cells":11139},{"EARLY_PHASE1":11140,"PHASE1":11142,"PHASE2":11144,"PHASE3":11146,"PHASE4":11148,"NA":11150},{"trials":11141,"activeCount":100},[],{"trials":11143,"activeCount":100},[],{"trials":11145,"activeCount":100},[],{"trials":11147,"activeCount":100},[],{"trials":11149,"activeCount":100},[],{"trials":11151,"activeCount":100},[11152],{"nctId":11130,"briefTitle":11131,"status":180,"phases":11153,"primaryCompletion":3719,"completion":3719,"start":7441,"enrollment":100,"conditions":11154,"interventions":11155},[92],[11134,5979],[11115,11136,11137],{"intervention":11137,"totalTrials":150,"cells":11157},{"EARLY_PHASE1":11158,"PHASE1":11160,"PHASE2":11162,"PHASE3":11164,"PHASE4":11166,"NA":11168},{"trials":11159,"activeCount":100},[],{"trials":11161,"activeCount":100},[],{"trials":11163,"activeCount":100},[],{"trials":11165,"activeCount":100},[],{"trials":11167,"activeCount":100},[],{"trials":11169,"activeCount":100},[11170],{"nctId":11130,"briefTitle":11131,"status":180,"phases":11171,"primaryCompletion":3719,"completion":3719,"start":7441,"enrollment":100,"conditions":11172,"interventions":11173},[92],[11134,5979],[11115,11136,11137],{"intervention":11175,"totalTrials":150,"cells":11176},"Certolizumab",{"EARLY_PHASE1":11177,"PHASE1":11179,"PHASE2":11181,"PHASE3":11183,"PHASE4":11185,"NA":11187},{"trials":11178,"activeCount":100},[],{"trials":11180,"activeCount":100},[],{"trials":11182,"activeCount":100},[],{"trials":11184,"activeCount":100},[],{"trials":11186,"activeCount":100},[],{"trials":11188,"activeCount":100},[11189],{"nctId":11190,"briefTitle":11191,"status":578,"phases":11192,"primaryCompletion":5664,"completion":5664,"start":8657,"enrollment":150,"conditions":11193,"interventions":11195},"NCT01582568","EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment",[],[11194],"Crohns Disease",[11175],{"intervention":11197,"totalTrials":150,"cells":11198},"Duloxetine",{"EARLY_PHASE1":11199,"PHASE1":11201,"PHASE2":11203,"PHASE3":11205,"PHASE4":11207,"NA":11209},{"trials":11200,"activeCount":100},[],{"trials":11202,"activeCount":100},[],{"trials":11204,"activeCount":100},[],{"trials":11206,"activeCount":100},[],{"trials":11208,"activeCount":100},[],{"trials":11210,"activeCount":100},[11211],{"nctId":11212,"briefTitle":11213,"status":578,"phases":11214,"completion":1105,"start":4600,"enrollment":972,"conditions":11215,"interventions":11217},"NCT00425230","Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain",[92],[11216],"Chronic Phantom Limb Pain",[11197],{"intervention":11219,"totalTrials":150,"cells":11220},"Urine Culture",{"EARLY_PHASE1":11221,"PHASE1":11223,"PHASE2":11225,"PHASE3":11227,"PHASE4":11229,"NA":11231},{"trials":11222,"activeCount":100},[],{"trials":11224,"activeCount":100},[],{"trials":11226,"activeCount":100},[],{"trials":11228,"activeCount":100},[],{"trials":11230,"activeCount":100},[],{"trials":11232,"activeCount":100},[11233],{"nctId":11234,"briefTitle":11235,"status":578,"phases":11236,"primaryCompletion":3757,"completion":3757,"start":1121,"enrollment":394,"conditions":11237,"interventions":11238},"NCT02198833","Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract Infection",[92],[388],[11219],{"intervention":10276,"totalTrials":150,"cells":11240},{"EARLY_PHASE1":11241,"PHASE1":11243,"PHASE2":11245,"PHASE3":11247,"PHASE4":11249,"NA":11251},{"trials":11242,"activeCount":100},[],{"trials":11244,"activeCount":100},[],{"trials":11246,"activeCount":100},[],{"trials":11248,"activeCount":100},[],{"trials":11250,"activeCount":100},[],{"trials":11252,"activeCount":100},[11253],{"nctId":10268,"briefTitle":10269,"status":180,"phases":11254,"primaryCompletion":1431,"completion":1431,"start":5468,"enrollment":100,"conditions":11255,"interventions":11256},[92],[10272,10273],[10275,3689,4450,10276,10277],{"intervention":10277,"totalTrials":150,"cells":11258},{"EARLY_PHASE1":11259,"PHASE1":11261,"PHASE2":11263,"PHASE3":11265,"PHASE4":11267,"NA":11269},{"trials":11260,"activeCount":100},[],{"trials":11262,"activeCount":100},[],{"trials":11264,"activeCount":100},[],{"trials":11266,"activeCount":100},[],{"trials":11268,"activeCount":100},[],{"trials":11270,"activeCount":100},[11271],{"nctId":10268,"briefTitle":10269,"status":180,"phases":11272,"primaryCompletion":1431,"completion":1431,"start":5468,"enrollment":100,"conditions":11273,"interventions":11274},[92],[10272,10273],[10275,3689,4450,10276,10277],{"intervention":11276,"totalTrials":150,"cells":11277},"Omegaven",{"EARLY_PHASE1":11278,"PHASE1":11280,"PHASE2":11282,"PHASE3":11284,"PHASE4":11286,"NA":11288},{"trials":11279,"activeCount":100},[],{"trials":11281,"activeCount":100},[],{"trials":11283,"activeCount":100},[],{"trials":11285,"activeCount":100},[],{"trials":11287,"activeCount":100},[],{"trials":11289,"activeCount":100},[11290],{"nctId":11291,"briefTitle":11292,"status":108,"phases":11293,"primaryCompletion":11294,"completion":11295,"start":3647,"enrollment":11296,"conditions":11297,"interventions":11300},"NCT00738101","Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants",[92],"2019-03-27","2020-03-27",293,[11298,11299],"Cholestasis","Cholestasis of Parenteral Nutrition",[11276],{"intervention":11302,"totalTrials":150,"cells":11303},"SMOFlipid",{"EARLY_PHASE1":11304,"PHASE1":11306,"PHASE2":11308,"PHASE3":11310,"PHASE4":11312,"NA":11314},{"trials":11305,"activeCount":100},[],{"trials":11307,"activeCount":100},[],{"trials":11309,"activeCount":100},[],{"trials":11311,"activeCount":100},[],{"trials":11313,"activeCount":100},[],{"trials":11315,"activeCount":100},[11316],{"nctId":11317,"briefTitle":11318,"status":11319,"phases":11320,"conditions":11321,"interventions":11323},"NCT02412566","SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury","APPROVED_FOR_MARKETING",[],[11298,11322],"Growth Failure",[11302],{"intervention":11325,"totalTrials":150,"cells":11326},"Hydrocortisone sodium acetate",{"EARLY_PHASE1":11327,"PHASE1":11329,"PHASE2":11331,"PHASE3":11333,"PHASE4":11335,"NA":11337},{"trials":11328,"activeCount":100},[],{"trials":11330,"activeCount":100},[],{"trials":11332,"activeCount":100},[],{"trials":11334,"activeCount":100},[],{"trials":11336,"activeCount":100},[],{"trials":11338,"activeCount":100},[11339],{"nctId":11340,"briefTitle":11341,"status":108,"phases":11342,"primaryCompletion":3647,"completion":3647,"start":4600,"enrollment":1135,"conditions":11343,"interventions":11345},"NCT00529841","Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia",[92],[11344],"Adrenal Hyperplasia, Congenital",[11325],{"intervention":11347,"totalTrials":150,"cells":11348},"Human recombinant leptin",{"EARLY_PHASE1":11349,"PHASE1":11351,"PHASE2":11353,"PHASE3":11355,"PHASE4":11357,"NA":11359},{"trials":11350,"activeCount":100},[],{"trials":11352,"activeCount":100},[],{"trials":11354,"activeCount":100},[],{"trials":11356,"activeCount":100},[],{"trials":11358,"activeCount":100},[],{"trials":11360,"activeCount":100},[11361],{"nctId":11362,"briefTitle":11363,"status":108,"phases":11364,"primaryCompletion":8657,"completion":3811,"start":1297,"enrollment":876,"conditions":11365,"interventions":11367},"NCT01511016","Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome",[92],[11366],"HIV Lipodystrophy",[11347],{"intervention":11369,"totalTrials":150,"cells":11370},"Dexamethasone 4 mg",{"EARLY_PHASE1":11371,"PHASE1":11373,"PHASE2":11375,"PHASE3":11377,"PHASE4":11379,"NA":11381},{"trials":11372,"activeCount":100},[],{"trials":11374,"activeCount":100},[],{"trials":11376,"activeCount":100},[],{"trials":11378,"activeCount":100},[],{"trials":11380,"activeCount":100},[],{"trials":11382,"activeCount":100},[11383],{"nctId":11384,"briefTitle":11385,"status":180,"phases":11386,"primaryCompletion":5561,"completion":5561,"start":49,"enrollment":100,"conditions":11387,"interventions":11389},"NCT01641419","Trial Comparing Duration of Analgesia After Popliteal Fossa Sciatiac Nerve Block With Ropivacaine 0.5% When Combined With Placebo, Dexamethasone 4mg or Dexamethasone 8 mg",[92],[11388],"Pain, Sciatic Block",[11369,11390],"Dexamethasone 8 mg",{"intervention":11390,"totalTrials":150,"cells":11392},{"EARLY_PHASE1":11393,"PHASE1":11395,"PHASE2":11397,"PHASE3":11399,"PHASE4":11401,"NA":11403},{"trials":11394,"activeCount":100},[],{"trials":11396,"activeCount":100},[],{"trials":11398,"activeCount":100},[],{"trials":11400,"activeCount":100},[],{"trials":11402,"activeCount":100},[],{"trials":11404,"activeCount":100},[11405],{"nctId":11384,"briefTitle":11385,"status":180,"phases":11406,"primaryCompletion":5561,"completion":5561,"start":49,"enrollment":100,"conditions":11407,"interventions":11408},[92],[11388],[11369,11390],{"intervention":11410,"totalTrials":150,"cells":11411},"Oral tranexamic acid",{"EARLY_PHASE1":11412,"PHASE1":11414,"PHASE2":11416,"PHASE3":11418,"PHASE4":11420,"NA":11422},{"trials":11413,"activeCount":100},[],{"trials":11415,"activeCount":100},[],{"trials":11417,"activeCount":100},[],{"trials":11419,"activeCount":100},[],{"trials":11421,"activeCount":100},[],{"trials":11423,"activeCount":100},[11424],{"nctId":11425,"briefTitle":11426,"status":108,"phases":11427,"primaryCompletion":11428,"completion":11428,"start":171,"enrollment":876,"conditions":11429,"interventions":11431},"NCT01428713","Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study",[92],"2013-06",[11430],"Menorrhagia",[11410,11432],"Oral Contraceptive Pills",{"intervention":11432,"totalTrials":150,"cells":11434},{"EARLY_PHASE1":11435,"PHASE1":11437,"PHASE2":11439,"PHASE3":11441,"PHASE4":11443,"NA":11445},{"trials":11436,"activeCount":100},[],{"trials":11438,"activeCount":100},[],{"trials":11440,"activeCount":100},[],{"trials":11442,"activeCount":100},[],{"trials":11444,"activeCount":100},[],{"trials":11446,"activeCount":100},[11447],{"nctId":11425,"briefTitle":11426,"status":108,"phases":11448,"primaryCompletion":11428,"completion":11428,"start":171,"enrollment":876,"conditions":11449,"interventions":11450},[92],[11430],[11410,11432],{"intervention":10580,"totalTrials":150,"cells":11452},{"EARLY_PHASE1":11453,"PHASE1":11455,"PHASE2":11457,"PHASE3":11459,"PHASE4":11461,"NA":11463},{"trials":11454,"activeCount":100},[],{"trials":11456,"activeCount":100},[],{"trials":11458,"activeCount":100},[],{"trials":11460,"activeCount":100},[],{"trials":11462,"activeCount":100},[],{"trials":11464,"activeCount":100},[11465],{"nctId":10571,"briefTitle":10572,"status":108,"phases":11466,"primaryCompletion":2848,"completion":8681,"start":1103,"enrollment":668,"conditions":11467,"interventions":11468},[92],[10575,10576,10577,10578,5979],[10552,10580],{"intervention":10122,"totalTrials":150,"cells":11470},{"EARLY_PHASE1":11471,"PHASE1":11473,"PHASE2":11475,"PHASE3":11477,"PHASE4":11479,"NA":11481},{"trials":11472,"activeCount":100},[],{"trials":11474,"activeCount":100},[],{"trials":11476,"activeCount":100},[],{"trials":11478,"activeCount":100},[],{"trials":11480,"activeCount":100},[],{"trials":11482,"activeCount":100},[11483],{"nctId":10117,"briefTitle":10118,"status":108,"phases":11484,"primaryCompletion":7536,"completion":3459,"start":1146,"enrollment":5182,"conditions":11485,"interventions":11486},[92],[1390,1887],[10122,1302,10123,10124,10125,10126],{"intervention":10123,"totalTrials":150,"cells":11488},{"EARLY_PHASE1":11489,"PHASE1":11491,"PHASE2":11493,"PHASE3":11495,"PHASE4":11497,"NA":11499},{"trials":11490,"activeCount":100},[],{"trials":11492,"activeCount":100},[],{"trials":11494,"activeCount":100},[],{"trials":11496,"activeCount":100},[],{"trials":11498,"activeCount":100},[],{"trials":11500,"activeCount":100},[11501],{"nctId":10117,"briefTitle":10118,"status":108,"phases":11502,"primaryCompletion":7536,"completion":3459,"start":1146,"enrollment":5182,"conditions":11503,"interventions":11504},[92],[1390,1887],[10122,1302,10123,10124,10125,10126],{"intervention":10124,"totalTrials":150,"cells":11506},{"EARLY_PHASE1":11507,"PHASE1":11509,"PHASE2":11511,"PHASE3":11513,"PHASE4":11515,"NA":11517},{"trials":11508,"activeCount":100},[],{"trials":11510,"activeCount":100},[],{"trials":11512,"activeCount":100},[],{"trials":11514,"activeCount":100},[],{"trials":11516,"activeCount":100},[],{"trials":11518,"activeCount":100},[11519],{"nctId":10117,"briefTitle":10118,"status":108,"phases":11520,"primaryCompletion":7536,"completion":3459,"start":1146,"enrollment":5182,"conditions":11521,"interventions":11522},[92],[1390,1887],[10122,1302,10123,10124,10125,10126],{"intervention":10125,"totalTrials":150,"cells":11524},{"EARLY_PHASE1":11525,"PHASE1":11527,"PHASE2":11529,"PHASE3":11531,"PHASE4":11533,"NA":11535},{"trials":11526,"activeCount":100},[],{"trials":11528,"activeCount":100},[],{"trials":11530,"activeCount":100},[],{"trials":11532,"activeCount":100},[],{"trials":11534,"activeCount":100},[],{"trials":11536,"activeCount":100},[11537],{"nctId":10117,"briefTitle":10118,"status":108,"phases":11538,"primaryCompletion":7536,"completion":3459,"start":1146,"enrollment":5182,"conditions":11539,"interventions":11540},[92],[1390,1887],[10122,1302,10123,10124,10125,10126],{"intervention":10126,"totalTrials":150,"cells":11542},{"EARLY_PHASE1":11543,"PHASE1":11545,"PHASE2":11547,"PHASE3":11549,"PHASE4":11551,"NA":11553},{"trials":11544,"activeCount":100},[],{"trials":11546,"activeCount":100},[],{"trials":11548,"activeCount":100},[],{"trials":11550,"activeCount":100},[],{"trials":11552,"activeCount":100},[],{"trials":11554,"activeCount":100},[11555],{"nctId":10117,"briefTitle":10118,"status":108,"phases":11556,"primaryCompletion":7536,"completion":3459,"start":1146,"enrollment":5182,"conditions":11557,"interventions":11558},[92],[1390,1887],[10122,1302,10123,10124,10125,10126],{"intervention":10338,"totalTrials":150,"cells":11560},{"EARLY_PHASE1":11561,"PHASE1":11563,"PHASE2":11565,"PHASE3":11567,"PHASE4":11569,"NA":11571},{"trials":11562,"activeCount":100},[],{"trials":11564,"activeCount":100},[],{"trials":11566,"activeCount":100},[],{"trials":11568,"activeCount":100},[],{"trials":11570,"activeCount":100},[],{"trials":11572,"activeCount":100},[11573],{"nctId":10332,"briefTitle":10333,"status":108,"phases":11574,"primaryCompletion":1622,"completion":1622,"start":600,"enrollment":2040,"conditions":11575,"interventions":11576},[92],[10336],[10338,10339,10340,10305],{"intervention":10339,"totalTrials":150,"cells":11578},{"EARLY_PHASE1":11579,"PHASE1":11581,"PHASE2":11583,"PHASE3":11585,"PHASE4":11587,"NA":11589},{"trials":11580,"activeCount":100},[],{"trials":11582,"activeCount":100},[],{"trials":11584,"activeCount":100},[],{"trials":11586,"activeCount":100},[],{"trials":11588,"activeCount":100},[],{"trials":11590,"activeCount":100},[11591],{"nctId":10332,"briefTitle":10333,"status":108,"phases":11592,"primaryCompletion":1622,"completion":1622,"start":600,"enrollment":2040,"conditions":11593,"interventions":11594},[92],[10336],[10338,10339,10340,10305],{"intervention":10340,"totalTrials":150,"cells":11596},{"EARLY_PHASE1":11597,"PHASE1":11599,"PHASE2":11601,"PHASE3":11603,"PHASE4":11605,"NA":11607},{"trials":11598,"activeCount":100},[],{"trials":11600,"activeCount":100},[],{"trials":11602,"activeCount":100},[],{"trials":11604,"activeCount":100},[],{"trials":11606,"activeCount":100},[],{"trials":11608,"activeCount":100},[11609],{"nctId":10332,"briefTitle":10333,"status":108,"phases":11610,"primaryCompletion":1622,"completion":1622,"start":600,"enrollment":2040,"conditions":11611,"interventions":11612},[92],[10336],[10338,10339,10340,10305],{"intervention":11614,"totalTrials":150,"cells":11615},"acamprosate",{"EARLY_PHASE1":11616,"PHASE1":11618,"PHASE2":11620,"PHASE3":11622,"PHASE4":11624,"NA":11626},{"trials":11617,"activeCount":100},[],{"trials":11619,"activeCount":100},[],{"trials":11621,"activeCount":100},[],{"trials":11623,"activeCount":100},[],{"trials":11625,"activeCount":100},[],{"trials":11627,"activeCount":100},[11628],{"nctId":11629,"briefTitle":11630,"status":180,"phases":11631,"primaryCompletion":3647,"completion":3647,"start":8911,"enrollment":100,"conditions":11632,"interventions":11633},"NCT00640952","Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease",[92],[4383],[11614],{"intervention":11635,"totalTrials":150,"cells":11636},"lactated ringers",{"EARLY_PHASE1":11637,"PHASE1":11639,"PHASE2":11641,"PHASE3":11643,"PHASE4":11645,"NA":11647},{"trials":11638,"activeCount":100},[],{"trials":11640,"activeCount":100},[],{"trials":11642,"activeCount":100},[],{"trials":11644,"activeCount":100},[],{"trials":11646,"activeCount":100},[],{"trials":11648,"activeCount":100},[11649],{"nctId":11650,"briefTitle":11651,"status":3474,"phases":11652,"primaryCompletion":191,"completion":191,"start":11653,"enrollment":3759,"conditions":11654,"interventions":11659},"NCT04330742","The Effect of Fluids on Aortic VTI During C-section",[],"2020-03-25",[11655,11656,11657,11658],"Pregnancy Related","Hemorrhage","Fluid Overload","Labor Complication",[11635],{"intervention":1435,"totalTrials":150,"cells":11661},{"EARLY_PHASE1":11662,"PHASE1":11664,"PHASE2":11666,"PHASE3":11668,"PHASE4":11670,"NA":11672},{"trials":11663,"activeCount":100},[],{"trials":11665,"activeCount":100},[],{"trials":11667,"activeCount":100},[],{"trials":11669,"activeCount":100},[],{"trials":11671,"activeCount":100},[],{"trials":11673,"activeCount":100},[11674],{"nctId":1427,"briefTitle":1428,"status":108,"phases":11675,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1350,"conditions":11676,"interventions":11677},[92],[29],[1434,1038,1355,411,1271,1038,1270,1435]]